Novel imaging techniques for intraoperative assessment of tumour resection margins in breast-conserving surgery by Grootendorst, Maarten Ruben
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 














































Abstract	There	 is	 a	 clear	 need	 for	 more	 accurate	 techniques	 to	 assess	 tumour	 resection	margins	intraoperatively	in	breast-conserving	surgery	(BCS),	as	to	date	an	average	10	 –	 30%	 of	 patients	 undergoing	 BCS	 require	 a	 re-operation	 to	 achieve	 clear	margins.	 This	 thesis	 evaluates	 two	 novel	 imaging	 techniques	 for	 intraoperative	tumour	 margin	 assessment,	 Terahertz	 Pulsed	 Imaging	 (TPI)	 and	 Cerenkov	Luminescence	Imaging	(CLI),	that	have	been	developed	with	a	view	to	reducing	re-operation	rates	in	BCS.		 Both	techniques	were	evaluated	in	a	first-in-human,	single	centre	study	to	demonstrate	 proof-of-principle	 and	 feasibility.	 A	 TPI	 handheld	 probe	 system	(Teraview	Ltd.,	UK)	was	used	to	scan	breast	samples	ex	vivo,	and	the	TPI	data	was	correlated	with	 histopathology	 to	 assess	 diagnostic	 accuracy.	 CLI	was	 evaluated	intraoperatively	by	scanning	excised	BCS	specimens	from	patients	that	received	2-deoxy-2-(18F)fluoro-D-glucose	 (18F-FDG)	 preoperatively	 using	 an	 investigational	CLI	 imaging	system	(Lightpoint	Medical	Ltd.,	UK).	An	 increased	Technetium-99m	(99mTc)	 nanocolloid	 activity	 of	 150	 MBq	 was	 used	 to	 facilitate	 sentinel	 node	detection.	 Radiation	 doses	 to	 theatre	 staff	 were	 measured.	 CLI	 images	 were	analysed	 postoperatively,	 and	 margin	 status	 correlated	 with	 histopathology	results.			 The	TPI	handheld	probe	discriminated	invasive	breast	cancer	from	benign	breast	tissue	with	a	high	sensitivity	(86%)	and	an	encouraging	degree	of	accuracy	(75%).	Accurate	discrimination	of	cancer	from	tissue	containing	a	high	percentage	of	fibrous	cells	proved	challenging	due	to	the	similarities	in	the	THz	pulse	between	these	two	types	of	tissue.	Intraoperative	18F-FDG	CLI	showed	to	be	a	feasible	and	low-risk	procedure.	Good	agreement	was	 found	between	CLI	 and	histopathology	for	clear	margins	of	excision.	Sentinel	nodes	could	be	successfully	detected	using	
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the	gamma	probe	and	blue	dye,	and	radiation	dose	to	staff	was	low.	Elimination	of	image	 artefacts	 from	 tissue	 dissection	 with	 the	 monopolar	 diathermy	 device	 is	needed	to	further	refine	CLI.	In	 conclusion,	 both	 TPI	 and	 18F-FDG	 CLI	 are	 promising	 techniques	 for	intraoperative	assessment	of	tumour	resection	margins	in	BCS,	warranting	larger	studies	 to	 assess	 the	 diagnostic	 accuracy	 of	 each	 technique	 on	 different	 cancer	types	including	DCIS,	and	the	impact	on	re-operation	rates.				
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1. Introduction	to	breast	cancer	and	tumour	resection	margins	in	
breast-conserving	surgery		This	 chapter	 provides	 an	 overview	 on	 the	 clinical	management	 of	 breast	 cancer	including	 breast	 cancer	 surgery,	 the	 importance	 of	 tumour	 resection	margins	 in	breast-conserving	surgery	(BCS),	and	the	armamentarium	of	techniques	available	to	 assess	 tumour	 margins	 intraoperatively.	 This	 thesis	 evaluates	 two	 novel	imaging	 techniques	 for	 intraoperative	 tumour	margin	assessment,	 and	 the	 scope	and	aims	of	each	project	are	outlined	at	the	end	of	this	chapter.		
1.1 Breast	cancer	key	facts	Breast	cancer	is	by	far	the	most	common	cancer	among	women	worldwide,	and	in	2012	 an	 estimated	 1.67	 million	 women	 were	 diagnosed	 with	 the	 disease,	accounting	 for	 25%	 of	 all	 female	 cancers	 (1).	 In	 Europe	 approximately	 460,000	women	 are	 diagnosed	 annually,	making	 it	 the	most	 frequently	 diagnosed	 cancer	(2).	Among	men,	breast	cancer	 is	 far	 less	common,	accounting	 for	<1%	of	breast	cancer	cases.			 With	 the	 introduction	 of	 breast	 cancer	 screening	 in	 the	 1980’s,	 and	 a	greater	 life	 expectancy	 among	 the	world’s	 population,	 there	 has	 been	 a	 gradual	increase	 in	 breast	 cancer	 incidence.	 Currently	 the	 estimated	 lifetime	 risk	 to	develop	breast	cancer	is	1	in	8	for	women	in	the	United	Kingdom	and	the	United	States	 (3,4).	 Despite	 the	 fact	 that	 early	 diagnosis	 and	 more	 effective	 treatment	have	 lowered	 the	mortality	 rate,	with	approximately	131,000	deaths	per	annum,	breast	 cancer	 remains	 the	 most	 frequent	 cause	 of	 cancer	 death	 in	 women	 in	Europe	(2).	
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1.2 Classification	of	breast	cancer	Breast	 cancer	 comprises	 a	heterogeneous	disease	 consisting	of	 several	 subtypes,	each	associated	with	a	distinct	variability	in	biological	and	clinical	characteristics.	Breast	 cancer	 prognosis	 depends	 on	 a	 variety	 of	 factors,	 including	 patient	 age,	tumour	type,	tumour	size	and	grade,	lymph	node	status,	lymphovascular	invasion	and	receptor	status,	and	these	factors	are	of	key	importance	when	determining	the	most	suitable	 form	of	 treatment	(5).	Advances	 in	molecular	and	genetic	profiling	have	 added	 additional	 prognosticators,	 and	 a	 brief	 overview	 of	 the	 latest	developments	in	this	field	will	also	be	provided	in	this	section.			
1.2.1 Types	of	breast	cancer	All	breast	cancers	derive	from	the	terminal	ductal	lobular	unit,	and	can	be	roughly	classified	 into	 non-invasive	 and	 invasive	 cancer.	 Classification	 of	 breast	 cancer	involves	 histological	 assessment	 of	 morphological	 based	 features	 and	immunohistochemical	(IHC)	analyses.	Non-invasive	breast	cancers,	also	known	as	carcinoma	 in	 situ,	 are	 cancers	 that	 have	 not	 yet	 broken	 through	 the	 basement	membrane,	and	are	thus	confined	within	the	ductal	lobular	units	without	invading	the	breast	stroma.	Ductal	carcinoma	in	situ	(DCIS)	is	the	most	common	form	of	in	
situ	breast	cancer,	comprising	approximately	90%	of	non-invasive	breast	cancers,	and	 starts	within	 the	 duct	 system	 (6).	 DCIS	 generally	 is	 asymptomatic,	 although	some	patients	may	present	with	a	small	palpable	lump.	DCIS	is	classified	into	three	categories,	 i.e.	 low-grade,	 intermediate-grade	and	high-grade,	 the	 latter	being	the	most	aggressive	with	the	highest	potential	to	progress	to	 invasive	cancer.	 If	DCIS	cells	 die	 and	pile	 up,	 tiny	 specks	of	 calcium	 form	within	 the	broken	 cells	 (called	microcalcifications).	 These	 calcifications	 are	 usually	 very	 small	 and	 sometimes	difficult	 to	 identify	 on	 imaging,	 and	 in	 combination	 with	 its	 impalpable	 nature,	
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DCIS	 causes	 additional	 challenges	 for	 accurate	 preoperative	 and	 intraoperative	identification.		 Over	 time	 cancer	 cells	 can	 penetrate	 through	 the	 wall	 of	 the	 ducts	 and	lobules,	thereby	infiltrating	the	breast	stroma.	Invasive	carcinomas,	in	contrast	to	
in	 situ	 carcinomas,	 tend	 to	 form	 firm/hard	 palpable	 lesions.	 The	 most	 common	form	 of	 invasive	 breast	 cancer,	 and	 breast	 cancer	 in	 general,	 is	 invasive	 ductal	carcinoma/no	 special	 type	 (NST).	NST	 is	 found	 in	 40	 –	 75%	of	 all	 breast	 cancer	patients	 (7).	 Its	 descriptive	 is	 based	 on	 the	 lack	 of	 sufficient	 morphological	characteristics	to	be	classified	into	a	specific	histological	subtype.	Invasive	lobular	carcinoma	(ILC)	comprises	5	–	15%	of	invasive	breast	tumours,	and	in	contrast	to	NST	this	type	of	cancer	is	well	characterised	by	a	proliferation	of	small	cells	with	a	diffuse	 growth	 pattern	 (7).	 Far	 less	 common	 types	 of	 invasive	 breast	 cancer	include	 medullary	 carcinoma	 (1	 –	 7%),	 tubular	 carcinoma	 (<2%),	 mucinous	carcinoma	(~2%),	inflammatory	breast	cancer	(~1%),	Paget’s	disease		(<1%),	and	phylloides	tumour	(<1%)	(7).		
1.2.2 Receptor	status	Breast	cancer	cells	may	express	a	variety	of	receptors.	Characterisation	of	receptor	status	is	performed	by	IHC	analyses,	and	is	of	importance	in	selecting	appropriate	systemic	 therapies	 (Section	1.3.4).	The	 three	most	 important	 receptors	 in	breast	cancer	are	oestrogen	(ER),	progesterone	(PR)	and	human	epidermal	growth	factor	receptor	2	(HER2).	ER	and	PR	are	hormone	receptors,	and	pathology	reporting	of	ER	 status	 is	 required	 as	 per	 UK	 national	 guidelines	 (8).	 ER	 is	 reported	 semi-quantitatively	with	recording	of	both	the	proportion	and	 intensity	of	nuclear	cell	reactivity.	 Most	 histopathology	 laboratories	 categorise	 ER	 according	 to	 Allred	score;	a	score	of	3	or	more	is	defined	as	ER	positive	(9).	The	same	scoring	system	
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and	 cut-off	 is	 often	used	 to	 define	PR	positivity.	 The	 Survival,	 Epidemiology	 and	End	Results	 (SEER)	programme	which	 included	 a	 total	 of	 155,175	breast	 cancer	patients,	 found	that	63%	of	women	have	ER-positive	and	PR-positive	(ER+/PR+)	tumours,	13%	had	ER+/PR-	tumours,	3%	had	ER-/PR+	tumours	and	21%	had	ER-/PR-	tumours	(10).	ER+/PR+	tumours	were	associated	with	a	lower	breast-cancer	mortality	risk	than	ER+/ER-,	ER-/PR+	and	ER-/PR-	tumours	across	the	majority	of	clinical	characteristics	examined	including	age,	 tumour	size,	stage	and	grade,	and	axillary	 lymph	node	status.	Another	study	 found	 that	patients	with	ER+	 tumours	have	an	improved	disease-free	survival	(DFS)	and	overall	survival	(OS)	compared	to	patients	with	ER-	 tumours,	while	PR+	tumours	only	showed	an	 increase	 in	OS	compared	to	PR-	tumours	(11).		HER2	is	a	member	of	the	human	epidermal	growth	factor	receptor	(EGFR)	family,	and	according	to	UK	guidelines	HER2	status	should	be	assessed	in	invasive	breast	 cancers	 using	 IHC	 as	 first	 line	 and	 in	 situ	 hybridisation	 as	 second	 line	technique	(12).	Scores	of	0	or	1+	are	defined	as	HER2	negative,	and	3+	scores	as	HER2	positive.	Borderline	 cases	with	2+	 scores	on	 IHC	are	generally	 categorised	based	on	the	number	of	Her2	gene	copies	on	in	situ	hybridisation;	a	ratio	of	2.00	or	more	 is	 regarded	HER2	positive	 (13).	 Approximately	 13	 –	 20%	of	 breast	 cancer	patients	are	HER2	positive	(8).	A	large	retrospective	analysis	performed	by	Ross	et	
al.	 based	 on	 over	 15,000	 patients	 from	 47	 studies	 found	 that	 in	 a	 majority	 of	patients	and	studies,	HER2	positive	(HER2+)	tumours	were	associated	with	poorer	prognosis	(14).		Triple-negative	 breast	 cancers	 (TNBCs)	 are	 defined	 as	 tumours	 lacking	expression	of	ER,	PR	and	HER2.		These	tumours	are	found	and	in	approximately	12	–	17%	of	breast	cancer	patients	(15).	Although	described	as	one	group,	TNBC	is	a	heterogeneous	 class	 consisting	 of	 different	 subtypes	 (16).	 	 Several	 studies	 have	
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shown	that	TNBCs	are	associated	with	adverse	prognosis	in	terms	of	DFS	and	OS	up	 to	 5	 years	 from	 diagnosis	 compared	 to	 non-TNBCs	 (16-18).	 Other	characteristics	 of	 TNBCs	 include	 diagnosis	 at	 younger	 age,	 higher	 histological	grade,	higher	rate	of	nodal	positivity,	and	larger	tumour	size	(18).				
1.2.3 Molecular	classifications	Although	 traditional	 histopathological	 methods	 enable	 classification	 of	 breast	cancer	into	different	subtypes,	identical	histological	forms	may	respond	differently	to	 therapy.	 This	 has	 led	 to	 further	 investigation	 into	 the	 complex	 biology	 and	molecular	 pathways	 underlying	 the	 phenotypic	 diversity	 amongst	 breast	carcinomas.	 The	 first	 comprehensive	 gene	 expression	 study	 using	 DNA	microarrays	 was	 performed	 by	 Perou	 et	 al.	 (19).	 They	 identified	 four	 intrinsic	molecular	 subtypes:	 ER+/luminal,	 HER2+,	 basal-like,	 and	 normal	 breast-like.	 A	subsequent	 study	 revealed	 that	 the	 luminal	 epithelial	 group	 could	 be	 further	divided	 into	at	 least	 two	subtypes	based	on	differences	 in	expression	of	 luminal-specific	 genes:	 Luminal	 A	 and	 Luminal	 B	 (20).	 A	 significant	 variation	 in	 clinical	outcome	 was	 seen	 between	 patients	 belonging	 to	 the	 various	 groups,	 including	poor	 prognosis	 for	 the	 basal-like	 subtype.	 Prat	 et	 al.	 identified	 another	 intrinsic	subtype	known	as	Claudin-low	or	mesenchymal-like	(21).		Recent	work	involving	gene	expression	has	provided	more	insight	into	the	mechanisms	 and	 genes	 that	 drive	 tumourigenesis,	 and	 the	 complex	 biology	underlying	 breast	 cancer	 heterogeneity	 (22).	 A	 landmark	 study	 by	 Curtis	 et	 al.	revealed	 that	 inherited	 variants	 and	 acquired	 somatic	 copy	 number	 aberrations	(CNAs)	 were	 associated	 with	 altered	 gene	 expression	 in	 approximately	 40%	 of	genes;	cis-	 and	 trans-acting	CNAs	were	particularly	dominant	 (23).	Based	on	 the	
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CNAs	they	identified	a	total	of	10	novel	molecular	subgroups,	each	associated	with	distinct	clinical	outcomes.			 Gene	expression	profiling	also	enabled	identification	of	distinct	prognostic	signatures	(24).		This	has	led	to	the	development	of	diagnostic	tests	including	the	MammaPrint	and	Oncotype	DX	that	aid	in	predicting	clinical	outcomes	for	patients,	and	help	determining	which	patients	may	benefit	from	chemotherapy	(25).		Although	comprehensive	molecular	and	genetic	profiling	of	breast	cancer	is	still	 in	 its	 infancy,	 rapid	 progress	 is	 being	 made	 and	 molecular	 information	 is	already	 included	 in	 the	 classification	 of	 breast	 cancer	 in	 addition	 to	 traditional	clinical	 and	 histopathological	 information.	 A	 true	 prognostic	 or	 predictive	 value	may	be	a	combination	of	all	the	above,	and	future	gains	in	further	understanding	the	 biological	 complexities	 of	 breast	 cancer	will	 hopefully	 allow	developing	 new	targeted	therapies	that	enable	more	personalised	breast	cancer	treatment.			
1.3 Breast	cancer	management	The	management	of	breast	cancer	is	a	multidisciplinary	effort	 involving,	amongst	others,	 breast	 care	 nurses,	 surgeons,	 radiologists,	 pathologists,	 medical	oncologists,	 radiotherapists	 and	 geneticists.	 Strategies	 for	 breast	 cancer	management	 are	 ever	 evolving,	 and	 evidence-based	 guidelines	 are	 continuously	being	 improved.	 In	 all	 centres	 in	 the	 UK,	 patient	 management	 is	 discussed	 at	multidisciplinary	 meetings	 (MDMs)	 where	 a	 multitude	 of	 variables	 including	clinical	findings,	imaging	and	histopathological	results	are	reviewed.	By	integrating	the	 clinical	 management	 decision	 from	 the	 MDM	 with	 the	 patient’s	 preference,	tailored	treatments	are	formulated	for	each	individual	patient.		
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1.3.1 Diagnosis	Methods	 used	 by	 clinicians	 to	 diagnose	 breast	 cancer	 are	 based	 on	 ‘triple’	assessment,	 consisting	 of	 clinical	 examination,	 imaging	 and	 histopathological	assessment.	 Clinical	 assessment	 is	 performed	 by	 obtaining	 a	 detailed	 medical	history	 in	 combination	 with	 physical	 examination.	 Symptoms	 (pain,	 lump,	 skin	changes,	 and	 nipple	 discharge),	 duration	 of	 complaints,	 parity,	 age,	 drug	 history	(hormonal	 supplements),	 and	 family	 history	 are	 of	 importance	 in	 adequate	assessment	 of	 the	 patient’s	 medical	 history.	 Physical	 examination	 involves	systematically	 feeling	 for	 any	 abnormal	 lumps	 in	 the	 breast,	 axilla,	 and	supraclavicular	regions.		Mammography	 and	 ultrasound	 (US)	 imaging	 are	 the	 primary	 imaging	techniques	used	to	diagnose	breast	cancer.	Mammography	uses	low	energy	x-rays	(usually	 around	 30kVp)	 to	 identify	 changes	 in	 the	 density	 of	 breast	 tissue,	architectural	 distortion	 and	 microcalcifications.	 Besides	 serving	 as	 a	 diagnostic	tool	in	symptomatic	cases,	mammography	is	the	mainstay	imaging	technology	for	breast	 cancer	 screening.	 The	 sensitivity	 and	 specificity	 of	 mammography	 range	from	69	–	90%	(26).	However,	diagnostic	accuracy	 is	diminished	 in	women	with	denser	 breast	 tissue,	 lobular	 cancer,	 DCIS	without	 associated	microcalcifications	and	multifocal	 cancer,	 thus	 limiting	 the	 usefulness	 of	mammographic	 imaging	 in	these	patients.					 US	 imaging	 is	 mostly	 used	 in	 addition	 to	 mammography,	 and	 has	 been	shown	to	improve	the	diagnostic	performance	compared	to	mammography	alone	(27).	US	examination	is	particularly	useful	in	aiding	the	identification	of	tumours	in	patients	with	dense	breast	 tissue	on	screening	mammography	(28).	 	 	The	 typical	sensitivity	 and	 specificity	 of	 a	 trained	 ultrasound	 operator	 is	 around	 96%	 and	65%,	respectively	(29).	However,	US	imaging	of	the	breast	is	limited	by	substantial	
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inter-operator	variability	(30),	and	has	a	tendency	to	underestimate	the	extend	of	DCIS	(31).		 Magnetic	resonance	imaging	(MRI)	is	another	important	imaging	technique	for	 diagnosing	 breast	 cancer	 in	 a	 subgroup	 of	 patients.	 By	 administering	 an	intravenous	 bolus	 injection	 of	 Gadolinium,	 areas	 of	 increased	 vascularity	 are	enhanced,	 thus	 revealing	 detailed	 information	 about	 anatomical	 abnormalities.	Studies	 have	 shown	 that	 MRI	 is	 more	 sensitive	 in	 detecting	 multifocal	 and	multicentric	 cancers	 than	 mammography	 and	 US	 (32-35),	 especially	 in	 invasive	lobular	 carcinoma	 (36).	 The	 reported	 specificity	 of	 MRI,	 however,	 is	 low	 to	moderate	 ranging	 between	 72	 -	 75%	 (37,38).	 It	 was	 initially	 thought	 that	preoperative	MRI	might	improve	surgical	care	by	helping	to	plan	the	extent	of	local	resection	 of	 the	 tumour,	 and	 potentially	 reduce	 re-excision	 rates	 in	 patients	undergoing	 breast-conserving	 surgery	 (BCS).	 Houssami	 et	 al.	 showed	 that	 MRI	encourages	 more	 extensive	 surgery	 by	 converting	 BCS	 patients	 to	 undergo	 a	mastectomy	 or	 wider	 resection	 of	 the	 preserved	 breast	 (39).	 However,	 due	 to	false-positive	 findings	 1.1%	 of	 patients	 underwent	 an	 unnecessary	 mastectomy,	and	in	4.4%	additional	tissue	excision	could	have	been	averted.	Two	randomised	controlled	trials	and	two	large	cohort	studies	found	that	overall	preoperative	MRI	was	not	associated	with	improved	margin	status	or	reduction	in	re-operation	rate,	although	Pengel	et	al.	found	that	MRI	resulted	in	a	more	complete	tumour	excision	in	patients	with	NST	cancers	(40-43).	In	patients	with	pure	DCIS	preoperative	MRI	also	does	not	improve	surgical	management.	A	recent	meta-analysis	by	Fancellu	et	
al.	showed	no	reduction	in	positive	margins	or	re-operations	in	DCIS	patients	who	had	preoperative	MRI	and	those	who	did	not	(44).	The	suboptimal	specificity	and	potential	 for	 inappropriate	surgical	management,	amongst	other	 factors,	resulted	in	 a	 recommendation	 by	 the	 European	 Society	 of	 Breast	 Cancer	 Specialists	
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(EUSOMA)	to	only	use	preoperative	MRI	in	a	subgroup	of	patients	with	a	diagnosis	of	 invasive	 lobular	 cancer,	 high	 risk	 patients,	 patients	 eligible	 for	 partial	 breast	irradiation,	 and	 patients	 with	 >1	 cm	 discrepancy	 in	 tumour	 size	 between	mammography	and	US	that	is	expected	to	impact	on	treatment	decision	(45).	Overall	 the	 preoperative	 imaging	 techniques	 outlined	 above	 provide	information	 on	 the	 location	 and	 size	 of	 the	 tumour	 preoperatively,	 but	 these	techniques	 have	 limited	 intraoperative	 capabilities.	 The	 correlation	 between	tumour	size	and	 location	on	preoperative	 imaging	and	histopathological	 analysis	remains	 suboptimal,	 thereby	 creating	 an	 element	 of	 uncertainty	 when	 deciding	how	much	 tissue	 is	 to	be	 excised	 intraoperatively.	Hence,	 surgeons	 can	only	use	this	information	as	a	rough	guide	to	define	the	margins	of	the	tumour.		 After	imaging	techniques	have	identified	a	suspicious	breast	lesion,	the	cells	within	that	lesion	are	sampled	to	confirm	the	diagnosis.	This	is	done	by	obtaining	a	core	 needle	 biopsy	 or	 fine-needle	 aspiration	 biopsy	 (FNAB),	 which	 is	 usually	performed	under	X-ray	or	US	guidance.				
1.3.2 Breast	cancer	surgery	Most	 women	 with	 breast	 cancer	 undergo	 some	 type	 of	 surgery	 to	 remove	 the	primary	tumour	and	lymph	nodes	in	the	axilla.	The	goal	of	surgical	treatment	is	to	achieve	 locoregional	control	and	to	stage	 the	disease	 to	plan	adjuvant	 treatment.	Over	 the	 last	 century	breast	 cancer	 surgery	has	 significantly	 changed	by	moving	from	radical	to	a	more	conservative	intervention.	The	main	types	of	surgery	to	the	breast	and	axilla	are	described	below.			
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1.3.2.1 Surgery	to	the	breast	During	most	of	 the	19th	 and	20th	 century	breast	 cancer	patients	were	 treated	by	complete	removal	of	the	breast,	a	procedure	known	as	mastectomy.	In	the	time	of	Halsted	 and	 colleagues,	 around	 the	 start	 of	 the	 20th	 century,	 the	 radical	mastectomy	was	the	gold	standard	of	treatment	(46,47).	This	procedure	involved	removal	of	 the	breast,	pectoralis	muscles	and	axillary	and	supraclavicular	 lymph	nodes,	and	had	severe	mutilating	effects	on	patients	in	terms	of	functional	outcome	and	cosmesis.	Due	to	an	improved	understanding	of	the	lymphatic	anatomy	and	its	role	in	the	dissemination	of	tumour	cells,	and	advancements	in	the	development	of	radiotherapy,	 less	 extensive	 forms	 of	 breast	 surgery	were	 developed	 (48).	 	 This	included	 the	 modified	 radical	 mastectomy	 (MRM),	 a	 procedure	 similar	 to	 the	radical	mastectomy,	but	without	removal	of	the	pectoralis	major	muscle.	An	early	study	found	similar	OS	rates	for	MRM	compared	to	radical	mastectomy,	indicating	that	 less	 extensive	 surgery	 could	 be	 equally	 effective	 (49).	 This	 finding	 was	confirmed	 in	 the	 prospective	 randomised	National	 Surgical	 Adjuvant	 Breast	 and	Bowel	Project	trial	(NSABP	B-04)	(50).	In	this	study	patients	were	randomised	to	radical	mastectomy	or	total	mastectomy	(removal	of	the	breast	and	pectoral	fascia	without	removal	of	the	pectoral	muscles)	plus	radiotherapy.	DFS	and	OS	between	both	groups	were	found	to	be	similar;	this	was	true	for	node-negative	patients	as	well	as	node-positive	patients.		 The	observation	that	less	radical	surgery	could	provide	similar	oncological	outcomes	 lead	 to	 the	 revolutionising	development	of	BCS	 combined	with	whole-breast	radiotherapy	for	patients	with	early	stage	breast	cancer,	which	is	now	the	treatment	of	choice	in	this	group	of	patients.	The	aim	of	BCS,	also	called	wide	local	excision	(WLE)	or	lumpectomy,	is	to	remove	the	primary	tumour	while	conserving	as	 much	 healthy	 breast	 tissue	 as	 possible	 to	 provide	 a	 good	 cosmetic	 outcome,	
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minimise	 physical	 trauma	 and	 expedite	 recovery.	 A	 randomised	 controlled	 trial	performed	by	Fisher	et	al.	showed	that	stage	I	and	II	breast	cancer	patients	treated	with	 BCS	 and	 postoperative	 radiotherapy	 after	 5-years	 had	 no	worse,	 or	 in	 fact	even	better	DFS	and	OS,	compared	to	patients	undergoing	total	mastectomy	(51).	The	 oncological	 safety	 of	 BCS	 in	 combination	 with	 radiotherapy	 for	 both	 early	invasive	 cancer	 and	 DCIS	 has	 been	 confirmed	 in	 large	 randomised	 controlled	studies	with	follow-up	periods	of	up	to	20	years	(52-62).	The	early	breast	cancer	trialists’	collaborative	group	(EBCTCG)	performed	a	meta-analysis	using	data	from	17	 randomised	 controlled	 trials	 that	 started	 before	 the	 year	 2000	 to	 assess	 the	recurrence	rate	and	breast	cancer	death	rate	from	BCS	and	adjuvant	radiotherapy	(63).	 They	 found	 a	 pooled	 5-year	 recurrence	 rate	 (locoregional	 or	 distant)	 of	10.6%	and	31.1%	for	node-negative	and	node-positive	patients	respectively;	the	5-year	breast	cancer	death	rate	was	4.6%	and	19.8%,	respectively.		Some	of	these	studies	provided	preliminary	evidence	that	involved	tumour	resection	 margins	 on	 postoperative	 histopathological	 analysis,	 i.e.	 tumour	 cells	close	or	at	the	margin	of	excision,	is	associated	with	an	increased	local	recurrence	(LR)	 rate	 if	 re-excision	 of	 additional	 tissue	 is	 not	 performed	 (53,55,61).	 An	 in	depth	description	of	tumour	resection	margins	and	its	relation	to	LR	is	provided	in	Section	1.4.	The	 choice	 between	 BCS	 with	 radiotherapy	 or	 mastectomy	 depends	 on	several	factors,	including	size	and	extent	of	the	tumour	(relative	to	the	size	of	the	breast),	 multifocality,	 multicentricity,	 the	 presence	 of	 diffuse	 carcinoma	 in	 situ,	patient	preference	and	the	male	breast	(64).	A	combination	of	an	increased	use	of	screening	mammography,	and	neoadjuvant	chemotherapy	and	endocrine	therapy	to	 downstage	 the	 size	 of	 the	 tumour,	 has	 significantly	 increased	 the	 number	 of	patients	suitable	for	BCS.	Currently	approximately	two-thirds	of	newly	diagnosed	
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breast	cancer	patients	 in	the	United	Kingdom	and	the	United	States	undergo	BCS	as	 initial	 treatment	 (65,66).	 The	 current	 standard	 management	 for	 impalpable	breast	 cancer	 in	 patients	 undergoing	 BCS	 is	 preoperative	 imaging	 and	 tumour	localized	 surgical	 excision	 using	 wire-guided	 localisation	 (WGL),	 radioguided	occult-lesion	 localisation	 (ROLL)	 or	 radioactive-seed	 localisation	 (RSL)	 (67).	Palpable	 breast	 tumours	 are	 excised	 based	 on	 the	 surgeon’s	 tactile	 and	 visible	assessment	 of	 the	 breast	 tissue	 during	 surgery.	 The	 excised	 WLE	 specimen	 is	oriented	intraoperatively	by	placing	sutures	and/or	metal	clips	and/or	ink	as	per	NHSBSP	 guidelines	 (8).	 However,	 the	 protocol	 for	 specimen	 orientation	 varies	between	different	centres	(68).	In	Guy’s	Hospital	the	following	protocol	is	used:	1	suture	 +	 clip	 =	 anterior,	 2	 sutures	 +	 clips	 =	 superior,	 3	 sutures	 +	 clips	 =	inferior/nipple.	 Intraoperative	 imaging	 or	 histopathology	 may	 be	 performed	 to	assess	tumour	resection	margins	as	discussed	in	more	detail	in	Section	1.5.	The	 tumour	 specimen	 is	 then	 sent	 for	 postoperative	 histopathological	analysis	to	obtain	decisive	information	on	tumour	size	and	grade,	receptor	status,	presence	of	 lymphovascular	 invasion,	and	tumour	margin	status	(8).	An	 in-depth	description	of	the	histopathological	procedure	for	assessing	tumour	margin	status	postoperatively	is	provided	in	Section	1.4.	Patients	with	positive	histological	margins,	 defined	 as	 tumour	 cells	 at	 the	inked	 resection	 edge	 on	 postoperative	 analysis,	 have	 approximately	 a	 two-fold	greater	risk	of	developing	a	LR	than	patients	with	negative	margins	(Section	1.4).	These	 patients	 are	 recommended	 to	 undergo	 re-excision	 surgery	 in	 order	 to	reduce	the	risk	for	LR	by	obtaining	clear	resection	margins.	This	involves	a	second	operation	in	the	form	of	a	re-excision	(a	procedure	where	a	further	slice	of	tissue	is	excised)	 or	 in	 some	 cases	 a	 mastectomy	 where	 there	 is	 extensive	 margin	involvement.		The	re-excised	tissue	undergoes	a	similar	postoperative	histological	
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examination	 procedure	 as	 the	WLE	 specimen	 to	 determine	 if	 all	 the	 cancer	 has	been	excised,	and	further	surgery	is	required	if	the	initial	re-excision	fails	to	obtain	clear	margins.	What	constitutes	an	adequate	negative	tumour	resection	margin	is	currently	the	subject	of	intense	debate	as	discussed	in	more	detail	in	Section	1.4.1	and	 Section	 1.4.2,	 and	 therefore	 the	 treatment	 strategy	 of	 patients	 with	 close	margins	(i.e.	tumour	cells	within	a	certain	distance	from	the	inked	resection	edge)	varies	per	country	and	treatment	centre.			Mastectomies	are	generally	performed	in	patients	that	are	not	suitable	for	BCS,	 including	 patients	 with	 a	 large	 tumour	 (particularly	 in	 women	 with	 small	breasts),	 a	 centrally	 located	 tumour,	 multifocal	 disease	 or	 associated	 extensive	DCIS,	or	in	patients	where	initial	BCS	along	with	one	or	more	re-excisions	has	not	completely	 removed	 the	 cancer.	 Breast	 reconstruction	 can	 be	 carried	 out	 if	clinically	indicated	and	as	per	patient’s	preference.	The	options	include	immediate	versus	 delayed,	 and	 prosthetic	 versus	 autologous	 reconstruction.	 Each	 type	 of	mastectomy	encompasses	the	removal	of	virtually	all	breast	tissue,	and	therefore	positive	tumour	margins	resulting	from	incomplete	removal	of	the	tumour	rarely	occur.			
1.3.2.2 Surgery	to	the	axilla	The	 lymphatic	 system	of	 the	breast	predominantly	drains	 to	 lymph	nodes	 in	 the	axilla	(69),	making	the	axilla	one	of	the	main	routes	for	breast	cancer	metastasis.	Axillary	 lymph	 node	 status	 (positive	 or	 negative)	 and	 the	 number	 of	 involved	lymph	nodes	are,	together	with	the	characteristics	of	the	primary	tumour,	the	most	important	 prognostic	 indicators	 in	 breast	 cancer,	 and	 determine	 what	 type	 of	adjuvant	 treatment	 is	 warranted	 (70).	 There	 are	 two	 main	 types	 of	 axillary	
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surgery:	 axillary	 lymph	node	dissection	 (ALND)	 and	 sentinel	 lymph	node	biopsy	(SLNB).			 ALND	 has	 been	 the	 standard	 approach	 for	 axillary	 nodal	 staging,	 and	depending	 on	 the	 anatomic	 relationship	 of	 the	 nodes	 to	 the	 pectoralis	 minor	muscle,	involves	dissection	of	all	lymph	nodes	in	axillary	level	1,	2	or	3	(64).	ALND	causes	 both	 early	 and	 late	 morbidities	 for	 the	 patient,	 with	 complications	 that	include	 pain,	 numbness,	 limited	 shoulder	 movement,	 and	 breast-cancer	 related	lymphedema	(71,72).	The	latter	can	affect	manual	dexterity	and	cause	significant	morbidity.	Moreover,	only	25	–	30%	of	women	with	early	breast	cancer	are	lymph	node	positive	(71,73),	so	most	women	who	previously	routinely	underwent	ALND	were	 exposed	 to	 the	 complications	 of	 this	 procedure,	with	no	 associated	 clinical	benefit.	In	light	of	this,	and	the	finding	that	lymphatic	spread	of	breast	cancer	cells	to	 the	 axilla	 appears	 to	 follow	 a	 regular	 pattern	 (74,75),	 a	 more	 conservative	approach	 to	 stage	 the	 axilla	 in	 the	 form	 of	 a	 SLNB	was	 developed	 (76,77).	 The	sentinel	 lymph	 node	 (SLN)	 is	 defined	 as	 the	 node	 receiving	 direct	 lymphatic	drainage	 from	the	 tumour,	and	 therefore	 is	most	 likely	 to	harbour	cancer	cells	 if	the	primary	breast	tumour	has	metastasised.	To	identify	SLNs,	a	radioactive	tracer,	blue	dye	or	both	are	 injected	 locally	 in	 the	breast,	 and	after	accumulation	of	 the	tracers,	 the	 surgeon	 uses	 a	 gamma	 probe	 (a	 handheld	 scintillation	 counter	detecting	 gamma	 photons)	 and/or	 the	 blue	 discolouration	 to	 locate	 the	 SLN.	 By	removing	 only	 a	 limited	number	 of	 lymph	nodes,	 SLNB	 significantly	 reduces	 the	morbidity	 associated	 with	 ALND,	 while	 DFS	 and	 OS	 have	 been	 shown	 to	 be	equivalent	 (78,79).	 SLNB	 is	 now	 the	 standard	 method	 for	 staging	 the	 axilla	 in	clinically	and	radiologically	node	negative	breast	cancer	patients.	McMasters	et	al.	performed	 a	 large	 clinical	 study	 to	 identify	 the	 optimal	 technique	 for	 SLNB,	 and	
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found	that	 the	combined	technique	of	radioisotope	and	blue	dye	was	superior	 to	each	standalone	technique	in	terms	of	 false-negative	rates,	with	a	non-significant	difference	in	detection	rate	(80).	In	the	United	Kingdom	the	combined	technique	is	recommended	 as	 per	 National	 Institute	 for	 Health	 and	 Care	 Excellence	 (NICE)	guidelines	(81).		 The	 excised	 SLNs	 (together	 with	 the	 primary	 tumour)	 are	 sent	 for	postoperative	histopathological	 analysis	 to	determine	 if	 the	 SLN	 is	 involved,	 and	results	are	obtained	several	days	after	 the	procedure.	 In	addition	 to	 the	analysis	performed	 postoperatively,	 some	 centres	 use	 intraoperative	 histological,	cytological	or	molecular	techniques	to	assess	if	the	removed	SLNs	contain	tumour	cells	 (82).	 Based	 on	 the	 postoperative	 histopathological	 results,	 lymph	 node	involvement	is	staged	according	to	the	American	Joint	Committee	on	Cancer	(AJCC)	TNM	system	(83).	Isolated	tumour	cells	(ITCs)	are	defined	as	single	tumour	cells	or	a	cluster	of	cells	<0.2	mm,	micrometastases	as	tumour	deposits	>0.2	mm	and	≤2.0	mm,	 and	macrometastases	 as	 tumour	 deposits	 >2.0	mm.	 Patients	 with	 ITCs	 are	considered	 lymph	 node	 negative,	 while	 those	 with	 micrometastases	 and	macrometastases	 lymph	 node	 positive.	 Previous	 guidelines	 would	 have	recommended	patients	with	positive	SLNs	 to	undergo	 further	axillary	 surgery	 in	the	 form	 of	 an	ALND	 (81,84).	However,	 the	 preferred	 treatment	 in	 SLN	 positive	patients	is	currently	subject	of	 intense	debate	based	on	evidence	from	the	Z0011	trial	(85)	and	the	AMAROS	trial	(86).	The	Z0011	study	showed	that	patients	with	clinical	T1	and	T2	tumours	and	a	positive	SLN	undergoing	BCS	with	whole-breast	radiotherapy	and	systemic	therapy	do	not	benefit	from	additional	ALND	in	terms	of	 DFS	 and	OS.	 The	 AMAROS	 trial	 demonstrated	 similar	 DFS	 and	OS	 in	 T1	 –	 T2	invasive	breast	cancer	patients	with	SLN	metastases	treated	with	ALND	or	axillary	radiotherapy	 without	 ALND,	 respectively.	 Although	 both	 studies	 have	 some	
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important	 limitations	which	 fall	 outside	 the	 scope	 of	 this	 thesis,	 its	 results	 have	changed	 clinical	 practice,	 and	 the	 option	 to	 avoid	 ALND	 in	 a	 selective	 group	 of	patients	with	low	to	moderate	axillary	tumour	burden	should	now	form	part	of	the	discussion	 between	 clinician	 and	 patient	 to	 decide	 on	 the	 optimal	 treatment	strategy	(87).		
1.3.3 Radiotherapy	Radiotherapy	can	be	administered	to	the	breast	and/or	lymph	nodes	in	the	axilla	and	supraclavicular	fossa.	In	this	section	the	value	of	radiotherapy	in	treating	BCS	patients	will	be	discussed	with	a	specific	focus	on	its	effects	in	respect	to	tumour	margin	 status.	 The	 clinical	 and	 oncological	 importance	 of	 radiotherapy	 in	mastectomy	patients	and	patients	with	nodal	disease	will	not	be	described	as	this	falls	outside	the	scope	of	this	thesis.		Several	 large	 randomised	 trials	 have	 demonstrated	 the	 importance	 of	whole-breast	 external	 beam	 radiotherapy	 (EBRT)	 in	 achieving	 acceptable	oncological	outcomes	in	invasive	and	in	situ	breast	cancer	patients	undergoing	BCS	(52,54,59,62).		The	meta-analysis	performed	by	the	EBCTCG	group	found	that	the	10-year	breast	cancer	recurrence	(locoregional	or	distant)	was	roughly	50%	lower	in	 invasive	 breast	 cancer	 patients	 treated	 with	 BCS	 and	 whole-breast	 EBRT	compared	to	BCS	without	radiotherapy,	while	15-year	breast	cancer	mortality	was	reduced	by	 a	 sixth	 (63).	A	 recently	 conducted	meta-analysis	 comparing	BCS	 and	whole-breast	EBRT	to	BCS	alone	in	patients	with	DCIS	also	found	a	50%	reduction	in	LR	rate	after	10-years	(88).	Breast	cancer	mortality	did	not	significantly	differ	between	the	two	groups.		The	 EORTC	 trial	 investigated	 the	 impact	 of	 a	 complementary	 boost	radiation	dose	to	the	site	of	local	excision	on	LR	and	OS	in	early	stage	breast	cancer	
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patients	with	microscopically	 negative	 tumour	margins	 after	 BCS	 (89).	 Although	patients	receiving	a	boost	had	an	improved	LR,	there	was	no	difference	in	OS	while	a	significantly	higher	number	of	patients	had	severe	 fibrosis.	Boost	 irradiation	 is	therefore	only	recommended	in	invasive	breast	cancer	patients	with	a	high-risk	of	LR,	i.e.	patients	with	high	tumour	grade,	<50	years	of	age,	extensive	DCIS,	vascular	invasion	or	positive	or	close	margins	(87).	A	 meta-analysis	 by	 Houssami	 et	 al.	 showed	 that	 patients	 with	 invasive	cancer	and	microscopically	positive	margins	have	a	higher	risk	of	LR	compared	to	patients	with	negative	margins,	regardless	of	whether	whole-breast	EBRT	is	given	(90).	Besides,	the	use	of	a	higher	boost	(18	–	26	Gy)	instead	of	the	standard	10	Gy	also	does	not	seem	to	improve	LR	or	OS	(91,92).	A	recent	meta-analysis	by	Nilsson	
et	al.	showed	that	in	DCIS	patients	with	positive	margins	a	boost	dose	could	reduce	the	risk	of	LR	compared	to	no	boost	(93).	However,	the	authors	emphasise	that	the	level	 of	 evidence	 for	 this	 observation	was	 very	 low	due	 to	 a	 lack	 of	 randomised	controlled	trial	data.		Thus,	based	on	current	evidence	whole-breast	EBRT	with	or	without	a	boost	dose	cannot	 replace	 the	need	 for	 re-excision	surgery	 to	mitigate	the	negative	oncological	outcome	of	positive	margins.		Since	 early	 2000	 a	 more	 localised	 type	 of	 breast	 radiotherapy	 has	 been	developed	in	the	form	of	accelerated	partial	breast	irradiation	(APBI),	a	technique	in	 which	 only	 the	 original	 tumour	 site	 is	 targeted.	 APBI	 can	 be	 delivered	 using	several	 modalities,	 including	 intraoperative	 radiotherapy	 (IORT),	 multicatheter	interstitial	 brachytherapy,	 intracavitary	 brachytherapy	 and	 EBRT	 (94).	 IORT	 is	administered	in	a	single	session	at	the	time	of	surgery,	and	is	designed	to	provide	a	large	radiation	dose	 to	a	 target	 tissue,	while	avoiding	 irradiation	 to	 intrathoracic	structures	such	heart,	lung	and	oesophagus	(95).	Since	the	definitive	treatment	is	completed	at	the	time	of	surgery	or	shortly	afterwards,	IORT	has	the	potential	to	
34	
significantly	 reduce	 the	 number	 of	 treatment	 visits,	 thereby	 reducing	 the	substantial	 burden	 on	 women	 from	 approximately	 6	 weeks	 of	 conventional	postoperative	radiotherapy.			 To	date	only	two	randomised	controlled	trials	have	compared	whole-breast	EBRT	 with	 IORT	 in	 patients	 undergoing	 BCS:	 the	 TARGIT-A	 trial	 (96)	 and	 the	ELIOT	 trial	 (97).	 The	TARGIT-A	 trial	 recruited	 a	 total	 of	 3451	 early-stage	breast	cancer	 patients	 aged	 45	 years	 and	 older	 with	 a	 diagnosis	 of	 invasive	 ductal	carcinoma.	 Patients	 in	 the	 TARGIT	 group	 received	 a	 single	 treatment	 of	radiotherapy	at	the	time	of	surgery	(pre-pathology)	or	after	surgery	by	re-opening	the	 wound	 (post-pathology);	 whole-breast	 EBRT	 was	 given	 if	 the	 postoperative	histopathology	report	showed	adverse	features	(tumour	margin	<1	mm,	extensive	
in	situ	disease,	or	unexpected	ILC).	The	5-year	risk	for	LR	was	significantly	higher	in	the	TARGIT	group	compared	to	the	EBRT	group	(3.3%	versus	1.3%,	p	=	0.042).	Breast	cancer	mortality	was	much	the	same	between	groups	(2.6%	versus	1.9,	p	=	0.56),	 while	 non-breast	 cancer	 mortality	 was	 significantly	 lower	 (1.4%	 versus	3.5%,	 p	 =	 0.0086).	 The	 latter	 was	 mainly	 attributed	 to	 fewer	 deaths	 from	cardiovascular	 causes	 and	 other	 cancers.	 An	 individual	 comparison	 of	 the	 pre-pathology	TARGIT	arm	and	post-pathology	TARGIT	arm	with	the	EBRT	group	still	showed	a	higher	LR	rate	for	both	forms	of	IORT	treatment,	although	the	difference	in	 the	 prepathotology	 arm	 became	 non-significant	 and	 within	 the	 prespecified	2.5%	 inferiority	 margin.	 	 This	 highlights	 the	 potential	 importance	 of	 delivering	IORT	at	the	time	of	initial	surgery	to	maximise	treatment	efficacy.	The	ELIOT	trial	recruited	a	total	of	1305	patients	aged	between	48	and	75	years	with	early-stage	breast	 cancer	 of	 ≤2.5	 cm	 in	 size.	 IORT	 was	 administered	 intraoperatively	 as	 a	single	 dose	 of	 radiotherapy	with	 electrons.	 A	 significantly	 higher	 5-year	 LR	 rate	
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was	found	in	the	IORT	arm	compared	to	the	EBRT	arm	(p<0.001);	OR	did	not	differ	between	groups.		The	 results	 of	 the	 TARGIT-A	 trial	 and	 ELIOT	 trial	 outlined	 above	 were	considered	 suboptimal	 in	 terms	 of	 oncological	 safety.	 Long-term	 results	 from	prospective	randomised	studies	of	other	APBI	techniques	are	yet	to	be	published.	The	ASTRO	and	GEC-ESTRO	guidelines	therefore	currently	only	accept	the	use	of	APBI	outside	of	a	clinical	trial	in	a	specific	group	of	patients	with	a	low	risk	for	LR	(98,99)		
1.3.4 Systemic	therapy	Systematic	 therapy	 in	 the	 form	 of	 chemotherapy,	 endocrine	 therapy	 and	biologically	 targeted	 therapy	 has	 contributed	 significantly	 to	 the	 reduction	 in	recurrence	 rate	 and	 breast	 cancer	mortality	 observed	 over	 the	 last	 two	 decades	(100).	Systemic	therapies	can	be	a	combination	of	different	approaches	and	can	be	administered	 in	 conjunction	 to	 surgery	 and/or	 radiotherapy	 in	 an	 adjuvant	 or	neoadjuvant	 setting.	 The	 decision	 to	 recommend	 adjuvant	 systemic	 therapy	depends	 on	 tumour	 size	 and	 grade,	 number	 of	 involved	 axillary	 lymph	 nodes,	hormone-receptor	 status	 and	 HER2	 expression	 (64).	 In	 the	 adjuvant	 setting	 the	main	 aim	 of	 systemic	 treatment	 is	 to	 control	 any	 occult	 disease,	 reduce	 the	recurrence	 rate,	 and	 improve	 long-term	 survival	 (101).	 Neoadjuvant	 systemic	therapy	 is	used	 in	early-stage	breast	cancer	patients	 to	 increase	the	potential	 for	BCS	by	downstaging	the	tumour,	thus	avoiding	a	mastectomy.	It	is	also	used	as	first	line	of	 treatment	 in	patients	with	unresectable,	 locally	advanced	breast	cancer	to	reduce	 the	 size	 of	 the	 tumour	 in	 order	 to	 enable	 surgery.	 However,	 this	 section	focuses	only	on	the	established	systematic	treatments	used	in	early	breast	cancer	patients.		
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1.3.4.1 Chemotherapy	Adjuvant	chemotherapy	prolongs	DFS	and	OS	in	patients	with	early	breast	cancer.	A	 meta-analysis	 by	 the	 EBCTCG	 found	 that	 standard	 CMF	 (6	 cycles	 of	cyclophosphamide,	methotrexate	and	5-fluorouracil	given	4	weekly)	and	standard	4AC	(4	cycles	of	doxorubicin	and	cyclophosphamide	given	intravenous	3-weekly)	were	 equally	 effective,	 providing	 a	 relative	 reduction	 in	 breast	 cancer	mortality	rate	of	20	–	25%	(102).	Regimens	with	a	significantly	 lower	dose	per	cycle	were	found	to	be	somewhat	less	effective,	while	by	adding	a	taxane	to	4AC	or	by	giving	a	substantially	 greater	dose	of	non-taxane	 chemotherapy	 (CAF	and	CEF),	 a	 further	proportional	reduction	in	breast	cancer	mortality	of	15	–	20%	could	be	obtained.	The	 EBCTCG	 concluded	 that,	 on	 average,	 the	 use	 of	 polychemotherapy	 reduces	breast	cancer	mortality	by	about	a	third.	However,	chemotherapeutic	agents	may	cause	 significant	 short	 and	 long-term	 side	 effects	 including	 nausea,	 alopecia,	myelosuppression,	 infertility	 and	 cardiotoxicity.	 Hence,	 the	 efficacy	 of	 using	polychemotherapy	 regimens	 needs	 to	 be	 balanced	 against	 the	 effects	 of	 the	associated	toxicity	on	quality	of	life	and	survival	(103).		 Neoadjuvant	 chemotherapy	 (NAC)	has	been	 shown	 to	be	equally	 effective	as	adjuvant	chemotherapy	for	early	breast	cancer	in	terms	of	OS	(104).	The	main	advantage	of	NAC	over	adjuvant	chemotherapy	is	that	it	enables	more	patients	to	be	treated	with	BCS,	avoiding	a	mastectomy	in	approximately	25%	of	patients.	An	additional	 advantage	 is	 that	 it	 facilitates	monitoring	 of	 tumour	 response,	 and	 in	tumours	that	are	not	chemosensitive	the	treatment	regimen	can	be	altered,	which	could	save	patients	from	unnecessary	toxic-side	effects.			
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1.3.4.2 Endocrine	therapy	Endocrine	 therapy	 aims	 to	 prevent	 the	 growth-stimulatory	 effects	 of	 oestrogen	signalling	 in	 patients	 with	 ER+	 breast	 cancer,	 either	 by	 blocking	 the	 ER	 or	 by	reducing	 the	 production	 of	 oestrogen	 (64).	 Tamoxifen	 acts	 as	 an	 ER	 antagonist,	thereby	inhibiting	the	expression	of	many	oestrogen-regulated	genes	required	for	tumour	growth	(105).	Tamoxifen	has	been	the	standard	treatment	 in	ER+	breast	cancer	 patients	 based	 on	 evidence	 from	 early-randomised	 controlled	 trials	showing	a	significant	prolongation	of	DFS	in	ER+	patients	treated	with	tamoxifen	(106,107).	A	meta-analysis	performed	by	the	EBCTCG	in	2005	showed	that	5	years	of	adjuvant	tamoxifen	compared	to	no	tamoxifen	in	ER+	early	stage	breast	cancer	decreases	breast	cancer	recurrence	and	breast	cancer	mortality	by	approximately	25%	(101).	This	 finding	was	 largely	 irrespective	of	 the	use	of	chemotherapy,	age	or	tumour	characteristics.	Although	rare,	severe	toxicities	from	tamoxifen	include	an	 increased	 risk	 of	 endometrial	 cancer	 and	 thromboembolism;	 more	 common	side	effects	include	hot	flushes	and	gynaecological	complications	(108).	Aromatase	 inhibitors	 (AIs)	 have	 emerged	 as	 the	 treatment	 of	 choice	 in	postmenopausal	 ER+	 breast	 cancer	 patients.	 AIs	 reduce	 the	 concentration	 of	oestrogen	by	binding	to	the	aromatase	enzyme,	thereby	preventing	the	conversion	of	androgens	to	oestrogen.	This	hinders	stimulation	of	ER+	tumour	cells,	especially	in	 postmenopausal	 women	 where	 oestrogen	 is	 predominantly	 produced	 by	 the	peripheral	 tissues.	 A	 recent	 meta-analysis	 comparing	 AI-based	 treatments	 with	tamoxifen	 in	 postmenopausal	women	with	 ER+	 early	 breast	 cancer	 showed	 that	AIs	 significantly	 reduce	 recurrence	 rate,	 either	 as	 5-year	 monotherapy,	 2-year	treatment	followed	by	3-years	of	tamoxifen,	or	after	2-3	years	of	tamoxifen	(109).	The	 pooled	 data	 from	 the	 three	 treatment	 regimens	 combined	 showed	 that	 AI-based	 treatments	 significantly	 reduced	 recurrence	 rates	 (30%	 proportional	
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reduction)	and	breast	cancer	mortality	(15%	proportional	reduction)	compared	to	tamoxifen	 alone.	 The	 use	 of	 AIs	was	 associated	with	 fewer	 endometrial	 cancers,	but	 more	 bone	 fractures.	 Based	 on	 these	 findings	 current	 clinical	 guidelines	recommend	 that	AI-based	 therapy	 should	be	offered	 to	postmenopausal	women,	especially	those	at	high	risk	for	breast	cancer	recurrence	(110).		
1.3.4.3 Biologically	targeted	therapy	HER2	 is	 overexpressed	 in	 approximately	 20	 –	 30%	 of	 patients	 and	 its	overexpression	 is	 associated	 with	 a	 worse	 prognosis	 (64).	 Trastuzumab	 is	 a	humanized	monoclonal	antibody	targeting	the	extracellular	subdomain	IV	of	HER2,	thereby	 reducing	 tumour	 growth	 through	 several	 molecular	 mechanisms	 (111).	Studies	 have	 shown	 that	 1-year	 of	 adjuvant	 trastuzumab	 and	 chemotherapy	significantly	improves	DFS	and	OS	compared	to	patients	not	receiving	trastuzumab	(112-114).	Following	these	results,	1-year	of	trastuzumab	in	addition	to	adjuvant	chemotherapy	 has	 become	 the	 standard	 of	 care	 for	 patients	 with	 HER2+	 early-stage	breast	cancer.	Although	clinically	beneficial,	use	of	trastuzumab	is	associated	with	 an	 increased	 risk	of	 congestive	heart	 failure	 (115),	 and	 close	monitoring	of	cardiac	 function	 before	 and	 during	 the	 treatment	 period	 is	 therefore	 necessary	(81,87).		In	 the	 neoadjuvant	 setting,	 studies	 have	 evaluated	 dual	 anti-HER2+	blockage	therapies	using	trastuzumab	in	combination	with	lapatinib.	Lapatinib	is	a	small	tyrosine	kinase	inhibitor	that	binds	to	the	kinase	region	of	EGFR	and	HER2.	Dual	 blockage	 with	 lapatinib	 showed	 improved	 pathologic	 complete	 response	(pCR)	 compared	 to	 one	HER2+	 agent	 (116);	 early	 results	 from	 the	UK	EPHOS-B	trial	 even	 showed	pCR	 in	 a	 quarter	 of	 patients	within	 11	days	 of	 therapy	 (117).	However,	the	neoALTTO	trial	did	not	find	a	significant	improvement	in	OS	(118).	
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Dual	blockage	therapy	with	lapatinib	and	trastuzumab	in	the	neoadjuvant	setting	is	therefore	based	on	the	currently	available	evidence	is	not	recommended	(110).			
1.4 Tumour	resection	margins	For	over	20	years	BCS	has	been	the	standard	of	care	for	treatment	of	early	stage	breast	cancer	patients,	and	several	prospective	randomised	controlled	trials	have	demonstrated	 that	 BCS	 and	 whole-breast	 EBRT	 is	 equivalent	 to	 mastectomy	 in	terms	of	survival	(Section	1.3.2.1).	Obtaining	clear	resection	margins	is	important	in	BCS	as	incomplete	resection	of	the	tumour	is	associated	with	an	increased	risk	for	LR,	which	could	potentially	impact	on	OS	as	approximately	1	in	4	breast	cancer	patients	that	develop	a	LR	die	from	their	disease	(63).	However,	the	definition	of	a	clear	 tumour	margin	 is	still	 subject	of	debate.	Defining	the	optimal	margin	width	requires	a	balance	between	local	control	and	acceptable	cosmetic	outcome,	while	minimizing	re-excision	rates,	patient	discomfort	and	treatment	costs.		There	 is	global	consensus	that	patients	with	a	positive	histological	margin	after	BCS,	defined	as	tumour	cells	at	the	inked	resection	margin	on	postoperative	analysis,	 should	 undergo	 further	 surgery	 (re-excision	 or	mastectomy)	 to	 reduce	the	 risk	 for	 LR	 associated	 with	 positive	 margins.	 Houssami	 et	 al.	 showed	 in	 a	recent	 meta-analysis	 that	 for	 patients	 with	 early-stage	 invasive	 breast	 cancer	treated	 with	 BCS	 and	 whole-breast	 EBRT	 the	 odds	 ratio	 for	 LR	 was	 2.44	 (95%	confidence	interval	CI	1.97	–	3.03)	for	a	positive	margin	compared	with	a	negative	margin	of	tumour	cells	>0	mm	from	the	inked	resection	edge	(90).	The	increased	risk	 was	 not	 mitigated	 by	 favourable	 biology,	 delivery	 of	 systemic	 therapy	(endocrine	therapy,	chemotherapy,	biologic	therapy)	or	radiation	boost.	A	positive	resection	 margin	 in	 patients	 with	 DCIS	 who	 had	 BCS	 and	 radiotherapy	 is	 also	associated	with	an	increased	risk	for	LR.	A	meta-analysis	by	Wang	et	al.	and	Dunne	
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Guideline	 DCIS5	 Invasive	cancer	NCCN,	2016	(121)	 ≥1	mm	 No	tumour	on	ink	St.	Gallen,	2015	(122)4	 Not	specified1	 No	tumour	on	ink	ABS,	2015	(123)4	 ≥1	mm	 ≥1	mm	SSO-ASTRO,	2014	(124)	 Not	specified2	 No	tumour	on	ink3	NICE,	2009	(81)	 ≥2	mm	 Not	specified		NCCN:	National	Comprehensive	Cancer	Network,	ABS:	Association	of	Breast	Surgery,	SSO-ASTRO:	Society	of	Surgical	Oncology	–	American	Society	for	Radiation	Oncology.	NICE:	National	Institute	for	Health	and	Care	Excellence	1. 80%	of	panellists	felt	that	margins	should	be	greater	for	pure	DCIS	than	for	invasive	cancer,	but	no	recommendation	was	made	on	the	exact	margin	width			2. For	patients	with	pure	DCIS	SSO-ASTRO	recommends	 the	guidelines	 set	out	by	NCCN,	 i.e.	 ≥1	mm	3. This	 guideline	 does	 not	 apply	 to	 patients	 receiving	 neoadjuvant	 chemotherapy	 or	 APBI,	 or	patients	not	receiving	whole-breast	EBRT	4. No	details	are	provided	on	the	type	of	radiotherapy	or	systemic	therapy	to	which	the	guideline	applies	5. There	are	no	individual	guidelines	on	margin	width	for	pleomorphic	LCIS	due	to	 lack	of	data.	The	DCIS	guidelines	therefore	also	apply	to	pleomorphic	LCIS.			Secondly,	 the	 dilemma	 of	 margin	 evaluation	 is	 also	 a	 result	 of	 a	 lack	 of	standardization	 in	 the	 histopathological	 assessment	 of	 tumour	 margins,	 and	technical	 issues	 related	 to	 WLE	 specimen	 handling	 (both	 surgical	 and	pathological).	 WLE	 specimens	 are	 generally	 serial	 sliced	 or	 sliced	 in	 a	 cruciate	fashion	 (a	 method	 known	 as	 radial	 block	 examination);	 for	 both	 methods	additional	 shave	 margins	 may	 be	 taken	 (Figure	 1).	 The	 preferred	 technique	depends	 amongst	 other	 factors	 on	 the	 type	 of	 tumour,	 the	 tumour	 size	 and	location,	 the	 size	 of	 the	WLE	 specimen	 and	 the	 pathologist’s	 preference	 (8).	 All	methods	 have	 in	 common	 that	 the	margins	 assessed	 under	 the	microscope	 only	represent	 a	 fraction	 of	 the	 surface	 of	 the	 WLE	 specimen,	 and	 a	 calculation	 by	Tucker	 et	 al.	 showed	 that	 the	 percentage	 of	 the	WLE	 surface	 area	 available	 for	microscopic	evaluation	ranges	between	<1%	and	12%	depending	on	 the	method	used	 (125).	Thus,	 a	negative	margin	on	one	single	 slide	 is	not	 representative	 for	the	 margin	 status	 of	 the	 entire	 specimen.	 Besides,	 studies	 have	 shown	 that	 the	
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margin	 status	 and	 number	 of	 involved	margins	 differ	 depending	 on	 the	margin	evaluation	method	used	(126-128).			
	Figure	1:	Histopathological	techniques	for	assessing	tumour	margins	of	wide	local	excision	 specimens.	 Serial	 slicing	 in	 (A)	 the	 medial-lateral	 plane	 and	 (B)	 the	superficial-deep	plane.	After	serial	slicing	blocks	are	taken	from	suspicious	areas,	and	examined	for	nearest	margins	and	tumour	size.	(C)	Radial	block	examination.	The	specimen	is	sampled	as	four	blocks	taken	in	the	medial-lateral	and	superior-inferior	direction,	and	the	margin	distance	is	then	measured	for	each	block.	TSR	=	tumour	 superior	 radial;	 LR	 =	 lateral	 radial;	 TL	 =	 tumour	 lateral;	 TIR	 =	 tumour	inferior	 radial;	 TM	 =	 tumour	 medial;	 MR	 =	 medial	 radial	 (D)	 Shaved	 margin	examination.	 This	 technique	 is	 often	 performed	 in	 addition	 to	 serial	 slicing	 or	radial	 block	 examination.	 SS	 =	 superior	 shave;	 SLS	 =	 superolateral	 shave;	 LS	 =	lateral	 shave;	 ILS	 =	 inferolateral	 shave;	 IS	 =	 inferior	 shave;	 IMS	 =	 inferomedial	shave;	MS	=	medial	shave;	SMS	=	superomedial	shave.	Image	was	reproduced	from	
(8)	with	kind	permission	from	the	Royal	College	of	Pathologists.  	Technical	 specimen	 handling	 issues	 include	 inaccuracies	 in	 microscopic	 margin	evaluation	 due	 to	 a	 lack	 of	 clarity	 between	 surgeons	 and	 pathologists	 regarding	WLE	specimen	orientation	(129),	deformation	of	the	specimen	post-excision	which	decreases	 the	 tumour-free	 margin	 distance	 (130,131),	 and	 margin	 assessment	errors	due	to	difficulties	in	correctly	identifying	the	different	ink	colours	used	for	orientation	 (132).	 All	 of	 the	 above	 factors	 potentially	 influence	 the	 accuracy	 of	margin	evaluation,	and	limit	the	ability	to	identify	the	optimal	margin	width	from	
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comparing	data	on	the	association	between	margin	distance	and	LR	rates.	Lastly,	the	 lack	 of	 agreement	 in	 optimal	 margin	 width	 is	 due	 to	 differences	 in	interpretation	 of	 the	 available	 data	 from	 the	 studies	 published	 to	 date.	 This	obvious	reason	for	disagreements	in	margin	definitions	is	partially	a	consequence	of	the	aforementioned	two	points,	and	the	next	section	provides	a	clear	example	of	how	differences	in	data	interpretation	have	affected	current	guidelines	on	tumour	resection	margins.					
1.4.1 Views	on	optimal	margin	width	for	invasive	cancer	A	 survey	 amongst	 breast	 cancer	 clinicians	 in	 the	United	Kingdom	 (133)	 and	 the	United	 States	 (134)	 showed	 substantial	 variations	 in	 the	definition	of	 a	 negative	margin	for	invasive	cancer,	ranging	from	>0	mm	(called	‘no	tumour	on	ink’,	i.e.	no	tumour	 cells	 at	 the	 inked	 resection	margin)	 to	 >5	mm.	 The	 pivotal	 study	 in	 the	discussion	 on	 the	 optimal	 margin	 width	 in	 patients	 with	 invasive	 cancer	 is	 the	meta-analysis	by	Houssami	et	al.	(90).	This	study	aimed	to	systematically	examine	the	effect	of	margin	width	on	LR.	A	total	of	32,263	subjects	from	33	studies	were	included;	31	of	these	studies	were	retrospective.	Negative	margins	were	grouped	as	 tumour	 cells	 at	 >0	mm,	 1	mm,	 2	mm	 and	 5	mm	 respectively,	 and	 ORs	were	calculated	 with	 the	 1	mm	 group	 as	 referent.	 No	 statistical	 significant	 difference	was	found	between	margin	width	and	LR	rate	(p	=	0.12	for	>0	mm	versus	1	mm	versus	 2	mm	 versus	 5	mm,	 and	 p	 =	 0.90	 for	 1	mm,	 versus	 2	mm	 versus	 5	mm,	respectively).	 This	 finding	 in	 combination	 with	 the	 excellent	 10-year	 LR	 in	 the	NSABP	clinical	trials	that	used	narrow	margin	widths	(135),	and	the	difficulty	for	pathologists	 to	 reproducibly	 distinguish	 margin	 widths	 of	 >0	 mm	 from	 1	 mm,	formed	the	key	arguments	for	the	SSO-ASTRO	panel	to	recommend	‘no	tumour	on	ink’	as	an	acceptable	margin	width	(124,136)	(Table	1).	However,	opponents	of	the	
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SSO-ASTRO	 guideline	 argue	 that	 the	meta-analysis	 shows	 that	 negative	margins	have	a	statistically	significant	lower	risk	of	LR	than	close	margins	(OR	=	0.57,	p	<	0.001),	and	although	not	statistically	significant	there	is	a	trend	in	reduced	LR	rate	with	increased	margin	distance	(OR	1	mm	=	1,	OR	2	mm	=	0.91,	OR	5	mm	=	0.77,	p	=	0.9).	Instead	of	evidence	to	support	‘no	tumour	on	ink’	they	state	that	the	optimal	margin	width	based	on	the	results	of	 the	meta-analysis	 is	1	mm	(137).	This	 is	 in	line	with	a	recent	study	which	also	supported	an	optimal	margin	width	of	1	mm	for	invasive	disease	(138).	The	opponents	of	the	‘no	tumour	on	ink’	margin	definition	also	emphasise	the	weaknesses	of	the	meta-analysis	in	terms	of	study	design.	The	main	points	of	critique	include	that	instead	of	 ‘no	tumour	on	ink’	a	margin	of	1	mm	was	used	as	the	 referent	 to	 assess	 the	 relation	 between	 margin	 width	 and	 LR,	 and	 that	 the	multivariate	 analysis	 did	 not	 correct	 for	 some	 important	 covariates	 associated	with	 an	 increased	 risk	 for	 LR	 such	 as	 tumour	 stage	 and	 grade,	 HER2	 receptor	status,	radiation	dose	and	lymphovascular	invasion	(139).	The	former	means	that	the	data	does	not	 support	any	 claims	on	 the	oncological	 safety	of	 ‘no	 tumour	on	ink’.	 To	 adequately	 investigate	 the	 safety	 of	 ‘no	 tumour	 on	 ink’	 this	would	 have	required	choosing	a	hazard	ratio	of	1	as	the	standard	for	 ‘no	tumour	on	 ink’,	but	Houssami	and	colleagues	state	that	this	was	not	possible	due	to	the	small	number	of	studies	employing	the	 ‘no	tumour	on	ink’	definition	and	because	the	statistical	modelling	was	constrained	by	the	variability	in	negative	margin	definitions	(140).	The	same	paper	also	notes	that	whether	a	margin	of	‘no	ink	on	tumour’	is	adequate	for	ILCs,	TNBCs,	patients	of	young	age	or	with	an	extensive	intraductal	component	could	 not	 be	 examined	 as	 this	 information	 was	 not	 provided	 in	 the	majority	 of	studies	included	in	the	analysis	(140).	Thus,	no	recommendations	can	be	made	on	the	optimum	margin	for	patients	with	these	characteristics.	Another	limitation	of	
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the	meta-analysis	 is	 that	none	of	 the	33	studies	 included	for	analysis	had	central	pathology	review	of	margin	status.	A	central	pathologist	review	in	the	NSABP-06	study	 only	 confirmed	 ‘tumour	 on	 ink’	 in	 31%	 of	 the	WLE	 specimens	 that	 were	assessed	as	such	by	the	local	histopathologist,	indicating	that	inter-rater	variability	between	pathologists	can	introduce	inaccuracies	in	assessing	the	relation	between	margin	width	and	LR	(141).		In	the	last	few	years	there	have	not	been	any	papers	published	advocating	the	need	 for	margins	wider	 than	1	mm	in	patients	with	 invasive	disease,	neither	are	 wider	 margins	 recommended	 by	 the	 national,	 European	 or	 American	guidelines	used	to	date	(Table	1).	Thus,	although	the	debate	about	the	adequacy	of	‘no	tumour	on	ink’	and	≥1	mm	in	terms	of	oncological	outcome	is	far	from	over,	for	now	 there	 seems	 to	 be	 agreement	 that	 surgical	 treatment	 in	 the	 form	 of	 a	 re-excision	can	safely	be	avoided	for	margins	>1	mm	in	patients	with	invasive	cancer	treated	with	BCS	and	radiotherapy.		
1.4.2 Views	on	optimal	margin	width	for	DCIS	To	 date	 there	 is	 also	 no	 consensus	 about	 what	 constitutes	 a	 negative	 resection	margin	in	patients	with	DCIS,	and	the	definition	of	a	negative	margin	ranges	from	‘no	 tumour	 on	 ink’	 to	 more	 than	 a	 10	 mm	 free	 margin.	 A	 survey	 amongst	 388	American	 surgeons	with	an	 interest	 in	breast	 cancer	performed	 in	2009	showed	that	22%	would	accept	a	margin	of	1	mm	for	DCIS;	52%	a	margin	of	2	mm;	10%	a	margin	of	5mm;	and	only	4%	would	accept	a	margin	of	10	mm	(142).	‘No	tumour	on	 ink’	 was	 not	 included	 in	 the	 questionnaire.	 A	 recent	 survey	 amongst	 breast	units	 in	 the	United	Kingdom	 found	 that	 5	 of	 the	 76	 units	 (6.6%)	 considered	 ‘no	tumour	 on	 ink’	 as	 an	 acceptable	 margin;	 17	 units	 (22.6%)	 accepted	 a	 1	 mm	margin;	 28	 units	 (36.8%)	 used	 2	mm;	 and	 in	 only	 1	 unit	 (1.3%)	 5	mm	was	 the	
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acceptable	margin	(143).	Note	that	 in	both	surveys	the	majority	choose	2	mm	as	adequate	margin;	this	is	different	from	the	≥1	mm	margin	width	recommended	by	the	most	recent	NCCN	and	ABS	guidelines	(Table	1).	There	 are	 some	major	 differences	 between	DCIS	 and	 invasive	 cancer	 that	play	 an	 important	 role	 in	 the	 discussion	 about	 an	 adequate	 margin	 of	 excision,	including	the	clinical	features,	extent	and	spatial	distribution	of	DCIS,	and	the	fact	that	not	all	patients	receive	systemic	adjuvant	therapy	and	radiotherapy	in	routine	practice.	The	majority	of	DCIS	presents	as	clinically	impalpable	lesions,	often	with	microcalcifications,	which	may	be	more	extensive	than	determined	preoperatively	or	intraoperatively	(Section	1.3.1).	An	early	study	by	Holland	et	al.	reported	that	in	approximately	30%	of	patients	the	mammographic	size	of	DCIS	was	more	than	2	cm	smaller	than	the	histological	tumour	size	(144).	The	same	group	demonstrated	that	in	approximately	27%	of	patients	occult	foci	of	DCIS	can	be	found	more	than	2	cm	away	 from	the	supposed	margin	 (145).	A	negative	margin	 for	DCIS	 therefore	does	not	mean	the	absence	of	residual	unresected	tumour	in	the	breast;	it	is	rather	a	 surrogate	 marker	 for	 the	 likelihood	 and	 extensiveness	 of	 further	 residual	disease.	In	contrast	to	patients	with	invasive	cancer,	DCIS	patients	generally	do	not	receive	systemic	therapy	after	BCS	and	not	all	receive	radiotherapy.	Data	from	the	National	Cancer	Data	Base	showed	that	in	the	United	States	approximately	30%	of	patients	do	not	receive	radiotherapy	after	BCS	(146),	while	in	the	United	Kingdom	this	is	approximately	50%	(147).	Since	studies	have	shown	that	systemic	therapy	and	 radiotherapy	 significantly	 reduce	 recurrence	 rates	 in	 breast	 cancer	 patients	(Section	 1.3.3),	 a	 wider	 margin	 of	 excision	 in	 patients	 not	 receiving	 systemic	and/or	 radiotherapy	 may	 be	 required	 to	 reduce	 the	 risk	 for	 LR	 from	 residual	unresected	 DCIS.	 The	 aforementioned	 differences	 make	 the	 definition	 of	 an	adequate	margin	for	DCIS	even	more	complicated	than	for	invasive	disease.			
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(148)	 Multi	centre	 1973	–	1995	 1003	 60	 10	(100/1003)	 Tumour	on	ink	 10.8	(9/83)	 -1	
	 	 	 	 	 	 ≤2		 7.0	(11/158)	 	
	 	 	 	 	 	 >2		 4.0	(24/599)	 	
(151)	 Single	centre	 1986	–	2000	 103	 63	 13	(13/103)	 Tumour	on	ink	 31.3	(5/16)	 -2	
	 	 	 	 	 	 <1		 8.6	(3/35)	 	
	 	 	 	 	 	 1	–	5		 10.5	(2/19)	 	
	 	 	 	 	 	 >5		 4.3	(1/23)	 	
(150)	 Single	centre	 1978	–	2010	 1483	 75	 8.4	(124/1483)	 Tumour	on	ink	 10.3	(6/58)	 -3	
	 	 	 	 	 	 ≤2		 10.1	(27/268)	 	
	 	 	 	 	 	 2	–	10		 7.1	(35/492)	 	
	 	 	 	 	 	 >	10		 8.4	(56/665)	 	
(152)	 Multi	centre	 1972	–	1998	 213	 72	 17.4	(37/213)	 <1		 28.8	(21/73)	 -4	
	 	 	 	 	 	 1	–	10		 15.0	(15/100)	 	






















(153)1	 Single	centre	 1999	–	2009	 107	 58	 4	(4/107)	 <10		 23.1	(6/24)	 <0.01	
	 	 	 	 	 	 ≥10		 1.5	(1/83)	 	
(154)	 Single	centre	 1972	–	2004	 445	 57	 18	(79/445)	 Tumour	on	ink	 46.9	(15/32)	 -	
	 	 	 	 	 	 0.1	–	0.9		 34.0	(18/53)	 	
	 	 	 	 	 	 1.0	–	1.9		 35.0	(7/20)	 	
	 	 	 	 	 	 2.0	–	2.0		 24.4	(20/82)	 	
	 	 	 	 	 	 3.0	–	5.9		 20.5	(8/39)	 	
	 	 	 	 	 	 6.0	–	9.9		 9.1	(2/22)	 	
	 	 	 	 	 	 ≥10	 4.6	(9/197)	 	
(150)2	 Single	centre	 1978	–	2010	 1225	 75	 16	(201/1225)	 Tumour	on	ink	 25.0	(10/40)	 -	
	 	 	 	 	 	 ≤2	 25.1	(42/167)	 	
	 	 	 	 	 	 2	–	10		 16.8	(62/369)	 	
	 	 	 	 	 	 >	10		 13.4	(87/649)	 	
(152)	 Multi	centre	 1972	–	1998	 256	 72	 14.8	(38/256)	 <1		 33.3	(13/39)	 -3	
	 	 	 	 	 	 1	–	10		 18.5	(23/124)	 	
	 	 	 	 	 	 ≥10		 2.2	(2/93)	 	
(155)	 Multi	centre	 1987	–	2004	 222	 55	 8.6	(19/222)	 <1		 16.1	(5/31)	 -4	
	 	 	 	 	 	 1	–	9.9	 7.7	(5/65)	 	
	 	 	 	 	 	 ≥10		 7.1	(9/126)	 	1. Only	patients	with	DCIS	tumour	size	≤1	mm	were	included.		2. No	significant	correlation	between	margin	width	and	local	recurrence	was	found	for	patients	receiving	radiotherapy	(Table	2)		3. P-values	for	comparing	the	three	margin	width	groups	was	not	provided.	However,	the	probability	of	recurrence	within	8	year	for	<1	mm,	1	–	10	mm,	and	≥10	mm	was	0.58	±	0.13,	0.20	±	0.04,	and	0.03	±	0.02,	respectively.		4. A	trend	towards	an	increased	risk	of	local	recurrence	in	cases	<1	mm	compared	to	≥10	mm	was	found.	
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Table	 3	 shows	 the	 results	 from	 retrospective	 studies	 published	 on	 the	 relation	between	 margin	 width	 and	 recurrence	 rate	 in	 DCIS	 patients	 treated	 with	 BCS	alone.	All	studies	included	in	the	table	show	a	decrease	in	LR	when	margin	width	increases.	This	finding	is	in	line	with	the	results	from	a	network	meta-analysis	by	Wang	et	al.	using	data	from	7564	patients	(119).	They	showed	that	margins	≥	10	mm	were	associated	with	a	reduced	risk	of	LR	compared	to	a	2	mm	margin	(OR	=	0.43,	95%	CI	0.27	to	0.67).		The	data	in	Table	2	and	Table	3,	and	the	results	from	the	meta-analysis	by	Wang	et	al.	(119)	and	Dunne	et	al.	(120),	indicate	that	a	≥1	mm	margin	width	for	DCIS	 as	 recommended	 by	 ABS	 and	 NCCN	 may	 not	 be	 adequate	 for	 achieving	optimal	local	control,	especially	for	patients	not	receiving	radiotherapy.	However,	there	 are	 multiple	 factors	 associated	 with	 recurrence	 in	 DCIS,	 including	 age,	tumour	size,	type	and	grade,	and	possible	multifocality,	and	these	are	important	to	consider	when	defining	 the	 optimal	margin	width	 (156).	More	 importantly,	 data	from	 clinical	 studies	 on	 the	 long-term	 efficacy	 of	 specific	 margin	 distances,	obtained	from	DCIS	patients	treated	with	modern	surgery	and	adjuvant	therapy,	is	of	utmost	 importance	for	making	well-informed	recommendations	on	the	margin	width	 required.	 	 This	 will	 help	 decide	 which	 patients	 may	 benefit	 from	 a	 re-operation	to	obtain	wider	margins,	and	in	which	patients	a	re-excision	can	safely	be	avoided.		Regardless	of	the	relation	to	margin	width,	the	benefits	of	reduced	LR	should	 always	 be	 balanced	 against	 potential	 patient	 benefits	 and	 costs	 benefits	associated	with	re-excision	surgery.			
1.4.3 Re-operation	rates	for	invasive	cancer	and	DCIS	To	date	a	significant	number	of	patients	undergo	a	 re-operation	because	 tumour	margins	after	the	initial	BCS	procedure	are	deemed	inadequate.	Table	4	provides	
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an	 overview	 of	 the	 re-operation	 rates	 obtained	 from	 national	 population-based	studies	 performed	 in	 the	 United	 States,	 United	 Kingdom,	 Canada	 and	 The	Netherlands.	 This	 table	 shows	 that	 mean	 re-operation	 rates	 for	 invasive	 cancer	with	or	without	in	situ	disease	range	between	9.3	–	32.0%.	For	patients	with	pure	DCIS	 Van	 der	 Heijden	 et	 al.	 found	 a	mean	 re-excision	 rate	 of	 28.5%	 (157);	 this	corresponds	 with	 the	 findings	 from	 the	 UK	 Sloane	 Project	 showing	 a	 mean	 re-operation	rate	of	29%	(158).	Sole	DCIS	or	DCIS	in	the	presence	of	invasive	disease	is	generally	associated	with	a	higher	re-excision	rate	than	invasive	disease	alone,	which	 is	 partially	 due	 to	 the	 clinical	 and	 histopathological	 differences	 between	DCIS	 and	 invasive	 cancer	 as	 described	 in	 Section	 1.4.2.	 Some	 studies	 found	 a	significantly	 higher	 rate	 of	 re-excision	 for	 lobular	 cancers	 compared	 to	 ductal	cancers	 (157,159),	 which	 may	 be	 attributed	 to	 the	 diffuse	 growth	 pattern	 of	lobular	 disease,	 although	 this	 difference	 was	 not	 demonstrated	 in	 the	 study	 by	McCahill	et	al.	(160).		 Among	 patients	 that	 require	 a	 re-operation	 to	 the	 affected	 breast,	approximately	40	–	50%	in	the	United	Kingdom	and	The	Netherlands	choose	for	a	mastectomy	(159,161).	These	patients	thus	initially	opted	for	breast	conservation	as	 the	 preferred	 treatment	 option,	 but	 ended	 up	 having	 their	 breast	 completely	removed.	Of	 the	patients	 that	choose	re-excision	surgery,	7.4	–	12.5%	required	a	second	surgical	intervention	in	the	form	of	a	re-reexcision	or	final	mastectomy	to	completely	clear	their	cancer	(160-162).				
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Table	4:	Multi	centre	studies	performed	after	the	year	2000	on	re-operation	rates	in	BCS		
Study	 No.	of	centres	 Period	 Total	no.	
of	patients	
Mean	re-operation	rate	in	%	
DCIS	 Invasive	 Invasive	±	DCIS1	(157)	 96	 2008	–	2009	 6250	 28.5			 	 9.32	(161)	 156	 2005	–	2008	 45793		 	 18.0		 29.5			(160)	 4	 2003	–	2008	 2006		 	 	 22.93	(162)	 -	 2003	–	2013	 87449		 	 	 30.94	(163)	 26	 2000	–	2002	 489		 	 	 26.2		(159)	 16	 2006	–	2007	 1923	 	 	 32.05	1. Invasive	cancers	with	or	without	ductal	carcinoma	in	situ	(DCIS).	This	group	also	includes	patients	with	invasive	lobular	cancer	2. This	is	not	the	actual	re-operation	rate	but	the	percentage	of	patients	with	an	inadequate	surgical	margin	that	would	have	required	re-excision	surgery	as	per	national	protocol.	Invasive	lobular	cancers	had	a	statistically	significant	higher	number	of	‘inadequate’	margins	than	invasive	ducal	carcinomas	(p<0.001)	3. No	statistically	significant	difference	was	found	in	re-operation	rate	between	patients	with	invasive	ductal	carcinoma	and	invasive	lobular	carcinoma	(p	=	0.17)	4. Re-operation	rate	decreased	significantly	from	39.5%	in	2003	and	2004	to	23.1%	in	2011	to	2013	(p	<	0.001).	Diagnosis	of	carcinoma	in	situ	was	associated	with	an	increased	risk	of	re-excision	on	multivariate	analysis	(odds	ratio	1.57,	95%	CI	1.49	–	1.65)	5. Re-operation	rate	was	36.4%	for	lobular	cancers	and	27.9%	for	ductal	cancers.	This	difference	was	statistically	significant	(p	=	0.01).	Patients	with	lobular	cancers	were	54%	more	likely	to	undergo	re-excision		
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Re-operations	have	a	significant	impact	on	patients	and	healthcare	systems.	They	can	 potentially	 result	 in	 an	 increased	 rate	 of	 surgical	 complications	 (164),	compromise	cosmetic	outcome	(165),	and	increase	anxiety	and	stress	for	patients	and	 their	 families.	 Re-excision	 surgery	 also	 presents	 a	 high	 cost	 burden	 on	 the	healthcare	system.	A	recent	study	in	the	United	States	showed	that	the	costs	for	a	re-excision	 were	 $4721	 (£3654)	 per	 patient	 (166).	 These	 costs	 are	 likely	 to	 be	even	higher	if	the	patient	ends	up	having	a	mastectomy,	and	need	to	be	multiplied	for	patients	that	require	two	or	more	re-operations	to	obtain	clear	margins.		The	studies	in	Table	4	showed	a	large	variation	in	re-excision	percentages	between	centres	 (157,159,160),	 and	 individual	 surgeons	 (160,162,163).	McCahill	
et	al.	demonstrated	that	one	institution	performed	a	second	operation	in	only	1.7%	of	patients	with	negative	margins	(defined	as	 ‘no	tumour	on	ink’),	while	this	was	20.9%	at	another	institution	(p<0.001)	(160).	More	importantly,	47.9%	of	patients	had	 a	 re-operation	 for	 cancer	 found	 at	 0	 –	 0.9	mm	 from	 the	margin,	 20.2%	had	margins	1.0	–	1.9	mm,	and	in	6.3%	of	cases	margins	were	2.0	–	2.9	mm.	Another	study	 found	 that	 approximately	 40.0%	 of	 repeat	 operations	 was	 performed	 for	margins	<0.1	–	2.0	mm	(167).	These	findings	show	that	a	significant	number	of	re-excisions	 are	 performed	 for	 close	 but	 negative	 margins.	 This	 highlights	 the	importance	 for	 obtaining	 consensus	 on	 the	 definition	 of	 an	 adequate	 excision	margin	 as	 the	 current	 differences	 cause	 significant	 variations	 in	 clinical	management,	thus	impacting	on	patient	wellbeing	and	health	economics.		In	an	attempt	to	decrease	the	re-operation	rate	several	methods	to	facilitate	more	complete	tumour	excision	at	the	time	of	the	initial	BCS	procedure	have	been	proposed.	 These	 include	 the	 use	 of	 routine	 cavity	 shavings,	 oncoplastic	 BCS	techniques	 and	 techniques	 to	 intraoperatively	 assess	 tumour	 resection	margins.	Routine	 shavings	 and	 oncoplastic	 BCS	 will	 be	 briefly	 discussed	 in	 the	 next	 two	
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sections,	 while	 an	 extensive	 overview	 of	 the	 intraoperative	 margin	 assessment	techniques	 and	 their	 potential	 for	 reducing	 re-operation	 rates	 is	 provided	 in	Section	1.5		
1.4.4 Routine	cavity	shavings		The	 main	 aim	 of	 performing	 routine	 cavity	 shavings	 (RCS)	 in	 addition	 to	conventional	BCS	 is	 to	 sample	 extra	 tissue	 from	 the	 four	 radial	margins,	with	or	without	the	anterior	and	posterior	margin,	to	decrease	the	positive	margin	and	re-operation	rate.	Routine	shavings	are	different	from	selective	shavings;	the	latter	is	standard	practice	in	BCS	as	surgeons	excise	margins	where	the	tumour	is	deemed	to	 be	 close	 based	 on	 intraoperative	 imaging	 or	 gross	 evaluation.	 RCS	 has	 been	introduced	in	the	1990s,	but	so	far	no	meta-analysis	or	systematic	review	has	been	published	on	the	oncological	and/or	cosmetic	outcomes	of	this	technique.	Table	5	shows	the	results	from	2	important	randomised	controlled	studies	performed	after	2000	comparing	the	positive	margin	rate	of	conventional	BCS	with	RCS.	These	 studies	 show	 that	RCS	 can	 significantly	 reduce	positive	margin	 rates.	Single	 centre,	 retrospective	 studies	 have	 reported	 similar	 findings	 (168-170).		These	 results	 show	 the	 potential	 benefit	 of	 RCS	 in	 centres	 with	 a	 high	 rate	 of	incomplete	 tumour	 excision	 with	 standard	 BCS.	 However,	 RCS	 is	 likely	 to	 be	 of	limited	value	to	institutions	with	a	positive	margin	rate	and/or	re-excision	rate	of	20%	or	less	with	conventional	BCS.		An	important	potential	limitation	of	RCS	is	a	reduced	cosmetic	outcome	due	to	 excision	 of	 a	 higher	 volume	 of	 breast	 tissue.	 Several	 studies	 have	 compared	excision	 volumes	 between	 standard	 BCS	 and	 RCS,	 with	 contradictory	 results.	Guidroz	 et	 al.	 (171)	 and	 Jones	 et	 al.	 (172)	 showed	 no	 significant	 difference	 in	excision	volume,	while	Chagpar	et	al.	(173)	and	Huston	et	al.	(170)	found	that	the	
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total	 volume	 of	 tissue	 excised	 was	 significantly	 larger	 in	 the	 RCS	 group.	 The	excised	tissue	volumes	between	these	studies	differed	markedly	for	both	the	BCS	and	RCS	group,	highlighting	the	variation	amongst	surgeons	and	centres	in	surgical	practice,	 and	 the	need	 for	 randomised	 controlled	multi	 centre	 studies	and	meta-analyses	 to	 robustly	 assess	 the	 impact	 of	 RCS	 on	 excision	 volume	 and	 cosmetic	outcome.		Chagpar	 et	 al.	 recently	 performed	 a	 cost-analysis	 to	 assess	 the	 potential	 cost	benefits	 of	 RCS	 compared	 to	 standard	BCS	 (174).	 They	 found	 that	 although	RCS	significantly	reduced	re-excision	rates	 (27.6%	for	BCS	versus	10.9%	for	RCS,	p	<	0.01),	 direct	 hospital	 costs	 were	 higher	 due	 to	 increased	 operating	 room	 time	($1137	versus	$1315,	p	=	0.03)	and	pathology	costs	from	processing	and	analysing	additional	 tissue	 slides	 ($795	 versus	 $1195,	 p<0.01).	 Overall	 there	 was	 no	significant	difference	in	total	costs	between	BCS	and	RCS	($11,219	versus	$10,476,	p	 =	 0.40).	 This	 finding	 in	 combination	 with	 the	 limited	 improvement	 in	 re-operation	rate	 in	centres	with	a	rate	of	20%	or	 less,	questions	the	real	benefit	of	RCS	for	patients	and	healthcare	systems,	especially	now	oncoplastic	techniques	are	being	used	more	often	as	described	in	the	next	section.		
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Table	5:	Randomised	controlled	trials	comparing	positive	margin	rate	of	conventional	BCS	and	BCS	plus	routine	cavity	shavings			














2011	–	2013	 Invasive:	>0	mm	DCIS:	≥1	mm	 235	 45	 33.6	(39/116)		 19.3	(23/119)	 0.01	(172)	 Randomised	controlled	trial,	single	centre		
2009	–	2012	 Invasive:	>1	mm	DCIS:	>2	mm	 752	 13	 45.2	(14/31)	 15.6	(7/45)	 <0.01	
1. RCS	=	routine	cavity	shavings	2. One	patient	had	bilateral	cancer.	For	both	breasts	BCS	was	performed,	so	the	total	number	of	breast	specimens	was	76		
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1.4.5 Oncoplastic	breast-conserving	surgery	techniques	Oncoplastic	 BCS	 techniques	 have	 emerged	 over	 recent	 years	 as	 a	 further	refinement	 of	 standard	 BCS.	 This	 type	 of	 surgery	 enables	 surgeons	 to	 excise	 a	larger	 tissue	 volume	 with	 wider	 surgical	 margins,	 while	 minimizing	 potential	deformities	and	maximizing	cosmetic	outcome	by	immediate	reconstruction	of	the	conserved	breast	at	the	time	of	initial	surgery.	Multiple	oncoplastic	BCS	techniques	have	 been	 introduced;	 the	 most	 appropriate	 technique	 depends	 amongst	 other	factors	on	the	volume	of	tissue	to	be	excised	and	the	location	of	the	tumour	(175).		 De	La	Cruz	et	al.	performed	the	largest	comprehensive	literature	review	to	date	on	the	oncologic	outcomes	of	oncoplastic	BCS	(176).	They	included	55	studies	and	 evaluated	 data	 from	over	 6000	patients.	 Studies	with	 over	 5-year	 follow-up	showed	excellent	mean	LR,	DFS	 and	OS	 rates	 of	 6.0%	 (range	0	 –	14.6%),	 85.4%	(range	 59.6	 –	 100%)	 and	 93.4%	 (range	 82.9	 –	 100%),	 respectively.	 Although	results	 varied	 amongst	 the	 studies	 included	 in	 the	 review,	 the	 vast	 majority	 of	studies	showed	recurrence	and	survival	rates	comparable	to	patients	undergoing	conventional	BCS.	Oncological	safety	has	also	been	confirmed	in	another	review	on	oncoplastic	BCS	(177).		In	the	studies	included	by	De	La	Cruz	et	al.	mean	positive	margin	rate	and	re-excision	rate	was	 low;	10.8%	(range	0	–	39.7%)	and	6.0%	(range	0	–	26.7%),	respectively	 (176).	 Positive	margin	 rates	were	 not	 significantly	 different	 for	 the	different	 margin	 definitions	 used	 in	 the	 included	 studies	 (p	 =	 0.162).	 A	 meta-analysis	 comparing	 standard	BCS	with	 oncoplastic	BCS	 found	 significantly	 lower	positive	margin	 rates	 (21%	 versus	 12%,	 p<0.001)	 and	 re-excision	 rates	 (14.6%	versus	 4%,	 p<0.001)	 for	 the	 oncoplastic	 technique	 (178).	 Importantly,	 cosmetic	outcome	has	shown	to	be	as	good	or	better	than	with	standard	BCS	(178,179).		
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Overall	 these	 studies	 indicate	 that	 oncoplastic	 breast	 conservation	 in	patients	 with	 early-stage	 invasive	 breast	 cancer	 is	 a	 safe	 treatment	 option	 that	potentially	provides	a	low	positive	margin	and	re-excision	rate,	and	good	cosmetic	outcome	 without	 compromising	 recurrence	 or	 survival.	 Large	 randomised	controlled	trials	are	needed	to	further	evaluate	the	clinical	and	health-economical	benefits	of	oncoplastic	BCS	versus	conventional	BCS.		
1.5 Techniques	for	intraoperative	assessment	of	tumour	margins	Despite	 the	 limitations	described	 in	Section	1.4,	 the	 ‘gold	 standard’	 for	assessing	tumour	 margin	 status	 to	 date	 is	 postoperative	 histopathological	 analysis.	 The	results	 from	 histopathology	 typically	 become	 available	within	 5-7	working	 days	after	 the	 initial	 BCS	 procedure,	 thus	 requiring	 patients	 with	 inadequate	 margin	clearance	 to	 undergo	 a	 delayed	 second	 operation	 to	 obtain	 clear	 margins.	Regardless	of	the	type	of	surgical	technique	used,	i.e.	BCS	alone,	BCS	plus	routine	cavity	 shavings,	 or	 oncoplastic	 BCS,	 accurate	 assessment	 of	 tumour	 resection	margins	intraoperatively	would	enable	surgeons	to	excise	additional	breast	tissue	in	 the	 scenario	 of	 close	 margins	 at	 the	 time	 of	 initial	 surgery,	 thus	 potentially	preventing	the	need	for	a	re-operation.					 There	 are	 several	 important	 criteria	 that	 should	 be	 considered	 when	developing	 or	 evaluating	 intraoperative	margin	 assessment	 technologies.	 Firstly,	the	 time	 required	 to	 assess	 tumour	 resection	margins	 should	 be	 within	 a	 time-window	 that	 is	 acceptable	 for	 providing	 surgical	 guidance	 during	 the	 BCS	procedure.	 Ideally	 information	 on	 margin	 status	 is	 provided	 real-time,	 but	 in	general	20	–	30	minutes	is	considered	to	be	within	acceptable	limits.	An	important	factor	 in	determining	the	acceptable	 length	of	 the	procedure	 is	 the	 impact	on	re-excision	 rates;	 longer	 examination	 times	may	 be	 feasible	 but	 only	 if	 it	 does	 not	
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affect	 quality	 of	 care	 and	 significantly	 reduces	 overall	 treatment	 costs.	 Secondly,	high	 diagnostic	 performance	 in	 terms	 of	 accuracy,	 sensitivity	 and	 specificity	 is	paramount.	Of	key	importance	in	this	is	the	ability	to	detect	DCIS	accurately,	as	this	is	one	of	the	main	causes	of	inadequate	surgical	excision	in	BCS	to	date.	There	are	several	 factors	 that	 potentially	 affect	 diagnostic	 accuracy,	 including	 lateral	resolution	(the	ability	to	distinguish	two	individual	points	in	a	plane	parallel	to	the	field	of	view),	axial	resolution	(the	ability	to	distinguish	two	individual	points	in	a	plane	perpendicular	to	the	field	of	view),	and	tissue	sampling	area.	Intraoperative	margin	assessment	techniques	should	have	millimetric	resolution	to	identify	small	tumour	 foci	 in	 (focally)	 positive	 margins,	 and	 to	 accurately	 detect	 tumour	 cells	within	a	 few	millimetres	of	 the	 tissue’s	surface.	The	 tissue	sampling	area,	 i.e.	 the	surface	 area	 of	 the	 tissue	 that	 can	 be	 assessed	 in	 one	 single	 measurement,	 is	preferably	large	to	prevent	potential	user	errors	and	to	facilitate	rapid	assessment	of	WLE	specimens	and/or	surgical	cavities.		Thirdly,	the	technique	needs	to	be	safe	for	patients	and	clinical	staff.	This	requirement	is	of	special	concern	for	techniques	employing	radioactivity	including	Cerenkov	Luminescence	imaging	(CLI)	(Chapter	3).	Fourthly,	the	overall	costs	of	the	technology	need	to	be	relatively	low	to	provide	potential	 cost	 savings	 for	 the	 health	 care	 provider	 and	 the	 payer.	 Again,	 this	ultimately	depends	on	the	impact	of	the	technique	on	re-operation	rate	and	quality	of	 care.	 Lastly,	 wide	 clinical	 adoption	 requires	 the	 intraoperative	 margin	assessment	 technique	 to	 be	 pragmatic	 and	 implementable	 in	 existing	 clinical	workflows.	 Effort	 should	 be	 made	 to	 minimize	 the	 labour	 intensiveness	 of	 the	technology,	while	avoiding	complex	logistics	to	maximize	ease-of-use.	Criteria	that	are	of	secondary	importance	are	the	applicability	of	the	technology	to	other	solid	cancers	 that	 would	 benefit	 from	 intraoperative	 tumour	margin	 assessment	 (e.g.	prostate,	 colorectal	 and	 head	 and	 neck	 cancer),	 the	 ability	 to	 intraoperatively	
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assess	 lymph	 node	 status,	 and	 the	 dimensions	 of	 the	 equipment.	 Small	 sized	equipment	that	can	be	used	inside	an	operating	theatre	or	in	an	adjacent	room	is	preferred	 to	enable	short	 lines	of	communication	between	 the	surgical	 team	and	the	operator	of	the	equipment.				To	 date	 there	 are	 a	 number	 of	 techniques	 available	 to	 assess	 tumour	resection	margins	intraoperatively,	either	in	current	clinical	use,	or	in	the	research	phase,	 and	 all	 these	 techniques	 aim	 to	 reduce	 re-operation	 rates.	 The	 next	 two	sections	 provide	 a	 thorough	 overview	 of	 each	 individual	 technique	 and	 its	 pros	and	cons	in	light	of	the	criteria	mentioned	above.			
1.5.1.1 Clinically	established	techniques	The	 established	 techniques	 to	 assess	 tumour	 resection	margins	 intraoperatively	can	 be	 divided	 into	 imaging	 techniques	 providing	 information	 at	 a	macroscopic	level,	 and	 histopathological	 techniques	 that	 assess	 margins	 microscopically.	Imaging	 techniques	 include	 intraoperative	 digital	 specimen	 radiography	 (IDSR)	and	 intraoperative	 ultrasound	 guided	 resection	 (IOUS),	 while	 intraoperative	histopathological	 techniques	 entail	 frozen	 section	 analysis	 (FSA)	 and	 imprint	cytology	 (IC).	 Several	 reviews	 have	 been	 published	 describing	 these	 techniques	(180-182).	Very	recently,	St	John	et	al.		published	a	meta-analysis	on	the	diagnostic	performance	of	 the	 established	 techniques	 for	 intraoperative	margin	 assessment	(183).	The	primary	outcome	measure	of	the	study	was	diagnostic	accuracy	of	each	technique	 compared	 with	 gold-standard	 histopathology.	 Pooled	 sensitivity	 and	specificity	 were	 calculated,	 as	 well	 as	 pooled	 positive	 and	 negative	 likelihood	ratios,	and	diagnostic	odd	ratios.	Secondary	outcome	measures	 included	positive	margin	rate	and	re-operation	rate.	The	results	from	this	meta-analysis	are	shown	
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in	Table	 6.	 Results	 from	additional	 papers	 not	 included	 in	 the	meta-analysis	 are	also	shown.		
Intraoperative	digital	specimen	radiography	IDSR	 is	used	 to	acquire	 two-dimensional	 images	 from	excised	WLE	specimens	 in	the	 operating	 theatre.	 Prior	 to	 imaging,	 metal	 surgical	 clips	 are	 applied	 to	 the	specimen	 to	enable	anatomical	orientation	on	 the	x-ray	 image.	 Image	acquisition	takes	 less	 than	 5	 seconds	 per	 image,	 and	 by	 rotating	 the	 specimen	 in	 between	images	 multiple	 views	 can	 be	 obtained	 to	 assess	 the	 adequacy	 of	 excision.	 The	meta-analysis	from	St	John	et	al.	included	9	IDSR	studies	containing	data	from	715	patients	 (183).	 Six	 studies	 were	 retrospective	 and	 3	 studies	 were	 prospective.	Pooled	sensitivity	was	53%	(95%	CI	45	–	61%);	pooled	specificity	was	84%	(95%	CI	77	–	89%)	(Table	6).	Pooled	positive	and	negative	likelihood	ratio	was	3.3	(95%	CI	2.1	–	5.0)	and	0.56	(95%	CI	0.46	–	0.69),	 respectively.	Heterogeneity	between	studies	was	low	and	not	significant	(I2	0%,	Cochran	Q	0.188),	indicating	that	there	was	consistency	between	studies	in	terms	of	study	design	and	diagnostic	accuracy	of	 IDSR.	Positive	margin	 rate	and	re-excision	 rates	 in	 the	 studies	 included	 in	 the	analysis	 ranged	between	7.0	–	42.0%	and	5.0	–	37.1%,	 respectively.	Bathla	et	al.	and	 Kaufmann	 et	 al.	 demonstrated	 that	 use	 of	 IDSR	 resulted	 in	 an	 absolute	reduction	 in	 positive	 margin	 rate	 of	 22.6%	 and	 8.0%,	 respectively	 (184,185).	Despite	 its	 potential	 for	 reducing	 re-operation	 rates,	 an	 important	 limitation	 of	IDSR	 is	 that	 in	 situ	 cancers	 are	 only	 detected	 if	 microcalcifications	 are	 present,	which	 is	 one	of	 the	 explanations	 for	 the	 suboptimal	 sensitivity	 in	Table	6.	Other	limitations	 include	 the	 potential	 to	 overestimate	 the	 margin	 distance	 due	 to	underestimation	of	the	tumour	size	on	the	radiography	image,	unreliable	specimen	orientation	 if	 surgical	 marker	 clips	 are	 missing	 or	 positioned	 wrongly,	 and	
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inaccurate	 margin	 assessment	 in	 specimens	 with	 irregular	 margins	 due	 to	spiculated	 lesions	 and	 opacities	 (186).	 These	 limitations	 all	 impact	 on	 the	diagnostic	performance	of	IDSR.			
Intraoperative	ultrasound	guided	resection	IOUS	 is	 a	method	of	 excising	a	 tumour	under	direct	visualisation,	 thus	providing	the	surgeon	with	real-time	information	of	the	tumour	extent.	Prior	to	excision	the	US	 probe	 is	 directed	 over	 the	 lesion	 to	 define	 every	 margin	 of	 excision,	 and	immediately	 post-excision	 ex	 vivo	 US	 examination	 of	 the	 WLE	 specimen	 is	performed	 to	 confirm	 the	 tumour	 has	 been	 completely	 excised	with	 a	 sufficient	margin.	IOUS	can	also	be	used	to	assess	the	post-excision	surgical	cavity.			In	 the	 4	 studies	 included	 in	 the	 meta-analysis	 of	 St	 John	 et	 al.,	 pooled	sensitivity,	specificity,	positive	likelihood	ratio	and	negative	likelihood	ratio	were	59%	(95%	CI	36	–	79%),	81%	(95%	CI	66	–	91%),	3.2	(95%	CI	2.0	–	5.2)	and	0.5	(95%	CI	0.32	–	0.80),	respectively	(183)	(Table	6).	These	results	are	comparable	to	IDSR.	 However,	 due	 to	 the	 small	 number	 of	 studies	 and	 the	 significant	heterogeneity	 between	 studies	 (I2	 96%,	 Cochran	 Q	 41.3),	 which	 amongst	 other	factors	 was	 a	 result	 of	 inconsistencies	 in	 diagnostic	 accuracy	 between	 studies,	caution	 should	 be	 taken	 when	 interpreting	 these	 findings.	 Studies	 reporting	 on	positive	margin	and	re-excision	rate	show	values	ranging	between	3.1	–	34.4	and	2.0	–	20.8%,	respectively	(183)	(Table	6).	The	highest	rates	were	found	in	patients	with	 pure	 DCIS,	 indicating	 the	 challenge	 of	 accurate	 identification	 of	microcalcifications	 on	 sonography	 (187).	 A	 meta-analysis	 by	 Ahmed	 et	 al.	comparing	 IOUS-guided	surgery	with	WGL	surgery	 in	patients	with	non-palpable	breast	cancer	demonstrated	a	statistically	significantly	lower	positive	margin	rate	for	IOUS,	while	no	difference	in	resection	volume	was	found	(188).	An	advantage	
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of	IOUS	over	other	localisation	techniques	used	for	non-palpable	breast	cancer,	i.e.	WGL,	ROLL	and	RSL,	is	that	the	need	for	preoperative	localisation	can	be	avoided.	This	 prevents	 potential	 scheduling	 issues	 on	 the	 day	 of	 surgery	 between	 the	radiology	department	and/or	nuclear	medicine	department,	and	the	surgery	unit	(67).	 IOUS-guided	 surgery	 has	 been	 shown	 not	 to	 extend	 tumour	 excision	 time	compared	to	palpation-guided	excision	(14	min	versus	15	min,	p	=	0.38),	indicating	that	the	technique	is	time-efficient	(189).	Besides,	a	recent	study	comparing	IOUS	and	 palpation-guided	 BCS	 found	 an	 improved	 cosmetic	 outcome	 and	 patient	satisfaction	 for	 the	 IOUS	group	 (190).	Although	 these	 results	 clearly	 indicate	 the	potential	of	IOUS	for	significantly	improving	quality	of	care	in	BCS,	especially	since	US	probes	are	widely	available	in	centres	worldwide,	widespread	implementation	of	 this	 technique	has	been	 limited	by	 the	 inability	 of	 surgeons	 to	 acquire	 formal	training	by	a	senior	breast	radiologist	that	is	required	for	obtaining	accreditation	in	 breast	 ultrasonography	 (67).	 This	 is	 partially	 due	 to	 the	 lack	 of	 breast	ultrasonography	courses	offered	by	the	national	societies	of	breast	surgery,	but	the	initial	resistance	from	the	radiology	community	to	train	surgeons	in	the	adequate	use	of	this	technique	is	also	likely	to	play	a	role.	Sufficient	training	is	essential	as	successful	application	of	IOUS	has	a	learning	curve	(191),	and	the	inconsistencies	in	diagnostic	accuracy	between	studies	included	in	the	meta-analysis	of	St	John	et	




Frozen	Section	Analysis	FSA	 for	 intraoperative	margin	 assessment	 is	 used	 in	 several	 solid	 cancer	 types,	including	colorectal,	gastric,	prostate	and	breast	cancer,	and	this	technique	has	not	undergone	significant	changes	since	its	introduction	in	the	1990s.	In	breast	cancer,	the	 excised	WLE	 specimen	 is	 oriented	with	 sutures	 and/or	 surgical	 clips	 as	 per	local	protocol,	 the	margins	are	 inked,	 and	 the	 specimen	 is	 then	 thinly	 sliced	and	inspected.	 Sections	 from	 suspected	 tissue	 areas	 (e.g.	 macroscopically	 suspect	lesion,	palpable	lesion	or	microcalcifications	seen	on	preoperative	mammography)	are	 then	 frozen,	cut,	 stained	and	analysed	microscopically	 to	evaluate	 the	closest	margin	of	resection.	The	microscopic	margin	status	on	FSA	is	then	reported	back	to	the	surgeon,	and	any	re-excised	margins	may	also	be	submitted	for	FSA.		St	John	et	al.	assessed	the	diagnostic	accuracy	of	FSA	using	data	from	9	studies.	Pooled	sensitivity	and	specificity	were	86%	(95%	CI	78	–	91%)	and	96%	(95%	CI	92	 –	 98%),	 respectively	 (183)	 (Table	 6).	 Pooled	 positive	 likelihood	 ratio	 and	negative	likelihood	ratio	were	21.6	(95%	CI	10.4	–	44.8)	and	0.15	(95%	CI	0.09	–	0.23),	respectively.	Thus,	diagnostic	performance	of	FSA	seems	substantially	better	than	IDSR	or	IOUS,	but	one	should	note	that	heterogeneity	between	the	9	included	studies	 was	 high	 (I2	 97%,	 Cochran	 Q	 58.24).	 An	 earlier	 systematic	 review	comparing	 conventional	 postoperative	 histopathology,	 FSA	 and	 IC	 also	 found	 a	high	 diagnostic	 performance	 for	 FSA;	 pooled	 mean	 and	 standard	 deviation	 for	sensitivity	and	specificity	was	83	±	13%	(range	58.1	–	100%)	and	95	±	8%	(range	77.8	–	100%),	respectively	(192)	(Table	6).	The	authors	of	the	systematic	review	also	calculated	pooled	mean	and	standard	deviation	for	re-excision	rate.	This	was	10	±	6%	(range	0	–	41.6%)	for	FSA;	significantly	lower	compared	to	the	35	±	3%	reported	 for	 conventional	 histopathology	 (p<0.0001).	 Two	 single	 centre	 studies	showed	 higher	 false-negative	 findings	 in	 patients	 with	 DCIS,	 small	 non-palpable	
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tumours	 and	 post-neoadjuvant	 therapy,	 indicating	 that	 diagnostic	 performance	may	 be	 lower	 in	 this	 group	 of	 patients	 (193,194).	 As	 with	 conventional	postoperative	histopathology,	FSA	only	assesses	a	small	amount	of	tissue	from	the	WLE	specimen,	thus	potentially	missing	involved	tumour	margins	in	tissue	that	is	not	analysed	microscopically.	Moreover,	FSA	requires	a	relatively	large	part	of	the	specimen,	 which	 may	 compromise	 postoperative	 histopathological	 evaluation.	Besides,	FSA	requires	significant	human	resources	and	the	expertise	of	an	on-site	histopathologist,	which	is	not	always	readily	available.	Another	important	concern	when	 using	 FSA	 is	 the	 time	 required	 to	 perform	 the	 procedure;	 Esbona	 et	 al.	reported	a	mean	duration	of	27	minutes	with	a	maximum	of	53	minutes	in	a	study	that	 did	 total	 circumference	 sampling	 of	 the	 WLE	 specimen	 (192).	 This	 could	increase	 surgery	 time,	ultimately	 reducing	 the	number	of	 operations	 that	 can	be	performed	per	day,	and	may	affect	quality	of	care	as	more	and	longer	anaesthesia	is	 required.	Osborn	et	 al.	performed	 a	 cost-effectiveness	 analysis	 and	 found	 that	FSA	is	only	cost-effective	for	institutions	with	a	re-excision	rate	of	more	than	36%	(195).	Due	to	these	limitations	FSA	is	not	used	widely;	a	recent	study	by	Harness	et	
al.	amongst	SSO-ASTRO	panellists	showed	that	only	5%	of	the	panel	members	used	FSA	in	their	institution	(134).			
Imprint	cytology	IC	has	been	proposed	as	a	simple	and	more	rapid	alternative	to	FSA.	The	excised	WLE	specimen	is	oriented	and	pressed	onto	specifically	coated	glass	slides	to	make	an	 imprint	 of	 all	 6	 tumour	 resection	 margins.	 The	 principle	 is	 based	 on	 the	difference	 in	 cellular	 surface	 characteristics;	 malignant	 cells	 show	 less	 cohesion	and	are	therefore	more	likely	to	adhere	to	the	slides	than	benign	cells.	Slides	are	then	 air-dried,	 stained,	 and	 analysed	 microscopically	 by	 a	 cytopathologist.	 By	
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analysing	 a	 larger	 tissue	 surface	 area,	 sampling	 errors	 inherent	 to	 FSA	 are	 less	likely	 to	 occur.	Moreover,	 IC	 preserves	 the	WLE	 specimen	 and	 its	 tumour-tissue	relationships,	 thus	 minimising	 the	 risk	 of	 compromising	 postoperative	histopathology.	However,	with	 IC	 only	 superficial	 tumour	 cells	 are	detected,	 and	information	on	the	margin	width	(i.e.	distance	from	tumour	cells	to	the	specimen	edge)	 and	 focality	 (i.e.	 quantity	 of	 cancerous	 cells	 approaching	 the	 cut	 edge)	cannot	be	obtained.			 St	 John	 et	 al.	 included	 1129	 patients	 from	 11	 IC	 studies	 in	 their	 meta-analysis	 (183).	 They	 found	 a	 diagnostic	 accuracy	 comparable	 to	 FSA.	 Pooled	sensitivity,	 specificity,	 positive	 likelihood	 ratio	 and	 negative	 likelihood	 ratio	 of	91%	(95%	IC	71	–	97%),	95%	(95%	IC	90	–	98%),	18.9	(95%	CI	9.2	–	38.9)	and	0.10	 (95%	 CI	 0.03	 –	 0.34),	 respectively	 (Table	 6).	 	 These	 results	 were	 slightly	better	than	the	findings	reported	in	an	earlier	systematic	review	by	Esbona	et	al.	(192)	(Table	6);	they	found	a	pooled	mean	and	standard	deviation	for	sensitivity	and	specificity	of	72	±	38%	(range	8.3	–	99%)	and	97	±	3%	(range	92	–	100%),	respectively.	 There	 was	 no	 statistically	 significant	 difference	 in	 sensitivity	 and	specificity	between	 IC	and	FSA	 (p	=	0.53	and	p	=	0.58,	 respectively),	but	 IC	 took	considerably	less	time	(mean	13	min	versus	27	min).		Pooled	mean	re-excision	rate	was	11	±	4%	(range	0	–	33%);	significantly	lower	than	the	35	±	3%	for	standard	postoperative	histopathology	(p	=	0.001).	In	both	the	study	by	St	John	et	al.	(183)	and	Esbona	et	al.	(192)	large	variations	were	found	for	sensitivity,	indicating	that	substantial	 differences	 in	 diagnostic	 performance	 between	 institutions	 and	operators	 may	 be	 present.	 Cox	 et	 al.	 demonstrated	 the	 applicability	 of	 IC	 for	patients	with	pure	DCIS;	a	positive	margin	rate	of	only	6.8%	was	observed	in	the	104	 patients	 included	 in	 the	 study	 (196).	 A	 small	 study	 by	 Valdes	 et	 al.	 in	 12	patients	with	 invasive	 lobular	carcinoma	found	a	high	number	of	 false-negatives,	
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resulting	in	a	sensitivity	and	specificity	of	8.3%	and	98.3%	respectively	(197).		The	authors	explain	 that	due	 to	 individual	 tumour	cells	 embedded	 in	 fibrous	 stroma,	and	numerous	microscopic	 satellite	 foci	 often	observed	 in	 lobular	 cancers,	 false-negative	 findings	 are	 more	 likely,	 thus	 questioning	 the	 value	 of	 IC	 in	 invasive	lobular	disease.	Important	pitfalls	of	the	technique	include	errors	in	interpretation	based	 on	 specimen	 surface	 irregularity,	 cauterization,	 dryness,	 or	 over-interpretation	 of	 atypical	 cells	 (198,199).	 Besides,	 successful	 implementation	 of	the	 technique	 requires	 cytopathology	 training	 and	 certification.	 Current	 work	focuses	 on	 developing	 automated	 analysis	 tools	 for	 interpreting	 IC	 slides,	which	could	 potentially	 reduce	 the	 workload	 of	 the	 cytopathologist	 and	 the	 costs	associated	 with	 IC	 (199).	 However,	 whether	 this	 will	 help	 increase	 the	 small	number	of	 centres	 that	 currently	use	 IC	 for	margin	 assessment	 in	breast	 cancer,	2%	based	 on	 an	 SSO-ASTRO	audience	 poll	 by	Harness	et	 al.,	 remains	 to	 be	 seen	(134).		
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Table	6:	Diagnostic	performance	of	clinically	established	techniques	for	intraoperative	tumour	margin	assessment		





















(183)	 Meta-analysis	 715	 -3	 53.0	 84.0	 -	 -	 Detection	of	in	situ	disease;		Underestimation	of	tumour	size/overestimation	of	margin	distance;		Accurate	image	interpretation	challenging		
	 (185)	 Cohort,	prospective,	single	centre		
121	 29	 36.0	 71.0	 20.0	(8.0)	 -	
Imprint	
cytology	
(183)	 Meta-analysis	 1129	 -	 91.0	 95.0	 -	 -	 Labour	intensive;		Interpretation	of	IC	slides	prone	to	errors;		No	information	on	margin	width	and/or	focality		
	 (192)	 Systematic	review	 2296	 -4	 72.0	 97.0	 -	 11.0	
Ultrasound	 (183)	 Meta-analysis		 482	 -	 59.0	 81.0	 -	 -	 Diagnostic	accuracy	operator	dependent;		Limited	training	opportunities;		Suboptimal	resolution	especially	for	systems	with	centre	frequency	below	10MHz		
	 (189)	 Randomised	controlled	trial,	multi	centre		
134	 0	 -	 -	 3.1	(14.3)	 2.0	
	 (200)2	 Case-control,	retrospective,	single	centre	 155	 155	 -	 -	 34.4	 20.8	(9.7)	
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(183)	 Meta-analysis	 1979	 -	 86.0	 96.0	 -	 -	 Lengthy	(~30	min);		Labour	intensive;		Small	percentage	of	total		WLE	specimen	analysed		
	 (192)	 Systematic	review		 3675	 -5	 83.0	 95.0	 -	 10.0		 	 	 	 	 	 	 	 	1. In	studies	that	only	reported	the	number	of	specimens	it	was	assumed	that	each	patient	only	had	one	specimen	scanned		2. Only	patients	with	pure	DCIS	were	included	3. The	meta-analysis	from	St	John	et	al.	included	studies	that	contained	patients	with	invasive	disease	with	or	without	DCIS,	as	well	as	pure	DCIS.	A	breakdown	of	the	diagnostic	accuracy	per	tumour	type	is	not	provided	4. Exact	number	of	DCIS	patients	is	not	specified	but	in	4	out	of	the	8	studies	DCIS	was	present	in	the	dataset	5. Exact	number	of	DCIS	patients	is	not	specified	but	in	11	out	of	the	15	studies	DCIS	was	present	in	the	dataset		
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1.5.1.2 Novel	investigational	techniques	To	 address	 the	 limitations	 of	 the	 established	 techniques	 available	 for	intraoperative	assessment	of	tumour	margins,	several	novel	techniques	have	been	developed	 in	 the	 last	 two	 decades.	 These	 include	 the	 MarginProbe,	 diffuse	reflectance	 spectroscopy	 (DRS),	 optical	 coherence	 tomography	 (OCT),	 Raman	spectroscopy	 (RS),	 near-infrared	 fluorescence	 imaging	 (NIRF)	 and	 the	 intelligent	knife	(iKnife).	An	explanation	of	each	technique	and	the	results	published	to	date	in	 breast	 cancer	 is	 provided	 below.	Other	 techniques	 that	may	 be	 promising	 for	assessing	 tumour	margins	 in	 the	 near	 future	 include	 photoacoustic	 imaging	 and	the	 ClearEdge.	 These	 techniques	 are	 still	 in	 an	 earlier	 stage	 of	 development	 and	therefore	will	only	be	discussed	briefly.	Note	that	apart	from	the	MarginProbe	all	published	 results	 on	 investigational	 techniques	 for	 intraoperative	 margin	assessment	come	from	observational	studies;	no	reports	have	been	published	yet	on	the	use	of	these	techniques	to	guide	surgical	excision	and	assess	the	impact	on	positive	margin	and	re-excision	rate	(Table	7).		
MarginProbe	The	 MarginProbe	 (Dune	 Medical,	 Caesarea,	 Israel)	 uses	 radiofrequency	spectroscopy	to	detect	minute	differences	 in	electromagnetic	properties	between	benign	 and	 malignant	 breast	 tissue.	 The	 device	 consists	 of	 a	 console	 and	 a	detachable,	single-use,	sterile	handheld	probe	with	an	effective	measurement	area	of	 7mm	 and	 a	 detection	 depth	 of	 about	 1	 mm	 (201).	 The	 small	 sampling	 area	makes	 the	MarginProbe	prone	 to	user	 errors	 as	 focally	positive	margins	may	be	missed.	Each	measurement	 takes	approximately	1	 to	5	 seconds	 to	 complete,	 and	results	are	displayed	on	the	display	of	the	console	as	a	‘positive’	or	‘negative’	read-out.	 Most	 studies	 report	 that	 a	 maximum	 of	 8	 measurements	 per	 margin	 were	
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performed;	total	imaging	time	is	therefore	less	than	5	minutes.	In	2012	the	device	received	Federal	Drug	Administration	approval	as	a	diagnostic	tool	to	aid	tumour	margin	evaluation	in	BCS.	Two	 randomised	 controlled	 trials	 and	 three	 prospective	 cohort	 studies	have	 evaluated	 the	 performance	 of	 the	 MarginProbe,	 with	 mixed	 results.	Sensitivity	 and	 specificity	 for	 detecting	 breast	 cancer	 ranged	 from	70.0	 –	 75.2%	and	46.4	–	70.0%	(Table	7).	Pappo	et	al.	reported	that	the	diagnostic	accuracy	was	affected	 by	 tissue	 heterogeneity;	 lower	 sensitivities	 and	 specificities	were	 found	for	 tissue	 containing	 less	 than	 50%	 of	 a	 single	 tissue	 type,	 indicating	 that	 the	device	 is	 less	 sensitive	 for	 detecting	 small	 tumour	 foci	 (202).	 They	 also	 found	 a	lower	detection	rate	for	pure	DCIS	compared	to	invasive	cancer	(63%	versus	70%,	respectively).		The	two	randomised	controlled	trials	by	Schnabel	et	al.	(203)	and	Allweis	et	
al.	 (204)	 both	 showed	 a	 reduction	 in	 re-excision	 rate	 in	 the	 MarginProbe	 arm	compared	 to	 the	 control	 arm	 (19.8%	 versus	 25.8%	 and	 5.6%	 versus	 12.7%,	respectively),	 although	 in	 the	 trial	 by	 Allweis	 et	 al.	 this	 difference	 was	 not	statistically	 significant	 (p	 =	 0.098).	 The	 MarginProbe	 may	 also	 facilitate	 more	complete	tumour	excision	 in	patients	with	non-palpable	DCIS;	Thill	et	al.	 found	a	re-excision	 rate	 of	 18.0%	 when	 the	 MarginProbe	 was	 used	 compared	 to	 a	historical	 re-excision	 rate	 of	 38.8%	 (205).	 However,	 the	 real	 benefits	 of	 the	MarginProbe	 in	 this	 patient	 population	 remains	 to	 be	 determined,	 as	 large	randomised	 studies	 have	 not	 yet	 been	 performed	 for	 patients	 with	 pure	 DCIS.	Another	potential	downside	related	to	the	use	of	the	MarginProbe	is	an	increase	in	tissue	 volume	 excised	 as	 shown	 in	 both	 randomised	 controlled	 trials	 (204,206).	This	may	impact	on	cosmetic	outcome	and	overall	patient	satisfaction.		
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Diffuse	reflectance	spectroscopy	DRS	as	a	tool	for	margin	assessment	in	BCS	was	first	described	in	2000	by	Biglio	et	
al.	 (207).	 By	 illuminating	 tissue	 with	 light	 in	 the	 visible	 or	 near-infrared	 (NIR)	wavelength	 range,	 diffuse	 reflectance	 spectra	 can	 be	 obtained	 that	 provide	information	 on	 the	 intrinsic	 light	 absorption	 and	 scattering	 properties	 of	 breast	tissue	(208).	In	the	visible	–	NIR	range	the	primary	absorbers	in	the	breast	include	β-carotene,	 oxygenated	 and	 deoxygenated	 haemoglobin,	 while	 the	 primary	scatterers	 are	 cells	 and	 nuclei.	 Since	 changes	 in	 human	 tissue	 associated	 with	malignant	 transformation	 include	 alterations	 in	 cellular	 composition	 and	morphology,	vascularization,	and	metabolic	rate,	diffuse	reflectance	spectra	can	be	used	 as	 an	 intrinsic	 contrast	 to	 differentiate	 malignant	 from	 benign	 tissue.	Depending	 on	 the	 wavelength	 and	 tissue	 optical	 properties	 DRS	 has	 a	 sensing	depth	of	0.5	–	8.0	mm	(209).	Table	7	shows	that	sensitivity	and	specificity	ranges	between	67	–	85%	and	67	 –	 96%,	 respectively.	 The	 highest	 sensitivity	 and	 specificity	 of	 85%	 and	 96%	reported	 by	 Keller	 et	 al.	was	 obtained	 by	 combining	 DRS	with	 autofluorescence	imaging,	 indicating	 that	 a	 multimodal	 imaging	 approach	 may	 provide	 superior	results	 (210).	Apart	 from	Laughney	et	al.	all	 studies	 in	Table	7	used	a	 fiberoptic	DRS	 probe	 to	 acquire	 reflectance	 spectra	 from	 tumour	 margins.	 An	 important	limitation	 of	 these	 probes	 is	 their	 small	 sampling	 area,	 which	 affects	 the	acquisition	 time	 and	 increases	 the	 likelihood	 for	 sampling	 errors	 as	 with	conventional	histopathology.	Brown	et	al.	reported	that	the	time	required	to	scan	a	single	 resection	margin	was	 20	 –	 25	minutes,	which	 is	 far	 too	 long	 for	 use	 in	 a	surgical	setting	(211).	In	an	effort	to	increase	the	sampling	area,	and	consequently	decrease	 acquisition	 times,	 planar	 fibreless	 DRS	 systems	 have	 been	 developed	(209,212).	These	 systems	enable	non-contact	 tissue	 imaging	with	a	 substantially	
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larger	 field	 of	 view	 (FOV).	 Laughney	 et	 al.	 were	 able	 to	 image	 an	 area	 of	approximately	 14x20	 cm	with	 an	 acquisition	matrix	 of	 696x520	 pixels	 to	 give	 a	pixel	 resolution	of	 201x366	microns	 (209).	However,	 as	with	 all	 optical	 imaging	technologies,	 the	 detected	 spatial	 resolution	 is	 limited	 by	 the	 physics	 of	 light	transport	in	tissue,	so	the	practical	resolution	is	lower.	While	these	developments	enable	 shorter	 acquisition	 times,	 improvements	 in	 data	 processing	 for	 near-real	time	diagnostic	feedback	are	required	to	facilitate	implementation	of	DRS	into	an	intraoperative	setting.	Another	factor	that	may	challenge	 in	vivo	DRS	is	alteration	of	the	reflectance	spectra	from	absorption	of	(visible)	light	by	blood	and	coloured	dyes,	 including	 the	blue	dye	used	 in	patients	undergoing	SLNB.	Future	studies	 in	which	 DRS	 is	 used	 to	 guide	 surgical	 decision-making	 will	 determine	 the	 true	potential	of	DRS	for	reducing	positive	margin	and	re-excision	rate.		
Optical	coherence	tomography	OCT	has	emerged	as	a	high-resolution	optical	diagnostic	 imaging	modality	that	 is	being	 used	 in	 ophthalmology,	 gastroenterology,	 cardiology,	 gynaecology,	neurology	and	dermatology	(213).	More	recently,	OCT	has	been	investigated	as	a	technique	 to	 assess	 breast	 tumour	 margins.	 OCT	 is	 the	 optical	 equivalent	 to	ultrasound,	but	instead	of	acoustic	waves	it	is	based	on	the	reflection	of	light	from	a	NIR	 light	 source.	By	measuring	 the	 reflected	 light,	 cross-sectional	 tomographic	images	of	the	tissue	microstructure	can	be	obtained	with	a	micron-scale	resolution	similar	 to	 histopathology,	 and	 a	 penetration	 depth	 between	 200	 μm	 and	 2	 mm	depending	on	the	tissue	composition	(214).	The	contrast	observed	on	OCT	images	reflects	 the	 spatial	 variations	 in	 index	 of	 refraction	 within	 the	 tissue,	 and	 the	ability	 to	 differentiate	 between	 benign	 and	 malignant	 breast	 tissue	 is	 amongst	other	factors	due	to	the	increase	in	nuclear-to-cytoplasm	ratio	and	the	increase	in	
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cellular	and	nuclear	density	associated	with	oncogenesis	(214).	As	with	DRS,	OCT	does	 not	 require	 physical	 disruption,	 processing,	 sectioning	 or	 staining	 of	 the	tissue,	nor	is	there	a	need	for	an	exogenous	contrast	agent.		Studies	performed	to	date	show	a	sensitivity	of	60.0	–	100%	and	specificity	of	69.0	–	92.1%	(Table	7).	Zysk	et	al.	(215)	and	Erickson-Bhatt	et	al.	(216)	both	used	a	handheld	OCT	imaging	probe,	while	Nguyen	et	al.	employed	an	OCT	system	that	did	not	require	tissue	contact	(214).		Variants	of	conventional	OCT	systems	based	on	 optical	 coherence	 microelastography	 (217)	 and	 polarization-sensitive	 OCT	(218)	 are	 currently	 being	 developed,	 aiming	 to	 further	 improve	 the	 contrast	between	 benign	 and	 malignant	 breast	 tissue.	 Important	 strengths	 of	 OCT	 over	some	other	 technologies	 is	 the	ability	 for	 in	vivo	assessment	of	 the	resection	bed	(216),	 and	 its	 potential	 for	 intraoperative	 lymph	 node	 assessment	 (219).	Wide-field	 OCT	 systems	 may	 be	 able	 to	 overcome	 the	 current	 limitation	 of	 a	 small	sampling	area,	but	reports	published	to	date	have	not	yet	evaluated	the	diagnostic	performance	of	such	systems	(220).	Moreover,	due	to	 the	high	volume	of	 images	acquired	with	OCT,	advances	in	automated	tissue	type	classification	are	needed	to	speed	 up	 image	 interpretation	 and	 reduce	 labour-intensity	 (221).	 Future	interventional	 studies	 should	 not	 only	 assess	 the	 impact	 of	 OCT	 on	 oncological	outcomes,	but	also	the	effect	on	cosmesis	as	OCT	may	increase	the	volume	of	tissue	excised	due	to	false-positive	findings	(215).		
Raman	spectroscopy	Raman	 scattering	 is	 the	 inelastic	 scattering	 of	 photons	 upon	 interaction	 with	molecules.	 The	 change	 in	 photon	 energy	 level	 as	 a	 result	 of	 inelastic	 scattering	depends	 on	 the	 vibrational	 energy	 of	 the	 molecule	 involved,	 and	 thus	 Raman	spectra	 contain	 information	 on	 a	 molecular	 level	 that	 can	 be	 used	 to	 detect	
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changes	 in	 cells	 and	 tissues	 (222).	 	 Inelastic	 scattering	 is	 relatively	 rare,	 i.e.	approximately	1	in	10	million	scatter	events	are	inelastic,	and	RS	is	therefore	much	less	 efficient	 than	 other	 optical	 techniques	 including	 DRS	 and	 OCT	 that	predominantly	depend	on	elastic	scattering.	Hence,	obtaining	a	sufficient	signal-to-noise	 ratio	 in	 a	 time-window	 that	 is	 acceptable	 for	 intraoperative	 use	 is	challenging,	 and	 RS	 may	 require	 strict	 control	 of	 the	 light	 environment	 (for	example	 by	 using	 a	 light	 tight	 box)	 to	 reduce	 ‘noise’	 from	 ambient	 light	 sources	(223).	Similar	to	TPI	as	explained	in	Chapter	2,	 the	use	of	RS	for	tissue	diagnosis	requires	 developing	 a	 classification	 model	 based	 on	 a	 ‘training’	 dataset.	 These	models	 use	mathematic	 algorithms	 to	 identify	 unique	 fingerprints	 in	 the	 Raman	spectra,	 and	are	 then	applied	 to	data	 from	prospective	measurements	 to	predict	the	type	of	tissue.	In	order	for	RS	to	provide	optimal	diagnostic	accuracy	in	a	wide	patient	population,	the	training	dataset	should	contain	data	from	as	many	patients	and	 tumour	 types	 as	possible.	The	 same	 is	 true	 for	TPI.	 	Acquiring	 such	a	 large-scale	 dataset	 is	 a	 time-consuming	 and	 potentially	 costly	 endeavour	 due	 to	 the	heterogenetic	 nature	 of	 breast	 cancer.	 	 In	 a	 study	by	Haka	 et	 al.,	Raman	 spectra	from	 specimens	 containing	 pure	 DCIS	 were	 excluded	 from	 analysis	 as	 this	pathology	was	not	 included	 in	 the	 training	dataset	used	 for	diagnostic	algorithm	development	(223).		 Deng	 et	 al.	 recently	 published	 a	 meta-analysis	 on	 the	 diagnostic	performance	of	RS	 for	 discriminating	benign	 from	malignant	 breast	 tissue	 (224)	(Table	7).	A	total	of	7	studies	were	included;	all	these	studies	were	done	in	an	ex	
vivo	setting	by	applying	RS	to	excised	tissue	specimens.	4	studies	used	fresh	tissue	specimens,	while	3	studies	used	frozen-thawed	tissue.	All	studies	compared	RS	to	gold	 standard	 histopathology.	 Pooled	 sensitivity	 was	 92%	 (95%	 CI	 86	 –	 96%);	pooled	specificity	was	97%	(95%	CI	93	–	98%).	Subgroup	analysis	showed	that	the	
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diagnostic	performance	of	RS	was	higher	 in	studies	 that	acquired	more	than	200	Raman	spectra	for	tissue	classification	compared	with	studies	using	less	than	200	spectra,	indicating	that	longer	acquisition	times	per	measurement	may	be	required	for	optimal	discriminative	power.	 Interestingly,	 studies	using	 frozen	 tissue	had	a	significantly	higher	sensitivity	and	specificity	than	studies	using	fresh	tissue,	which	is	likely	due	to	changes	in	optical	properties	as	a	result	of	freezing	(225).	Based	on	these	findings	one	might	question	the	value	of	using	frozen-thawed	specimens	to	evaluate	 technologies	 intended	 for	 intraoperative	 use	 on	 fresh	 non-processed	specimens.		Proof-of-principle	for	using	RS	to	scan	the	post-excision	surgical	cavity	has	been	 provided	 by	 Haka	 et	 al.	 (226).	 Although	 their	 dataset	 only	 contained	 1	spectrum	 from	 a	 histologically	 positive	 margin,	 the	 overall	 accuracy	 of	 the	diagnostic	algorithm	was	93.3%,	thus	showing	the	potential	for	in	vivo	RS.	RS	has	also	 been	 successfully	 used	 for	 ex	 vivo	assessment	 of	 axillary	 lymph	node	 status	(227).	 In	 order	 for	RS	 to	 provide	near	 real-time	diagnostic	 information,	 ongoing	developments	 focus	on	ways	 to	decrease	 image	acquisition	 times.	An	 interesting	development	 is	 the	 use	 of	 multi-model	 imaging	 by	 integrating	 fluorescence	 and	Raman	spectroscopy.	This	approach	 is	 currently	being	evaluated	 in	a	pre-clinical	setting	(228,229).	Other	groups	are	exploring	the	use	of	exogenous	nanoparticles	to	 increase	 RS	 signal	 intensity	 (222),	 but	 such	 contrast	 agents	 require	 stringent	regulatory	approval	before	being	used	in	a	clinical	setting,	and	thus	provide	a	less	attractive	option	for	fast	translation	of	RS	from	bench	to	bedside.				
Near-infrared	fluorescence	imaging		In	NIRF	a	fluorophore	is	administered	systemically	or	locally	in	the	tumour,	after	which	the	target	area	is	irradiated	by	an	external	laser	that	emits	light	in	the	NIR	
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wavelength	 range	 (700	 –	 900	nm).	Upon	 excitation,	 the	 fluorophore	will	 release	photons	 of	 a	 higher	 NIR	 wavelength,	 which	 are	 captured	 by	 an	 NIRF	 camera	system	 and	 digitally	 converted	 into	 an	 image	 of	 the	 tumour	 site	 in	 real	 time.	Several	excellent	reviews	have	been	published	recently	describing	NIRF	for	image-guided	surgery,	including	its	use	for	NIRF-guided	SLNB	(230-232).	The	 last	 years	 have	 seen	 great	 advances	 in	 the	 development	 of	NIRF	 camera	systems	 and	 NIRF	 probes	 (232,233).	 Probes	 can	 broadly	 be	 divided	 into	 non-targeted	 probes,	 targeted	 probes	 which	 target	 enzymes	 and	 receptors	 that	 are	upregulated	in	cancer	cells,	and	targeted	probes	that	exploit	 the	catalytic	activity	of	 a	 target	 to	 generate	 an	 imaging	 signal.	The	 latter	 two	are	of	most	 interest	 for	NIRF-guided	resection,	as	these	tracers	have	the	potential	to	provide	the	surgeon	with	 tumour-specific	 molecular	 information	 on	 the	 location	 and	 extent	 of	 the	lesion.	However,	progression	to	the	clinic	has	so	far	been	limited	primarily	because	the	development	of	clinical-grade	contrast	agents	is	expensive	and	time-intensive	with	 regards	 to	 risk	 regulatory	 aspects,	 and	 substantial	 delays	 have	 often	 been	encountered	because	of	IP	issues	or	fear	of	litigation	(234,235).	As	a	result	of	this,	there	are	to	date	no	tumour-targeted	fluorescent	tracers	that	have	Food	and	Drug	Administration	(FDA)	or	European	Medical	Agency	(EMA)	approval	(236),	and	all	the	published	studies	 to	date	on	NIRF	 for	 image-guided	surgery	 in	breast	 cancer	have	 been	 pre-clinical	 (231,232).	 Phase	 I/II	 clinical	 studies	 in	 breast	 cancer	 are	now	 also	 underway,	 assessing	 the	 safety	 and	 feasibility	 of	 a	 protease-activated	tracer	 (NCT02391194),	 and	 tracers	 targeting	 VEGF	 (NCT01508572),	 c-MET	(EudraCT	 number	 2014-003554-13),	 and	 cathepsins	 (NCT01626066	 and	NCT02438358).	 Results	 from	 the	 cathepsin-targeted	 tracer,	 LUM015,	 were	recently	presented	at	the	Annual	Meeting	of	the	American	Association	for	Cancer	Research	 (237).	 LUM015	 did	 not	 demonstrate	 any	 adverse	 pharmacological	
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activity,	 and	was	 selectively	 taken	up	 in	 tumours,	 resulting	 in	a	mean	 tumour	 to	normal	 fluorescence	 ratio	 of	 5.4.	 The	 increased	 tumour	 fluorescence	 was	significantly	higher	than	normal	tissue	fluorescence	(p<0.0001).	Results	 from	the	other	clinical	studies	are	eagerly	awaited	to	obtain	further	insight	in	the	feasibility	of	NIRF	imaging	as	a	tool	 to	 improve	the	accuracy	of	 tumour	excision	 in	patients	undergoing	BCS.			
iKnife	The	iKnive	detects	cancer	by	using	rapid	evaporative	ionisation	mass	spectroscopy	(REIMS)	 to	analyse	 the	 smoke	 from	evaporating	 tissue	during	 surgical	 resection.	This	 system	 consists	 of	 a	 commercially	 available	 electrosurgical	 pencil	 that	 has	been	 slightly	 modified	 to	 transfer	 the	 aerosol	 to	 a	 distant	 mass	 spectrometer,	which	 provides	 audio-visual	 information	 on	 tissue	 diagnosis	 within	 0.7	 –	 2.5	seconds.	 As	 with	 DRS,	 RS	 and	 TPI,	 tissue	 classification	with	 the	 iKnive	 requires	training	of	a	classification	algorithm	to	recognise	the	features	in	the	mass	spectra	that	can	then	be	used	to	differentiate	benign	from	malignant	tissue.	This	demands	a	 large-scale	 database	 with	 data	 from	 a	 wide	 variety	 of	 tumour	 sub-types	 to	account	for	potential	differences	in	spectra	due	to	tissue	heterogeneity.		In	2013	Balog	et	al.	published	results	on	the	diagnostic	performance	of	the	iKnive	 to	 discriminate	malignant	 from	benign	 tissue	 (238)	 (Table	 7).	 The	 breast	training	 dataset	 contained	 data	 from	 a	 total	 of	 16	 patients;	 10	 invasive	 lobular	carcinomas,	 4	 invasive	 ductal	 carcinomas	 and	 2	 adenomas.	 Classification	 was	performed	on	only	2	breast	cancer	patients,	both	with	invasive	lobular	carcinomas,	and	showed	a	sensitivity	and	specificity	of	100%.	Differentiation	of	malignant	from	benign	breast	tissue	was	predominantly	based	on	differences	in	the	composition	of	membrane	 phospholipids.	 More	 recently	 a	 conference	 abstract	 was	 published,	
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showing	a	sensitivity	and	specificity	of	93.0%	and	91.9%	respectively	on	a	dataset	containing	 spectra	 from	 89	 excised	 breast	 specimens	 from	 66	 patients	 (239)	(Table	 7).	 Their	 dataset	 did	 not	 contain	 DCIS,	 so	 the	 ability	 of	 the	 iKnife	 to	accurately	 detect	 DCIS	 is	 yet	 to	 be	 determined.	 Practical	 limitations	 of	 the	technology	 include	 the	 limited	 speed	 of	 surgical	 resection	 (~1mm/s)	 to	 obtain	sufficient	mass	spectroscopic	information,	and	the	need	to	cauterise	tissue	in	order	to	establish	the	tissue	diagnosis.				
Other	techniques	Photoacoustic	 imaging	 combines	 optical	 imaging	 with	 US.	 Tissue	 is	 illuminated	with	a	short-pulsed	light	beam,	and	absorption	of	the	optical	photons	causes	tissue	to	expand,	which	generates	a	characteristic	sound	wave	that	is	detected	by	an	US	transducer	 to	 form	 an	 image.	 This	 image	 represents	 a	 spatial	 map	 of	 optical	absorption	from	endogenous	absorbers	(e.g.	haemoglobin,	melanin	and	water),	or	exogenous	contrast	agents	such	as	dyes	or	nanoparticles	(240).	Pre-clinical	studies	have	shown	the	ability	of	photoacoustic	imaging	to	accurately	image	tumours	and	assess	 the	 completeness	of	 tumour	 resection	 (241-243),	but	 clinical	 results	have	not	yet	emerged	in	literature.	The	 ClearEdge	 is	 a	 battery	 operated	 hand-held	 device	 equipped	 with	 a	sterile	 single-use	 probe	 that	 images	 an	 area	 of	 13x13	 mm.	 The	 device	discriminates	 benign	 from	 malignant	 breast	 tissue	 using	 bio-impedance	spectroscopy.	A	 recent	paper	 assessed	 the	diagnostic	performance	of	 this	device	on	335	margins	 from	58	patients	 (244)	 (Table	7).	 Sensitivity	and	specificity	was	87.3%	 and	 75.6%,	 respectively.	 In	 the	 49	 patients	 where	 margin	 excision	 was	guided	by	the	readings	of	the	device,	re-operation	rate	was	8%,	compared	to	a	re-
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excision	 rate	 of	 37%	 if	 the	 device	would	 not	 have	 been	 used.	 These	 results	 are	promising,	and	data	from	larger	studies	is	eagerly	awaited.																
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Table	7:	Diagnostic	performance	of	investigational	techniques	for	intraoperative	tumour	margin	assessment	










596	 161	 75.2	 46.4	
Suboptimal	sensitivity	and	specificity;		Accurate	detection	of	DCIS	challenging;		Potential	for	increased	excision	volume;		Small	sampling	area	
	 (204)	 Randomised	controlled	trial,	multi	centre		
293	 20	 -1	 -1	
	 (202)	 Cohort,	prospective,	multi	centre		
76	 16	 70.0	 70.0	
	 (245)	 Cohort,	prospective,	multi	centre		





48	 3	 79.0	 67.0	 			 (210)	 Cohort,	prospective,	single	centre					
28	 -	 85.0	 96.0	 	
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Technique	 Study	 Study	design	 No.	of	




70	 9	 74.0	 86.0	 Long	acquisition	times	(>20	min);		Small	sampling	area	of	handheld	DRS	probes;		Artefacts	from	blood	and	coloured	dyes	if	present	on	tissue	surface		
	 (209)	 Cohort,	prospective,	single	centre		
47	 1	 79.0	 93.0	
	 (207)	 Cohort,	prospective,	single	centre		




47	 15	 60.02	 69.02	 Image	analysis	time-consuming	and	labour-intensive;		Small	sampling	area;		Artefacts	from	blood	and	coloured	dyes	if	present	on	tissue	surface				
	 (214)	 Cohort,	prospective,	single	centre		
37	 15	 100	 82.0	
	 (216)3	 Cohort,	prospective,	single	centre		
35	 23	 91.7	 92.1	
Raman	
spectroscopy	
(224)	 Meta-analysis	 699	 -4	 92.0	 97.0	 Weak-signal	intensity;		Control	of	light	environment	may	be	required			
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Technique	 Study	 Study	design	 No.	of	
patients	 No.	of	patients	with	pure	DCIS	 Sensitivity	(%)	 Specificity	(%)	 Limitations	
iKnife	 (238)	 Cohort,	prospective,	single	centre		
2	 0	 100	 100	
Requires	physical	disruption	of	tissue;		No	data	on	performance	in	DCIS		 (239)	 Cohort,	prospective,	single	centre		
66	 0	 93.0	 91.9	
ClearEdge	 (244)	 Cohort,	prospective,	single	centre		
58	 -	 87.3	 75.6	 -5	
1. Study	did	not	report	sensitivity	and	specificity,	but	did	show	a	non-significant	reduction	in	re-excision	rate	between	the	device	arm	and	control	arm,	respectively	(5.6%	versus	12.7%,	p	=	0.098)	2. In	the	table	the	average	sensitivity	and	specificity	are	displayed.	Depending	on	the	margin	definition,	sensitivity	and	specificity	ranged	between	55	–	65%	and	68	–	70%,	respectively	3. This	study	also	used	OCT	for	scanning	the	post-excision	surgical	cavity,	but	sensitivity	and	specificity	were	only	provided	for	ex	vivo	WLE	specimen	assessment	4. Of	the	7	studies	included	in	the	meta-analysis	2	studies	obtained	Raman	spectra	from	DCIS.	Diagnostic	performance	is	reported	in	one	study,	showing	an	accuracy	of	94%	for	DCIS	5. Data	from	more	studies	is	required	to	be	able	to	thoroughly	evaluate	the	pros	and	cons	of	this	technology	for	assessing	tumour	margins		
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1.6 Summary	Over	 the	 last	 century	breast	 cancer	 surgery	has	 significantly	 changed	by	moving	from	radical	 to	 conservative.	 In	early-stage	breast	 cancer,	 the	primary	 treatment	option	 for	 the	 majority	 of	 women	 is	 BCS	 by	 WLE	 of	 the	 tumour.	 BCS	 aims	 to	completely	 excise	 the	 lesion	 with	 a	 sufficient	 margin	 of	 healthy	 tissue,	 and	 in	combination	with	 radiotherapy,	 BCS	 provides	 similar	 oncological	 outcomes	 than	mastectomy.	What	constitutes	an	adequate	tumour	resection	margin	 is	subject	of	intense	debate,	but	to	date	approximately	10	–	30%	of	BCS	patients	undergo	a	re-operation	 because	 tumour	 margins	 are	 deemed	 insufficient.	 Re-operations	potentially	have	several	negative	consequences	including	delay	in	commencement	of	adjuvant	therapy,	worse	cosmesis,	and	increased	patient	anxiety	and	health	care	costs.	 Surgical	 techniques	 in	 the	 form	 of	 routine	 cavity	 shavings	 or	 oncoplastic	BCS	may	 be	 performed	 in	 an	 attempt	 to	 reduce	 re-excision	 rates,	 but	 success	 of	such	approaches	are	limited	due	to	inherent	microscopic	nature	of	breast	cancer,	making	the	use	of	palpation	and	visual	inspection	to	accurately	assess	the	extent	of	the	 tumour	 and	 margins	 of	 excision	 challenging.	 Several	 imaging	 and	histopathological	 techniques	to	assess	tumour	resection	margins	 intraoperatively	are	 currently	 available	 for	 clinical	 use,	 but	 these	 techniques	 have	 failed	 to	penetrate	 routine	 practice	 due	 to	 limitations	 in	 terms	 of	 diagnostic	 accuracy,	reporting	 times,	 logistics	or	 technical	demands.	A	variety	of	novel	 intraoperative	margin	assessment	techniques	have	emerged	in	recent	years,	which	are	currently	being	evaluated	 in	a	clinical	 trial	setting.	Results	on	the	speed,	cost-effectiveness,	and	usability	of	these	techniques	have	not	yet	been	published,	and	information	on	the	 impact	 on	 re-excision	 rate	 is	 limited.	 Thus,	 the	 potential	 value	 of	 these	
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techniques	 for	 improving	quality	of	care	 in	BCS	and	reducing	health	care	costs	 is	yet	unknown.																									
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1.7 Aim	This	 thesis	 aims	 to	 evaluate	 two	 novel,	 innovative	 imaging	 techniques	 to	intraoperatively	assess	tumour	resection	margins	in	BCS:		1. Terahertz	Pulsed	Imaging	(TPI)		2. Cerenkov	Luminescence	Imaging	(CLI)		To	 use	 TPI	 for	 scanning	 tumour	 resection	 margins	 on	 excised	 WLE	 specimens	Teraview	 Ltd.	 (Cambridge,	 UK)	 has	 developed	 a	 TPI	 handheld	 probe	 system.	 A	first-in-human,	 single	 centre	 study	was	 performed	 to	 evaluate	 the	 ability	 of	 this	device	to	discriminate	benign	from	malignant	breast	tissue	ex	vivo	(Section	2.3).		To	 use	 CLI	 for	 assessing	 tumour	 resection	 margins	 on	 excised	 WLE	 specimens	Lightpoint	 Medical	 Ltd.	 (Chesham,	 UK)	 has	 developed	 an	 intraoperative	 CLI	imaging	 device.	 A	 first-in-human,	 single	 centre	 clinical	 trial	 was	 performed	 to	evaluate	 the	 feasibility,	 safety,	 and	performance	of	 intraoperative	 18F-FDG	CLI	 to	assess	tumour	margin	status	in	breast	cancer	patients	undergoing	BCS	with	SLNB	or	with	ALND	(Section	3.4).									
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2. Terahertz	pulsed	 imaging	to	assess	 tumour	resection	margins	
in	breast-conserving	surgery	This	 chapter	 describes	 terahertz	 pulsed	 imaging	 (TPI)	 and	 its	 application	 for	imaging	cancer,	with	a	specific	focus	on	the	feasibility	of	TPI	for	margin	assessment	in	breast	cancer.	The	first	part	of	this	chapter	provides	an	introduction	to	terahertz	(THz)	 radiation,	THz	 imaging	 systems,	 and	 the	 interaction	of	THz	 radiation	with	biological	tissue.	This	is	followed	by	an	overview	of	the	published	literature	on	the	use	of	THz	in	cancer	imaging	to	date,	and	the	studies	undertaken	in	breast	cancer.	The	 last	 part	 of	 this	 chapter	 focuses	 on	 the	 first-in-human	 ex	 vivo	 study	 I	 have	conducted	to	evaluate	the	ability	of	a	handheld	TPI	device	to	discriminate	benign	from	malignant	breast	tissue.			
2.1 Introduction	to	terahertz	radiation	and	terahertz	pulsed	imaging	THz	radiation	covers	the	frequency	range	from	0.1-10	THz	on	the	electromagnetic	spectrum	(1	THz	=	1012	Hz),	corresponding	to	a	wavelength	of	3	mm	-	30	μm.	The	THz	spectrum	was	previously	known	as	the	‘THz	gap’,	due	to	a	lack	of	efficient	THz	sources	and	detectors.	This	changed	in	1975	with	the	advent	of	the	Auston	Switch;	an	optically-gated	photoconductive	 emitter	 to	 generate	 and	detect	THz	 radiation	(247).	 Furthermore,	 the	 development	 of	 stable,	 turnkey	 ultrafast	 lasers	 in	 the	1980s	 helped	 accelerate	 progress	 in	 the	 development	 of	 THz	 technology	 (248).		Since	 then,	THz	 technology	has	advanced	 rapidly.	Optimised	THz	generators	and	detectors	 have	 evolved,	 and	 affordable	 THz	 systems	 are	 now	 commercially	available.	As	a	result	of	 this,	THz	has	become	a	new	area	 for	research	 in	physics,	biology,	materials	science	and	medicine.	Between	1994	and	2013,	 the	number	of	
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THz	related	journal	publications	has	almost	grown	exponentially,	and	THz	related	biomedical	research	is	being	conducted	by	several	groups	worldwide	(249).			
2.1.1 Terahertz	systems	The	plethora	of	THz	applications	has	resulted	in	the	development	of	a	wide	variety	of	THz	systems.	Among	others,	the	laser	source	used,	the	technique	for	generation	and	 detection	 of	 THz	 electromagnetic	 (EM)	waves,	 the	 image	 geometry,	 and	 the	consideration	 of	 using	 spectroscopy	 or	 imaging	 are	 all	 components	 that	 can	 be	modified	 in	 terahertz	 systems	 depending	 on	 the	 type	 of	 application	 and	 user	requirements.		
Continuous	wave	versus	pulsed	wave	Depending	 on	 the	 laser	 source,	 THz	 radiation	 can	 be	 generated	 as	 a	 continuous	wave	 (CW)	 or	 as	 a	 pulsed	 wave.	 The	 former	 typically	 generates	 radiation	 of	 a	single	fixed	frequency,	and	is	therefore	generally	restricted	to	applications	where	only	 features	 at	 specific	 frequencies	 are	 of	 interest	 (250).	 Pulsed	wave	 systems	generate	 broadband	 THz	 radiation	 up	 to	 several	 THz,	 with	 the	 possibility	 of	coherent	 detection.	 Such	 a	 system	 is	 used	 in	 this	 project.	 Coherent	 detection	comprises	 the	 recording	 of	 the	 amplitude	 and	 phase	 of	 THz	 waves	 in	 the	 time	domain,	which	can	be	used	to	obtain	more	details	of	the	target	such	as	spectral	and	depth	information	(251).	This	broadens	the	applicability	of	pulsed	wave	systems,	but	 due	 to	 the	 higher	 costs	 of	 a	 pulsed	 laser	 source	 these	 systems	 are	 generally	more	expensive.					
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Generation	and	detection	of	THz	radiation	The	 most	 common	 setup	 used	 in	 pulsed	 wave	 THz	 systems	 comprises	 a	femtosecond	 (1	 fs	 =	 10-15	 sec)	 laser	 and	 a	 photoconductive	 emitter	 and	detector	(250).	The	emitter	consists	of	a	semiconductor	crystal	and	two	planar	electrodes	(Figure	 2).	 The	 incidence	 of	 the	 laser	 pulse	 on	 the	 photoconductive	 emitter	releases	 electron-hole	 pairs.	 Applying	 an	 electric	 field	 across	 the	 two	 electrodes	then	accelerates	these	charge-carriers.	As	a	result	of	accelerating	the	electron-hole	pairs,	electromagnetic	THz	waves	are	produced	which	then	radiate	into	free	space.	The	 spectral	 range	 of	 the	 generated	 THz	 waves	 depend	 on	 various	 conditions,	including	 the	 shape	 and	 power	 of	 the	 input	 laser	 pulse,	 the	 voltage,	 and	 the	characteristics	of	the	crystal	used	in	the	photoconductive	emitter	(252).	
	Figure	2:	Terahertz	photoconductive	emitter.	 In	 this	example	a	100	 femtosecond	(fs)	 800	 nm	 laser	 pulse	 is	 incident	 on	 a	 semiconductor	 crystal	 made	 of	 low	temperature	gallium	arsenide	(LT-GaAs),	resulting	in	the	emission	of	THz	pulses.	
Image	was	reproduced	from	(253)	with	kind	permission	from	Elsevier.		Detection	of	THz	radiation	essentially	works	in	reverse	order	to	THz	emission.	THz	electromagnetic	 waves	 incident	 on	 the	 photoconductive	 receiver	 accelerate	 the	electron-hole	 pairs	 produced	 by	 the	 incident	 femtosecond	 laser	 beam.	 The	amplitude	 of	 the	 resultant	 electric	 field	 is	 then	 measured.	 By	 measuring	 the	
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amplitude	at	a	number	of	discrete	time	points,	an	entire	THz	pulse	profile	can	be	reconstructed	 in	 the	 selected	 time	 domain	 range	 (254),	 and	 analysis	 of	 the	 THz	pulse	can	provide	unique	information	about	the	sample	of	interest.		
System	geometries		THz	 systems	 can	 operate	 in	 two	 geometries:	 reflection	 and	 transmission.	 In	 the	former	THz	radiation	reflected	off	 the	sample	 is	detected,	while	 in	 the	 latter	THz	radiation	 that	 is	 transmitted	 through	 the	 sample	 is	 detected.	 Due	 to	 the	 strong	attenuation	 in	 biological	 tissue	 as	will	 be	 further	 explained	 in	 Section	 2.1.3,	 THz	imaging	 in	 transmission	 geometry	 is	 limited	 to	 very	 thin	 samples	 (typically	 less	than	 a	 few	millimetres)	 in	 order	 to	 acquire	data	with	 a	 sufficient	 signal-to-noise	ratio	(255).	Obtaining	thin	samples	is	challenging	because	fresh	tissue	is	soft	and	highly	 deformable.	 Besides,	 thin	 samples	 are	 more	 susceptible	 to	 drying,	 which	could	 affect	 the	 properties	 of	 the	 tissue	 in	 the	THz	 frequency	 range.	 Conversely,	samples	used	for	imaging	in	reflection	geometry	are	preferably	a	few	millimetres	thick	 to	 prevent	 interference	 of	 THz	 pulses	 reflected	 from	 non-tissue	 structures	located	 underneath	 the	 tissue	 sample	 (253).	 These	 factors	 should	 carefully	 be	considered	when	deciding	on	the	preferred	imaging	geometry.	For	the	purpose	of	using	THz	imaging	to	distinguish	malignant	from	benign	breast	tissue	in	an	ex	vivo	setting,	a	reflection-based	imaging	system	is	required,	as	excised	breast	specimens	are	much	thicker	than	a	few	millimetres.			
Terahertz	pulsed	spectroscopy	and	Terahertz	pulsed	imaging		THz	 pulsed	 spectroscopy	 (TPS)	 is	 primarily	 performed	 to	 determine	 the	 optical	properties,	 i.e.	absorption	coefficient	and	refractive	 index,	of	a	sample	 in	the	THz	frequency	domain.	 	TPS	was	 first	described	 in	1995	by	Hu	et	al.	 (256).	 In	TPS,	a	
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Fourier	 transform	 is	 applied	 to	 the	 time	 domain	 data,	 thereby	 obtaining	information	in	the	frequency	domain.	By	performing	an	analysis	on	the	frequency	domain	data	as	described	 in	detail	by	Fitzgerald	et	al.	 (254)	and	Ashworth	et	al.	(257),	 the	 complex	 refractive	 index	 can	 be	 extracted,	 from	which	 the	 frequency	dependent	real	refractive	index	and	real	absorption	coefficient	can	be	derived.	Terahertz	 pulsed	 imaging	 (TPI)	 can	 be	 viewed	 as	 an	 extension	 of	 TPS,	whereby	THz	pulses	from	a	sample	are	detected	over	one	(x)	or	two	(x,	y)	spatial	dimensions	 to	 create	 an	 image	 (258).	 In	 2-dimensional	 imaging	 each	 spatial	coordinate	(x,	y)	acquires	THz	pulses,	and	these	pulses	can	be	analysed	in	both	the	time	and	frequency	domain	to	obtain	unique	biological	information	on	the	sample.	It	 is	 also	 possible	 to	 look	 within	 a	 sample,	 as	 THz	 waves	 are	 reflected	 at	 an	interface	 of	 two	 structures	 with	 a	 different	 refractive	 index.	 THz	 waves	 from	deeper	 located	structures	will	be	reflected	at	a	slightly	 later	 time	point,	and	thus	the	 depth	 of	 each	 structure	 can	 be	 estimated	 by	 analysing	 the	 time	 it	 requires	before	a	THz	wave	is	detected.	This	‘time-of-flight’	technique	enables	obtaining	TPI	images	that	provide	a	3D-view	of	a	layered	structure	(259).			
2.1.2 Terahertz	contrast	mechanisms	in	biological	tissue	The	contrast	observed	in	TPI	of	biological	tissue	is	indirectly	a	result	of	differences	in	 the	 absorption	 coefficient	 and	 refractive	 index	 within	 the	 tissue	 sample.	Although	 the	 underlying	 mechanism	 behind	 the	 change	 in	 optical	 properties	 of	tissue	 in	 the	THz	 frequency	range	 is	not	 fully	understood,	 it	 is	known	that	water	plays	 an	 important	 role.	 In	 water,	 and	 other	 polar	 liquids,	 the	 hydrogen	 bonds	between	molecules	(intermolecular)	and	within	a	single	molecule	(intramolecular)	strongly	 vibrate	 in	 the	 THz	 frequency	 range	 (260).	 As	 a	 result	 of	 this	 strong	vibrational	 sensitivity,	 THz	 radiation	 is	 highly	 absorbed	 by	 water.	 Since	 water	
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molecules	 are	 the	main	 component	 in	 biological	 structures	 and	within	 cells,	 the	high	sensitivity	of	THz	to	water	provides	an	intrinsic	contrast	mechanism	that	can	be	 exploited	 for	 biomedical	 applications.	 Cancers,	 including	 breast	 cancer,	 are	known	 to	 have	 higher	 water	 content	 when	 compared	 with	 benign	 tissue,	 thus	making	THz	imaging	an	especially	promising	modality	in	cancer	diagnostics	(261-266).	The	increased	water	content	in	cancers	is	amongst	other	factors	thought	to	be	 a	 result	 of	 impeded	 diffusion	 due	 to	 increased	 cellularity,	 neovascularisation,	necrosis	 and	 inflammation	 (261,263).	 However,	 water	 content	 is	 not	 the	 sole	source	of	contrast	 in	THz	imaging	of	cancers	as	shown	by	studies	on	dehydrated,	wax-embedded	tissue	samples	(267-269).	It	has	been	suggested	that	the	observed	contrast	in	the	absence	of	water	is	due	to	differences	in	proteins	and	lipid	content	present	 in	 certain	 cancers,	 or	 from	 other	 cellular	 or	 structural	 changes	(263,270,271).	 Current	work	 focuses	 on	 obtaining	 a	 better	 understanding	 of	 the	contrast	mechanisms	 that	 contribute	 to	 the	differences	observed	 in	THz	 imaging	between	 benign	 and	 malignant	 tissue.	 An	 improved	 understanding	 of	 these	mechanisms	 could	 enable	 identification	 of	 changes	 in	 the	 composition	 and	physiology	of	biological	tissue	based	on	the	characteristics	of	the	THz	pulse	(272).			
2.1.3 Penetration	depth	and	spatial	resolution		The	 high	 absorption	 of	 THz	 by	 water	 limits	 the	 penetration	 of	 the	 radiation	 in	biological	tissue.	The	penetration	depth	is	dependent	on	the	frequency	of	the	THz	radiation,	 the	absorption	coefficient	of	 the	 tissue,	and	 the	signal-to-noise	 ratio	of	the	imaging	system.	MacPherson	et	al.	found	that	for	a	signal-to-noise	ratio	of	1000	at	1	THz,	the	penetration	depth	in	skin	and	adipose	tissue	was	0.5	mm	and	3	mm,	respectively	 (255).	 The	 deeper	 penetration	 of	 THz	 radiation	 in	 adipose	 tissue	 is	due	 to	 lower	 water	 content	 compared	 to	 skin	 tissue,	 which	 results	 in	 a	 lower	
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absorption	coefficient	in	the	THz	frequency	range.	Overall,	 it	 is	 important	to	note	that	higher	 frequencies	penetrate	 less	deeply	 into	 tissue	 than	 lower	 frequencies.	The	handheld	TPI	probe	used	in	the	breast	study	(Section	2.3.2.1)	has	a	bandwidth	of	0.1	–	1.8	THz.	 In	adipose	tissue,	of	which	the	breast	predominantly	consists,	 it	can	 therefore	 be	 assumed	 that	 the	 penetration	 depth	 will	 be	 a	 few	 millimetres	maximum.	Hence,	this	device	is	specifically	suited	for	imaging	tumour	cells	within	a	few	millimetres	of	the	resection	border,	and	is	not	applicable	to	imaging	deeper	located	structures.			 Image	resolution	is	also	an	important	aspect	when	using	TPI	for	biomedical	imaging.	Resolution	can	be	divided	into	lateral	resolution	and	axial	resolution.	The	former	 is	 defined	 as	 the	 distance	 at	which	 two	 points	 are	 distinguishable	 in	 the	direction	 perpendicular	 to	 the	 direction	 of	 the	 THz	 pulse,	while	 the	 latter	 is	 the	distance	 between	 two	 distinguishable	 points	 in	 the	 direction	 parallel	 to	 the	direction	of	 the	THz	pulse.	Lateral	resolution	 is	calculated	by	using	 the	Rayleigh-based	equation	(273):	
!"#$%"& !"#$%&'($) = 1.22 !2 ! sin! =  0.61 ! !" 	where	 λ	 is	 the	 wavelength,	 n	 the	 refractive	 index	 of	 the	 sample,	 θ	 the	 angle	 at	which	the	reflected	THz	pulse	enters	the	system,	and	NA	 the	numerical	aperture.	For	 radiation	 with	 a	 frequency	 of	 1.8	 THz	 and	 0.1	 THz,	 and	 a	 system	 with	 an	optimal	optical	arrangement	in	which	NA	is	1,	the	lateral	resolution	is	135	μm	and	1.83	mm,	respectively.	Axial	resolution	depends	on	the	system’s	bandwidth	(BW)	and	 the	 refractive	 index	 of	 the	 sample	 (n),	 and	 can	 be	 calculated	 by	 using	 the	following	equation	(255):	 !"#$% !"#$%&'($) = !2!"#	
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where	c	is	the	speed	of	light	in	air	(approximately	3	x	108	m	s-1).		The	bandwidth	of	the	handheld	TPI	probe	system	 is	1.7	THz	(0.1	–	1.8	THz).	Assuming	a	refractive	index	 of	 1.6,	 2.0	 and	 2.2	 at	 1	 THz	 for	 adipose,	 fibrous	 and	 tumour	 tissue	respectively	(274),	 the	axial	resolution	of	 the	system	ranges	between	0.04	–	0.06	mm	(40	–	60	μm).	It	should	be	noted	that	the	lateral	and	axial	resolution	calculated	above	 present	 the	 theoretical	 limits,	 and	 depend	 amongst	 other	 factors	 on	 the	system	configurations	(including	the	number	of	pixels	and	pixel	size),	fluctuations	in	 the	 laser	 source	 and	 the	 quality	 of	 the	 measurement	 itself.	 The	 practical	resolution	of	TPI	systems	will	be	 lower,	but	unfortunately	no	data	is	available	on	the	 lateral	 and	 axial	 resolution	 of	 the	 TPI	 handheld	 probe	 system	 used	 in	 the	breast	study	(Section	2.3.2.1).	As	 explained	 in	 this	 section,	 lateral	 resolution,	 axial	 resolution	 and	penetration	 depth	 are	 all	 frequency	 dependent.	 Higher	 frequency	 THz	 radiation	provides	 a	 better	 image	 resolution,	while	 decreasing	 the	 penetration	 depth.	 The	0.1	 –	 1.8	 THz	 frequency	 range	 of	 the	 TPI	 handheld	 probe	 is	 a	 good	 trade-off	between	high	imaging	resolution	and	a	sufficient	penetration	depth	that	meets	the	positive	margin	definition	of	<1	mm	as	per	current	ABS	consensus	(Table	1).			
2.1.4 Biological	effects	of	terahertz	radiation	Due	 to	 the	 recent	 surge	 in	 the	 use	 of	 TPI	 for	 biomedical	 applications,	 and	 the	expected	increase	in	the	near	future,	there	has	been	vast	scientific	 interest	 in	the	effects	 of	 THz	 radiation	 on	 biological	 tissue	 (275).	 The	 energy	 level	 of	 THz	radiation	with	a	wavelength	of	1	THz	is	roughly	4.14	meV,	which	is	much	less	than	the	keV	and	MeV	energies	that	are	typical	for	X-ray	beams	(276).	Moreover,	this	is	far	 below	 the	 typical	 energy	 (several	 eVs)	 required	 to	 remove	 electrons	 from	biological	 molecules,	 and	 thus	 THz	 is	 a	 non-ionising	 type	 of	 radiation	 (277).	
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Because	 of	 its	 lower	 energy,	 THz	 radiation	 interacts	 differently	 with	 living	 cells	than	high-energy	ionizing	radiation	from	for	example	ultraviolet	 light,	X-rays	and	gamma	rays.	The	current	understanding	of	 the	biological	effects	of	THz	radiation	is,	however,	still	limited	(277).	Most	studies	have	found	that	THz	radiation	did	not	cause	DNA	damage	 (278-282),	 although	one	 study	did	 find	 changes	 indicative	of	DNA	damage	in	human	skin	tissue	exposed	to	THz	radiation	(283).	Changes	in	gene	expression	 after	 exposure	 to	 THz	 radiation	 have	 also	 been	 reported	 (284-289).	Some	 of	 these	 studies	 report	 upregulation	 of	 inflammation	 genes	 and	 gene	instability	 that	 could	 lead	 to	an	 increased	cancer	 risk	 (287,289),	 although	others	found	 that	 these	changes	were	not	 carcinogenic;	 it	has	even	been	suggested	 that	THz	radiation	could	provide	new	therapeutic	treatments	for	certain	skin	diseases	(285,286).	 The	 risk	 for	 damaging	 effects	 to	 occur	 is	 amongst	 other	 factors	dependent	on	the	tissue	type,	study	design	(in	vitro,	ex	vivo,	in	vivo)	and	exposure	conditions	 including	 the	 energy	 density,	 duration	 and	 frequency	 of	 the	 THz	radiation	(277).	Since	these	factors	were	very	different	in	all	the	above	studies,	it	is	difficult	 to	 draw	 any	 conclusions	 on	 the	 effects	 of	 THz	 radiation	 on	 biological	tissues.	Besides,	 no	 studies	have	been	published	 to	date	on	 the	 effects	 on	breast	tissue,	so	the	safety	of	THz	in	breast	cancer	remains	unknown.	Hence,	further	work	is	needed	to	establish	the	THz	exposure	conditions	that	induce	damaging	effects	in	biological	tissue	in	general,	and	breast	tissue	in	particular.			
2.2 Terahertz	for	cancer	imaging	As	 described	 above	 the	 sensitivity	 of	 THz	 radiation	 to	 changes	 in	water	 content	and	tissue	composition,	 in	combination	with	its	submillimeter	imaging	resolution	and	low	energy	levels,	make	THz	a	potential	application	for	imaging	cancers.	Most	of	the	work	on	the	use	of	THz	for	imaging	malignancies	has	focused	on	skin,	colon	
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and	breast	cancer.	A	description	of	the	results	published	to	date	in	these	types	of	cancer	can	be	found	in	the	sections	below.	The	studies	discussed	specifically	focus	on	 fresh	tissue	specimens	as	opposed	to	processed	specimens,	 i.e.	 formalin	 fixed,	paraffin	embedded	or	freeze	dried	tissue,	as	processing	of	human	tissue	alters	its	water	 content	 and	 structure,	 which	 in	 turn	 affects	 the	 tissue’s	 response	 to	 THz	radiation.	This	prevents	accurate	comparison	of	results	from	studies	on	processed	samples	with	studies	using	fresh	unprocessed	samples,	including	the	TPI	handheld	probe	breast	study	discussed	in	Section	2.3.	In	addition	to	its	use	in	imaging	skin,	colon	and	breast	cancer,	studies	have	also	shown	that	THz	technology	can	successfully	be	applied	for	ex	vivo	imaging	of	oral	 (290,291),	 gastric	 (292,293),	 and	 brain	 cancer	 specimens	 (294),	 as	 well	 as	metastatic	 lymph	nodes	 in	patients	with	 cervical	 cancer	 (295).	These	 small	 pilot	studies	 have	 all	 used	 processed	 specimens	 rather	 than	 fresh	 specimens,	 and	 a	detailed	description	of	these	findings	is	therefore	not	provided.			
2.2.1 	Skin	cancer	Skin	cancer	 is	 the	most	common	 form	of	cancer	globally	and	can	be	divided	 into	non-melanocytic	 and	melanocytic	 types	 (296).	 Skin	 cancers	 are	 often	 treated	 by	surgical	 excision,	where	 the	 aim	 is	 to	 excise	 the	 tumour	with	 a	margin	 of	 a	 few	millimetres	of	healthy	tissue	(296).	Ideally	Moh’s	micrographic	surgery	is	used;	a	technique	 where	 the	 tumour	 is	 excised	 in	 layers,	 and	 each	 layer	 is	 assessed	histologically	during	surgery	to	obtain	information	on	the	tumour	margin	distance.	Although	Moh’s	surgery	has	a	success	rate	of	approximately	95%	(297),	it	is	time-consuming	and	labour	intensive,	and	a	non-invasive	method	to	accurately	diagnose	skin	cancer	and	facilitate	delineation	of	tumour	margins	would	be	a	major	benefit	to	patients	and	healthcare	systems	(298).	
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The	use	of	TPI	to	non-invasively	diagnose	basal	cell	carcinoma	(BCC),	which	accounts	 for	approximately	80%	of	all	non-melanomatous	skin	cancers,	was	 first	described	 in	 2003	 by	 Woodward	 et	 al.	 (299).	 They	 scanned	 21	 excised	 skin	samples	 ex	 vivo	 with	 a	 0.1	 –	 2.7	 THz	 broadband	 imaging	 device	 in	 reflection	geometry.	 The	 raw	 THz	 waveforms	 were	 filtered	 to	 remove	 high	 and	 low	frequency	 noise,	 and	 divided	 by	 a	 reference	 waveform,	 to	 obtain	 processed	waveforms	 (called	 impulse	 functions).	 THz	 images	were	 generated	 based	 on	 the	minimum	peak	value	(Emin)	of	the	impulse	function	of	each	pixel,	and	a	significant	difference	 between	 the	 Emin	 of	 BCC	 and	 normal	 skin	 tissue	 was	 found.	 This	enabled	distinguishing	benign	from	malignant	skin	tissue	on	TPI	(Figure	3).	
	Figure	 3:	 Ex	 vivo	 TPI	 of	 skin	 tissue	 containing	 basal	 cell	 carcinoma.	 Left:	photographic	 image	 of	 BCC	 (solid	 boundaries)	 and	 benign	 skin	 tissue	 (dashed	boundary).	Centre:	Histograms	showing	the	Emin	values	and	standard	deviations	for	BCC	areas	d1	and	d2,	and	benign	tissue	areas	n1	and	n2.	Right:	TPI	image	with	clear	contrast	between	BCC	and	benign	tissue	that	enables	identification	of	tumour	margins.	Image	was	reproduced	from	(299)	with	kind	permission	from	Elsevier.		In	 2004,	 Wallace	 et	 al.	 confirmed	 the	 ability	 of	 TPI	 to	 image	 BCC	 ex	 vivo	 in	reflection	mode,	 and	 also	 showed	 that	 TPI	 could	 be	 used	 in	 vivo	 to	 identify	 the	extent	of	BCC	and	delineate	 the	margins	of	 excision	using	a	portable	TPI	 system	(TPI	Scan,	TeraView	Ltd.,	UK)	(300).	Scanning	a	2	cm2	area	took	roughly	4	minutes	and,	although	not	real-time,	showed	that	images	could	be	acquired	within	a	time-period	suitable	to	guide	surgical	excision.	
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TPS	 measurements	 of	 fresh	 tissue	 with	 a	 THz	 spectrometer	 (TPI	Spectra1000,	 TeraView	 Ltd.,	 UK)	 revealed	 that	 BCC	 has	 a	 higher	 absorption	coefficient	 and	 refractive	 index	 than	 benign	 skin	 tissue,	which	was	 attributed	 to	the	 higher	 water	 content	 found	 in	 BCC	 (301).	 These	 findings	 thus	 offer	 an	explanation	for	the	observed	contrast	in	TPI	of	BCC.		A	 CW	 THz	 imaging	 system	 as	 a	 lower-cost	 alternative	 for	 the	 pulsed	imaging	 systems	 described	 above	 has	 also	 been	 successfully	 used	 in	 ex	 vivo	imaging	of	fresh	BCC	specimens	(302).	The	same	research	group	also	showed	that	besides	water,	tryptophan	could	be	a	potential	intrinsic	biomarker	for	THz	imaging	of	skin	cancer,	as	this	component	of	the	human	skin	proved	to	be	sensitive	to	THz	radiation	in	the	1.84	THz	range	(271).		A	combination	of	optical	and	CW	THz	imaging	has	also	been	described	for	imaging	 non-melanocytic	 skin	 cancer	 (303).	 Six	 BCC	 and	 three	 squamous	 cell	carcinoma	 samples	 were	 scanned	 ex	 vivo.	 THz	 proved	 useful	 in	 indicating	 the	approximate	 location	 of	 the	 tumour,	 while	 the	 optical	 images	 provided	 the	morphological	 detail	 needed	 to	 demarcate	 the	 boundaries	 of	 the	 tumour.	 This	indicates	 that	 for	 optimal	 delineation	 of	 non-melanocytic	 skin	 cancers	 (and	potentially	 other	 cancers	 as	 well),	 a	 combination	 of	 imaging	 modalities	 may	 be	preferred.		It	 is	 currently	 not	 yet	 known	whether	THz	 imaging	 can	be	 used	 to	 image	melanocytic	 skin	 cancers,	 nor	 is	 there	 information	 on	 the	 ability	 of	 THz	 to	differentiate	between	types	of	skin	cancer,	so	 further	studies	to	 investigate	other	skin	lesions	are	warranted	(253).			
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2.2.2 Colon	cancer	Colon	 cancer	 screening	 aims	 to	 detect	 pre-cancerous	 dysplastic	 polyps	 and	cancerous	 lesions	 at	 an	 early	 stage	 as	 the	 prognosis	 of	 colon	 cancer	 improves	profoundly	 if	 the	 disease	 is	 detected	 and	 treated	 early	 (304).	 Subjects	 with	abnormal	screening	results	undergo	a	colonoscopy	during	which	suspicious	areas	are	 biopsied	 to	 establish	 a	 diagnosis.	 However,	 identifying	malignant	 lesions	 on	endoscopic	 imaging	 can	be	 challenging,	 especially	 because	dysplastic	 tissue	 (and	some	 inflammatory	diseases)	 can	be	hard	 to	distinguish	 from	malignant	disease.	Implementation	 of	 THz	 imaging	 in	 an	 endoscopic	 system	 could	 therefore	 aid	 in	more	accurate	detection	of	colon	cancer.		The	 use	 of	 THz	 technology	 to	 image	 colon	 cancer	 was	 first	 described	 in	2011	(305).	Typically	around	30	minutes	post	excision,	cancerous,	dysplastic	and	healthy	colon	tissue	was	scanned	from	a	total	of	30	patients,	using	a	reflection	THz	imaging	 system	 (TPIimaga1000,	 TeraView	 Ltd.,	 UK).	 It	 was	 found	 that	 the	absorption	 coefficient	 and	 refractive	 index	 were	 higher	 for	 neoplastic	 tissue	(cancer	 and	 dysplasia)	 than	 for	 benign	 tissue.	 Staining	 of	 the	 pathology	 slides	revealed	 differences	 in	 angiogenesis	 of	 blood	 vessels	 and	 lymphatic	 vessels	between	 normal	 colon	 tissue,	 dysplastic	 tissue	 and	 cancer,	 indicating	 that	 the	observed	contrast	may	be	due	to	differences	in	water	content	as	well	as	structural	differences.	 A	 total	 of	 17	 parameters	 in	 the	 time	 and	 frequency	 domain	 were	calculated	from	the	impulse	functions,	with	the	aim	of	constructing	an	automated	model	for	the	classification	of	healthy,	dysplastic	and	cancerous	colon	tissue.	Initial	results	based	on	logistic	regression	analysis	showed	a	sensitivity	and	specificity	of	82%	 and	 77%	 for	 distinguishing	 healthy	 from	 dysplastic	 and	 cancerous	 tissue,	respectively.	Sensitivity	and	specificity	 for	discriminating	healthy	 from	dysplastic	tissue	alone	was	89%	and	71%,	 respectively.	 Interestingly,	 the	parameter	values	
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from	 samples	 consisting	 of	 the	 same	 tissue	 type,	 but	 obtained	 from	 different	patients,	showed	variations.	The	authors	suggest	that	adjusting	for	these	patient-to-patient	 variations	 (also	 called	 inter-patient	 variability),	 by	 using	 the	 healthy	tissue	 measurements	 of	 each	 individual	 patient	 as	 a	 reference	 to	 calibrate	 the	system,	 could	 improve	 the	 contrast	 between	 healthy,	 dysplastic	 and	 cancerous	colon	tissue,	thus	improving	the	discriminative	power.	Eadie	 et	 al.	 used	 the	 17	 parameters	 from	 the	 same	 ex	 vivo	 colon	 tissue	dataset	 and	 applied	 additional	 analyses	 to	 evaluate	 whether	 the	 diagnostic	accuracy,	 i.e.	 sensitivity	 and	 specificity,	 could	 be	 improved	 (306).	 Both	 principal	component	analysis	(PCA)	and	decision	trees	were	applied	to	the	17	parameters	to	reduce	 the	 number	 of	 inputs,	 and	 thereby	 model	 complexity,	 while	 preventing	overfitting	 of	 the	 data.	 By	 reducing	 the	 number	 of	 data	 inputs,	 data	 reduction	methods	 also	 improve	 the	 efficiency	 of	 the	 algorithm	 compared	 to	 using	 the	 full	dataset,	 which	 enables	 near	 real-time	 classification	 required	 to	 use	 THz	 in	 an	intraoperative	 setting.	 Neural	 networks	 and	 support	 vector	 machine	 (SVM)	algorithms	were	 used	 to	 provide	 tissue	 classifications	 based	 on	 cross-validation.	By	 using	 such	 intelligent	 analysis	 methods,	 diagnostic	 accuracy	 improved	remarkably.	 Depending	 on	 which	 data	 reduction	 and	 classification	 method	 was	used,	 sensitivity	 and	 specificity	 for	 classifying	 healthy	 from	 both	 dysplastic	 and	cancerous	 tissue	 exceeded	 92%	 and	 87%	 respectively,	 while	 for	 healthy	 and	dysplastic	 tissue	 values	 higher	 than	 96%	 and	 87%	 were	 reported.	 By	 applying	these	 methods	 to	 the	 data	 obtained	 from	 three	 new	 patients	 who	 were	 not	included	in	the	initial	dataset,	they	were	able	to	show	that	the	technique	could	be	generalized	to	further	patients,	and	that	patient	specific	calibration	of	the	system	as	suggested	by	Reid	et	al.	may	not	be	needed.	However,	classification	in	one	of	the	three	patients	was	 less	accurate,	 indicating	 that	 inter-patient	variations	may	still	
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cause	problems,	 and	 that	 a	 larger	 dataset	 is	 required	 to	 draw	 conclusions	 about	the	feasibility	of	a	‘one-size	fits	all’	approach.			In	 order	 to	 use	 THz	 imaging	 to	 aid	 in	 vivo	 discrimination	 of	 benign	 and	cancerous	 colon	 tissue	 during	 colonoscopy,	 implementation	 of	 the	 technology	within	 a	 clinical	 endoscope	 is	 paramount.	 Several	 groups	 have	 worked	 on	developing	THz	endoscopic	 imaging	systems	(307-310).	So	 far,	Doradla	et	al.	 are	the	only	ones	who	tested	the	performance	of	their	device	on	human	cancer	tissue	(310).	A	total	of	six	formalin	fixed	specimens	(three	cancerous	and	three	benign)	were	imaged	ex	vivo	with	a	prototype	single-channel	CW	THz	endoscopic	system	in	reflection	mode.	An	increased	reflection	was	found	in	malignant	tissue	compared	to	 healthy	 tissue,	 which	 was	 attributed	 to	 greater	 scattering	 form	 structural	changes	in	the	diseased	tissue	including	an	increased	vasculature.	Although	these	results	appear	to	be	a	promising	step	towards	the	use	of	THz	technology	to	image	organs	previously	inaccessible,	in	vivo	studies	are	needed	to	assess	the	real	benefit	of	THz	in	aiding	detection	of	cancerous	colon	lesions.		
2.2.3 Breast	cancer	Breast	 tissue	 in	 patients	 with	 breast	 cancer	 can	 be	 sub-divided	 into	 fibrous,	adipose	and	tumour	tissue.	Various	research	groups	have	studied	the	ability	of	THz	technology	to	discriminate	between	benign	breast	 tissue	and	tumour	tissue,	with	the	 aim	 of	 eventually	 using	 THz	 imaging	 for	 intraoperative	 tumour	 margin	evaluation	 to	 reduce	 re-excision	 rates	 in	 BCS.	 This	 section	 provides	 a	 non-exhaustive	overview	of	the	results	published	to	date.				 The	application	of	THz	 technology	 to	breast	 cancer	was	 first	proposed	by	Fitzgerald	et	al.	in	2004	(311).		Freshly	excised	breast	samples	were	scanned	using	a	 portable	 TPI	 imager	 (TPI	 Scan,	 TeraView	 Ltd.,	 UK).	 This	 device	 operates	 in	
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reflection	 geometry	 and	 emits	 broadband	 radiation	 of	 0.1	 –	 3.0	 THz.	 Impulse	functions	 were	 obtained	 by	 processing	 the	 raw	 THz	 waveforms,	 and	 two	parameters	 in	 the	 time	 domain	 were	 calculated	 and	 used	 to	 construct	 the	 THz	image:	 the	minimum	value	Emin,	 and	 the	 ratio	 between	 the	minimum	value	 and	the	 maximum	 value	 Emin/Emax.	 By	 using	 these	 parameters	 they	 were	 able	 to	demonstrate	the	ability	of	TPI	to	image	both	invasive	ductal	carcinomas	and	DCIS.		Based	on	 the	 results	of	 this	pilot	 study,	 a	more	 comprehensive	 study	was	conducted	 using	 the	 same	 imaging	 device	 (312).	 A	 total	 of	 22	 excised	 breast	samples	 from	 22	 women	 were	 scanned.	 All	 samples	 were	 fresh	 at	 the	 time	 of	measurement,	 except	 two	 DCIS	 samples	 that	 had	 been	 fixed	 in	 formalin	 before	scanning.	 Samples	 were	 scanned	 for	 less	 than	 5	 minutes	 and,	 similar	 to	 the	previous	study,	THz	 images	were	constructed	by	using	 the	parameters	Emin	and	
Emin/Emax.	The	THz	 images	were	evaluated	by	comparing	 the	size	and	shape	of	the	tumour	on	histopathology	with	the	size	and	shape	of	the	tumour	region	on	TPI	(Figure	4).	In	all	22	samples,	there	was	excellent	correlation	between	histological	tumour	 size	 and	 tumour	 size	 on	 TPI	 (correlation	 coefficient	 >	 0.82	 for	 both	parameters).	A	good	correlation	between	tumour	shape	on	histopathology	and	TPI	was	also	 found;	 a	median	 correlation	of	0.71	and	0.69	 for	Emin	 and	Emin/Emax,	respectively.	This	study	confirmed	the	ability	of	TPI	to	distinguish	invasive	ductal	carcinoma	from	benign	breast	tissue,	and	also	showed	the	potential	for	identifying	invasive	lobular	carcinoma	and	pure	DCIS.			
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	Figure	4:	TPI	image	using	the	parameter	Emin	(A)	and	histopathology	image	(B)	of	invasive	ductal	carcinoma.	The	tumour	size	and	shape	on	TPI	correlate	well	with	histopathology	 (outlined	 in	 black).	 Image	 was	 reproduced	 from	 (312)	 with	 kind	
permission	from	the	Radiological	Society	of	North	America	(RSNA).			To	 better	 understand	 the	 origin	 of	 contrast	 observed	 between	 benign	 and	malignant	 breast	 tissue	 on	TPI,	Ashworth	et	 al.	 used	TPS	 to	measure	 the	 optical	properties	of	fibrous	adipose	and	tumour	tissue	(274).	A	total	of	105	breast	tissue	samples	 from	 20	 patients	 were	 measured	 with	 a	 0.1	 –	 4.0	 THz	 spectrometer	(TPIspectra1000,	TeraView	Ltd.,	UK)	in	transmission	geometry	within	24	hours	of	excision.	To	ensure	that	the	moisture	content	of	the	specimens	remained	constant,	the	samples	were	kept	in	a	refrigerated,	humidified	environment	before	scanning.	After	 scanning,	 the	 samples	were	 submitted	 to	a	breast	histopathologist	who	 for	each	 sample	 reported	 the	 percentage	 content	 of	 adipose,	 fibrous	 and	 tumour	tissue.	 Samples	were	 considered	 suitable	 for	 the	 study	 if	more	 than	 50%	 of	 the	sample	consisted	of	one	of	these	three	tissue	types	and	could	therefore	be	grouped	accordingly	 into	 ‘benign	 adipose’,	 ‘benign	 fibrous’,	 or	 ‘cancer’.	 Based	 on	histopathology,	 a	 total	 of	 74	 samples	 with	 a	 ‘homogeneous’	 tissue	 content	 (i.e.	containing	>50%	of	one	tissue	type)	were	included	for	analysis.	A	clear	difference	was	found	in	the	refractive	index	between	the	three	tissue	types	in	the	frequency	range	0	–	2.0	THz	(Figure	5A).	Tumour	had	the	highest	refractive	index,	followed	
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by	 fibrous	 and	 adipose	 tissue.	 The	 greatest	 difference	 between	 the	 three	 tissue	types	 was	 found	 at	 0.32	 THz.	 The	 difference	 in	 absorption	 coefficient	 was	 less	profound	(Figure	5B).	Adipose	tissue	had	a	markedly	lower	absorption	coefficient,	but	 the	coefficients	of	 fibrous	stroma	and	cancer	showed	overlap	 for	most	of	 the	frequency	range.		
	
	Figure	 5:	 Optical	 properties	 of	 adipose,	 fibrous	 and	 cancerous	 breast	 tissue	measured	 by	 TPS.	 (A)	 Refractive	 index	 (B)	 Absorption	 coefficient.	 Error	 bars	represent	95%	confidence	intervals	(CI).	The	types	of	breast	cancer	included	in	the	‘tumour’	group	are	not	reported	by	the	authors.	Image	was	reproduced	from	(274)	
with	kind	permission	from	the	Optical	Society	of	America	(OSA).		Based	 on	 the	 spectroscopy	 data,	 simulations	 were	 performed	 to	 predict	 the	impulse	functions	of	all	3	tissue	types	when	TPI	in	reflection	would	be	performed.		As	 expected	 from	 the	 clear	 differences	 in	 absorption	 coefficient	 and	 refractive	index,	 the	 impulse	 function	 from	 adipose	 tissue	was	 very	 different	 compared	 to	fibrous	 and	 cancer	 tissue	 (Figure	 6).	 The	 latter	 two	 tissue	 types	 showed	 very	subtle	differences,	indicating	that	accurate	discrimination	between	benign	fibrous	and	 malignant	 breast	 tissue	 using	 TPI	 might	 be	 challenging.	 The	 shape	 of	 the	simulated	impulse	functions	is	different	from	the	impulse	functions	obtained	with	the	TPI	handheld	probe	(Figure	11).	This	is	due	to	differences	in	processing	of	the	
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raw	 THz	 pulses.	 Details	 on	 the	 processing	 steps	 used	 to	 obtain	 the	 simulated	impulse	functions	in	Figure	6	can	be	found	in	(313).	
	Figure	 6:	 Simulated	 TPI	 impulse	 functions	 from	 fibrous,	 adipose	 and	 cancerous	breast	 tissue.	 The	 shape	 of	 the	 impulse	 function	 from	 fibrous	 and	 tumour	 show	small	differences;	most	of	these	differences	are	present	around	the	maximum	and	minimum	amplitude.	The	signal	from	adipose	tissue	is	clearly	distinct.	Image	was	
reproduced	 from	 (274)	 with	 kind	 permission	 from	 the	 Optical	 Society	 of	 America	
(OSA).		Following	on	from	their	work	published	in	2006	(312),	Fitzgerald	et	al.	extended	the	 TPI	 breast	 tissue	 dataset	 to	 include	 a	 total	 of	 51	 breast	 samples	 from	 51	patients	(314).	By	correlating	the	TPI	 image	to	the	histopathology	image,	regions	of	interest	were	selected	from	areas	of	fibrous,	adipose	and	cancerous	tissue.	Only	the	fibrous	and	tumour	THz	pulses	were	included	for	analysis	to	specifically	assess	the	 ability	 of	 TPI	 to	 distinguish	 these	 two	 types	 of	 tissue.	 No	 information	 is	provided	on	 the	 type	of	 tumours	 included	 in	 the	dataset.	Different	data	 analyses	methods	 were	 used	 with	 the	 aim	 to	 identify	 the	 method	 providing	 the	 best	performance	 in	 terms	 of	 accuracy.	 A	 total	 of	 10	 parameters	 in	 the	 time	 and	frequency	domain	were	calculated	from	the	impulse	function.	In	addition	to	these	
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‘heuristic’	 parameters,	 data	 reduction	 using	 PCA	was	 applied	 to	 the	 full	 impulse	function	as	well	as	to	all	ten	parameters.	Tissue	classification	was	performed	using	SVM.	They	found	accuracies	exceeding	90%;	PCA	applied	to	all	10	parameters	gave	the	highest	accuracy	of	91.9%.	These	results	show	that	despite	the	similarities	 in	THz	pulses,	 the	TPI	Scan	system	(TeraView	Ltd.,	UK)	can	accurately	discriminate	fibrous	from	cancerous	breast	tissue.	However,	the	TPI	Scan	system	is	not	suitable	for	intraoperative	assessment	of	WLE	specimens;	the	device	uses	a	sample	holder	to	image	samples	with	a	maximum	size	of	20	x	20	mm,	which	requires	larger	tissue	specimens	 to	 be	 sliced	 to	 obtain	 samples	 that	 fit	 the	 dimensions	 of	 the	 holder.	Thus,	 in	order	to	use	the	TPI	Scan	for	intraoperative	margin	assessment	it	would	require	sectioning	multiple	areas	from	all	six	margins	of	the	intact	WLE	specimens.	This	 is	 not	 appropriate	 in	 the	 routine	 setting	 in	 the	 operating	 theatre,	 as	 excess	manipulation	 of	 tissue	 close	 to	 or	 at	 the	 resection	 margin	 could	 affect	 margin	assessment	 on	 gold-standard	 postoperative	 histopathology,	 thus	 potentially	compromising	patient	care.	Hence,	using	TPI	for	assessing	tumour	margins	ideally	requires	 a	 device	 that	 could	be	used	 to	 scan	 excised	WLE	 specimens	of	 any	 size	intraoperatively	 without	 the	 need	 to	 manipulate	 or	 incise	 the	 intact	 specimen.	Based	 on	 these	 requirements	 Teraview	 Ltd.	 (Cambridge,	 UK)	 developed	 a	handheld	TPI	probe	system.	A	detailed	description	of	 this	device	can	be	 found	 in	Section	2.3.2.1.	A	small	study	was	performed	to	test	whether	the	prototype	version	of	the	handheld	 TPI	 probe	 system	 showed	 promise	 in	 discriminating	 benign	 from	malignant	 breast	 tissue	 (315).	 Breast	 tissue	 samples,	 obtained	 from	 sectioning	freshly	excised	mastectomy	specimens	or	WLE	specimens,	were	measured	ex	vivo	for	20	seconds.	Prior	 to	measuring,	a	disposable,	protective	sheath	was	wrapped	around	 the	 imaging	 probe	 to	 prevent	 contamination	 from	 biological	 tissue.	 THz	
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pulses	were	emitted	and	detected	over	a	length	of	7	mm	with	a	scan	speed	of	4	Hz,	i.e.	 in	 1	 second	 an	 area	 of	 7	 mm	 was	 scanned	 4	 times.	 	 For	 each	 sample	 the	histopathologist	reported	the	percentage	of	each	tissue	type	as	adipose,	fibrous,	or	tumour,	 and	 ‘homogeneous’	 samples	 containing	 >75%	 of	 one	 ‘pure’	 tissue	 type	were	used	for	analysis.	Four	parameters	from	the	reflected	impulse	function	were	calculated	 for	 the	 three	 tissue	 types	 and	 subsequently	 compared	 (Figure	 7).	Similar	 to	 the	 results	 obtained	 with	 the	 TPI	 Scan,	 adipose	 tissue	 showed	 clear	differences	 compared	 to	 fibrous	 and	 tumour	 tissue,	 respectively.	 However,	 no	differences	were	found	between	fibrous	tissue	and	cancer	for	Power	at	0.119	THz	and	Max	Amplitude,	and	only	minute	differences	were	seen	for	Pulse	Integral	and	
Full	 Width	 Half	 Maximum	 (FWHM).	 Large	 95%	 confidence	 intervals	 (CI)	 were	present	 in	 Pulse	 Integral	 and	 Power	 at	 0.119	 THz.	 Although	 the	 authors	 do	 not	discuss	 reasons	 for	 the	observed	 ranges,	potential	 explanations	 for	 the	observed	variations	 could	 be	 inter-patient	 variability	 or	 inconsistencies	 in	 the	 THz	 pulses	produced	by	the	TPI	system	(Section	2.3.3.4).	The	performance	of	the	device	was	not	 assessed	 in	 terms	 of	 accuracy,	 sensitivity	 and	 specificity,	 but	 the	 lack	 of	contrast	between	fibrous	tissue	and	tumour	for	all	four	parameters	indicates	that	misclassifications	between	these	two	types	of	tissues	are	likely	to	occur.	The	 tissue	 samples	 that	 were	 scanned	 with	 the	 prototype	 TPI	 handheld	probe	 in	 the	 study	 of	 Ashworth	 et	 al.	 are	 not	 an	 accurate	 representation	 of	 the	tissue	 composition	 found	 at	 the	 resection	 border	 of	 patients	 with	 ‘close’	 or	‘positive’	 margins	 as	 the	 tumour	 samples	 used	 for	 analysis	 consisted	 of	 	 >75%	tumour	 cells.	 Involved	 margins	 are	 often	 identified	 microscopically	 as	 a	 small	number	 of	 tumour	 cells	 immersed	 in	 a	 ‘background’	 of	 fibrous	 and/or	 adipose	tissue	(316).	These	small	tumour	islands	are	thus	very	likely	to	only	cause	a	subtle	change	 to	 the	 incident	 THz	 pulse;	 the	 information	 in	 the	 THz	 pulse	 will	 be	
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predominantly	 from	the	benign	 tissue	background.	Thus,	accurate	discrimination	of	 tumour	 samples	 with	 a	 lower	 tumour	 cell	 percentage,	 which	 is	 a	 better	representation	of	the	composition	found	clinically,	will	be	even	more	challenging.		
	Figure	7:	Average	parameter	values	for	adipose,	fibrous	and	tumour	tissue	scanned	with	 the	 prototype	 TPI	 handheld	 probe	 system.	 The	 values	 are	 normalised	 to	fibrous	tissue.	The	error	bars	represent	95%	CI.	Image	was	reproduced	from	(315)	
with	kind	permission	from	Institute	of	Electrical	and	Electronics	Engineers	(IEEE).		
2.2.4 Summary	In	 the	 last	 three	decades	THz	 technology	has	 rapidly	advanced	and,	 to	date,	THz	imaging	systems	are	used	in	a	variety	of	biomedical	applications.	THz	radiation	is	sensitive	 to	 changes	 in	 water	 content	 and,	 combined	 with	 its	 sensitivity	 to	molecular	 and	 structural	 changes,	 this	 is	 thought	 to	 be	 the	 underlying	 contrast	mechanism	 to	 distinguish	 benign	 and	 malignant	 tissue	 on	 TPI.	 This	 unique	sensitivity,	 in	 combination	 with	 the	 submillimeter	 imaging	 resolution	 and	 low	energy	levels,	makes	TPI	of	particular	interest	for	cancer	imaging.		TPI	 has	 been	 successfully	 used	 for	 ex	 vivo	 imaging	 of	 oral,	 gastric,	 skin,	colon	 and	 breast	 cancer.	 Studies	 in	 breast	 cancer	 have	 found	 that	 the	 main	challenge	is	accurate	discrimination	of	benign	fibrous	from	malignant	tissue,	whilst	adipose	 tissue	 can	 be	 more	 easily	 identified.	 All	 these	 studies	 used	 static	 THz	
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systems	 that	 could	only	 image	 small	 tissue	 samples	 (<2	 cm)	obtained	 from	non-diagnostic	breast	tissue.	In	addition,	the	homogeneous	tissue	samples	analysed	in	these	 studies	 are	 not	 truly	 representative	 of	 the	 tissue	 composition	 found	 in	patients	with	‘close’	or	‘positive’	tumour	resection	margins,	and	the	ability	of	TPI	to	detect	tumour	at	a	margin,	where	a	mixture	of	benign	and	tumour	tissue	is	more	commonly	seen,	is	therefore	yet	to	be	determined.	To	 facilitate	 the	 use	 of	 TPI	 to	 scan	 tumour	 resection	margins	 on	 excised	WLE	specimens,	Teraview	Ltd.	has	developed	a	TPI	handheld	probe	 system.	The	next	section	describes	the	first-in-human	study	conducted	to	evaluate	the	ability	of	this	probe	to	discriminate	benign	from	malignant	breast	tissue	using	samples	that	better	resemble	the	tissue	composition	found	at	the	edge	of	WLE	specimens.																
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2.3 First-in-human	clinical	 study	 to	evaluate	 the	ability	of	a	 terahertz	
pulsed	 imaging	 handheld	 probe	 to	 discriminate	 benign	 from	
malignant	breast	tissue	ex	vivo		
2.3.1 Aim	A	 first-in-human,	 single	 centre	 study	was	 performed	 to	 evaluate	 the	 ability	 of	 a	handheld	TPI	probe	to	discriminate	benign	from	malignant	breast	 tissue	 in	an	ex	




2.3.2.1 TPI	handheld	probe	system	In	this	study,	version	2.0	of	the	TPI	handheld	probe	system	is	used	(Teraview	Ltd.	Cambridge,	 UK)	 (Figure	 8).	 	 This	 system	 consists	 of	 a	main	 unit	 that	 contains	 a	femtosecond	 laser	 (Menlo	 Systems	 GmbH,	 Martinsreid,	 Germany)	 that	 produces	780	 nm	 laser	 pulses	 at	 a	 rate	 of	 100	MHz.	 The	 pulses	 are	 guided	 down	 optical	fibres,	 contained	 within	 a	 metallic	 cable	 called	 the	 “umbilical	 cord”,	 to	 the	handheld	imaging	probe.		
	Figure	 8:	 TPI	 handheld	 probe	 system.	 (A)	 Main	 unit	 with	 computer	 monitor,	handheld	imaging	probe	and	black	umbilical	cord	(visible	on	the	right).	(B)	Close	up	of	 the	handheld	 imaging	probe.	(C)	Close	up	of	 the	head	of	 the	 imaging	probe	showing	 the	 black	 quartz	 window.	 The	 probe	 scans	 an	 area	 of	 15	 x	 2	mm,	 and	acquires	data	from	26	pixels	(red	dots).			Within	the	 imaging	probe	 laser	pulses	are	 incident	on	a	photoconductive	emitter	and	detector	(Figure	9).	This	results	in	the	production	and	detection	of	THz	pulses	of	 bandwidth	 0.1	 –	 1.8	 THz.	 An	 oscillating	mirror	 guides	 the	 THz	 pulses	 onto	 a	quartz	 window	 present	 at	 the	 tip	 of	 the	 probe.	 By	 controlled	 rotation	 of	 this	mirror,	an	area	of	15	x	2	mm	is	scanned	with	a	frequency	of	4	Hz.	The	15	mm	axis	contains	a	total	of	26	pixels,	thus	providing	a	pixel	resolution	of	approximately	0.6	mm.	During	scanning	each	pixel	acquires	THz	pulses	over	time	to	form	a	TPI	image	(Figure	11).		
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	Figure	 9:	 Schematic	 illustration	 of	 the	 TPI	 handheld	 probe	 system.	 The	 emitted	laser	pulses	are	split	into	a	“pump	beam”	and	a	“probe	beam”.	The	pump	beam	is	guided	through	the	optical	fibres	in	the	umbilical	cord,	and	subsequently	incident	on	the	photoconductive	emitter	to	produce	THz	pulses.	The	probe	beam	is	guided	onto	 the	 photoconductive	 detector	 to	 detect	 the	 THz	 pulses	 reflected	 from	 the	tissue	sample.	By	altering	the	path	length	of	the	probe	beam,	the	time	of	arrival	at	the	detector	in	respect	to	the	incident	THz	pulse	can	be	changed,	thus	sampling	the	THz	pulse	in	the	time	domain.			
2.3.2.2 Tissue	preparation	and	TPI	data	acquisition	Between	 August	 2013	 and	 August	 2014,	 breast	 tissue	 from	 patients	 who	underwent	BCS	or	mastectomy	at	Guy’s	Hospital	in	London	were	scanned	with	the	TPI	 handheld	 probe	 after	 written	 informed	 consent	 was	 obtained	 (REC	 12-EE-0493).	 	 Excised	 BCS	 or	 mastectomy	 specimens	 were	 taken	 from	 the	 operating	theatre	 to	 the	 adjacent	 King’s	 Health	 Partners	 Cancer	 Biobank,	 where	 the	specimens	 were	 inked	 and	 sliced	 by	 an	 Advanced	 Practitioner	 as	 per	 standard	protocol.	Subject	to	the	amount	of	tissue	that	was	required	for	diagnostic	purposes,	tissue	 samples	were	obtained	with	 an	average	 length,	width	and	 thickness	of	10	mm,	5	mm	and	2	mm,	respectively.		
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Prior	to	scanning	the	tissue	samples,	a	Tegaderm	layer	(3M	Tegaderm	Film,	3M,	Berkshire,	UK)	was	applied	to	the	probe’s	quartz	window,	and	the	remainder	of	 the	 probe	 was	 wrapped	 in	 a	 disposable	 protective	 sheath	 to	 prevent	contamination	 from	 tissue.	 A	 60	 second	 water	 measurement	 was	 performed	 to	assess	 the	 signal	 intensity	 and	 shape	 of	 the	 THz	 pulses	 emitted	 by	 the	 TPI	handheld	probe	on	each	day	of	measurement.		Tissue	 samples	 were	 placed	 in	 a	 standard	 histology	 cassette	 (UnisetteTM,	Simport,	Beloeil,	Canada)	that	tightly	fitted	the	head	of	the	imaging	probe	to	enable	consistent	and	controlled	THz	measurements	(Figure	10).	All	tissue	samples	were	scanned	 within	 60	 minutes	 post	 excision.	 Each	 sample	 was	 measured	 for	 20	seconds	consecutively	by	positioning	the	probe	on	the	sample.	Upon	completion	of	each	 measurement	 a	 photograph	 of	 the	 sample	 in	 the	 cassette	 was	 taken,	 to	facilitate	accurate	correlation	of	the	TPI	data	with	the	final	histology	slide.			After	the	sample	was	scanned,	the	layer	of	Tegaderm	was	removed	from	the	probe’s	quartz	window	and	a	60	second	air	measurement	was	performed	that	was	used	as	a	reference	for	data	processing	(Section	2.3.2.3).	For	orientation	purposes	the	 top	and	the	right	surface	of	 the	 tissue	sample	were	then	 inked	red	and	black	respectively,	after	which	the	histology	cassette	containing	the	sample	was	closed,	and	 placed	 in	 formalin	 for	 24-48	 hours,	 processed	 and	 paraffin	 wax	 embedded.	Three	to	4	micron	sections	were	then	cut	and	stained	with	haematoxylin	and	eosin	(H&E).	 The	 histology	 slides	 were	 digitalised,	 and	 subsequently	 viewed	 and	analysed	 using	 a	 histopathology	 slide	 viewer	 software	 (NDP.view2,	 Hamamatsu,	UK).		 	
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	Figure	 10:	 TPI	 measurement	 of	 tissue	 sample.	 (A)	 TPI	 handheld	 probe	measurement	of	tissue	sample	positioned	in	histology	cassette.	Note	that	the	head	of	 the	 imaging	 probe	 tightly	 fits	 in	 the	 cassette,	 which	 facilitates	 applying	 a	consistent	pressure	throughout	the	measurement,	while	preventing	displacement	of	 the	probe.	 (B)	Photograph	of	 the	 tissue	sample	obtained	after	 the	sample	was	scanned.	The	imprint	of	the	probe	on	the	sample	is	clearly	visible.	This	photograph	was	 used	 to	 facilitate	 accurate	 correlation	 of	 TPI	 with	 histopathology.	 (C)	Photograph	 of	 tissue	 sample	 after	 it	was	 inked.	 Inking	was	 performed	 to	 enable	spatial	orienation	of	the	sample	when	analysed	microscopically	by	the	pathologist.			
2.3.2.3 THz	data	processing	During	data	acquisition	with	the	TPI	handheld	probe,	each	pixel	acquired	raw	THz	pulses	 throughout	 the	 duration	 of	 the	 measurement.	 These	 pulses	 were	deconvolved	 to	 extract	 meaningful	 information	 for	 discriminating	 benign	 from	malignant	 breast	 tissue.	 This	was	done	by	 converting	 the	 raw	THz	pulses	 to	 the	frequency	 domain	 using	 a	 Fast	 Fourier	 Transform	 function.	 A	 double	 Gaussian	filter	 was	 applied	 to	 suppress	 the	 high	 and	 low	 frequency	 noise	 components.	Waveforms	were	 then	 divided	 by	 an	 “air	without	 Tegaderm”	 reference	 that	was	acquired	 at	 the	 end	 of	 each	 measurement	 day.	 	 Referenced	 waveforms	 were	converted	back	to	the	time	domain,	and	aligned	to	compensate	for	small	offsets	in	the	 phase	 of	 the	 detected	 pulses	 due	 to	 changes	 in	 the	 optical	 path	 length	 that	occur	when	optical	fibres	in	the	umbilical	cord	slightly	deform	when	the	probe	is	moved	during	 scanning	 (251).	 	 All	 these	processing	 steps	were	performed	using	customised	software	written	 in	Python	(an	open	source	programming	 language);	
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the	software	was	developed	in	close	collaboration	with	Teraview	Ltd.	(Cambridge,	UK).	The	deconvolved	pulses	–	called	impulse	functions	-	of	each	pixel	were	then	imported	 into	MATLAB	 (Mathworks,	 USA),	 and	 averaged	 over	 time,	 resulting	 in	one	impulse	function	for	each	pixel.			
2.3.2.4 Correlation	of	TPI	data	with	histopathology	Accurate	correlation	between	the	TPI	 image	and	the	histopathology	slide	of	each	sample	 is	 paramount	 for	 evaluating	 the	 ability	 of	 the	 TPI	 handheld	 probe	 to	discriminate	benign	from	malignant	breast	tissue.	 	Correlation	was	performed	by	mapping	the	TPI	15	x	2	mm	scan	area	onto	the	digitalised	pathology	slide	(Figure	11).	 To	 ensure	 accurate	 correlation,	 the	 following	 protocol	was	 established.	 The	imprint	of	the	probe,	visible	on	the	photographs	taken	from	each	sample,	was	used	to	determine	how	the	probe	was	positioned	on	 the	sample	during	measurement.	The	 clear	 contrast	 between	 the	 air-tissue	 interface	 and	 adipose-fibrous/tumour	interface	on	TPI,	which	is	especially	pronounced	at	time	points	t	=	7.97	ps,	t	=	8.93	ps,	and	t	=	9.67	ps,	was	used	to	determine	the	location	and	number	of	pixels	that	contained	tissue	information	(Figure	11).	By	correlating	the	TPI	information	to	the	air-tissue	interface	and	tissue	composition	on	the	histopathology	slide,	the	15	x	2	mm	 scan	 area	was	mapped	 onto	 the	 digital	 histopathology	 image	 in	 the	 viewer	software	 (Figure	 11).	 If	 the	 number	 of	 tissue-containing	 pixels	 on	 TPI	 and	histopathology	differed	by	more	than	three,	the	sample	was	excluded	from	further	analysis,	as	accurate	correlation	could	not	be	assured.		
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	Figure	11:	Correlating	TPI	with	histopathology.	(A)	Typical	impulse	function	from	breast	 tissue	 containing	 a	 high	 percentage	 of	 tumour,	 fibrous,	 and	 adipose	 cells,	and	 air,	 respectively.	 Clear	 differences	 are	 seen	 between	 the	 impulse	 functions	from	 air	 and	 from	 tissue,	 and	 between	 adipose	 and	 tumour/fibrous	 samples,	especially	at	time	points	t	=	7.97	ps,	t	=	8.93	ps,	and	t	=	9.67	ps	(black	arrows).	(B)	TPI	 image	 from	 sample	 based	 on	 the	 amplitude	 of	 the	 impulse	 function	 at	 t	 =	7.97ps.	A	clear	contrast	can	be	seen	at	the	air-tissue	interface	at	pixel	5	and	pixel	17.	Note	 the	 ‘edge	 effect’	 at	 these	 interfaces,	 causing	 a	 distortion	 in	 the	 impulse	functions	of	these	pixels.	(C)	Digital	histopathology	slide	of	the	same	tissue	sample.	By	using	the	photograph	of	the	sample	in	combination	with	the	air-tissue	interface	visible	 in	 the	TPI	 image,	 the	TPI	15	x	2	mm	scan	area	can	be	accurately	mapped	onto	 the	 histopathology	 slide	 (black	 rectangle).	 The	 pixels	 are	 displayed	 as	intermittent	horizontal	 lines	at	0.6	mm	distance	in	the	scan	window.	Pixel	5	–	17		contain	 invasive	 ductal	 carcinoma/no	 special	 type	 (NST);	 the	 percentage	 of	tumour	cells	 in	each	pixel	area	ranges	between	5	–	10%.	The	 tissue	 immediately	surrounding	 the	 tumour	 cells	 (called	background)	 is	 composed	of	 fibrous	 tissue,	whilst	fatty	adipose	tissue	is	seen	inferiorly.			
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2.3.2.5 Histopathological	analysis	and	selection	of	TPI	data	The	 digital	 histopathology	 slide	 of	 each	 sample	 was	 analysed	 in	 the	 viewer	software	 by	 a	 Consultant	 breast	 histopathologist	 (S.E.P.).	 For	 each	 pixel,	 the	histopathologist	 assessed	 the	 tissue	 types	 (tumour,	 fibrous,	 or	 adipose),	 and	 the	percentage	 content	 of	 each	 tissue	 type	 present	 in	 the	 pixel	 area.	 Tissue	percentages	 were	 reported	 in	 5%	 intervals.	 In	 samples	 where	 the	 tumour	 type	could	not	be	reliably	assessed	(for	example	due	to	paucity	of	cells	or	crushing),	the	histopathologist	 used	 the	 clinical	 histopathology	 report	 to	 decide	 on	 the	 type	 of	tumour	present	in	the	sample.	For	a	subset	of	samples	an	intra-rater	variability	analysis	was	performed	to	assess	 the	ability	of	 the	histopathologist	 to	 consistently	 score	 the	 tissue	 samples	used	for	this	study.	More	specifically,	the	analysis	aimed	to	determine	how	often	a	pixel	would	be	assigned	to	a	different	tissue	percentage	subgroup	when	a	second	histopathological	evaluation	was	performed.	For	this	analysis,	a	total	of	92	pixels	from	7	tumour	samples	and	125	pixels	from	7	benign	samples	were	re-evaluated	by	 the	 same	 histopathologist	 eight	 weeks	 after	 the	 first	 analysis.	 To	 prevent	potential	 bias	 from	 a	 prior	 knowledge,	 the	 histopathologist	 was	 blinded	 to	 the	results	of	the	first	analysis	and	not	informed	that	a	re-evaluation	was	performed.	Weighted	kappa	coefficients	were	calculated	to	assess	the	agreement	in	subgroup	classification	 between	 evaluation	 1	 and	 2	 (kappa	 2	 function	 of	 the	 ‘irr’	 package	v0.84,	R	statistical	software	v3.2.2).	A	kappa	coefficient	(κ)	greater	than	0.80	was	considered	excellent	agreement	(317).	A	Wilcoxon	signed-rank	test	was	performed	to	 assess	 whether	 evaluation	 1	 was	 statistically	 significantly	 different	 from	evaluation	2.	The	level	of	significance	was	defined	as	p	<	0.05.		
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The	 information	 on	 the	 tissue	 composition	 of	 each	 pixel,	 obtained	 from	histopathology,	was	used	to	select	region-of-interests	(ROIs)	in	the	TPI	images.	To	avoid	selecting	distorted	 impulse	 functions	that	could	occur	due	to	“edge	effects”	present	at	 the	air-tissue	 interface	(314)	(Figure	11),	ROIs	needed	to	be	one	pixel	away	 from	 the	 edge	 of	 the	 sample.	 To	 account	 for	 potential	 inaccuracies	 in	 the	correlation	 between	 TPI	 and	 histopathology,	which	 could	 result	 in	 selecting	 TPI	data	with	a	different	 tissue	percentage	or	wrong	tissue	type,	 the	pixel	above	and	below	 the	 selected	ROI	needed	 to	be	of	 the	 same	 tissue	 type	as	 the	pixels	 in	 the	ROI,	and	the	percentage	content	of	the	respective	tissue	type	could	only	differ	by	a	maximum	of	10%.	Multiple	ROIs	could	be	selected	within	one	tissue	sample	as	long	as	these	criteria	were	met.			 Following	ROI	selection,	pixels	were	grouped	according	 to	 tissue	 type	and	tissue	percentage	(Table	9).	Pixels	containing	tumour	tissue,	and	pixels	containing	pure	 fibrous	 tissue	or	a	mixture	of	 fibrous	and	adipose	 tissue,	were	divided	 into	groups	of	20%	(i.e.	1	–	20%,	21	–	40%,	41	–	60%,	61	–	80%,	and	81	–	100%).	Pure	adipose	 pixels	were	 grouped	 separately	 in	 a	 “100%	 adipose”	 group,	 as	 previous	work	 has	 shown	 clear	 differences	 between	 the	 impulse	 function	 from	 adipose	tissue	and	fibrous	and	tumour	tissue,	respectively	(315).		
2.3.2.6 TPI	data	analysis	and	classification	Classification	of	each	of	the	selected	impulse	functions	as	malignant	or	benign	was	performed	 using	 two	 data	 analysis	 and	 classification	 methods:	 (1)	 heuristic	parameters	in	combination	with	support	vector	machine	(SVM)	classification	and	(2)	Gaussian	wavelet	deconvolution	with	Bayesian	classification.	 	
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2.3.2.6.1 Parameters	and	SVM	classifier	Each	pixel	from	the	handheld	probe	acquired	data	in	the	time	domain,	or	through	Fourier	transform,	in	the	spectral	(frequency)	domain.	Characterization	of	the	type	of	 tissue	 can	 be	 done	 by	 calculating	 parameters	 from	 the	 acquired	 time	 domain	pulses	 and	 frequency	 pulses,	 respectively.	 The	 ability	 of	 this	 so-called	 “heuristic	approach”	 to	 discriminate	 benign	 from	malignant	 breast	 tissue	was	 assessed	 by	classifying	 all	 pulses	 in	 the	 database	 using	 a	 SVM	 algorithm.	 This	 analysis	 was	performed	 in	 MATLAB	 (Matlab	 2013A,	 Mathworks	 Inc.,	 USA)	 using	 a	 software	script	 specifically	 developed	 for	 this	 project	 in	 close	 collaboration	 with	collaborators	from	the	University	of	Western	Australia.	Several	 parameters	 were	 calculated	 that	 captured	 different	 parts	 of	 the	pulse	shape,	including	amplitudes,	integrals,	linear	fits	and	quadratic	fits.	Many	of	these	 parameters	 can	 have	 a	 large	 range	 of	 time	 points	 and	 frequency	 points,	further	called	indices,	for	which	they	can	be	calculated.	From	all	parameters,	a	total	of	733	different	indices	were	evaluated.	A	receiver	operating	characteristic	(ROC)	analysis	was	performed	 to	 identify	 the	optimal	 time	or	 frequency	 index	 for	 each	parameter	 (318).	This	analysis	works	by	classifying	 the	 impulse	 function	of	each	pixel	 from	each	sample	as	either	malignant	or	benign,	depending	on	whether	the	value	of	each	parameter	 is	below	or	above	a	specifically	set	 threshold	value.	The	predicted	 classification	 is	 then	 compared	 to	 the	 true	 histopathological	classification	 to	 calculate	 sensitivity	 (the	 number	 of	 tumour	 pulses	 correctly	classified	 as	 tumour)	 and	 specificity	 (the	 number	 of	 benign	 pulses	 correctly	classified	 as	 benign).	 By	 plotting	 the	 sensitivity	 against	 1-specificiy	 for	 various	threshold	values,	a	ROC	curve	is	obtained.	The	area	under	the	ROC	curve	(AUROC)	is	 a	measure	 of	 the	 predictive	 power	 (i.e.	 performance)	 of	 each	 parameter.	 The	AUROC	value	ranges	from	0-1;	an	 ideal	parameter	has	an	AUROC	of	1,	whereas	a	
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random	guess	would	have	an	AUROC	of	0.5.	In	this	way,	the	best	performing	time	indices	for	each	time	domain	and	frequency	domain	parameter	could	be	identified.	Figure	12	shows	the	AUROC	values	for	the	amplitude	of	the	impulse	function	over	a	range	of	time	indices.		
	Figure	12:	AUROC	analysis	to	evaluate	the	discriminative	power	of	the	amplitude	parameter	 for	 time	 indices	 5.0	 –	 12.6	ps.	 The	highest	AUROC	values	 of	 0.72	 and	0.70	 were	 found	 at	 t	 =	 9.42	 ps	 and	 t	 =	 10.05	 ps	 respectively,	 and	 these	 two	parameters	were	therefore	selected	for	tissue	classification	with	SVM.		 The	 AUROC	 analysis	 was	 performed	 for	 three	 different	 subgroups	 of	 the	dataset.	 Firstly,	 AUROC	 values	 were	 calculated	 using	 all	 tumour	 and	 all	 fibrous	data.	 Pure	 adipose	 data	 was	 excluded	 from	 this	 analysis,	 as	 previous	 work	 has	shown	 that	adipose	 tissue	can	be	easily	 identified	due	 to	 the	 clear	differences	 in	the	 impulse	 function	 (315),	 and	 the	emphasis	 in	 this	work	 therefore	was	 to	 find	parameters	 that	 were	 strong	 in	 discriminating	 fibrous	 tissue	 from	 tumour.	Parameters	 with	 an	 AUROC	 value	 ≥	 0.7	 were	 selected.	 Secondly,	 to	 identify	additional	 parameters	 that	 performed	 specifically	 well	 for	 the	 most	 challenging	situation	of	 discriminating	 tumour	 from	pure	 fibrous	 tissue,	AUROC	values	were	
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calculated	using	all	tumour	data	and	100%	fibrous	data,	and	parameters	with	the	highest	AUROC	value	were	selected.	Lastly,	to	confirm	that	the	selected	parameters	were	also	strong	in	discriminating	tumour	from	pure	adipose	data,	AUROC	values	were	calculated	using	all	tumour	and	100%	adipose	data.		Correlation	between	parameters	 could	potentially	 cause	 overfitting	 of	 the	data,	 which	 affects	 the	 classification	 performance,	 as	 the	 noise	 in	 the	 data	 is	captured	 as	 opposed	 to	 the	 real	 tissue	 signal,	 while	 reducing	 efficiency	 of	 the	classification	algorithm	by	 increasing	 the	dimensionality	of	 the	data	 (319).	Thus,	including	 correlated	parameters	 in	 the	 analysis	 could	 result	 in	 a	 less	 robust	 and	less	 reliable	 outcome,	 whilst	 increasing	 computational	 time.	 The	 selected	parameters	 were	 therefore	 assessed	 for	 correlation	 by	 calculating	 the	 linear	correlation	 coefficient	 r	 for	 all	 possible	 pairs	 of	 parameters.	 Parameters	 were	considered	correlated	and	excluded	from	analysis	when	-0.7	<	r		>	0.7.			Uncorrelated	 parameters	 were	 used	 in	 a	 SVM	 classification	 algorithm	 to	predict	the	type	of	tissue	for	all	impulse	functions	in	the	dataset.	In	SVM,	a	training	data	set	is	used	in	which	each	of	the	data	points	are	marked	to	belong	to	one	of	two	binary	 categories,	 i.e.	 tumour	 or	 benign.	 These	 data	 points	 are	 represented	 in	 a	multidimensional	 space;	 the	 number	 of	 dimensions	 depends	 on	 the	 amount	 of	parameters	used	for	analysis.	SVM	then	constructs	a	boundary	to	separate	the	data	points	 of	 both	 categories.	 New	data	 points	 obtained	 from	 a	 so	 called	 “validation	dataset”	 are	 mapped	 into	 that	 same	 space,	 and	 based	 on	 which	 side	 of	 the	boundary	they	fall	on,	each	point	is	classified	as	tumour	or	benign,	respectively.	Since	 ‘close’	 or	 ‘positive’	 margins	 of	 excision	 in	 BCS	 are	 often	 identified	histologically	 as	 small	 number	 of	 tumour	 cells	 immersed	 in	 a	 benign	 tissue	background	of	 fibrous	and	adipose	 tissue,	 at	 the	edge	of	 a	WLE	specimen,	 it	 is	 a	prerequisite	 that	 the	TPI	handheld	probe	 is	highly	sensitive	 for	detecting	cancer.	
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To	maximize	 the	 sensitivity	 of	 the	 probe	 to	 identify	 cancer,	 training	 of	 the	 SVM	classifier	 was	 performed	 by	 marking	 pixels	 as	 tumour,	 if	 the	 pathologist	 had	identified	any	amount	of	cancer	cells	in	that	pixel	area.	Fibrous	and	adipose	pixels	solely	 consisted	 of	 benign	 tissue.	 SVM	 classification	 was	 performed	 for	 each	parameter	 individually,	 as	 well	 as	 for	 combinations	 of	 two,	 three	 or	 four	parameters	 respectively,	 to	 identify	 the	 parameter(s)	 that	 provided	 the	 best	classification	result	in	terms	of	accuracy.		2.3.2.6.2 Gaussian	wavelets	and	Bayesian	classifier	Tissue	classification	was	also	performed	using	Gaussian	wavelet	deconvolution	in	combination	with	a	Bayesian	classifier.	Gaussian	wavelet	deconvolution	is	a	 form	of	 signal	 processing	 that	 uses	different	 orders	 of	Gaussian	derivatives	 to	 expand	the	 information	 in	 the	 signal,	 while	 reducing	 the	 noise	 (320).	 In	 contrast	 to	heuristic	 parameters,	 Gaussian	wavelet	 deconvolution	 can	 be	 applied	 to	 the	 full	THz	impulse	function.	This	method	was	considered	a	suitable	approach	because	of	the	 similarities	 between	 the	 signal	 features	 of	 a	 Gaussian	 function	 and	 its	derivatives	(Figure	13),	and	the	TPI	 impulse	 functions	 from	breast	 tissue	(Figure	11).	Successful	application	of	wavelet	techniques	to	analyse	THz	data	has	also	been	demonstrated	by	other	groups	(321,322).	For	our	analysis,	Gaussian	derivatives	of	order	 0	 (normal	 Gaussian	 function),	 1,	 2,	 3	 and	 4	 were	 applied	 to	 the	 impulse	function	of	each	pixel.	Higher	order	Gaussian	derivatives	were	not	used	 to	avoid	potential	overfitting.		 The	Gaussian	deconvolved	data	were	then	fed	into	a	Bayesian	classification	algorithm	 (319).	 In	 contrast	 to	 binary	 classification	 performed	 with	 SVM,	 the	Bayesian	 algorithm	 can	 classify	 data-points	 into	 more	 than	 two	 classes;	 in	 our	study	 all	 impulse	 functions	 in	 the	 dataset	 were	 classified	 as	 adipose,	 fibrous	 or	
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cancerous,	respectively.	Adipose	and	fibrous	tissue	were	then	grouped	together	as	‘benign’	 in	 order	 to	 calculate	 the	 performance	 parameters	 described	 in	 Section	2.3.2.6.3.	 Similar	 to	 SVM,	 pixels	 were	 marked	 as	 tumour	 when	 containing	 any	amount	of	cancer	cells.		
	Figure	13:	Gaussian	derivatives	of	order	=	0,	1,	2,	3,	and	4,	respectively		2.3.2.6.3 Classification	of	TPI	data	Due	 to	 the	 relative	 small	 size	 of	 the	 dataset,	 training	 and	 validation	 of	 the	 SVM	classifier	 and	 Bayesian	 classifier	 were	 performed	 using	 leave-one-out-cross-validation	 (LLOCV).	 In	 LOOCV,	 all	 pixels	 from	 one	 sample	 are	 left	 out,	 and	 the	pixels	 from	 the	 remaining	 samples	 are	 used	 to	 train	 the	 classification	 algorithm.	The	trained	algorithm	is	then	applied	to	the	pixels	of	the	sample	that	was	left	out.	This	process	 is	repeated	for	all	 the	samples	 in	the	dataset	to	obtain	classification	results	 for	 all	pixels.	By	 comparing	 the	predicted	 tissue	 type	of	 each	pixel	 to	 the	true	 histological	 tissue	 type,	 accuracy,	 sensitivity,	 specificity,	 positive	 predictive	value	and	negative	predictive	value	were	calculated	using	the	equations	in	Table	8.	
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Accuracy	 is	 considered	 the	most	 clinically	 relevant	 parameter	 for	 evaluating	 the	performance	of	the	TPI	handheld	probe	as	it	takes	both	sensitivity	and	specificity	into	 account,	 thus	 providing	 information	 on	 the	 overall	 ability	 of	 the	 probe	 to	accurately	detect	both	tumour	and	benign	tissue.		




Tumour	 TP	 FP	 PPV	=	TP/(TP	+	FP)		
Benign	 FN	 TN	 NPV	=	TN/(TN	+	FN)			 Sens	=	TP/(TP	+	FN)	 Spec	=	TN/(TN	+	FP)	 Acc	=	(TP	+	TN)/	(TP	+	TN	+	FP	+	FN)		
2.3.2.7 TPI	handheld	probe	system	stability	Water	 is	 considered	 a	 homogeneous	 liquid	with	well-known	THz	 characteristics.	Data	acquired	from	water	measurements	therefore	provides	insight	in	the	stability	of	 the	 TPI	 handheld	 probe,	 as	 any	 fluctuations	 in	 the	 shape	 and	 intensity	 of	 the	detected	THz	pulses	are	induced	by	the	system	itself.	To	assess	the	signal	stability,	parameter	values	were	calculated	from	a	total	of	3	water	measurements	acquired	on	different	measurement	days.							
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2.3.3 Results	
2.3.3.1 Tissue	 sample	 characteristics	 and	 histopathology	 intra-rater	
reliability	In	 total,	 126	 samples	 from	 106	 patients	 were	 scanned;	 46	 samples	 from	 32	patients	met	 the	 strict	 criteria	 established	 to	 ensure	 accurate	 correlation	 of	 TPI	with	 histology,	 i.e.	 a	 photograph	 was	 available	 of	 the	 sample	 in	 the	 histology	cassette,	the	number	of	tissue	containing	pixels	on	TPI	and	histopathology	differed	by	3	or	less,	and	ROIs	could	be	selected	in	areas	with	a	tissue	content	varying	less	than	 10%.	 These	 samples	 were	 included	 for	 analysis.	 Of	 these,	 20	 samples	contained	 tumour;	 16	 invasive	 ductal	 carcinoma/no	 special	 type	 (NST),	 2	 NST	admixed	 with	 DCIS,	 2	 invasive	 lobular	 carcinoma	 (ILC).	 Twenty-two	 samples	contained	 pure	 fibrous	 tissue	 or	 a	 mixture	 of	 fibrous	 and	 adipose	 tissue,	 and	 4	samples	contained	pure	adipose	tissue.		The	 total	 number	 of	 pixels	 for	 analysis	was	 257;	 115	 tumour	 pixels,	 116	fibrous	 pixels	 and	 26	 pure	 adipose	 pixels	 (Table	 9).	 The	mean	number	 of	 pixels	selected	 per	 sample	 was	 5	 (range	 1	 –	 17).	 The	 tumour	 pixels	 predominantly	consisted	of	NST	(N	=	92)	and	ILC	(N	=	19).	Most	of	the	tumour	pixels	contained	a	low	 to	moderate	percentage	of	 tumour	 cells	 ranging	between	1	–	60%	(N	=	98).		Almost	 all	 tumour	 cells	 had	 a	 background	 of	 pure	 fibrous	 tissue;	 only	 5	 had	 a	background	containing	a	mix	of	fibrous	and	adipose.	Most	of	the	fibrous	pixels	had	a	high	percentage	of	fibrous	cells	ranging	between	81	–	100%	(N	=	91).	Only	26	of	the	257	pixels	consisted	of	pure	adipose	tissue. The	 intra-rater	 reliability	 analysis	 showed	 excellent	 agreement	 in	 cell	density	 subgroup	 classification	 between	 histopathological	 evaluation	 1	 and	evaluation	2	 (κ	=	0.89)	 (p	=	NS).	 	This	 confirmed	 that	 the	established	subgroups	reliably	reflected	the	tissue	composition	of	the	samples,	and	thus	could	be	used	to	
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groups	(%)	 NST	 NST	+	DCIS	 ILC	 No.	of	pixels	 BG	 No.	of	pixels	 BG	 No.	of	pixels	81	–	100		 3	 1	 	 4	 F	 91	 A	 26	61	–	80		 11	 2	 	 13	 F	 2	 A	 	41	–	60		 22	 	 6	 28	 F	 7	 A	 	21	–	40		 33	 1	 12	 46	 F:	43	F/A:	3	 3	 A	 	1	–	20			 23	 	 1	 24	 F:	22	F/A:	2	 13	 A	 	
No.	of	pixels	 92	 4	 19	 115	 	 116	 	 26	NST	=	 invasive	ductal	 carcinoma/no	special	 type;	DCIS	=	ductal	 carcinoma	 in	 situ;	 ILC	=	 invasive	lobular	 carcinoma;	 BG	 =	 background	 tissue.	 In	 our	 dataset	 the	 background	 consisted	 of	 fibrous	tissue	(F),	adipose	tissue	(A),	or	a	mixture	of	fibrous	and	adipose	tissue	(F/A).		*:	these	pixels	contained	100%	adipose	tissue		
2.3.3.2 Parameters	and	SVM	classification	A	 total	 of	 11	 parameters	 were	 selected	 based	 on	 the	 AUROC	 analysis:	 10	 time	domain	parameters	and	1	frequency	parameter	(Table	10).	A	visual	representation	of	 these	 parameters	 is	 shown	 in	 Appendix	 Figure	 27.	 Most	 of	 the	 time	 domain	parameters	capture	the	area	around	the	minimum	amplitude	of	the	pulse,	and	the	return	to	baseline	after	the	minimum.	P1	–	P7	were	selected	based	on	their	overall	ability	 of	 discriminating	 tumour	 from	pure	 fibrous	 tissue	 and	mixed	 fibrous	 and	adipose	 tissue,	 while	 P8	 –	 P11	 were	 specifically	 selected	 to	 enhance	 the	 TPI	probe’s	ability	to	discriminate	tumour	from	pure	fibrous	tissue	(Table	10).	All	11	parameters	showed	strong	discriminative	power	to	distinguish	tumour	from	pure	adipose	tissue	(mean	AUROC	=	0.97,	range	0.84	–	1.0).		
	
127	













P11	 Power	in	spectrum	at	frequency	=	1.11	THz	 0.82	(61	–	80%	T,	100%	F)	1. T	=	tumour,	F	=	pure	fibrous	tissue	or	a	mixture	of	fibrous	and	adipose	tissue,	100%	F	=	pure	fibrous	tissue	only													
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(%)	P1	 73	 87	 62	 65	 85	P2	 72	 81	 64	 65	 81	P3	 70	 77	 65	 64	 78	P4	 72	 77	 69	 67	 78	P5	 72	 92	 56	 63	 90	P6	 69	 86	 56	 61	 83	P7	 69	 87	 54	 61	 84	P8	 68	 90	 49	 59	 86	P9	 56	 69	 46	 51	 64	P10	 68	 93	 48	 59	 89	P11	 56	 56	 57	 51	 61	P1	and	P6	 75	 86	 66	 67	 85	P1,	P6	and	P11	 71	 72	 70	 66	 76	P1,	P6,	P9	and	P11	 67	 56	 75	 65	 68	
Gaussian	wavelets	 69	 87	 54	 60	 84	1. Positive	predictive	value	2. Negative	predictive	value		The	SVM	classification	results	of	the	individual	parameters,	and	the	combination	of	parameters	 that	 performed	 best	 in	 terms	 of	 accuracy,	 can	 be	 found	 in	 Table	 11.	The	performance	of	 all	parameter	 combinations	 can	be	 found	 in	Appendix	Table	19,	 Appendix	 Table	 20	 and	 Appendix	 Table	 21,	 respectively.	 Overall	 the	combination	 of	 P1	 and	 P6	 provided	 the	 best	 performance	 with	 an	 accuracy,	sensitivity,	 specificity,	 positive	 predictive	 value	 and	 negative	 predictive	 value	 of	75%,	 86%,	 66%,	 67%	 and	 85%,	 respectively.	 These	 values	 were	 obtained	 as	 a	result	of	16	of	the	115	tumour	pixels	being	misclassified	as	benign;	48	of	the	142	benign	pixels	were	misclassified	as	tumour.	Of	the	misclassified	tumour	pixels,	10	pixels	contained	NST	from	a	total	of	7	samples.	Six	contained	ILC;	5	of	those	were	from	a	single	sample.	All	misclassified	tumour	pixels	had	a	tumour	content	≤60%.	Of	the	48	misclassified	benign	pixels,	46	were	fibrous	pixels	containing	81	–	100%	fibrous	cells;	only	2	of	the	1	–	80%	fibrous	pixels	were	misclassified	as	tumour,	and	
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all	 26	 pure	 adipose	 pixels	 were	 correctly	 identified	 as	 benign.	 The	 two-dimensional	 parametric	 plot	 of	 P1	 and	 P6	 showed	 no	 clear	 differences	 between	tumour	 and	 high	 percentage	 fibrous	 tissue	 (Figure	 14A);	 this	 provides	 an	explanation	 for	why	most	 of	 the	 SVM	classification	 errors	 occurred	 in	 these	 two	tissue	 groups	 (Figure	14B).	 Pixels	with	 a	 high	 adipose	 content	 (1	 –	 80%	 fibrous	pixels	 and	 pure	 adipose	 pixels)	 were	 generally	 clearly	 different	 from	 pixels	containing	 a	 high	 percentage	 of	 fibrous	 tissue	 	 (81	 –	 100%)	 and	 cancer	 (Figure	14A).	The	accuracy,	 sensitivity,	 specificity,	positive	predictive	value	and	negative	predictive	value	for	discriminating	1	–	80%	fibrous	and	pure	adipose	tissue	from	tumour	 (i.e.	 excluding	 the	 predominantly	 fibrous	 group	with	 81	 –	 100%	purity)	was	87%,	86%,	96%,	98%,	75%,	respectively.	
	Figure	14:	Two-dimensional	parametric	plot	(A)	and	SVM	classification	results	(B)	for	 the	 combination	 of	 parameters	 P1	 and	 P6	 that	 performed	 best	 in	 terms	 of	accuracy.			
2.3.3.3 Gaussian	wavelets	and	Bayesian	classification	The	 accuracy,	 sensitivity,	 specificity,	 positive	 predictive	 value	 and	 negative	predictive	 value	 of	 Gaussian	 wavelet	 deconvolution	 and	 Bayesian	 classification	was	69%,	87%,	54%,	60%,	84%,	respectively	(Table	11).		Of	the	115	tumour	pixels,	
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15	were	misclassified	as	benign.	Nine	contained	NST	from	a	total	of	4	samples.	Six	pixels	contained	ILC;	5	of	those	were	from	a	single	sample.	All	misclassified	pixels	contained	≤60%	tumour	cells.		Sixty-six	of	the	142	benign	pixels	were	wrongly	classified	as	tumour;	64	of	these	 were	 81	 –	 100%	 fibrous	 pixels,	 only	 two	 1	 –	 80%	 fibrous	 pixels	 were	misclassified.	 All	 pure	 adipose	 pixels	 were	 correctly	 classified.	 The	 accuracy,	sensitivity,	 specificity,	 positive	 predictive	 value	 and	 negative	 predictive	 value	 of	the	 handheld	 probe	 for	 discriminating	 1	 –	 80%	 fibrous	 and	 pure	 adipose	 from	tumour	was	88%,	87%,	96%,	98%	and	77%,	respectively.			
2.3.3.4 TPI	handheld	probe	system	stability	Figure	 15	 shows	 that	 there	 are	 clear	 differences	 in	 the	 THz	 pulses	 between	measurement	days.	These	differences	are	present	in	both	the	signal	intensity	(P11)	and	 signal	 shape	 (P1	 –	 P10).	 The	 26	 pixels	 of	 a	 single	 measurement	 also	 show	differences,	albeit	less	profound	than	the	differences	between	measurement	days.	Variations	 within	 the	 60-second	 measurement	 period	 were	 also	 observed	 as	indicated	by	the	large	95%	CI	of	each	individual	pixel.			
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	Figure	15:	THz	pulses	from	TPI	handheld	probe	on	3	different	measurement	days	shown	 in	 red,	 blue,	 and	 green,	 respectively.	 Parameter	 values	 and	 95%	 CI	 are	shown	 for	 all	 11	 parameters.	 The	 differences	 observed	 between	 measurement	days	and	between	pixels	from	a	single	measurement	illustrate	the	challenges	of	the	system	in	terms	of	signal	stability.			
2.3.4 Discussion		This	first-in-human	study	has	evaluated	the	performance	of	a	TPI	handheld	probe	system	 to	 discriminate	 breast	 cancer	 from	 benign	 breast	 tissue	 in	 an	 ex	 vivo	setting.	 	 A	 total	 of	 257	 pixels	 acquired	 from	 scanning	 46	 breast	 tissue	 samples	were	included	for	analysis.	The	tumour	samples	predominantly	contained	low-to-moderate	tumour	cell	percentages,	resembling	the	tissue	composition	found	at	the	resection	border	of	WLE	specimens	from	patients	with	positive	margins.	Two	data	analysis	and	classification	methods	were	assessed:	(1)	parameters	in	combination	with	 SVM	 classification	 and	 (2)	 Gaussian	 wavelet	 deconvolution	 with	 Bayesian	classification.	 On	 the	 full	 dataset	 the	 former	 provided	 the	 best	 performance	 in	terms	of	accuracy	(75%).	Both	methods	had	excellent	sensitivity	(86%	and	87%,	respectively)	 and	 thus	 show	 promise	 for	 the	 identification	 of	 tumour	 at	 the	margins	 of	 WLE	 specimens,	 allowing	 immediate	 further	 excision	 of	 appropriate	
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margins	 and	 reducing	 subsequent	 second	operations/re-excision	 rates	 if	 the	TPI	handheld	probe	had	been	used	intraoperatively.	Specificity	was	66%	and	54%	for	SVM	and	Bayesian	respectively;	for	both	methods	the	lower	specificity	was	due	to	pixels	with	81	–	100%	fibrous	tissue	that	were	wrongly	classified	as	tumour.	The	accuracy,	sensitivity	and	specificity	increased	to	88%,	87%,	and	96%	respectively,	when	discriminating	samples	with	1	–	80%	fibrous	and	pure	adipose	tissue	from	tumour.				 The	 reported	 pooled	 sensitivity	 and	 specificity	 of	 the	 established	techniques	 to	 intraoperatively	assess	 tumour	margins	during	BCS	are	53%	(95%	CI	45	–	61%)	and	84%	(95%	CI	77	–	89%)	for	specimen	radiography,	59%	(95%	CI	36	–	79%)	and	81%	(95%	CI	66	–	91%)	for	ultrasound	imaging,	86%	(95%	CI	78	–	91%)	and	96%	(95%	CI	92	–	98%)	for	frozen	section	analysis,	and	91%	(95%	IC	71	–	97%)	and	95%	(95%	IC	90	–	98%)	 for	 imprint	cytology,	 respectively	 (183)	(Table	6).	Thus,	based	on	the	results	of	the	present	study,	the	TPI	handheld	probe	appears	 to	 perform	 similarly	 or	 better	 in	 terms	 of	 sensitivity,	 while	 the	performance	 in	 terms	of	 specificity	 is	 lower.	Compared	 to	 specimen	radiography	and	 ultrasound,	 which	 are	 also	 imaging	 technologies,	 TPI	 has	 the	 potential	advantage	 that	 image	 interpretation	 is	 not	 needed	 as	 the	 device	 can	 provide	 a	binary	read-out	(tumour	or	no	tumour).	This	may	overcome	the	need	for	training	that	 is	required	for	obtaining	ultrasound	accreditation	(Section	1.5.1.1).	Potential	advantages	 over	 the	 histopathological	 techniques	 frozen	 section	 analysis	 and	imprint	 cytology	 are	 the	 fact	 that	 TPI	 is	 non-invasive	 (i.e.	 no	 physical	 tissue	disruption	 is	 needed	 for	 assessing	 margin	 status),	 does	 not	 require	 an	 on-site	cytologist	or	histopathologist,	and	allows	for	assessing	a	larger	tissue	surface.			 There	are	currently	a	number	of	emerging	imaging	techniques	that	focus	on	enhancing	 intraoperative	margin	assessment.	These	 include	 techniques	based	on	
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radiofrequency	 spectroscopy	 (MarginProbe),	 bio-impedance	 spectroscopy	(ClearEdge),	rapid	evaporative	ionisation	mass	spectroscopy	(iKnive),	and	optical	imaging	 techniques	 that	 utilize	 the	 visible	 or	 near-infrared	 part	 of	 the	electromagnetic	 spectrum	 (diffuse	 reflectance	 spectroscopy,	 optical	 coherence	tomography,	 near-infrared	 fluorescence	 imaging	 and	 Raman	 spectroscopy)	(Section	1.5.1.2).	Results	published	to	date	have	shown	a	sensitivity	and	specificity	of	70	–	75%	and	46	–	70%	for	the	MarginProbe,	87%	and	76%	for	ClearEdge,	67	–	85%	and	67	–	96%	for	diffuse	reflectance	spectroscopy,	60	–	100%	and	69	–	92%	for	optical	coherence	tomography,	92%	(95%	CI	86	–	96%)	and	97%	(95%	CI	93	–	98%)	 for	 Raman	 spectroscopy,	 and	 93	 –	 100%	 and	 91.9	 –	 100%	 for	 the	 iKnive	(Table	7).	Although	the	performance	of	the	handheld	probe	in	this	first-in-human	study	is	somewhat	lower	than	some	of	these	other	emerging	techniques,	TPI	uses	a	different	 region	 of	 the	 electromagnetic	 spectrum	 and	 thus	 provides	complementary	information.	It	is	possible	that	combinations	of	technologies	could	significantly	improve	the	overall	accuracy	of	identifying	involved	margins.		Several	 papers	have	 reported	on	 the	 ability	 of	TPI	 to	discriminate	 freshly	excised	 benign	 from	malignant	 breast	 tissue	 (312,314,315,323).	 Ashworth	 et	 al.	performed	 a	 small	 pilot	 study	 using	 a	 prototype	 version	 of	 the	 TPI	 handheld	system	 (315);	 all	 other	 studies	 were	 conducted	 with	 systems	 not	 suited	 for	intraoperative	 imaging	 of	 WLE	 specimens.	 Similar	 to	 the	 present	 results,	 they	found	that	THz	impulse	functions	from	fibrous	tissue	and	breast	cancer	had	strong	similarities,	 while	 impulse	 functions	 from	 adipose	 tissue	 had	 clearly	 different	features.	However,	none	of	the	TPI	studies	in	breast	cancer	published	to	date	have	used	 a	 dataset	 representative	 of	 the	 tissue	 composition	 found	 at	 the	 resection	border	 of	 patients	 with	 positive	 margins,	 as	 all	 tumour	 samples	 included	 for	analysis	contained	>50%	tumour	cells.		Thus,	the	results	in	our	study	are	the	first	
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that	can	be	used	to	derive	insight	in	the	potential	benefits	of	TPI	in	enabling	more	accurate	and	complete	tumour	resection	in	BCS.		The	accuracy,	sensitivity	and	specificity	of	the	TPI	probe	for	discriminating	tumour	from	mixed	fibrous	and	adipose	tissue,	and	pure	adipose	tissue,	was	87%,	86%,	 and	 96%	 for	 SVM,	 and	 88%,	 87%	 and	 96%	 for	 Bayesian,	 respectively.	Discrimination	of	these	tissue	types	is	most	relevant	clinically,	as	the	incidence	of	breast	 cancer	 is	 highest	 in	 older	 women,	 who	 are	 likely	 to	 have	 fatty	 or	 mixed	fibrous	and	fatty	breasts	compared	to	younger	women	who	may	have	more	dense	breasts	primarily	composed	of	fibrous	tissue	(324).		While	the	results	of	this	feasibility	study	are	promising,	several	limitations	were	noted.	Firstly,	 there	were	marked	differences	 in	 the	THz	pulses	emitted	by	the	 TPI	 handheld	 probe	 system	 on	 different	 measurement	 days	 (Figure	 15).	 By	normalising	 the	 parameter	 value	 of	 tissue	 to	 the	 parameter	 value	 of	 water	measured	on	the	same	day,	one	could	adjust	for	this	source	of	variation.	This	could	improve	the	contrast	between	tumour	and	benign	breast	tissue,	which	ultimately	could	 allow	 for	 more	 accurate	 tissue	 classification.	 Secondly,	 the	 0.6	 mm	 pixel	distance	 used	 for	 correlating	 TPI	 and	 histopathology	 was	 based	 on	 a	 linear	movement	 of	 the	 THz	 pulse	 beam	 across	 the	 15	 x	 2	mm	 scan	 area.	However,	 in	practice	the	THz	beam	moves	faster	in	the	centre	of	the	scan	area	and	slows	down	upon	reaching	the	top	and	bottom	boundary,	resulting	in	a	larger	distance	between	pixels	 located	 in	 the	 centre	 compared	 to	 the	 edges.	 This	 introduces	 a	 degree	 of	inaccuracy,	which	was	not	accounted	for	 in	this	study.	Lastly,	 the	current	dataset	does	not	contain	THz	pulses	from	cases	of	pure	DCIS.	These	samples	could	not	be	assessed,	as	DCIS	is	generally	non-palpable	and	particularly	problematic	to	sample	in	 the	 fresh	 state	 without	 impairment	 of	 gold-standard,	 formalin	 fixed,	 paraffin	wax	 embedded	 histological	 assessment.	 However,	 DCIS	 is	 often	 the	 cause	 of	 the	
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3. Cerenkov	 luminescence	 imaging	 for	 intraoperative	 tumour	
margin	assessment	in	breast-conserving	surgery		This	 chapter	 describes	 CLI	 and	 the	 application	 of	 CLI	 in	 image-guided	 cancer	surgery,	with	a	specific	 focus	on	assessing	 tumour	resection	margins	 in	BCS.	The	first	part	of	this	chapter	outlines	the	characteristics	of	Cerenkov	radiation	and	CLI,	and	the	results	published	to	date	on	the	use	of	CLI	for	image-guided	surgery.	The	remaining	part	of	this	chapter	focuses	on	the	results	of	two-lead	in	studies	and	a	first-in-human	 clinical	 study	 I	 have	 conducted	 to	 evaluate	 the	 feasibility	 of	 2-deoxy-2-(18F)fluoro-D-glucose	 (18F-FDG)	 CLI	 for	 tumour	 margin	 assessment	 in	BCS.		
3.1 Introduction	 to	 Cerenkov	 luminescence	 and	 Cerenkov	
luminescence	imaging	CLI	is	a	novel	imaging	modality	that	was	first	used	to	image	cancer	in	vivo	in	2009	(326).	CLI	combines	molecular	and	optical	imaging	by	detecting	Cerenkov	photons	emitted	 by	 positron	 emission	 tomography	 (PET)	 imaging	 agents.	 Cerenkov	photons	are	emitted	by	a	charged	particle	 (positron	or	electron)	when	 travelling	through	a	dielectric	medium	at	a	velocity	greater	than	the	velocity	of	light	in	that	medium.		The	Cerenkov	phenomenon	seems	to	have	been	first	observed	by	Marie	Curie	in	the	late	19th	century.	In	her	biography	she	describes	observing	a	pale	blue	glow	from	 the	 radium	 containing	 bottles	 in	 her	 laboratory.	 The	 first	 person	 to	systematically	describe	Cerenkov	radiation	was	Pavel	Cerenkov,	and	together	with	Il’ja	 Mikhailovic	 Frank	 and	 Igor	 Yevgenyevich	 Tamm	 who	 developed	 the	
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theoretical	 framework,	 they	 won	 the	 Nobel	 Prize	 in	 Physics	 in	 1958	 for	 their	contribution	 to	 the	 discovery	 of	 the	 Cerenkov	 effect.	 To	 a	 layperson’s	 mind,	Cerenkov	 radiation	 is	 the	 blue	 glow	 in	 the	 cooling	 water	 basins	 that	 surround	nuclear	reactors.	After	its	discovery	in	2009,	CLI	has	gained	significant	scientific	interest	in	the	field	 of	 biomedical	 imaging.	 A	 search	 of	 Embase	 and	 Medline	 performed	 on	 28	December	2015	using	the	keywords	‘Cerenkov	Luminescence	Imaging’	provided	a	total	of	103	and	59	articles,	respectively.	Several	review	papers	have	outlined	the	various	 applications	 of	 CLI	 including	 its	 use	 in	 Cerenkov	 luminescence	 imaging	dosimetry	 (CLID),	 radionuclide	 therapy	monitoring,	 tumour	response	monitoring	and	 photoactivation	 therapy	 (327-331).	 An	 in-depth	 explanation	 of	 the	 complex	physics	underlying	Cerenkov	radiation	and	CLI	has	also	been	reported	(332,333);	a	simplified	explanation	with	an	emphasis	on	the	features	that	are	relevant	to	image-guided	surgery	is	provided	in	the	following	sections.		
3.1.1 The	basics	of	Cerenkov	radiation	Cerenkov	 radiation	 is	 produced	 when	 a	 charged	 particle	 travels	 through	 a	dielectric	medium,	 i.e.	a	medium	that	can	be	polarised	by	an	electric	 field,	with	a	speed	faster	than	the	speed	of	light	in	that	medium	(334).	When	propagating,	the	charged	 particle	 (a	 positively	 charged	 positron	 or	 negatively	 charged	 electron)	induces	a	local	polarization	by	displacing	the	positive	and	negative	charges	of	the	atoms	in	the	medium	(Figure	16).		
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	Figure	16:	A	charged	particle,	in	this	case	an	electron,	passing	through	a	dielectric	medium	with	 a)	 particle	 speed	 lower	 than	 speed	 of	 light	 in	medium	 b)	 particle	speed	larger	than	speed	of	light	in	medium.			In	a	situation	where	the	particle’s	velocity	does	not	exceed	the	speed	of	light	in	that	medium,	 the	 polarisation	 field	 surrounding	 the	 particle	 is	 perfectly	 symmetrical,	and	there	is	no	electric	field	at	larger	distances.	The	net	result	is	that	no	Cerenkov	radiation	is	emitted.	When	the	particle’s	speed	exceeds	the	speed	of	light	however,	the	polarisation	becomes	asymmetrical	along	the	track	of	the	particle,	resulting	in	a	dipole	electric	field	at	 larger	distances	from	the	particle.	 	As	the	particle	passes	the	 electrons	 of	 the	 atoms	 return	 to	 their	 ground	 state,	 thereby	 emitting	 the	transferred	energy	as	optical	photons	that	are	known	as	Cerenkov	radiation.	Thus,	Cerenkov	 radiation	 is	 produced	 as	 secondary	 emission;	 it	 is	 not	 the	 charged	particle	generating	light	but	the	medium	as	a	reaction	to	the	particle.		For	Cerenkov	radiation	to	be	emitted,	the	charged	particle	needs	to	exceed	a	certain	energy	threshold.	This	threshold	is	expressed	by	v ≥  !/!,	where	ν	is	the	charged	particle’s	velocity,	c	is	the	speed	of	light	in	vacuum,	and	η	is	the	refraction	index	 of	 the	 medium.	 From	 this	 expression	 becomes	 clear	 that	 the	 Cerenkov	threshold	 is	 related	 to	 the	 refractive	 index	 of	 the	 medium.	 By	 using	 the	relationship	 between	 the	 velocity	 of	 the	 particle	 and	 its	 energy	 as	 described	 by	
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equation	2	and	3	 in	Gill	et	al.,	 it	 is	 found	 that	 in	water	with	a	 refractive	 index	of	1.33	the	threshold	is	0.264	MeV	(335).	In	soft	tissues	the	refractive	index	typically	ranges	 from	1.36	–	1.40,	 resulting	 in	 a	 threshold	 for	 the	production	of	Cerenkov	radiation	of	approximately	0.219	–	0.250	MeV.	These	thresholds	are	lower	than	the	beta	 particle	 energies	 from	 radionuclides	 used	 in	 PET,	 and	 these	 radionuclides	thus	 emit	 Cerenkov	 radiation	 in	 both	 water	 and	 tissue	 (336).	 As	 the	 charged	particle	 travels	 through	 the	medium	 it	 loses	 energy	due	 to	 interactive	processes	with	 its	 surroundings	 including	 absorption	 and	 scattering,	 and	 eventually	 its	energy	falls	below	the	threshold	and	Cerenkov	light	is	no	longer	produced.	For	the	much	heavier	alpha	particles	 the	Cerenkov	threshold	 in	water	and	tissue	 is	1926	MeV	 and	 1673	 MeV,	 respectively	 (337).	 Although	 none	 of	 the	 energies	 from	existing	 alpha-emitting	 radionuclides	 come	 near	 this	 threshold	 (typical	 alpha	particle	 energies	 range	 between	 3	 and	 7	MeV),	 studies	 have	 shown	 emission	 of	Cerenkov	 photons	 by	 alpha-emitters	 (337-339).	 There	 are	 two	 explanations	 for	this	observation,	depending	on	the	type	of	radionuclide:	either	photons	arise	from	the	short-lived	beta-emitting	daughter	 radionuclides	of	 some	alpha	emitters	 (e.g.	Actinium-225),	 or	 they	 are	 produced	 by	 electrons	 that	 arise	 from	 Compton	scattered	 high-energy	 gamma	 photons.	 Regardless	 of	 the	 mechanism	 Cerenkov	radiation	 from	 alpha	 emitters	 is	 thus	 produced	 indirectly	 by	 secondary	 beta	particles.	 The	 pure	 gamma-emitter	 Technetium-99m	 (99mTc)	 is	 also	 able	 to	produce	 optical	 photons	 as	 shown	 by	 several	 groups	 (340-342).	 Although	 the	mechanism	of	this	optical	emission	is	not	yet	fully	understood,	it	is	assumed	to	be	from	OH	radicals	 that	are	excited	by	 the	 low	energy	Compton	electrons	 (340)	or	from	gamma	excitation	of	the	luminophores	that	are	present	in	99mTc	based	tracers	(e.g.	 the	 amino	 acids	 in	 99mTc-macroaggregates	 albumin)	 (342).	 This	 form	 of	luminescence	is	known	as	radio	luminescence	and	differs	from	Cerenkov	radiation;	
141	
it	 has	 a	 different	wavelength	 spectrum	and	 its	 signal	 intensity	 is	 lower	 in	 tissue	(343).	 The	 latter	 may	 provide	 additional	 challenges	 for	 its	 use	 in	 image-guided	interventions,	 and	 the	 remainder	 of	 this	 section	 will	 therefore	 solely	 focus	 on	Cerenkov	radiation.	The	 number	 of	 Cerenkov	 photons	N	 emitted	 per	 distance	 travelled	 x	 can	calculated	by	using	equation	1,	which	 is	derived	 from	 the	Frank-Tamm	equation	(335):	 !"!" = 2!" 1−  1!!!! 1!!!!!! !"	Here	 is	 α	 the	 fine	 structure	 constant	 (1/137),	 β	 is	 the	 ratio	 between	 particle’s	velocity	and	the	speed	of	light	in	vacuum	(ν/c),	and	the	integral	is	over	the	interval	λ1	to	λ2.	From	this	equation	it	follows	that	the	intensity	of	the	Cerenkov	radiation	depends	 on	 a	 particle’s	 velocity,	 and	 thus	 its	 energy.	 Fluorine-18	 (18F),	 the	most	commonly	 used	 radionuclide	 in	 PET	 imaging,	 has	 an	 average	 and	 maximum	 β-energy	of	250	keV	and	633	keV,	respectively.	As	a	result,	only	47%	of	the	decays	produce	a	positron	that	exceeds	the	energy	threshold	for	production	of	Cerenkov	radiation	 in	water	(332).	Yttrium-90	(90Y),	a	 radionuclide	often	used	 in	radiation	therapy,	has	a	much	higher	average	and	maximum	β-energy	of	934	keV	and	2.28	MeV	 respectively,	 and	 90%	 of	 its	 produced	 electrons	 are	 above	 the	 Cerenkov	threshold	 in	 water.	 Gill	 et	 al.	 recently	 studied	 47	 radionuclides	 widely	 used	 in	Nuclear	 Medicine,	 and	 used	 Monte	 Carlo	 simulations	 to	 quantify	 the	 expected	Cerenkov	light	yield	(photons/decay)	for	each	radionuclide	in	tissue	(η=1.4)	(335).	They	 found	 that	 18F	 emits	 2.58	 photons	 per	 decay	 in	 tissue;	 approximately	 23	times	 less	 than	 the	 58.5	 photons	 per	 decay	 emitted	 by	 90Y.	 The	 light	 yield	 from	some	commonly	used	radionuclides	in	order	from	high	to	low	are	shown	in	Table	12.	Although	it	is	important	to	realise	that	the	reported	light	yields	do	not	take	into	
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account	 the	 wavelength	 dependent	 absorption	 and	 wavelength	 dependent	scattering	 that	would	 occur	 in	 human	 tissue	 –	 this	would	 reduce	 the	 number	 of	detectable	 photons	 –	 it	 is	 clear	 that	 the	 signal	 intensity	 of	 CLI	 can	 be	 improved	significantly	 by	 using	 higher-energetic	 isotopes.	 However,	 even	 with	 the	 use	 of	such	 isotopes	 the	Cerenkov	 light	yield	 from	a	 single	 radioactive	decay	process	 is	low	 in	 comparison	 to,	 for	 example,	 the	 light	 yield	 from	 a	 single	 fluorescent	molecule.	 Fluorescein	 and	 Indocyanine	 green	 (ICG),	 fluorophores	 used	 in	fluorescence	 image-guided	 surgery,	 emit	 roughly	 3	 orders	 of	 magnitude	 more	photons	(344).	This	low	light	yield	requires	strict	control	of	the	light	environment	to	 obtain	 a	 sufficient	 signal-to-background	 ratio	 (SBR)	 when	 using	 CLI	 in	 an	intraoperative	setting	as	explained	below.	Another	characteristic	of	Cerenkov	light	is	its	broad	emission	spectrum	that	ranges	 from	 approximately	 400	 –	 900	 nm	 (326).	 The	 light	 intensity	 is	 inversely	proportional	 to	 the	 square	 of	 the	 wavelength	 (1/λ2).	 This	 is	 why	 Cerenkov	radiation	is	strongest	towards	the	blue	end	of	the	visible	spectrum,	and	hence	why	Cerenkov	radiation	appears	blue.		The	 fundamental	 resolution	 of	 Cerenkov	 radiation	 is	 determined	 by	 the	distance	over	which	a	β-particle	emits	light.	It	was	found	that	for	90Y	and	18F	this	distance	 is	approximately	2	mm	and	0.3	mm,	respectively	(332).	This	shows	that	lower-energetic	tracers	have	a	better	physical	resolution	limit,	but	the	downside	is	a	lower	light	yield	and	thus	sensitivity.						
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Table	12:	Relevant	characteristics	of	Cerenkov	radiation	and	CLI	for	image-guided	cancer	surgery.		Cerenkov	radiation	definition	 Optical	 radiation	emitted	by	 charged	particles	when	 travelling	 through	 a	 dielectric	 medium	with	 a	 speed	 larger	 than	 the	 speed	 of	 light	 in	that	medium		Threshold	energy	for	Cerenkov	radiation	emission	(335)	 Water	(η=1.33):	0.264	MeV	Biological	tissue	(η=1.36	–	1.40):	0.219	–	0.250	MeV		Cerenkov	radiation	is	emitted	by	 β+,	β-,	and	α-emitting	radionuclides		Cerenkov	 intensity	 from	 radionuclides	most	 commonly	 used	 in	 clinic	 in	 order	from	high	to	low	(335)		
90Y	>	68Ga	>	15O	>	124I	>	11C	>	89Zr	>	18F	>	131I	>	64Cu	
Cerenkov	radiation	spectrum	(326)	 400	-	900	nm		Fundamental	resolution	(332)	 0.3	-	2.00	mm		Camera	 requirements	 for	 Cerenkov	radiation	detection	 High-sensitivity	 optical	 cameras	 with	 single-photon	detection	capability		Typical	penetration	depth	in	tissue		 <1	 cm	 (depending	 on	 tissue	 composition	 and	radionuclide)			Typical	CLI	acquisition	times	 1	–	5	min		Types	of	images	acquired	with	CLI	 Photographic	image:	anatomical	information	Functional	 image:	 information	 on	 the	 uptake	and	location	of	the	radiopharmaceutical		Advantages	 of	 CLI	 for	 image-guided	cancer	surgery	 Ability	 to	 use	 clinically	 approved	 tumour-targeted	radiopharmaceuticals		Potential	 for	multi-modality	 imaging	with	 the	same	 tracer:	 preoperative	 imaging	 with	gamma-camera,	 PET	 or	 SPECT,	 intraoperative	imaging	 using	 CLI	 +/-	 beta-probe	 or	 gamma-probe		Small	 form	 factor	 of	 CLI	 equipment	 allowing	implementation	 of	 CLI	 technology	 in	intraoperative	 specimen	 chamber,	 flexible	endoscope	and	rigid	laparoscope		External	 excitation	 source	 not	 required:	 less	tissue	autofluorescence		Challenges	 of	 CLI	 for	 image-guided	cancer	surgery	 Faint	signal		Light-tight	imaging	conditions	required	Radiation	dose	to	patient	and	staff	Strict	regulations	for	use	of	radiotracers	Complex	 logistics	 that	 requires	 close	 multi-disciplinary	team	work			
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3.1.2 Characteristics	 of	 Cerenkov	 luminescence	 imaging	 from	 an	 image-
guided	surgery	perspective	CLI	images	can	be	acquired	by	detecting	the	Cerenkov	light	from	PET	tracers	using	ultra-high	sensitivity	optical	cameras	such	as	electron-multiplying	charge	coupled	device	 (EMCDD)	 cameras.	 The	 CLI	 image	 can	 be	 analysed	 semi-quantitatively	 in	photon	 radiance.	 CLI	 and	 PET	 are	 directly	 correlated	 due	 to	 both	 techniques	measuring	the	photons	produced	by	positron-emitting	radiopharmaceuticals;	PET	measures	 the	 annihilation	 photons	 and	 CLI	 measures	 the	 Cerenkov	 photons.	Several	studies	have	shown	a	strong	correlation	between	CLI	and	PET	for	different	radiopharmaceuticals	in	vitro,	ex	vivo	and	in	vivo,	thus	demonstrating	the	feasibility	of	 CLI	 for	 molecular	 imaging	 of	 living	 subjects.	 An	 overview	 of	 the	 published	literature	 on	 the	 correlation	 between	 CLI	 and	 PET	 is	 provided	 in	 Table	 13.	 This	table	also	includes	results	on	the	correlation	between	CLI	and	radiotracer	activity.	There	are	several	reasons	why	CLI	has	sparked	so	much	interest	in	the	field	of	 biomedical	 imaging,	 and	 why	 it	 is	 a	 promising	 technology	 to	 guide	 surgical	resection.	 Firstly,	 CLI	 images	 can	 be	 acquired	 with	 clinically	 approved	 tumour-targeted	 radiopharmaceuticals	 that	 have	 been	 used	 for	 over	 two	 decades	 in	molecular	 medical	 imaging	 (336).	 This	 provides	 great	 potential	 for	 rapid	translation	of	CLI	 into	 clinical	practice.	Especially	 the	possibility	 to	use	 the	most	commonly	 used	 PET	 radiopharmaceutical	 18F-FDG,	 facilitates	 wide	 clinical	adoption	 of	 CLI,	 as	 this	 is	 a	 versatile	 tracer	 that	 can	 be	 used	 in	 several	 solid	cancers,	 including	 melanoma,	 lung,	 colorectal,	 head	 and	 neck,	 breast	 and	oesophageal	cancer	(345).			
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Table	13:	Literature	overview	on	the	correlation	of	CLI	and	PET.		




Radiance	 %ID/g	 R2=0.93,	0.95,	0.93,	0.89	 18F-FDG	 In	vivo	 (346)	Radiance	 %ID/g	 R2=0.97	 18F-FDG	 In	vivo	 (336)	Radiance	 Activity	 R2=0.95	 18F-FDG	 In	vivo	 (347)	Radiance	 Activity	 R2=0.98	 18F-FDG	 In	vivo	 (348)	Radiance	 Activity	conc.	 R=0.51	 18F-FDG	 In	vivo	 (349)	Radiance	 %ID/cm3	 R2=0.83	 18F-FDG	 In	vivo	 (350)	Radiance	 %ID	 R2=0.82	 18F-FDG	 In	vivo	 (350)	Radiant	vol.	 Glycolytic	vol.	 R2=0.99	 18F-FDG	 In	vivo	 (350)	Radiance	 Activity	 R2=0.99	 18F	 In	vitro	 (351)	Radiance	 Activity	 R2=0.97	 18F-FDG	 In	vitro	 (352)	Radiance	 Activity	conc.	 R2=0.99	 18F-FDG	 In	vitro	 (349)	Radiance	 Activity	 R2=0.97	 18F-FDG	 Ex	vivo	 (347)	Intensity	 Activity	conc.	 R2=0.98	 68Ga	 In	vitro	 (353)	Intensity	 Activity	conc.	 R2=0.99	 68Ga	 In	vivo	 (353)	Radiance	 %ID/g	 R=0.89	 89Zr-trastuzumab	 In	vivo	 (354)	Radiance	 %ID/g	 R=0.98	 89Zr-J591	 In	vitro	 (338)	Radiance	 Activity	conc.	 R=0.98	 89Zr-J591	 In	vitro	 (338)	Radiance	 %ID/g	 R2=0.85	 89Zr-rituximab	 In	vivo	 (355)	Radiance	 Activity	 R2=0.98	 Na-131I	 In	vitro	 (356)	Radiance	 Activity	 R2=0.99	 131I-NGR	 In	vitro	 (357)	Radiance	 %IA/g	 R2=0.94,	0.98	 90Y-DOTA-AR	 In	vivo	 (358)	Radiance	 %IA/g	 R2=0.91,	0.99	 90Y-DOTA-AR	 Ex	vivo	 (358)	
146	
The	ability	to	use	clinically	approved	tumour-specific	tracers	is	an	important	advantage	 over	 conventional	 optical	 imaging	 techniques	 such	 as	 targeted	 near-infrared	fluorescence	imaging,	as	to	date	there	are	no	tumour-specific	fluorescent	tracers	 that	have	been	approved	by	 the	Food	and	Drug	Administration	 (FDA)	or	European	 Medical	 Agency	 (EMA)	 (236).	 Targeted	 fluorescence	 imaging	 faces	 a	significant	 commercial	 hurdle	 for	 clinical	 adoption	 because	 the	 process	 of	obtaining	 regulatory	 and	 reimbursement	 approval	 is	 costly	 and	 lengthy	 (234),	while	the	revenue	of	imaging	agents	is	often	low	compared	to	therapeutic	agents,	which	makes	 it	a	significantly	 	 less	 interesting	 investment	for	 industry	(235,359)	(Section	1.5.1.2).			 In	addition	to	the	already	approved	PET	tracers	a	significant	number	of	new	tracers	 are	 being	 developed	 for	 market	 approval	 including	 18F-FES,	 68Ga-PSMA,	
68Ga-DOTATOC,	18F-NaF,	18F-Choline,	and	18F-FDOPA	(360,361).		The	 ability	 to	 use	 the	 same	 tracer	 for	 both	 CLI	 and	 PET	 or	 SPECT	 enables	dual-modality	 molecular	 imaging.	 PET	 and	 SPECT	 provide	 preoperative	information	on	the	location	and	extent	of	the	tumour,	while	CLI	can	be	used	as	an	intraoperative	adjunct	to	aid	lesion	identification	and	guide	surgical	resection.	The	use	of	the	same	tracer	ensures	visualisation	of	the	same	structures	and	facilitates	a	more	accurate	comparison	between	modalities.	Depending	on	the	patient	pathway	and	 half-life	 of	 the	 tracer,	 preoperative	 and	 intraoperative	 imaging	 could	 be	performed	 using	 only	 one	 tracer	 injection,	 or	 by	 re-injecting	 the	 tracer.	 By	capturing	 a	 white-light	 image	 with	 a	 standard	 camera	 at	 the	 time	 of	 CLI	 image	acquisition,	 the	 functional	 information	 from	the	CLI	 image	can	be	combined	with	the	anatomical	and	structural	information	from	the	photograph,	thereby	providing	the	surgeon	with	information	on	the	nature,	 location	and	extent	of	the	cancerous	tissue.		
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Beta-emitting	radiopharmaceuticals	can	also	be	detected	by	a	beta-probe	or	gamma-probe	 (362-364),	 so	 these	 tools	 could	 potentially	 be	 used	 in	 addition	 to	CLI-guided	surgery	to	overcome	the	limited	penetration	depth	of	CLI	as	a	result	of	absorption	and	scattering.		The	optical	 imaging	systems	required	to	acquire	CLI	images	can	be	small	 in	dimension	or	use	fibreoptics	or	laparoscopic	capabilities.	Unlike	a	PET	system	this	provides	the	ability	to	use	CLI	in	an	operating	theatre	or	in	endoscopy	equipment,	and	examples	of	such	applications	are	provided	in	Section	3.2.		CLI	faces	a	number	of	challenges	for	routine	clinical	adoption.	As	mentioned	earlier	Cerenkov	luminescence	is	very	faint	due	to	the	small	number	of	optical	Cerenkov	photons	emitted	by	charged	particles.	In	biological	applications	the	signal	intensity	is	 further	 reduced	 by	 strong	 tissue	 attenuation	 from	 chromophores	 like	(oxy)haemoglobin	 and	 light	 scattering,	 which	 is	 more	 pronounced	 in	 the	 400	 –	650nm	 range	 (365,366).	 Consequently	 the	 acquisition	 time	 required	 to	 obtain	high-resolution	images	with	a	sufficient	signal-to-noise	ratio	(SNR)	is	 longer	than	with	 conventional	 optical	 imaging.	 Typical	 imaging	 times	 in	 pre-clinical	 and	clinical	 CLI	 studies	 range	 from	 1	 to	 5	 minutes	 (Table	 14).	 When	 imaging	 with	handheld	devices	(e.g.	endoscopes)	it	is	essential	that	during	image	acquisition	the	device	 is	 not	moved	 as	 this	 causes	 blurring	 of	 the	 image	 resulting	 in	 a	 reduced	image	quality.	In	an	in	vivo	environment	this	may	prove	especially	difficult	due	to	abdominal	activity	and	breathing	artefacts,	and	motion-correction	algorithms	may	be	needed	to	correct	for	this.		The	 weak	 light	 intensity	 also	 requires	 a	 light-tight	 environment,	 as	 any	leakage	of	ambient	light	will	overwhelm	the	CLI	signal.	Since	Cerenkov	radiation	is	strongest	 in	 the	 visible	 wavelengths	 it	 cannot	 be	 spectrally	 separated	 from	 the	
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much	brighter	ambient	 lights	currently	used	in	operating	theatres.	Control	of	 the	light	 environment	 is	 therefore	 currently	 achieved	 by	 imaging	 in	 a	 light-tight	specimen	 chamber	 or	 room	with	 light-sealed	 doors,	 or	 in	 anatomical	 areas	 that	provide	natural	darkness	(e.g.	gastrointestinal	tract).			An	often	mentioned	 limitation	of	 optical	 imaging	 in	 general	 is	 the	 limited	light	penetration	depth	and	thereby	the	inability	to	image	deep	located	tissue.	This	was	nicely	illustrated	by	Chin	et	al.,	who	calculated	the	reduction	in	signal	intensity	from	one	18F-isotope	and	one	ICG	molecule	in	1mm	of	tissue,	and	found	a	reduction	in	signal	intensity	of	77%	and	39%,	respectively	(344).	Because	Cerenkov	light	is	‘blue-weighted’	and	tissue	absorption	and	scattering	are	significantly	increased	for	these	wavelengths,	CLI	is	mainly	applicable	for	imaging	superficially	located	tissue,	and	specifically	suited	 for	 imaging	tumour	cells	within	a	 few	millimetre	 from	the	resection	border.	Due	 to	 the	 half-life	 dependency	 of	 radiotracers,	 the	window	 in	which	 CLI	imaging	 needs	 to	 be	 performed	 to	 obtain	 a	 sufficient	 SNR	 and	 image	 quality	 is	limited.	Well-designed	logistics	and	close	collaboration	between	nuclear	medicine,	radiology	and	surgical	departments	are	therefore	a	prerequisite	for	the	successful	implementation	of	CLI	in	current	clinical	and	surgical	workstreams.	A	challenge	for	CLI-guided	surgery	in	particular	is	the	radiation	exposure	to	patients	 and	 theatre	 staff	 from	 using	 radiopharmaceuticals.	 For	 patients	 the	effective	 dose	 from	 a	 300MBq	 18F-FDG	 injection	 is	 approximately	 6mSv;	 this	 is	comparable	to	the	radiation	dose	for	a	typical	chest	CT	scan	(367)	and	much	lower	than	 the	 20-2500	 mSv	 radiation	 exposure	 from	 diagnostic	 and	 interventional	fluoroscopy	procedures	(368).	Staff	members	that	work	 in	close	proximity	of	 the	patient	during	surgery	are	also	exposed	to	radiation.	The	received	radiation	dose	is	dependent	 on	 the	 time	 between	 injection	 and	 the	 start	 of	 the	 interventional	
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Indication	 Tumour	type	 Tracer	 Dose	 CLI	device	 Acquisition		
time	
Ref	Pre-clinical	 CLI-guided		tumour	resection		 HER2+	breast	cancer	 89Zr-DFO-trastuzumab	 4	MBq	 Ivis	optical	imager	 2	–	5	min	 (354)	Pre-clinical	 CLI-guided		tumour	resection		 Glioblastoma	 68Ga-3PRGD2	 3.7	MBq	 Ivis	optical	imager	 1	–	5	min	 (373)	Pre-clinical	 Cerenkov	luminescence	endoscopy		
Brain	glioma	 18F-FDG	 37	MBq	 Custom-build	flexible	fibre	endoscope	light-tight	box	 5	min	 (374)	
Pre-clinical	 Cerenkov	luminescence	endoscopy		
Glioblastoma	 90Y-PRGD2,		18F-FP-PRGD2	 8.1	MBq,	33	MBq	 Custom-build	flexible	fibre	endoscope	light-tight	box	 6	min	 (375)	
Pre-clinical	 Cerenkov	luminescence	endoscopy	 Colon	cancer	 18F-FDG	 24	MBq	 Clinically	approved	rigid	laparoscope	coupled	to	emCCD	camera	in	light-tight	box		
5	min	 (376)	
Clinical	 Cerenkov	luminescence	endoscopy	 Rectal	cancer	 18F-FDG	 9.25	MBq/kg	 Clinically	approved	flexible	fibre	endoscope	coupled	to	emCCD	camera		
5	min	 (348)	
Pre-clinical	 CLI-guided	lymph	node	mapping	 N/A	 68Ga-SPIONs1	 5	–	10	MBq	 CCD	camera	positioned	in	light-tight	box			 2	-10	min	 (377)	Pre-clinical	 CLI-guided	lymph	node	mapping	 N/A	 18F-FDG	 1.2	MBq	 Ivis	optical	imager	 2	min	 (378)	
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3.2 Applications	 of	 Cerenkov	 luminescence	 imaging	 for	 image-guided	
surgery		Various	 research	 groups	 have	 been	 successful	 in	 using	 CLI	 for	 image-guided	surgical	 interventions,	despite	 the	 limitations	mentioned	 in	 the	previous	 section.	The	section	below	provides	an	overview	of	the	results	published	to	date,	including	two	 clinical	 applications	 of	 CLI	 that	 are	 not	 directly	 related	 to	 image-guided	surgery.		The	 majority	 of	 the	 work	 published	 to	 date	 on	 the	 use	 of	 CLI	 to	 guide	surgical	 excision	 is	 pre-clinical,	 although	 one	 clinical	 study	 was	 also	 published	recently	(Table	14).	These	studies	show	the	ability	to	perform	CLI-guided	surgical	excision	of	tumours	using	a	variety	of	radiopharmaceuticals	(clinically	approved	as	well	 tracers	 used	 for	 research	 purposes	 only)	 and	 different	 CLI	 embodiments,	including	 standard	 Ivis	 optical	 imaging	 systems,	 custom-build	 flexible	 fibre	endoscope	 systems,	 and	 clinically	 approved	 rigid	 laparoscope	 and	 flexible	endoscope	systems	coupled	to	emCCD	cameras.	An	example	that	nicely	illustrates	CLI-guided	tumour	excision	is	shown	in	Figure	17.			An	 important	 advantage	of	 using	CLI	 in	 an	 endoscopic	 setting	 is	 that	 these	make	 use	 of	 anatomical	 dark	 chambers,	 so	 that	 there	 is	 no	 interference	 from	external	 light	sources.	Besides,	 this	 technology	can	also	be	 implemented	 in	other	types	 of	 endoscopes	 such	 as	 a	 bronchoscope	 or	 hysteroscope,	 and	 future	applications	of	CLI	could	for	example	focus	on	lung	cancer,	endometrial	cancer	and	metastatic	lymph	nodes	in	the	abdomen,	pelvis	and	thorax.	.			CLI	has	also	been	successfully	used	for	lymph	node	identification	and	image-guided	 lymph	 node	 excision	 using	 18F-FDG	 and	 68Ga-labelled	 superparamagnetic	iron	oxide	particles	(SPIONs)	(Table	14).			
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	Figure	 17:	 89Zr-DFO-trastuzumab	 CLI	 guided	 tumour	 excision.	 A)	 Empty	background	 image	acquired	prior	 to	surgery.	B)	 Image	acquired	pre-incision	and	C)	 post-incision	 when	 the	 tumour	 was	 exposed	 after	 the	 skin	 was	 removed.	 D)	Image	of	the	post	excision	surgical	cavity	and	the	excised	tumour	(left	top	corner).	No	CLI	 signal	 is	 left	 at	 the	 excision	 site,	 thus	 indicating	 complete	 removal	 of	 the	tumour.	 E)	 Image	 of	 excised	 tumour	 alone	 F)	 Image	 acquired	 straight	 after	 the	surgical	wound	was	 closed	with	 sutures.	 Image	was	 reproduced	 from	 (354)	with	
kind	permission	from	SAGE	Publications.		 Two	 other	 interesting	 clinical	 applications	 of	 CLI,	 although	 not	 directly	related	 to	 image-guided	 surgery,	 were	 also	 published	 recently.	 Spinelli	 et	 al.	imaged	 the	 thyroid	 gland	of	 a	 patient	 treated	 for	 hyperthyroidism	who	 received	550MBq	 of	 Iodine-131	 (131I)	 (379).	 By	 using	 an	 emCCD	 camera	 positioned	 in	 a	light-tight	room,	tracer	uptake	in	the	thyroid	could	be	visualised	with	a	2-minute	exposure	time.	This	application	is	of	clinical	interest	as	imaging	the	uptake	of	beta-emitting	radiopharmaceuticals	 could	provide	a	 rapid	and	 inexpensive	alternative	for	monitoring	radiation	doses	given	to	superficial	organs.			 Thorek	et	al.	evaluated	CLI	for	non-invasive	detection	of	nodal	disease	in	a	preoperative	 clinical	 setting	 (349).	 Patients	 with	 lymphoma,	 leukaemia	 and	
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metastatic	lymphadenopathy	scheduled	to	undergo	standard	clinical	18F-FDG	PET	were	 included.	 CLI	 imaging	was	 performed	 immediately	 after	 the	 PET-scan	 in	 a	dark	 room	 with	 a	 single-photon	 sensitive	 camera	 positioned	 on	 a	 standard	photography	 tripod.	 The	 preliminary	 results	 from	 four	 patients	 (2	 lymphoma,	 1	lung	cancer	and	1	breast	cancer)	showed	that	metastatic	lymph	nodes	in	the	neck	or	axilla	had	a	statistically	significant	higher	Cerenkov	signal	than	negative	nodes	(p	=	0.02),	and	this	finding	strongly	correlated	with	the	results	from	PET.	Figure	18	shows	an	example	of	a	positive	and	negative	axillary	lymph	node	on	preoperative	CLI	and	PET,	respectively.	
	Figure	18:		CLI	and	PET/CT	image	of	a	patient	with	a	positive	and	negative	node	in	the	left	and	right	axilla,	respectively.	CLI	image	and	grey-scale	photographic	image	overlaid	with	Cerenkov	signal	of	negative	node	(A	and	C)	and	positive	node	(B	and	D).	 The	 CLI	 signal	 from	 the	 positive	 lymph	 node	 colocalized	with	 the	 increased	signal	on	PET/CT.		This	research	was	originally	published	in	(349)	by	the	Society	of	
Nuclear	Medicine	and	Molecular	Imaging	(SNMMI),	Inc.		A	patient	population	that	can	benefit	from	accurate	preoperative	identification	of	nodal	 disease	 are	 breast	 cancer	 patients	 with	 involved	 lymph	 nodes.	 If	 positive	lymph	 nodes	 are	 identified	 preoperatively	 on	 CLI	 their	 treatment	 could	 convert	
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from	SLNB	 to	 immediate	ALND,	 thus	preventing	 the	patient	 from	undergoing	 an	unnecessary	 surgical	 procedure.	 Alternatively,	 these	 patients	 may	 undergo	neoadjuvant	chemotherapy	followed	by	SLNB	+/-	ALND.	Completion	of	this	study	(ClinicalTrials.gov	 Identifier	NCT01664936)	will	provide	 insight	 in	 the	real	value	of	CL	imaging	in	aiding	medical	and	surgical	decision-making	preoperatively.	
 
3.2.1 Summary	CLI	is	a	fast-emerging	optical	imaging	technology	that	has	rapidly	progressed	from	bench	to	bedside.	This	rapid	development	has	been	facilitated	by	the	ability	to	use	clinically	 approved	 tumour-targeted	 PET	 tracers	 including	 18F-FDG.	 Its	 high-resolution,	 wide	 applicability	 across	 a	 range	 of	 solid	 cancers,	 and	 small	 size	imaging	 equipment	makes	 CLI	 a	 suitable	 technique	 for	 image-guided	 surgery	 in	general,	and	intraoperative	margin	assessment	in	particular	due	to	the	millimetric	penetration	 depth	 of	 Cerenkov	 luminescence.	 The	 last	 section	 of	 this	 chapter	describes	 the	 first-in-human	 study	 conducted	 to	 evaluate	 the	 feasibility	 of	intraoperative	 18F-FDG	 CLI	 for	 margin	 assessment	 in	 patients	 undergoing	 BCS.	Prior	 to	 commencement	 of	 this	 first-in-human	 study	 two	 lead-in	 studies	 were	performed	 to	 assess	 the	 18F	 cross-talk	 and	 to	 determine	 the	 activity	 of	 99mTc-nanocolloid	 required	 to	 successfully	 perform	 standard	 of	 care	 SLNB	 in	 patients	undergoing	18F-FDG	CLI-guided	surgery.	These	lead-in	studies	are	described	in	the	next	section.		
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3.3 Lead-in	 studies	 to	assess	gamma	probe	cross-talk	 from	18F	and	 to	
determine	 the	 99mTc	 dose	 required	 to	 successfully	 perform	
standard	 of	 care	 sentinel	 lymph	 node	 biopsy	 in	 patients	
undergoing	18F-FDG	CLI	guided	surgery		One	 of	 the	main	 routes	 for	 breast	 cancer	metastasis	 is	 via	 the	 lymphatic	 system	towards	lymph	nodes,	predominantly	to	lymph	nodes	located	in	the	axilla	(Section	1.3.2.2).	 SLNB	 is	 the	 standard	 method	 of	 staging	 the	 axillary	 lymph	 nodes	 in	clinically	 and	 radiologically	 node	 negative	 breast	 cancer	 patients.	 The	 SLN	 is	defined	 as	 the	 node	 receiving	 direct	 lymphatic	 drainage	 from	 the	 tumour,	 and	therefore	considered	 to	have	 the	highest	chance	of	harbouring	cancer	cells	 if	 the	primary	 breast	 tumour	metastasizes.	 If	 the	 SLN	 is	 free	 of	 cancer	 cells,	 the	 other	lymph	 nodes	 in	 the	 axilla	 are	 also	 considered	 to	 be	 free	 and	 further	 axillary	treatment	can	be	omitted.	SLNB	is	often	performed	at	 the	same	time	as	BCS,	and	standard	practice	at	Guy’s	Hospital	is	based	on	the	combined	technique	of	blue	dye	and	the	radioisotope	99mTc.	Both	tracers	are	injected	locally	in	the	breast,	and	after	the	 tracers	 are	 accumulated	 in	 the	 SLN,	 the	 surgeon	 uses	 a	 gamma	 probe	(handheld	 scintillation	 counter)	 and/or	 the	 discolouration	 from	 the	 blue	 dye	 to	locate	the	SLN.	The	presence	of	18F-FDG	in	subjects	undergoing	18F-FDG	CLI-guided	surgery	(Section	3.4)	will	result	in	a	greater	than	normal	background	signal	being	detected	by	 the	 handheld	 gamma	 probe	 due	 to	 the	 down-scatter	 of	 511keV	 18F	 gamma	photons	 into	 the	 99mTc	 energy	 window.	 This	 cross-talk	 background	 could	potentially	hinder	detection	of	 low-activity	 SLNs	 in	patients	undergoing	 SLNB	at	the	time	of	BCS.			
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3.3.1 Aim	Two	lead-in	studies	were	conducted	prior	to	commencement	of	the	intraoperative	
18F-FDG	 CLI	 study	 to	 assess	 the	 18F	 cross-talk	 and	 to	 determine	 the	 99mTc	 dose	required	to	successfully	perform	standard	of	care	SLNB	in	patients	undergoing	18F-FDG	CLI	guided	surgery.	
	
3.3.2 Materials	and	Methods	
3.3.2.1 Lead-in	study	I:	SLNB	simulations	using	the	GAPS	simulator	To	 determine	 the	 effects	 of	 the	 cross-talk	 background	 on	 the	 detectability	 of	radioactive	 lymph	 nodes,	 a	 simulation	 study	 was	 performed	 using	 the	computerized	 gamma	 probe	 simulator	 (GAPS)	 (Figure	 19)	 (380).	 	 The	 GAPS	system	has	previously	been	used	in	the	UK	national	breast	SLNB	training	program	‘NEW	 START’,	 and	 provides	 simulations	 of	 the	 radioactivity	 distribution	 and	gamma	probe	response	that	allows	accurate	objective	assessment	of	the	surgeon’s	ability	to	localise	SLNs	on	the	surface	of	a	manikin	of	the	female	breast	and	axilla.	
	Figure	19:	Computerized	gamma	probe	simulator	(GAPS).	The	PC	is	connected	to	the	dummy	gamma	probe	via	the	interface	unit,	which	allows	tracking	the	position	of	 the	 gamma	 probe	 in	 relation	 to	 the	 virtual	 lymph	 node.	 During	 the	 SLNB	simulations	 the	 PC	 screen	 was	 turned	 away	 from	 the	 surgeons	 so	 they	 were	blinded	 to	 their	 localisation	 results.	 Image	was	 reproduced	 from	 (380)	with	 kind	
permission	from	Wolters	Kluwer	Health.		
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The	 measurements	 were	 performed	 by	 two	 breast	 surgeons	 (AP	 and	 AK),	 with	extensive	 experience	 of	 performing	 SLNB	 procedures.	 After	 one	 test	 case	 to	familiarize	the	surgeons	with	the	GAPS	system,	each	surgeon	was	presented	with	3	simulated	SLNB	cases	individually.	In	each	case	the	injection	site,	two	SLNs	and	a	spatially	 uniform	 18F	 background	 signal	 with	 Poisson	 distributed	 noise	 were	simulated.	The	simulated	SLN	count	rates	ranged	between	56	and	373	counts	per	second	 (cps),	 and	were	based	on	 a	150MBq	 99mTc	 injection,	 a	 SLN	 tracer	uptake	ranging	 from	 0.06%	 to	 0.4%	 of	 the	 administered	 dose,	 an	 average	 SLN	 depth	(30mm	from	the	axillary	skin	surface)	(381),	and	a	time	between	tracer	injection	and	SLN	detection	of	3	hours,	which	is	common	for	1-day	SLNB	protocols.	The	dose	of	150MBq	99mTc	is	markedly	higher	than	the	standard	dose	of	20MBq	used	for	1-day	SLNB	procedures	at	Guy’s	Hospital.	This	increased	dose	was	chosen	to	ensure	a	 significant	 rise	 in	 SLN	 count	 rate,	 thus	 facilitating	 SLN	 detection	 in	 a	 18F	background,	whilst	keeping	within	a	dose	range	that	is	well	established	(382).	The	range	in	SLN	%	tracer	uptake	covers	the	lower	spectrum	of	tracer	uptake	reported	in	literature	(383),	thus	assessing	the	surgeon’s	performance	in	the	clinically	most	challenging	situation	of	identifying	SLNs	with	a	low	count	rate.	The	18F	background	signal	was	set	to	a	mean	of	560	cps,	corresponding	to	an	18F-FDG	dose	of	5MBq/kg,	which	 is	 the	 dose	 CLI	 study	 patients	 received	 (Section	 3.4).	 Calibration	measurements	 of	 count	 rates	 from	 99mTc	 and	 18F	 sources	with	 the	 same	 gamma	probe	 system	 and	 high-energy	 collimator	 as	 in	 the	 CLI	 study,	 the	 Europrobe	 3	(Eurorad	 S.A.,	 France),	 were	 used	 to	 set	 the	 count	 rates	 simulated	 by	 the	 GAPS	system.	 The	 SNR,	 defined	 as	 the	 ratio	 of	 the	 node	 count	 rate	 to	 the	 background	count	rate,	varied	from	0.67	and	0.10	in	the	simulations.		The	 surgeons	 performed	 surface	 scans	 with	 the	 GAPS	 gamma	 probe	 to	localize	as	many	nodes	as	 they	could,	and	 indicated	when	 they	 thought	 they	had	
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localized	 a	 SLN.	 SLN	 detection	 was	 only	 considered	 successful	 if	 the	 surgeon	indicated	that	they	had	located	a	node,	and	if	the	position	pointed	at	by	the	probe	was	within	10mm	of	the	virtual	node.			
3.3.2.2 Lead-in	study	II:	gamma	probe	measurements	in	18F-FDG	PET	patients	Following	on	from	the	SLNB	simulations,	gamma	probe	measurements	of	the	axilla	were	performed	to	confirm	that	the	simulated	18F	background	signal	corresponded	to	the	gamma	probe	cross-talk	found	in	vivo.	After	 research	 ethics	 committee	 approval	 and	 written	 informed	 consent	was	obtained,	a	total	of	20	female	patients	scheduled	for	a	diagnostic	18F-FDG	PET	scan	were	included	at	the	PET	Centre	at	St	Thomas’s	Hospital	(ISRCTN29552671).	Approximately	60	minutes	after	receiving	an	intravenous	injection	of	18F-FDG,	but	prior	to	PET	imaging,	the	Europrobe	3	gamma	probe	with	a	high	energy	collimator	was	 used	 to	 perform	 10	 second	measurements	 of	 the	 lowest	 and	 highest	 count	rates	 in	 the	 left	 and	 right	 axilla,	 respectively.	 The	measurements	 of	 both	 axillae	were	 performed	 shortly	 after	 each	 other	 (within	 5	 minutes)	 so	 that	 effects	 of	radioactive	decay	between	measurements	were	negligible.	The	background	count	rate	was	also	measured,	 and	 the	10s	 count	 rates	were	averaged	 to	give	 cps.	The	gamma	 probe	 system	 and	 configurations	 used	 to	 perform	 the	 18F-FDG	 axillary	cross-talk	 measurements	 were	 the	 same	 as	 in	 the	 CLI	 study	 (Section	 3.4).	 The	axilla	was	defined	as	the	triangle	between	the	pectoralis	major,	the	latissimus	dorsi	and	 the	 edge	 of	 the	 breast.	 By	 placing	 the	 probe	 perpendicular	 to	 the	 skin,	 the	entire	 axilla	 was	 scanned.	 Patient	 and	 injection	 characteristics	 such	 as	 height,	weight	 and	 injected	 activity	 were	 recorded.	 An	 independent	 samples	 t-test	 was	performed	 to	 compare	 the	 highest	 signal	 in	 the	 right	 axilla	 and	 left	 axilla	respectively,	and	a	p-value	of	<0.05	was	considered	statistically	significant.				
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3.3.3 Results	
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3.3.3.2 Lead-in	 study	 II:	 Gamma	 probe	 measurements	 in	 18F-FDG	 PET	
patients		The	 patient	 and	 18F-FDG	 injection	 characteristics	 can	 be	 found	 in	 Table	 16.	 The	mean	and	standard	deviation	of	the	lowest	and	highest	gamma	probe	signal	in	the	right	 axilla	was	310	±	77	 cps	 (range	133	–	488)	 and	372	±	85	 cps	 (range	233	–	616),	 respectively.	 The	 mean	 and	 standard	 deviation	 of	 the	 lowest	 and	 highest	gamma	probe	signal	in	the	left	axilla	was	299	±	80	cps	(range	161	–	553)	and	359	±	74	cps	(range	236	–	582),	respectively.	The	highest	count	rate,	which	is	clinically	
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most	relevant	as	 it	causes	the	greatest	 interference	when	detecting	SLNs,	did	not	differ	between	left	and	right	axilla	(p	=	0.596),	thus	indicating	that	the	cross-talk	is	similar	in	both	axillae.	
	Table	 16:	 Patient	 and	 18F-FDG	 injection	 characteristics	 from	 the	 gamma	 probe	cross-talk	study	in	PET	patients.	
	
Characteristic	 Mean	(range)	Age	(years)	 61.5	(40-81)		Height	(cm)	 161	(145-178)		Weight	(kg)	 69.3	(45-101)	Blood	glucose	level	(mmol/L)	 5.7	(4.3-16.4)	Injected	Activity	(MBq)	 343.8	(307.5-387.0)	Time	between	injection	and	first	measurement	(min)	 59.7	(49-79)	Background	count	rate	(cps)	 12.5	(6.7-24.8)		
3.3.4 Discussion	The	SLNB	simulations	and	gamma	probe	cross-talk	measurements	in	18F-FDG	PET	patients	 showed	 that	 by	 using	 an	 increased	 administered	 activity	 of	 150MBq	
99mTc-nanocolloid,	a	gamma	probe	collimator	suitable	for	511	keV	energy	photons	and	 blue	 dye,	 surgeons	would	 be	 able	 to	 successfully	 detect	 SLNs	 in	 a	 5MBq/kg	
18F-FDG	background.		The	mean	gamma	probe	signal	found	in	the	left	and	right	axilla	in	18F-FDG	PET	patients	was	lower	than	the	560cps	(5MBq/kg)	used	in	the	SLNB	simulations.		The	 lower	values	probably	reflect	 the	renal	excretion	and	non-uniform	uptake	 in	
vivo;	 the	 560	 cps	 used	 in	 the	 simulations	 were	 obtained	 from	 gamma	 probe	calibration	 measurements	 with	 18F	 distributed	 in	 a	 water	 volume.	 The	 spatial	accuracy	with	which	the	two	surgeons	in	this	study	located	the	SLNs	(2.6	mm	and	4.0	mm,	respectively)	corresponded	to	 the	mean	 localisation	accuracy	of	3.8	mm	found	for	the	94	surgeons	participating	in	the	NEW	START	SLNB	training	program	
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(380).	Performance	may	have	improved	if	the	surgeon’s	would	have	performed	a	larger	number	of	cases.	Overall	the	investigators	were	confident	after	conducting	both	 lead-in	 studies	 that	 SLNB	 could	 be	 performed	 safely	 and	 successfully	 in	patients	 undergoing	 18F-FDG	 CLI	 guided	 surgery,	 and	 patient	 recruitment	 to	 the	CLI	study	commenced.																							
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3.4 Intraoperative	assessment	of	 tumour	resection	margins	 in	breast-
conserving	surgery	using	18F-FDG	Cerenkov	luminescence	imaging	
–	a	first-in-human	clinical	study		
3.4.1 Aim	A	 first-in-human,	 single	 centre	 clinical	 trial	 was	 performed	 to	 evaluate	 the	feasibility,	safety,	and	performance	of	intraoperative	18F-FDG	CLI	to	assess	tumour	margin	status	in	breast	cancer	patients	undergoing	BCS	with	SLNB	or	with	ALND.		
3.4.2 Materials	and	methods	
3.4.2.1 Patient	recruitment	and	patient	preparation	on	the	day	of	surgery	Research	 Ethics	 Committee	 approval	 was	 obtained	 prior	 to	 patient	 recruitment	(REC	 Ref:	 14/WM/0050)	 (ClinicalTrials.gov	 identifier	 NCT02037269).	 Between	June	 2014	 and	 February	 2016,	 patients	 with	 histologically	 confirmed	 invasive	breast	 cancer	 on	 core	 biopsy	 with	 or	 without	 associated	 DCIS,	 due	 to	 undergo	primary	 BCS	 with	 curative	 intent	 and	 SLNB	 or	 ALND,	 were	 recruited	 at	 Guy’s	Hospital	 in	 London	 after	 written	 informed	 consent	 was	 obtained.	 We	 excluded	patients	who	were	younger	than	30	years	of	age,	who	had	surgery	or	radiotherapy	in	 the	 operated	 breast	 in	 the	 past	 two	 years,	 who	 had	 received	 neoadjuvant	systemic	 therapy	 for	 their	 current	 cancer,	 who	were	 pregnant	 or	 lactating,	who	had	a	blood	glucose	level	of	≥	12	mmol/l	on	the	day	of	surgery	or	who	had	known	hypersensitivity	to	18F-FDG.	Females	of	childbearing	age	needed	to	have	a	negative	pregnancy	 test	 (by	 Beta	 HCG	 qualitative	 analysis),	 a	 history	 of	 a	 surgical	sterilisation,	or	a	history	of	no	menses	in	the	past	twelve	months.				
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On	 the	 day	 of	 surgery	 patients	 scheduled	 to	 undergo	 SLNB	 received	 a	periareolar	 intradermal	 injection	 of	 150	 MBq	 99mTc-albumin-nanocolloid	(NanocollTM,	GE	Healthcare,	UK)	 in	 a	 volume	of	0.1-0.15	ml.	The	 increased	 99mTc	activity	of	150	MBq	was	calculated	based	on	the	results	from	the	lead-in	cross-talk	studies	described	in	Section	3.3.	Patients	were	then	injected	intravenously	with	5	MBq/kg	18F-FDG	(up	to	a	maximum	of	300	MBq)	and	typically	45-60	min	post-18F-FDG	injection,	were	taken	to	the	operating	theatre	for	their	surgery.			
3.4.2.2 Surgery	and	intraoperative	specimen	radiography	Following	induction	of	anaesthesia,	patients	due	to	undergo	SLNB	were	injected	in	a	periareolar	subdermal	position	with	a	sterile	solution	of	2ml	Patent	Blue	V	and	3ml	of	normal	saline.	To	minimize	radiation	exposure	to	theatre	staff	from	18F-FDG	by	 reducing	 the	 time	 spend	 in	 close	 proximity	 of	 the	 patient,	 a	 standard	 breast	operating	 set	was	pre-arranged	on	a	 sterile	 tray.	 Surgery	 to	 the	breast	was	 then	carried	 out	 ahead	 of	 SLNB	 or	 ALND	 in	 an	 effort	 to	 minimize	 signal	 intensity	reduction	 from	 radiotracer	decay	 in	 the	 time	between	 18F-FDG	 injection	 and	CLI	imaging.	 The	 WLE	 specimen	 was	 excised	 using	 both	 monopolar	 diathermy	(Valleylab	 Force	 FXTM	 electrosurgical	 generator	 with	 HCP-01	 Skintact	 surgical	pencil)	and	scissors	or	scalpel.	The	excised	specimen	was	orientated	with	sutures	and	 metal	 surgical	 clips	 (1	 suture/clips	 =	 anterior	 margin,	 2	 sutures/clips	 =	superior	margin	and	3	sutures/clips	=	nipple	margin)	as	per	local	protocol.	Immediately	 post	 excision,	 all	 WLE	 specimens	 were	 x-rayed	intraoperatively	 using	 a	 Faxitron	 digital	 specimen	 radiography	 system	 (Faxitron	Bioptics,	 USA).	 The	 anterior	 and	 posterior	 margins	 of	 the	 specimen	 were	positioned	 in	 the	 imaging	plane	 to	enable	assessment	of	 the	 four	 radial	margins.	The	image	was	assessed	intraoperatively	and	excision	of	cavity	shave	margins	was	
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performed	if	the	tumour	was	believed	to	be	close	to	the	edge	of	the	specimen	on	radiography.	Following	excision	of	the	WLE	specimen,	SLNB	or	ALND	was	performed.	For	SLNB	 a	 Europrobe	 3	 gamma	 probe	 with	 a	 high-energy	 collimator	 was	 used	(Eurorad	SA,	France).	SLNs	were	defined	as	nodes	that	were	radioactive,	blue,	or	palpable	(384).	The	number	of	excised	SLNs,	the	ex	vivo	SLN	gamma	probe	signal	(counts	 per	 second	 –	 cps),	 and	 the	 presence	 of	 blue	 nodal	 discoloration	 were	recorded.	Upon	completion	of	the	procedure	the	gamma	probe	background	signal	in	the	axilla	was	measured.			
3.4.2.3 Intraoperative	CLI	of	WLE	specimens	and	lymph	nodes	Following	 specimen	 radiography,	 CLI	 imaging	 of	 the	 WLE	 specimen	 was	performed	 using	 a	 prototype	 intraoperative	 CLI	 imaging	 device	 (Lightpoint	Medical	 Ltd,	 UK)	 (Figure	 20).	 This	 system	 consists	 of	 a	 custom-built	 light-tight	dark	box	containing	two	optical	pathways:	one	for	CLI	imaging	and	one	for	white-light	imaging	for	anatomic	reference.	The	CLI	imaging	pathway	includes	an	ultra-fast	 f/.95	 lens	 and	 a	 reflex	 mirror	 to	 fold	 the	 optical	 pathway	 into	 an	 EMCCD	camera.	 The	 FOV	 of	 the	 CLI	 camera	 is	 8×8	 cm	 and	 the	 acquisition	 matrix	 is	512×512	 to	 give	 a	 pixel	 resolution	 of	 156.25	 microns.	 The	 EMCCD	 is	thermoelectrically-cooled	 to	 -80°C	and	 is	 radiation-shielded	with	 lead	 to	prevent	annihilation	 photons	 from	 scintillating	 in	 the	 EMCCD	 chip,	 i.e.	 “gamma	 strikes”.	The	white-light	imaging	pathway	provides	a	photographic	reference	image	using	a	standard	CMOS	camera.		
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	Figure	20:	Prototype	intraoperative	CLI	imaging	device.	(A	and	B)	Computer	aided	design	rendering.	The	red	object	indicates	the	location	of	the	tissue	specimen.	(C)	Specimen	 chamber.	The	 specimen	 table	 is	placed	on	a	parallelogram	 to	 facilitate	accurate	 positioning	 of	 the	 specimen	 in	 the	 centre	 of	 the	 FOV.	 (D)	 Schematic	diagram.	 Component	 labels:	 1)	 EMCCD	 camera,	 2)	 f/.95	 lens,	 3)	 Hinged	 reflex	mirror,	4)	CMOS	reference	camera,	5)	Specimen	table,	6)	Lead	radiation	shielding	for	 EMCCD	 camera,	 7)	 Focal	 zone,	 8)	 Fixed	 lens	 for	 reference	 camera,	 9)	 Filter	wheel,	10)	LED	RGB	light	array,	11)	Specimen	chamber.	The	purple	line	shows	the	optical	paths	 for	 the	EMCCD	camera	and	 the	 reference	camera	as	determined	by	the	angle	of	the	reflex	mirror.		The	WLE	specimen	was	positioned	on	a	specimen	table	consisting	of	a	black	metal	framework	with	a	transparent	sheet	of	cling	film	spanned	between	its	four	corners	(Figure	 20C).	 The	 margin	 of	 interest	 was	 positioned	 in	 the	 FOV	 by	 using	 the	surgical	sutures	to	guide	orientation,	and	subsequently	imaged.	Following	 intact	WLE	 specimen	 imaging,	 the	 surface	 of	 the	 specimen	was	immediately	 inked	 intraoperatively	 in	 order	 to	 preserve	 its	 orientation	 for	histopathological	 analysis.	 Six	 distinct	 ink	 colours	 (Davidson®,	 Bradley	 Products	
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Inc.,	 US)	 were	 applied	 to	 the	 6	 margins.	 The	 inked	 specimen	 was	 then	 incised	through	 the	 posterior	 margin	 to	 visualize	 the	 primary	 tumour	 and	 tumour	margins.	Following	incision,	the	incised	WLE	specimen	was	imaged.	In	one	patient	sequential	 image	 acquisition	 over	 a	 50-minute	 time-period	 was	 performed	 to	determine	the	half-life	(t1/2)	of	the	radiance	observed	in	the	tumour.			The	 first	 10	 patients	 were	 included	 in	 the	 optimization	 dataset	 and	 the	remaining	 12	 patients	 in	 the	 analysis	 dataset.	 In	 the	 first	 10	 patients	 the	 image	acquisition	 protocol	 was	 optimized	 by	 testing	 different	 image	 acquisition	 times	(100,	 300,	 400	 sec)	 and	 pixel	 binning	 settings	 (2x2,	 4x4,	 8x8).	 A	 300-sec	acquisition	time	and	8x8	pixel	binning	was	found	to	provide	sufficient	sensitivity	for	tumour	detection	and	good	spatial	resolution	(1.25	mm)	within	a	time-window	feasible	 for	 intraoperative	use,	and	these	settings	were	used	 in	 the	remaining	12	patients	 included	 in	 the	 analysis	 dataset.	 The	 EMCCD	 imaging	 parameters	 were	fixed	 at	 300x	 EM	 gain,	 3.3	 µs	 vertical	 pixel	 shift	 period,	 1	 MHz	 horizontal	 shift	frequency,	and	+1	clocking	voltage.	SLNs	 or	 palpable	 lymph	 nodes	 in	 ALND	 specimens	 were	 also	 imaged	intraoperatively	with	CLI	using	the	same	imaging	settings.	Excessive	adipose	tissue	surrounding	the	nodes	was	resected	prior	to	imaging.		Upon	 completion	 of	 WLE	 CLI,	 the	 radioactivity	 content	 of	 the	 WLE	specimen	was	 estimated	 using	 a	 radiation	 (scintillation)	monitor	 (Type	 41/44A,	Series	 300	 mini-monitor,	 ThermoScientific,	 USA)	 or	 handheld	 radiation	spectrometer	(Raymon10	GR1,	Kromek	PLC)	in	order	to	help	interpret	the	signal	intensity	 on	CLI.	Measurements	were	performed	 at	 several	 positions	 around	 the	specimen,	 and	 postoperatively	 the	 cps	 (type	 41)	 and	 spectra	 (Kromek)	 were	processed	and	decay-corrected	 to	 the	 time	of	CLI	 imaging	 to	obtain	radioactivity	estimates.	Prior	to	use	in	the	CLI	study	both	devices	were	calibrated.					
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After	 imaging	 was	 completed,	 all	 specimens	 were	 placed	 in	 a	 sufficient	volume	 of	 10%	 buffered	 formalin	 to	 ensure	 optimum	 fixation,	 and	 sent	 for	histopathological	analysis	the	next	day	as	per	standard	of	care.		
3.4.2.4 Radiation	safety	monitoring	The	 occupational	 radiation	 hazards	 of	 using	 99mTc-nanocolloid	 in	 the	 context	 of	SLNB	procedures	are	fairly	well	known	(385),	but	there	is	less	information	about	the	risks	posed	by	surgical	 techniques	using	18F-FDG.	To	ensure	compliance	with	United	 Kingdom	 legislation	 regarding	 ionising	 radiation	 (386-388)	 when	performing	18F-FDG	CLI	in	BCS	using	the	dual	radiotracers	99mTc-nanocolloid	and	
18F-FDG,	several	radiation	safety	measures	were	put	in	place.	Prior	to	starting	the	CLI	study	all	staff	received	training	sessions	to	become	familiar	with	the	radiation	control	procedures	and	occupational	risks,	and	to	learn	how	to	minimise	exposure	by	 reducing	 unnecessary	 time	 in	 close	 contact	 with	 the	 patient	 without	compromising	patient	care.	At	the	start	of	each	surgical	procedure	staff	members	were	 issued	 with	 electronic	 personal	 radiation	 dose	 (EPD)	 monitors	 (PDM-112	and	PDM-122,	Hitachi-Aloka	Medical	Ltd.,	 Japan)	 for	 the	body	(Luxel+,	Landauer,	UK),	and	thermo-stimulated	luminescent	(TLD)	ring	dosimeters	for	the	extremities	(Landauer,	 UK).	 The	 detection	 limit	 TLD	 ring	 dosimeter	 was	 100	 μSv.	 Body	dosimeters	were	worn	in	the	anterior	top	pocket	of	the	clothing	and	the	extremity	dosimeters	were	worn	with	the	TLD	facing	inwards	towards	the	palmer	side	of	the	hand.	All	staff	took	typical	surgical	precautions	to	avoid	body	fluid	contamination,	with	surgical	gowns	and	sterile	gloves	providing	a	barrier	to	radioactive	body	fluid	contamination.	 Contamination	 monitoring	 of	 staff,	 rooms,	 equipment	 and	 waste	was	 carried	 out	 after	 each	 procedure	 using	 a	 radiation	 monitor	 (Type	 41/44A,	Series	300	mini-monitor,	ThermoScientific,	USA).	As	99mTc	 is	the	 isotope	with	the	
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longest	half-life	 (6.02	hours)	 the	waste	 storage	 requirements	 for	CLI	procedures	are	 similar	 to	 standard	 SLNB	 procedures.	 Surgical	 items	 and	 clinical	 waste	contaminated	 with	 radioactivity	 were	 segregated	 and	 stored	 between	 1-7	 days	after	the	procedure	to	allow	for	natural	decay	of	the	radioactivity.	The	time	taken	for	 the	 various	 stages	 of	 the	 procedure,	 i.e.	 from	 induction	 of	 anaesthesia	 to	recovery,	were	recorded	for	each	procedure.		
3.4.2.5 Histopathology	Histopathological	analysis	of	WLE	specimens	and	lymph	nodes	was	performed	as	per	United	Kingdom	National	guidelines	(8).	The	WLE	specimen	was	serially	sliced	at	 2	mm	 intervals	 or	 sliced	 in	 a	 cruciate	 fashion.	 Representative	 sections	 of	 the	tumour	 and	 all	 6	 relevant	margins	 were	 selected	 by	 the	 pathologist,	 processed,	paraffin	wax	embedded	and	3	to	4	micron	sections	were	cut	and	stained	with	H&E.	In	the	last	patient	a	 large-format	pathology	block	was	obtained	from	the	full-face	tissue	surface	that	was	visible	on	the	incised	WLE	specimen	image	to	enable	point-to-point	correlation	of	CLI	and	histopathology.		Microscopic	 margin	 distance	 measurements	 of	 all	 6	 margins	 were	performed	 by	 a	 specialist	 experienced	 breast	 pathologist	 (S.E.P.).	 Microscopic	invasive	 tumour	 size	 and	whole	 tumour	 size	 (including	DCIS	 extending	 from	 the	main	 invasive	 mass)	 were	 also	 measured.	 Positive	 margins	 were	 defined	 as	invasive	 cancer	 or	 DCIS	 <1	mm	 from	 the	 specimen	 surface.	 Clear	margins	were	defined	 as	 invasive	 cancer	 or	 DCIS	 ≥1	 mm	 distant.	 The	 histological	 margin	distances	 were	 reported	 in	 increments	 of	 1	 mm,	 but	 margins	 more	 than	 5	 mm	were	reported	as	>5	mm.		Lymph	 nodes	 measuring	 5	 mm	 or	 less	 in	 maximum	 dimension	 were	typically	sliced	in	2	halves;	nodes	greater	than	5	mm	in	maximum	diameter	were	
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sliced	 thinly	 at	 2-mm	 intervals.	 All	 sections	 were	 processed	 and	 H&E	 stained.		Nodes	 were	 reported	 as	 normal	 or	 containing	 macrometastasis	 (≥2	 mm),	micrometastasis	(>0.2	mm,	<2	mm),	and	isolated	tumour	cells	(≤0.2	mm).		The	pathologist	was	blinded	to	the	interpretation	of	the	CLI	images	so	that	interpretation	 of	 margin	 distance,	 tumour	 size	 and	 lymph	 nodes	 would	 not	 be	biased. 	
3.4.2.6 Image	analysis	All	CLI	and	radiography	images	were	analysed	postoperatively	in	order	to	provide	a	 controlled	 and	 standardized	 analysis	 environment.	Measurements	 of	 the	mean	radiance	 (photons/s/cm2/sr)	 were	 performed	 by	 drawing	 ROIs	 on	 the	unprocessed	 CLI	 images	 using	 Mirada	 imaging	 software	 (Mirada	 XD3,	 Mirada	Medical,	 Oxford,	 UK).	 ROIs	 were	 selected	 in	 areas	 showing	 increased	 signal	intensity	 (‘tumour’)	 and	 no	 increased	 signal	 (‘tissue	 background’).	 Tumour-to-background	 ratios	 (TBRs)	 were	 calculated.	 	 Gamma	 strikes	 were	 excluded	 from	ROI	analysis.	The	tumour	radiance	from	the	sequential	incised	WLE	images	was	fit	to	a	monoexponential,	to	determine	the	radiance	half-life	(t1/2)	by	t1/2 = ln 2τ ,	where	τ	is	decay	constant.	Assessment	 of	 margin	 status	 on	 CLI	 was	 performed	 on	 the	 incised	 WLE	specimen	images.	The	analysis	was	done	independently	by	two	experienced	breast	surgeons	(AP	and	AK),	and	performed	prior	to	analysis	of	the	radiography	images	to	prevent	potential	confirmation	bias	from	a	priori	knowledge	of	the	radiological	margin	status.	Prior	to	analysis,	CLI	images	were	processed	by	applying	a	median	filter	 (filter	 size	 range	5	–	10,	 filter	 threshold	 range	10	–	15)	and	Gaussian	 filter	(filter	width:	1,	filter	threshold:	0.5).	A	stronger	Gaussian	filter	(filter	width:	4	or	5)	was	applied	to	images	with	a	low	TBR	to	increase	the	visibility	of	the	tumour.	The	
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preoperative	 diagnostic	 information	 that	 would	 typically	 be	 available	 to	 the	surgeon	was	provided	including	patient	age,	clinical	tumour	size,	screen	detected	(Y/N),	 mammographic	 tumour	 size,	 ultrasound	 tumour	 size,	 and	 histological	tumour	type,	grade	and	receptor	status	on	core	biopsy.	Per	patient,	a	colour	image	containing	information	on	specimen	orientation	was	shown	together	with	a	grey-scale	 image	 and	 Cerenkov	 image.	 All	 images	 were	 displayed	 on	 a	 standard	computer	monitor	(23”,	1920	x	1080	pixels,	250	cd/m2	luminance).	The	grey-scale	image	was	overlaid	with	the	Cerenkov	signal	to	provide	a	fused	image	containing	both	 functional	 and	 anatomical	 information.	 The	 leveling	 was	 set	 using	 the	software’s	default	 leveling,	and	manually	adjusted	based	on	the	surgeon’s	clinical	judgment.	 Both	 surgeons	 then	 independently	 reported	 whether	 an	 elevated	radiance	 from	 the	 tumour	 could	 be	 identified	 on	 CLI;	 in	 patients	 displaying	 an	elevated	tumour	radiance	the	margin	distance	of	the	margins	visible	in	the	image	was	 measured	 using	 the	 ruler	 function	 in	 the	 imaging	 software.	 The	 total	 time	required	to	complete	margin	assessment	was	approximately	2	min	per	patient.	As	an	 exploratory	 outcome	 measure,	 tumour	 size	 was	 also	 measured.	 Upon	completion	 of	 the	 measurements	 surgeons	 were	 asked	 whether,	 given	 the	 CLI	image,	they	would	have	performed	a	cavity	shaving	had	the	image	been	available	at	 the	 time	 of	 surgery,	 assuming	 there	was	more	 tissue	 to	 excise.	 Surgeons	 also	scored	 image	 quality	 on	 a	 5-point	 Likert	 scale:	 1	 =	 very	 poor	 –	 image	 not	interpretable,	2	=	poor	but	interpretable,	3	=	fair,	4	=	good,	5	=	very	good.	Following	 CLI	 image	 analysis,	 specimen	 radiography	 image	 analysis	 was	performed	 on	 a	 Coronis	 3MP	 screen	 (20.8”,	 1536	 x	 2048	 pixels,	 500	 cd/m2	luminance)	using	 standard	GE	PACS	 imaging	 software.	 Surgeons	were	presented	with	the	same	preoperative	diagnostic	information,	but	the	images	were	shown	in	a	different	order	to	avoid	potential	sequential	bias.	The	number	of	surgical	marker	
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clips	 was	 noted,	 and	 the	 reliability	 of	 specimen	 orientation	 assessed.	 If	 the	orientation	 was	 considered	 reliable,	 the	 margin	 distance	 and	 tumour	 size	 on	radiography	 was	 measured.	 Whether	 an	 additional	 cavity	 shaving	 would	 have	been	performed	based	on	the	radiography	image	was	also	noted.		The	 final	 histopathology	 results	 of	 the	 surgically	 excised	 tissue	 were	 not	available	 at	 the	 time	of	CLI	 and	 radiography	 image	analysis,	 and	 could	 therefore	not	bias	the	surgeon’s	assessment.		
3.4.2.7 Statistics	Weighted	 Kappa	 coefficients	were	 calculated	 to	 assess	 the	 agreement	 in	margin	distance	between	CLI	and	definitive	histopathology,	 and	 to	assess	 the	 inter-rater	agreement	between	surgeons	(‘irr’	package,	version	3.2.2,	R	statistical	software).	A	kappa	 coefficient	 (κ)	 greater	 than	 0.75	 was	 considered	 good	 agreement	 (317).	Agreement	 between	 histological	 tumour	 size	 and	 tumour	 size	 on	 CLI	 and	radiography	 respectively	 was	 assessed	 by	 calculating	 the	 mean	 difference	 in	tumour	size	±	std	and	intraclass	correlation	coefficients	(ICC)	(SPSS®	version	23.0;	IBM,	Chicago).		
3.4.3 Results	
3.4.3.1 Intraoperative	imaging	of	WLE	specimens	A	total	of	22	patients	were	included	in	the	study.	The	CLI	results	and	postoperative	histopathology	 results	 from	 the	 12	 patients	 included	 in	 the	 analysis	 dataset	 are	shown	 in	 Table	 17.	 The	mean	 administered	 18F-FDG	 activity	was	 295	 ±	 18	MBq	(range	 259	 –	 325).	 The	mean	 time	between	 18F-FDG	 injection	 and	WLE	 excision	was	86	±	26	min	(range	50	–	146),	and	the	mean	time	between	18F-FDG	injection	and	commencement	of	CLI	image	acquisition	was	118	±	26	min	(range	88	–	180).		
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1	 NST+DCIS	 2	 Pos/Neg	 -3	 -	 -	 -	 -	 13	 13	
2	 NST+DCIS	 3	 Neg/Pos	 453.59	 2.34	 6,	6	 >5	 *4	 22	 22	
3	 NST	 3	 Neg/Neg	 871.16	 3.22	 2,	2	28,	30	
3	
>5	 20,	18	 20	 20	
4	 NST+DCIS	 3	 Neg/Neg	 -3	 -	 -	 -	 -	 14	 14	
5	 NST+DCIS	 3	 Pos/Neg	 405.76	 2.03	 2,	3	 5	 18,	18	 20	 20	
6	 ILC	 2	 Pos/Neg	 544.04	 2.44	 9,	9	 >5	 20,	19	 22	 22	
7	 NST	 3	 Pos/Neg	 667.47	 2.72	 10,	11	 >5	 *4	 25	 25	
8	 NST+DCIS	 2	 Pos/Neg	 308.30	 1.63	 6,	8	16,	15	
>5	
>5	 19,19	 15	 35	
9	 NST+DCIS	 3	 Pos/Neg	 593.93	 3.08	 14,	13	6,	7	
>5	
>5	 14,	15	 18	 19	
10	 NST+DCIS	 3	 Pos/Neg	 648.29	 2.46	 8,	8	 >5	 22,	22	 19	 29	
11	 NST+DCIS	 2	 Pos/Neg	 466.03	 2.54	 15,	14	 >5	 13,	11	 13	 13	








1. NST:	invasive	ductal	carcinoma/no	special	type,	DCIS:	ductal	carcinoma	in	situ,	NST+DCIS:	NST	admixed	with	DCIS,	ILC:	invasive	lobular	carcinoma	2. TBR:	tumour-to-background	ratio	3. No	elevated	tumour	radiance	on	CLI		4. The	tumour	was	not	sufficiently	exposed	after	incision	and	therefore	tumour	size	in	medial-lateral	or	superior-inferior	direction	could	not	be	measured	5. In	the	8	patients	where	the	tumour	size	could	be	measured	on	CLI,	the	histopathological	tumour	size	displayed	in	the	table	is	the	tumour	size	measured	in	the	same	direction	as	the	tumour	size	measurement	on	CLI,	i.e.	in	the	medial-lateral	or	superior-inferior	direction.	In	patient	3,	11	and	12	the	largest	histological	invasive	and	whole	tumour	size	(i.e.	extent	of	DCIS	and	invasive	cancer)	was	measured	in	a	different	direction,	and	was	32	mm,	33	mm	and	25	mm,	respectively.			
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	Figure	21:	Decay	of	tumour	radiance	on	10	consecutive	CLI	images	from	an	incised	WLE	 specimen.	 The	 data	 points	 are	 fitted	 with	 a	 monoexponential	 function	 f	(x)= 548.55!!!.!!"! ,	which	gives	t1/2	is	115.5	min				
	 In	 the	 10	 patients	 with	 elevated	 tumour	 radiance,	 a	 total	 of	 60	 margins	could	 be	 assessed	 histologically,	 26	 margins	 were	 evaluable	 on	 specimen	radiography,	 and	 15	 margins	 were	 assessable	 on	 CLI.	 Of	 the	 45	 histological	margins	that	were	not	evaluable	on	CLI,	40	were	not	in	the	field-of-view	of	the	CLI	image,	and	5	could	not	be	assessed	due	to	migration	of	 the	specimen	orientation	ink	onto	the	margin	edge,	preventing	optical	margin	interrogation.	Eighteen	of	the	60	histological	margins	were	not	assessable	on	specimen	radiography	due	to	 the	inability	 to	 reliably	 orientate	 the	 specimen	 on	 the	 radiography	 image,	 and	 16	margins	were	not	in	the	image	field-of-view.	The	 margin	 distance	 from	 the	 15	 margins	 measured	 on	 CLI	 and	histopathology	is	shown	in	Table	17.	Two	margins	measured	between	1	and	5	mm	on	CLI	and	histopathology	(Figure	22)	(Figure	23);	the	remaining	13	margins	were	>5	mm	by	 both	modalities.	 There	was	 good	 agreement	 between	 the	 histological	margin	distance	and	 the	margin	distance	on	CLI	 as	measured	by	both	 surgeon	1	
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and	 surgeon	 2,	 respectively	 (κ	 surgeon	 1	 =	 0.76,	 κ	 surgeon	 2	 =	 0.86).	 The	agreement	in	margin	distance	between	surgeons	was	also	good	(κ	=	0.91).		Five	margins	could	be	assessed	on	both	CLI	and	specimen	radiography,	and	all	were	>5	mm	on	both	modalities,	as	well	as	histologically.	An	example	of	a	CLI,	radiography	 and	 histopathology	 image	 from	 a	 patient	 with	 >5	 mm	 resection	margin	width	is	shown	in	Figure	24.	Two	 patients	 (17%)	 had	 a	 positive	 margin	 on	 postoperative	histopathological	 analysis;	 both	were	medial	margins,	with	DCIS	 <1	mm	distant.	These	margins	were	 not	 visible	 in	 the	 CLI	 image	 as	 specimen	 incision	 had	 only	exposed	 the	 superior,	 inferior	 and	 posterior	 margins;	 the	 medial	 margin	 could	therefore	not	be	assessed.																
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	Figure	 22:	 WLE	 specimen	 from	 a	 patient	 with	 a	 grade	 3,	 ER-/HER2-,	 invasive	ductal	 carcinoma/no	 special	 type	 (NST).	 (A)	 Cerenkov	 image;	 (B)	 Grey-scale	photographic	 image	 overlaid	with	Cerenkov	 signal.	 An	 increased	 signal	 from	 the	tumour	is	visible	(white	arrows);	mean	radiance	is	871	±	131	photons/s/cm2/sr,	mean	TBR	is	3.22.	Both	surgeons	measured	the	posterior	margin	(outlined	in	blue	and	 location	 of	 measurement	 shown	 with	 small	 white	 arrow)	 as	 2	 mm,	 and	indicated	 that	a	 cavity	 shaving	would	have	been	performed	 if	 they	had	access	 to	the	CLI	image	during	surgery.	The	medial	margin	(outlined	in	green)	measured	>5	mm	 by	 both	 surgeons.	 Pathology	 ink	 prevented	 assessing	 the	 lateral	 margin;	 a	phosphorescent	signal	is	visible	(open	arrows).	Tumour	size	in	the	medial-lateral	direction	 measures	 20	 mm	 and	 18	 mm	 for	 surgeons	 1	 and	 2,	 respectively.	 (C)	Specimen	radiography	image	with	two	surgical	clips	marking	the	superior	margin	and	three	clips	marking	the	medial/nipple	margin.	The	absence	of	one	surgical	clip	to	mark	 the	 anterior	margin,	 and	 the	 odd	 position	 of	 the	 superior	margin	 clips,	prevented	 margin	 distance	 and	 tumour	 size	 measurements	 because	 reliable	orientation	 could	 not	 be	 assured.	 (D)	 Combined	 histopathology	 image	 from	 two	adjacent	 pathology	 slides	 on	which	 the	 posterior	margin	 (bottom	 of	 image)	 and	part	 of	 the	 primary	 tumour	 are	 visible	 (open	 arrows).	 The	 dashed	 vertical	 line	indicates	 the	 intersection	 between	 the	 two	 sections.	 The	 distance	 from	 the	posterior	 margin	 measured	 3	 mm	 microscopically	 (double	 arrow).	 The	 medial	margin,	 located	outside	the	right	side	of	the	image,	 is	>	5	mm.	The	medial-lateral	histological	invasive	tumour	size	measures	20	mm.		
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		Figure	23:	WLE	specimen	from	a	patient	with	a	grade	3,	ER+/HER2-,	NST	admixed	with	 high	 grade	 DCIS.	 (A)	 Cerenkov	 image;	 (B)	 Grey-scale	 photographic	 image	overlaid	 with	 Cerenkov	 signal.	 An	 increased	 signal	 from	 the	 tumour	 is	 visible	(white	arrows);	mean	radiance	is	406	±	51	photons/s/cm2/sr,	mean	TBR	is	2.03.	The	posterior	margin	(outlined	in	blue)	is	2	mm	or	3	mm	on	CLI	as	measured	by	surgeons	 1	 and	 surgeon	 2,	 respectively;	 both	 surgeons	would	 have	 performed	 a	cavity	shaving	if	the	image	had	been	available	intraoperatively.	The	medial	margin	(outlined	in	green)	is	>5	mm.	Tumour	size	in	the	medial-lateral	direction	measures	18	mm	according	to	both	surgeons.	(C)	Specimen	radiography	image.	Two	surgical	clips	 mark	 the	 superior	 margin;	 three	 surgical	 clips	 mark	 the	 medial/nipple	margin.	All	4	radial	margins	were	>5	mm	and	both	surgeons	indicated	they	would	not	have	performed	a	cavity	shaving.	Medial-lateral	 tumour	size	was	18	mm	and	21	 mm	 according	 to	 surgeons	 1	 and	 2,	 respectively.	 (D)	 Histopathology	 image	showing	 the	 posterior	margin	 (left	 side	 of	 image)	 and	 part	 of	 the	 tumour	 (open	arrows).	 The	 posterior	 margin	 was	 5	 mm	 distant	 histologically	 (double	 arrow).	The	medial	margin	 (not	 visible	 in	 image)	was	 >	 5	mm	distant.	 The	 invasive	 and	whole	tumour	size	both	measured	20	mm	histologically.							
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	Figure	24:	WLE	specimen	from	a	patient	with	a	grade	3,	ER+/HER2-,	NST	admixed	with	DCIS.	 (A)	Cerenkov	 image;	 (B)	Grey-scale	photographic	 image	overlaid	with	Cerenkov	 signal.	An	elevated	 signal	 (white	 arrow)	 from	 the	 tumour	 can	be	 seen.	Mean	 radiance	 is	 637	±	 47	photons/s/cm2/sr;	mean	TBR	 is	 1.63.	 Both	 surgeons	measured	the	posterior	margin	(outlined	in	blue;	measurement	shown	with	solid	arrow),	 medial	 margin	 (outlined	 in	 green;	 measurement	 shown	 with	 dashed	arrow)	and	lateral	margin	(outlined	in	red)	distances	as	>5	mm;	a	cavity	shaving	would	not	have	been	performed	based	on	 the	CLI	 image.	The	 tumour	size	 in	 the	medial-lateral	direction	was	12	mm	and	10	mm	as	measured	by	surgeons	1	and	2,	respectively.	(C)	Specimen	radiography	image	with	three	sets	of	surgical	clips	for	reliable	 specimen	 orientation:	 1	 clip	 =	 anterior,	 2	 clips	 =	 superior,	 3	 clips	 =	inferior/nipple.	All	four	radial	margins	were	>5	mm	as	measured	by	both	surgeons	and	did	not	prompt	resection	of	cavity	shave	margins.	Medial-lateral	tumour	size	measured	 by	 surgeon	 1	 and	 2	 was	 17	 mm	 and	 20	 mm,	 respectively.	 (D)	Histopathology	image	from	large-format	pathology	block.	The	image	is	rotated	to	facilitate	 correlation	 of	 histopathology	 and	 CLI.	 Part	 of	 the	 primary	 tumour	was	taken	for	storage	in	the	Tissue	Biobank	(open	arrow).	The	tumour	is	>5	mm	from	the	 posterior	margin	 (inked	 black	 and	 shown	with	 solid	 arrow),	 medial	 margin	(dashed	arrows)	and	lateral	margin	(not	visible	in	image).	The	invasive	and	whole	tumour	size	both	measured	14	mm	microscopically.				
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Tumour	margin	assessment	on	CLI	using	intact	WLE	specimen	images	could	not	 be	 performed	 due	 to	 image	 artefacts	 created	 by	 the	 monopolar	 diathermy	(Figure	 25).	 This	 artefact	 provided	 a	 focal	 signal	 with	 a	 radiance	 that	 often	exceeded	 the	 tumour	 radiance	 observed	 on	 incised	 CLI	 specimen	 images,	 and	 it	was	therefore	not	possible	to	discriminate	between	Cerenkov	 luminescence	from	tumour	 cells	 close	 or	 at	 the	 margin	 of	 excision	 on	 intact	 WLE	 specimens,	 and	luminescence	from	the	diathermy	artefact.		
	Figure	25:	Intact	WLE	specimen	showing	image	artefact	from	tissue	excision	with	monopolar	diathermy	device.	(A)	Colour	image	(B)	Grey-scale	photographic	image	overlaid	with	Cerenkov	signal.	An	elevated	radiance	from	cauterised	tissue	can	be	seen	(white	arrows).	Mean	radiance	is	3100	±	930	photons/s/cm2/sr.	This	patient	did	 not	 receive	 18F-FDG,	 and	 the	 elevated	 radiance	 is	 therefore	 not	 Cerenkov	luminescence	 from	 18F	 containing	 tumour	 cells.	 Note	 that	 the	 radiance	 is	approximately	3	times	higher	than	the	tumour	radiance	observed	on	incised	WLE	specimen	images	(Table	17).	
	 In	 8	 of	 the	 10	 patients	 tumour	 size	 could	 be	 measured	 on	 CLI,	 and	compared	to	histopathology;	the	agreement	is	shown	in	Table	17.	Invasive	tumour	size	 showed	 excellent	 agreement;	 mean	 difference	 for	 both	 surgeons	 combined	was	 -0.84	 ±	 2.8	mm.	 ICC	was	 0.84	 and	 0.81	 for	 surgeons	 1	 and	 2,	 respectively.	Whole	 tumour	 size	 (i.e.	 invasive	 carcinoma	 with	 surrounding	 DCIS)	 was	underestimated	 on	CLI;	mean	difference	 for	 both	 surgeons	 combined	was	 -4.7	 ±	5.0	 mm.	 ICC	 was	 0.65	 and	 0.69	 for	 surgeons	 1	 and	 2,	 respectively.	 Inter-rater	agreement	between	surgeons	was	excellent	(ICC	=	0.97).		
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The	 agreement	 between	 invasive	 tumour	 size	 on	 histopathology	 and	 on	radiography	was	good;	mean	difference	for	both	surgeons	combined	was	1.0	±	3.1	mm.	ICC	was	0.56	and	0.58	for	surgeons	1	and	2,	respectively.	Whole	tumour	size	was	underestimated	on	radiography;	mean	difference	for	both	surgeons	combined	was	-5.2	±	8.9	mm.		CLI	 image	quality	 in	the	10	patients	with	successful	CLI	was	scored	as	4.3	(range	4	–	5)	by	both	surgeons.			
3.4.3.2 Sentinel	lymph	node	detection	and	intraoperative	CLI	of	lymph	nodes		SLNB	was	performed	in	21	of	the	22	patients;	1	patient	underwent	an	ALND.	SLNs	were	 successfully	 identified	 in	 all	 21	patients.	A	 total	 of	 43	SLNs	were	 removed.	The	average	number	of	SLNs	per	patient	was	2	(range	1	–	4).	Two	of	the	21	SLNB	patients	had	macrometastatic	SLNs.		The	mean	gamma	probe	signal	of	the	‘hottest’	SLN	per	patient	was	4991	±	2521	cps	(range	8500	–	170).	The	mean	gamma	probe	signal	of	the	‘second	hottest’	SLN	was	 2505	 ±	 2632	 cps	 (range	 7368	 –	 50).	 Mean	 axillary	 background	 signal,	measured	in	13	patients,	was	192	±	70	cps	(range	55	–	270).	This	signal	is	lower	than	 the	 18F-FDG	 gamma	 probe	 cross-talk	 measured	 in	 the	 lead-in	 PET	 patient	study	 (Section	 3.3.3.2),	 and	 is	 mainly	 due	 to	 the	 longer	 time	 between	 18F-FDG	injection	 and	 SLNB	 (mean	93	±	 34	min).	 A	 total	 of	 7	 nodes	 had	 a	 gamma	probe	signal	 below	 the	 background	 signal;	 6	 of	 these	 were	 blue.	 This	 indicates	 the	importance	of	using	the	combined	technique	of	radioisotope	and	blue	dye	 in	18F-FDG	 CLI	 guided	 breast	 surgery,	 as	 low-uptake	 nodes	 may	 be	 missed	 if	 gamma	probe	detection	is	used	alone.		All	SLNB	procedures	were	performed	with	the	monopolar	diathermy	device	and	 due	 to	 the	 observed	 image	 artefact	 from	 diathermy	 on	 CLI,	 the	 SLN	 images	
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could	 not	 be	 analysed.	 The	 patient	 that	 underwent	 an	 ALND	 had	 one	 palpable	lymph	node	 that	was	 intraoperatively	dissected	 from	 the	ALND	specimen	with	a	surgical	scalpel.	This	lymph	node	showed	an	elevated	radiance	measuring	10	mm	in	longest	dimension	(Figure	26).	Mean	radiance	was	468	±	10	photons/s/cm2/sr;	signal-to-empty	 background	 ratio	 was	 3.1.	 On	 histopathology	 a	 9	 mm	macrometastasis	was	found.	The	increased	signal-to-empty	background	ratio,	and	the	correspondence	between	CLI	signal	dimension	and	tumour	size,	illustrates	the	potential	of	CLI	for	intraoperative	identification	of	positive	lymph	nodes.					
	Figure	 26:	 Macrometastatic	 lymph	 node.	 (A)	 Cerenkov	 image	 (B)	 grey-scale	photographic	 image	 overlaid	 with	 Cerenkov	 signal.	 CLI	 imaging	 was	 performed	intraoperatively	after	the	lymph	node	was	excised	from	the	ALND	specimen	using	a	 surgical	 scalpel.	 An	 elevated	 radiance	 can	 be	 observed	 measuring	 10mm	 in	longest	 dimension.	 Mean	 radiance	 is	 468	 ±	 10	 photons/s/cm2/sr.	 (C)	Histopathology	 image	 from	 lymph	 node	 showing	 a	 9mm	 macrometastasis.	Extranodal	spread	can	also	be	seen	(open	arrow).		
182	












Surgeon	 46	 34	±	15	 8	–	74	 270	 676	
Anaesthetist	 22	 11	±	5	 0	–	18	 1111	 2778	
NM	technologist	 22	 9	±	4	 1	–	15	 1333	 3333	
Anaesthetist	assistant	 22	 6	±	3	 0	–	11	 1818	 4545	
Trial	Co-coordinator	 21	 5	±	2	 1	–	10	 2000	 5000	
Recovery	Nurse	 43	 4	±	3	 0	–	14	 1429	 3571	
Scrub	Nurse	 22	 2	±	1	 0	–	5	 4000	 10000	
Periphery	Nurse	 23	 1	±	1	 0	–	4	 5000	 12500	
Research	fellow	 36	 1	±	2	 0	–	13	 1538	 3846	
Ward	Nurse	 15	 0	 0	–	1	 20000	 50000	
Tissue	Biobank	Practitioner	 14	 0	 0	–	1	 20000	 50000	1. N:	number	of	measurements	2. Based	on	maximum	dose	per	procedure	per	staff	group	3. ICRP:	International	Commission	on	Radiological	Protection	4. USNRC:	United	States	Nuclear	Regulatory	Commission				
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3.4.4 Discussion	This	 first-in-human	 study	 evaluated	 the	 feasibility	 of	 intraoperative	 18F-FDG	 CLI	for	 assessing	 tumour	 margin	 status	 in	 patients	 with	 invasive	 breast	 cancer	undergoing	BCS,	and	SLNB	or	ALND.	Tumour	margin	assessment	on	CLI	could	be	performed	 in	 10	 of	 the	 12	 patients	 in	 the	 analysis	 dataset,	 and	 there	was	 good	agreement	 on	 margin	 width	 between	 CLI	 and	 definitive	 histopathology.	 An	exploratory	 outcome	measure	 assessed	 the	 correlation	 between	 tumour	 size	 on	CLI	 and	 histopathology;	 the	 size	 on	 CLI	 and	 histopathology	 correlated	 well	 for	invasive	 cancer,	 while	 whole	 tumour	 size	 (invasive	 with	 associated	 DCIS)	 was	underestimated	 on	 CLI.	 Results	 from	 the	 radiation-monitoring	 program	demonstrated	that	the	procedure	can	be	carried	out	safely	while	maintaining	low	radiation	exposures	to	the	staff	involved.		 In	 2	 patients	 margin	 assessment	 could	 not	 be	 performed	 because	 the	tumours	did	not	display	elevated	radiance	on	CLI.	The	absence	of	signal	 in	 these	patients	 is	probably	due	to	the	small	 tumor	size,	a	 factor	known	to	be	associated	with	lower	18F-FDG	uptake	(389),	and	the	late	time	points	at	which	these	tumors	were	 imaged	 (135	 min	 and	 180	 min	 post	 18F-FDG	 injection;	 the	 first	 and	 third	longest	injection-imaging	time	of	all	patients).	Unsuccessful	CLI	imaging	due	to	the	absence	 of	 a	 detectable	 tumor	 signal	 highlights	 the	 importance	 of	 ongoing	developments	focused	on	improving	detection	sensitivity	of	CLI	camera	systems	to	aid	detection	of	tumours	with	low	18F-FDG	uptake	including	lower	grade	tumours	and	DCIS	(390).			 Since	 its	 discovery	 in	 2009,	 CLI	 has	 rapidly	 emerged	 as	 a	 powerful	technique	 for	 cancer	 imaging.	 Three	 clinical	 pilot	 studies	 of	 CLI	 have	 been	published	 to	 date.	 These	 have	 focused	 on	 the	 use	 of	 CLI	 to	 image	radiopharmaceutical	uptake	in	the	thyroid,	CLI	for	non-invasive	detection	of	nodal	
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disease,	 and	 Cerenkov	 luminescence	 endoscopy	 to	 aid	 detection	 of	 cancerous	lesions	 in	 the	 GI	 tract	 (348,349,379).	 To	 our	 knowledge,	 this	 is	 the	 first	 clinical	report	of	intraoperative	CLI.	The	feasibility	of	intraoperative	CLI	as	shown	in	this	study	in	combination	with	the	wide	applicability	of	18F-FDG	across	a	range	of	solid	cancers	provides	a	stepping	stone	for	clinical	evaluation	of	this	technology	in	other	cancer	types.	The	low	radiation	exposure	to	staff	found	in	this	study	is	in	accordance	with	previously	 reported	 exposure	 levels	 from	 18F-FDG	 guided	 breast	 surgery	procedures	 (369,371),	 and	 comparable	 to	 the	 radiation	 dose	 reported	 for	interventional	 cardiology	 procedures	 (1	 –	 50	 μSv)	 (391).	 Surgeons	 received	 the	highest	maximum	dose	per	procedure:	74	μSv	(Table	18).	The	number	of	18F-FDG	CLI-guided	 BCS	 procedures	 that	 could	 be	 performed	 in	 a	 routine	 clinical	 setting	depends	on	the	occupational	radiation	exposure	limits	per	country	(Table	18).	In	the	 United	 Kingdom	 these	 limits	 are	 based	 upon	 the	 recommendations	 of	 the	International	 Commission	 on	 Radiological	 Protection	 (ICRP)	 (392),	 with	 an	occupational	 annual	dose	 limit	of	20	mSv	 (386).	 In	 the	United	States,	 the	annual	occupational	 limit	 is	 set	 by	 the	 United	 States	 Nuclear	 Regulatory	 Commission	(USNRC)	at	50	mSv	(393).	It	should	be	noted	that	surgeons	and	theatre	staff	might	perform	other	work	involving	radiation,	which	should	also	be	considered	as	part	of	their	annual	exposure.	Furthermore,	good	practice	would	dictate	that	the	radiation	exposure	 from	 a	 procedure	 should	 be	 kept	 As	 Low	 As	 Reasonable	 Achievable	(ALARP),	i.e.	well	below	the	dose	limits.	In	practice	in	the	UK,	if	a	worker	is	likely	to	receive	annually	more	than	6mSv	they	would	be	designated	a	classified	worker,	necessitating	annual	medical	surveillance	and	longer	term	record	keeping	of	their	radiation	 exposure.	 Decisions	 on	 whether	 it	 is	 justified	 to	 classify	 workers	
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performing	 higher	 radiation	 dose	 procedures	 would	 have	 to	 take	 into	 careful	consideration	the	potential	clinical	and	societal	benefit	of	the	technique.			 Image	artefacts	on	CLI	 from	tissue	excised	with	 the	monopolar	diathermy	device	 prevented	 tumour	 margin	 assessment	 on	 intact	 WLE	 specimens	 and	assessment	 of	 SLNs.	 Although	 the	 source	 of	 this	 ‘false-signal’	 is	 not	 yet	 fully	understood,	current	evidence	 from	pre-clinical	experiments	points	 towards	 long-lived,	thermally-induced	chemiluminescence	(394).	Since	the	emission	seems	to	be	related	 to	 temperature,	which	 can	 reach	up	 to	250°C	at	 the	 tip	of	 the	diathermy	device,	 an	 electrosurgical	 device	 (PEAK	 Plasmablade,	 Medtronic,	 USA)	 that	operates	at	much	lower	temperature	is	currently	being	tested	(395).	In	addition	to	potentially	facilitating	margin	assessment	on	intact	WLE	specimens,	an	advantage	of	 low-temperature	 devices	 over	monopolar	 diathermy	 is	 the	 reduced	 collateral	tissue	 damage,	 which	 could	 also	 improve	 the	 accuracy	 of	 assessing	 tumour	resection	margins	on	histopathology	(396).				 Although	 CLI	 imaging	 of	 incised	WLE	 specimens	 is	 feasible	 for	 assessing	tumour	margin	status,	this	approach	has	some	important	limitations	over	margin	assessment	on	 intact	 specimens.	Firstly,	migration	of	 the	wet	pathology	 ink	onto	the	 margin	 edge	 immediately	 after	 specimen	 incision	 can	 hinders	 margin	interpretation	with	 CLI.	Methods	 to	 accelerate	 drying	 of	 inks	 by	 applying	 acetic	acid	 to	 the	 painted	 tissue	 or	 by	 using	 fast	 drying	 inks	may	 be	 solutions	 to	 this	problem,	but	this	has	not	been	tested	in	this	study.	Secondly,	in	our	institution,	as	per	 the	 guidance	 of	 the	 breast	 histopathologist	 (S.E.P.),	 specimen	 incision	 could	only	be	performed	through	the	posterior	margin	to	ensure	accurate	postoperative	histological	assessment	of	radial	margins.	Consequently,	only	a	limited	number	of	margins	 could	 be	 assessed	 with	 CLI	 per	 patient.	 A	 general	 limitation	 of	 using	incised	WLE	specimens	to	assess	 tumour	margins	 is	 that	only	a	small	part	of	 the	
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specimen	 is	 exposed,	 and	 as	with	 conventional	 histopathology	 this	 increases	 the	likelihood	of	sampling	errors.	Due	to	the	aforementioned	limitations,	the	only	two	histologically	positive	margins	were	 ‘missed’	 as	 they	were	not	 visible	on	 the	CLI	image.	 Hence,	 whilst	 the	 current	 dataset	 does	 demonstrate	 correlation	 between	CLI	 and	histopathological	 clear	margins,	 it	 does	not	 contain	data	 to	 confirm	 that	intraoperative	 18F-FDG	 CLI	 enables	 accurate	 assessment	 of	 close	 or	 positive	margins	 <1	 mm.	 In	 order	 to	 assess	 more	 margins	 per	 patient	 using	 incised	specimens,	 specimen	 incision	 may	 be	 performed	 in	 multiple	 planes,	 but	 good	communication	between	surgeons	and	pathologists	 is	paramount	 in	order	 to	not	compromise	patient	care.	A	 randomised,	 controlled,	 multi	 centre	 clinical	 study	 sponsored	 by	Lightpoint	medical	is	scheduled	to	commence	in	late	2016	to	evaluate	the	effect	of	intraoperative	 18F-FDG	 CLI	 on	 re-operation	 rate	 and	 quality	 of	 life	 in	 breast-conserving	 surgery	 (ClinicalTrials.gov	 identifier	 NCT02666079).	 The	 study	 will	run	across	an	anticipated	7	study	sites	in	the	UK	and	Germany,	recruiting	a	total	of	442	 female	 patients.	 Apart	 from	 a	 reduced	 age	 limit	 of	 ≥18	 years	 of	 age,	 the	inclusion	 and	 exclusion	 criteria	 are	 the	 same	 as	 in	 the	 current	 study.	Randomisation	will	be	done	prior	to	surgery	in	a	1:1	ratio.	 In	the	treatment	arm,	patients	will	 receive	 5	MBq/kg	 18F-FDG	prior	 to	 surgery,	 and	 150	MBq	99mTc-nanocolloid	and	blue	dye	 if	SLNB	 is	performed	(similar	 to	 the	present	study).	To	minimize	 the	 image	artefact	 from	the	monopolar	diathermy	device,	 surgeons	are	recommended	 to	 perform	 tissue	 dissection	 using	 the	 PEAK	 Plasmablade	 or	scissors/scalpel.	 Specimen	 imaging	will	 be	 performed	 intraoperatively	 using	 the	CE-marked	LightPath™	Imaging	System	(Lightpoint	Medical	Ltd,	UK).	The	smaller	FOV	 of	 6	 x	 6	 cm	 and	 improved	 imaging	 software	 of	 this	 device	 may	 provide	substantial	 improvements	 in	sensitivity	over	 the	 investigational	CLI	camera	used	
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in	 the	present	 study.	The	CLI	 images	will	 be	 assessed	 intraoperatively	 to	 inform	the	surgeons	on	the	margin	status	of	 the	WLE	specimen,	aiming	to	achieve	more	complete	 tumour	 excision.	 In	 the	 control	 arm	BCS	with	 or	without	 SLNB	will	 be	performed	 according	 to	 local	 practice.	 The	 primary	 outcome	 measure	 is	 the	recommendation	by	the	study	site’s	multidisciplinary	team	to	re-operate	within	1	to	 6	 weeks	 post-initial	 surgery	 according	 to	 local	 practice.	 Secondary	 outcome	measures	 include	 volume	 of	 excision,	 duration	 of	 surgery	 (skin	 to	 skin),	 SLN	identification	rate	(if	performed),	radiation	dose	 to	staff,	quality	of	 life,	cosmesis,	disease	specific	survival	and	overall	survival.	To	allow	site	familiarisation	with	the	study	procedures,	the	LightPathTM	system	and	the	Plasmablade	device	(if	used),	the	first	25	patients	will	be	included	in	the	lead-in	phase	of	the	study.	Upon	completion	of	the	lead-in	phase,	the	study	will	be	temporarily	paused	to	analyse	the	data	and	identify	potential	 areas	 for	 improvement.	 	 This	will	 enable	determining	whether	CLI	 images	 from	 intact	 WLE	 specimens	 excised	 with	 the	 Plasmablade	 and/or	scalpel	 and/or	 scissors	 can	 be	 used	 to	 assess	 tumour	margin	 status.	 In	 order	 to	accurately	discriminate	between	negative	and	positive	 tumour	margins	on	 intact	specimen	 images,	 it	 is	 of	 key	 importance	 to	 identify	 signal	 characteristics	 (e.g.	signal	intensity	or	signal	focality)	that	enable	discrimination	between	‘true	signals’	and	‘false	signals’.	This	will	also	be	required	in	order	to	use	CLI	for	intraoperative	assessment	 of	 lymph	 nodes,	 which	 is	 an	 exploratory	 outcome	 measure	 of	 the	randomised	 controlled	 study.	 By	 analysing	 larger	 subgroups	 of	 patients	 with	 a	range	of	tumour	types	(including	pure	DCIS),	tumour	sizes,	histological	grade	and	hormone	 receptor	 status,	 further	 insight	 should	 be	 obtained	 into	 which	 breast-cancer	patient	populations	may	most	benefit	from	CLI-guided	surgery.		
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4. General	discussion	and	future	work	This	 thesis	evaluated	 two	novel	 imaging	 techniques,	TPI	and	CLI,	 that	have	been	developed	 to	 assess	 tumour	 resection	 margins	 intraoperatively	 in	 patients	undergoing	BCS,	with	a	view	 to	 reducing	 re-operation	 rates.	The	performance	of	both	techniques	was	assessed	in	a	first-in-human,	single	centre	study	intending	to	demonstrate	proof-of-principle	and	feasibility	in	a	clinical	environment.			 The	TPI	 study	 evaluated	 a	TPI	handheld	 imaging	probe	 that	 enables	non-invasive	assessment	of	WLE	specimens.	This	device	was	used	to	measure	 freshly	excised	 breast	 samples	 in	 an	 ex	 vivo	 setting	 (Section	 2.3).	 Histopathological	analysis	of	the	46	samples	included	for	analysis	showed	that	>85%	of	the	tumour	data	 (98	 of	 the	 115	 pixels)	was	 obtained	 from	 samples	with	 a	 low-to-moderate	percentage	 of	 tumour	 cells,	 which	 closely	 resembles	 the	 mixture	 of	 benign	 and	tumour	 tissue	 commonly	 seen	 at	 the	 resection	 border	 of	 WLE	 specimens	 from	patients	with	positive	margins.	To	our	knowledge	this	is	the	first	time	TPI	has	been	evaluated	 on	 a	 dataset	 that	 is	 clinically	 representative	 for	BCS.	 By	 incorporating	the	 histopathological	 information	 on	 tissue	 type	 and	 cell	 density	 in	 the	 protocol	used	for	subsequent	data	analysis	and	tissue	classification,	it	was	found	that	tissue	composition	 is	 a	 key	 factor	 for	 the	 performance	 of	 TPI	 in	 breast	 cancer.	 In	 our	study	the	highest	accuracy	for	discriminating	benign	from	malignant	breast	cancer	on	the	full	dataset	was	75%,	while	earlier	work	by	Fitzgerald	et	al.	and	Truong	et	
al.	 using	 data	 from	 homogeneous	 breast	 samples	 (>50%	 of	 one	 tissue	 type)	reported	 an	 accuracy	 of	 92%	 and	 93%,	 respectively	 (314,323).	When	 excluding	high	dense	fibrous	tissue	containing	>80%	fibrous	cells	from	our	dataset,	accuracy	increased	to	88%	in	our	study.	These	findings	highlight	the	importance	for	future	clinical	 TPI	 studies	 to	 obtain	 in-depth	 histopathological	 information	 from	 the	samples	included	in	the	analysis,	and	to	assure	that	the	diagnostic	accuracy	of	TPI	
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is	assessed	on	a	dataset	 that	 is	 truly	reflective	of	 the	clinical	 situation	where	 the	intension	is	to	use	the	device.			 The	CLI	study	evaluated	18F-FDG	CLI	for	intraoperative	assessment	of	WLE	specimens	 and	 lymph	nodes	 using	 a	 prototype	 CLI	 imaging	 device.	 Results	 from	two	lead-in	studies	showed	that	in	order	to	successfully	perform	SLNB	at	the	time	of	 intraoperative	 CLI	 with	 a	 18F-FDG	 dose	 of	 5MBq/kg,	 it	 is	 required	 to	 use	 an	increased	 99mTc	 dose	 of	 150	 MBq,	 and	 a	 high-energy	 gamma	 probe	 collimator	(Section	 3.3).	 To	 our	 knowledge	 no	 reports	 have	 been	 published	 so	 far	 on	 the	ability	 to	 successfully	 perform	 SLNB	 in	 combination	with	 18F-FDG	 guided	 breast	surgery.	If	18F-FDG	intraoperative	CLI	is	to	be	used	in	other	solid	cancer	types	that	routinely	perform	99mTc-guided	SLNB	at	the	time	of	primary	tumour	excision	(e.g	head	and	neck	cancers	and	melanoma),	experiments	should	be	performed	prior	to	clinical	use	to	establish	the	required	99mTc	dose	and	optimal	SLNB	protocol.		 In	the	main	study	to	evaluate	18F-FDG	CLI	for	assessing	tumour	margin	and	lymph	node	status,	good	agreement	was	found	between	the	margin	width	on	CLI	and	histopathology	 using	 incised	WLE	 specimens	 (Section	 3.4).	However,	 due	 to	the	small	sampling	area	and	the	potentially	limited	number	of	margins	that	can	be	assessed,	 the	 clinical	 applicability	 of	 this	 approach	may	 require	 refining.	 Planar	imaging	 of	 intact	 WLE	 specimens	 would	 enable	 margin	 assessment	 of	 a	 much	larger	 surface	 area,	 thereby	 significantly	 reducing	 the	 likelihood	 for	 sampling	errors.	Moreover,	by	using	intact	specimens	there	is	no	need	for	specimen	inking	or	 physical	 tissue	 disruption,	 thus	 improving	 the	 ease-of-use	 of	 the	 technology	while	preventing	potential	margin	interpretation	errors	from	migration	of	the	wet	pathology	ink.	In	order	to	potentially	enable	tumour	margin	assessment	on	intact	WLE	specimens	it	is	of	key	importance	to	gain	a	better	understanding	of	the	image	artefact	 caused	by	 the	monopolar	 diathermy	device.	 This	 phenomenon	 seems	 to	
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have	not	yet	been	described	in	published	literature	to	date.	A	key	experiment	that	should	 be	 conducted	 is	 to	 obtain	 the	 wavelength	 spectrum	 of	 the	 diathermy-induced	 optical	 signal.	 By	 using	 bandpass	 filters	 with	 a	 wavelength	 ranging	between	400	–	900	nm,	the	emission	spectrum	of	the	artefact	can	be	compared	to	the	Cerenkov	radiation	spectrum.	The	Cerenkov	signal	is	heavily	weighted	towards	the	 blue	 end	 of	 the	 visible	 spectrum	 (400	 –	 450	 nm)	 (Section	 3.1.1),	 so	 if	 the	diathermy	 signal	 is	 predominantly	 present	 at	 higher	wavelengths,	 optical	 filters	can	 be	 installed	 in	 the	 filter-wheel	 of	 the	 LightPathTM	 system	 to	 filter	 out	 the	‘unwanted’	higher-wavelength	photons,	while	minimizing	CLI	signal	loss.	In	theory	this	 could	even	prevent	 the	need	 to	change	current	surgical	practice	by	allowing	surgeons	to	use	conventional	electrosurgery	when	performing	CLI-guided	surgery.		 Both	 the	TPI	 study	and	CLI	 study	did	not	 include	data	 from	patients	with	pure	 DCIS,	 so	 a	 key	 question	 that	 remains	 unanswered	 is	 the	 ability	 of	 the	 TPI	handheld	imaging	probe	and	18F-FDG	CLI	to	accurately	detect	DCIS.	The	TPS	study	performed	 by	 Ashworth	 et	 al.	 showed	 that	 breast	 cancer	 had	 a	 higher	 index	 of	refraction	than	fibrous	and	adipose	breast	tissue	respectively,	and	concluded	that	this	difference	enabled	discrimination	of	benign	 from	malignant	breast	 tissue	on	TPI	 (274).	Unfortunately	 they	did	not	 specify	 the	 tumour	 types	 included	 in	 their	analysis.	 Repeating	 their	measurements	 on	 a	 variety	 of	 breast	 cancers	 including	pure	DCIS	would	 provide	 valuable	 information	 on	 the	 optical	 properties	 of	 each	tumour	 type	 in	 the	 terahertz	 frequency	 range.	 This	 information	 would	 help	 in	gaining	further	insight	in	the	applicability	of	TPI	to	different	types	of	breast	cancer.			 The	 success	 of	 emerging	 technologies	 for	 intraoperative	 tumour	 margin	assessment,	 and	 the	ability	 for	 rapid	 translation	 from	bench	 to	bedside,	will	 rely	upon	a	variety	of	factors	that	are	outlined	in	Section	1.5.	Amongst	these	are	spatial	resolution	 and	 penetration	 depth,	 turnaround	 time,	 practicality	 and	
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implementability	 into	 existing	 clinical	 workflows,	 cost-effectiveness,	 diagnostic	accuracy	and	ultimately	reduction	in	re-excision	rate.	This	thesis	provides	a	unique	opportunity	to	compare	the	pros	and	cons	of	TPI	and	CLI	based	on	some	of	these	criteria.		Both	techniques	employ	a	broadband	wavelength	range,	0.17	–	3.0	mm	for	TPI	and	400	–	900	nm	for	CLI,	and	because	of	the	longer	wavelength	of	terahertz	radiation	 the	 fundamental	 resolution	 of	 TPI	 is	 inferior	 to	 optical	 imaging	techniques	that	use	light	 in	the	visible	or	NIR	wavelength	range	such	as	OCT	and	NIRF	imaging.	However,	since	the	Cerenkov	photons	in	18F-FDG	CLI	are	indirectly	produced	 by	 the	 positrons	 from	 18F-decay,	 the	 fundamental	 resolution	 of	 CLI	 is	determined	by	the	distance	over	which	the	positrons	emit	light.	For	18F	this	is	0.3	mm	(Table	12).	Thus,	although	 the	 fundamental	 resolution	of	 18F-FDG	CLI	 is	 still	superior	to	the	fundamental	resolution	of	TPI	for	the	vast	majority	of	the	0.1	–	1.8	THz	 spectrum	 of	 the	 TPI	 handheld	 probe,	 the	 differences	 are	 less	 profound	 in	comparison	to	other	emerging	optical	imaging	techniques.		The	pixel	resolution	of	both	devices	is	excellent;	0.6	mm	for	the	TPI	handheld	probe	and	1.25	mm	for	the	prototype	CLI	imaging	camera	when	8x8	binning	is	used	as	per	the	current	image	protocol.	 Depending	 on	 the	 sensitivity	 of	 the	 LightpathTM	 device	 the	 pixel	resolution	 in	 the	 RCT	may	 be	 further	 improved	 by	 using	 lower	 binning	 settings	(e.g.	4x4	or	2x2).	Both	TPI	and	18F-FDG	CLI	have	a	tissue	penetration	depth	in	the	range	of	5	mm	or	less,	which	is	perfectly	suited	for	the	‘no	tumour	on	ink’,	‘≥1	mm’	or	‘≥2	mm’	guidelines	that	are	currently	being	used	in	clinical	practice	(Table	1).	The	limited	tissue	penetration	could	be	an	advantage	over	the	established	imaging	techniques	for	 margin	 assessment	 (IDSR	 and	 IOUS),	 and	 some	 of	 the	 emerging	 imaging	techniques	 that	 employ	 light	 in	 the	 NIR	 frequency	 range	 (Raman	 spectroscopy,	
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OCT	and	NIRF	imaging).	X-ray	radiation	and	ultrasound	waves	penetrate	tissue	up	to	several	tenth	of	centimetres,	while	depending	on	the	frequency,	NIR	light	can	be	detected	at	a	depth	of	10	–	15	mm	(344).	This	may	cause	errors	in	tumour	margin	assessment	 if	 histopathological	 negative	 margins	 are	 wrongly	 diagnosed	 as	involved	on	intraoperative	imaging.		Techniques	for	intraoperative	assessment	of	tumour	margins	in	BCS	should	provide	a	diagnosis	within	20	–	30	minutes	maximum.	Both	techniques	meet	this	requirement.	 The	 acquisition	 time	 of	 TPI	 and	 CLI	 in	 the	 current	 studies	was	 20	seconds	and	5	minutes,	 respectively.	Due	 to	 the	small	15x2	mm	scan	area	of	 the	TPI	 handheld	 probe	multiple	measurements	 should	 be	 performed	 to	 adequately	assess	 each	 tumour	 margin.	 The	 optimal	 number	 of	 measurement	 points	 per	margin	depends	on	the	balance	between	sampling	accuracy	and	acquisition	time.	Most	studies	evaluating	the	MarginProbe,	a	handheld	device	that	also	has	a	small	fingerprint,	report	a	maximum	number	of	8	measurements	per	margin.	Based	on	the	 measurement	 time	 of	 20	 seconds	 used	 in	 the	 current	 TPI	 study,	 and	 8	measurements	 per	 margin,	 assessing	 all	 six	 margins	 would	 require	 16	minutes.	Increasing	the	number	of	measurement	points	may	be	feasible,	but	would	require	a	 reduction	 in	 acquisition	 time	 per	 measurement	 to	 stay	 within	 time-window	considered	 acceptable	 for	 intraoperative	 tumour	 margin	 assessment	 in	 BCS.	Whether	 the	TPI	acquisition	 time	can	be	 reduced	depends	on	 the	signal-to-noise	ratio	 required	 for	 maintaining	 optimal	 diagnostic	 accuracy,	 and	 this	 should	 be	explored	in	the	next	TPI	study.	For	CLI	a	maximum	of	3	to	4	images	from	an	intact	WLE	specimen	is	 likely	to	be	sufficient	 to	capture	all	6	margins	because	multiple	margins	 can	 be	 assessed	 per	 image.	 Due	 to	 the	 limited	 tissue	 surface	 that	 is	exposed,	assessment	of	tumour	margin	status	on	incised	specimens	only	requires	acquisition	 of	 a	 single	 image.	 Thus,	 regardless	 of	 whether	 incised	 or	 intact	
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specimens	are	used,	CLI	imaging	can	be	performed	within	20	to	25	minutes.	Since	the	 LightpathTM	 system	 that	 will	 be	 used	 in	 the	 RCT	 is	 expected	 to	 have	 an	improved	 sensitivity,	 it	would	be	 interesting	 to	 evaluate	whether	 the	acquisition	time	can	be	reduced	without	compromising	diagnostic	accuracy.	TPI	 can	 be	 easily	 introduced	 into	 existing	 clinical	workflows	 because	 the	technique	does	not	require	the	use	of	an	exogenous	contrast	agent	to	discriminate	benign	from	malignant	breast	tissue,	and	the	non-ionizing	energy	level	of	terahertz	radiation	 means	 that	 for	 scanning	 excised	 WLE	 specimens	 there	 are	 no	 safety	concerns	for	patients	and	staff.	In	contrast,	the	ionizing	radiation	from	radiotracers	required	for	CLI	provides	some	important	logistical	and	regulatory	challenges	for	clinical	adoption	(Section	3.1.2	and	Section	3.4).	From	our	own	experience	another	key	factor	for	successful	implementation	of	CLI	in	clinical	practice	is	thorough	and	careful	 education	 of	 patients	 and	 all	 staff	 involved	 in	 the	 patient	 care	 pathway.	These	training	sessions	should	provide	adequate	and	understandable	information	on	 the	 radiation	 exposure	 levels	 of	 18F-FDG	 CLI,	 and	 address	 common	misconceptions	around	the	perceived	and	actual	dose-related	health	risks.	According	 to	 the	 results	 from	 the	 meta-analysis	 of	 St	 John	 et	 al.,	 the	diagnostic	 accuracy	 of	 emerging	 techniques	 should	 at	 least	 meet	 the	 53	 –	 91%	sensitivity	 and	 81	 –	 96%	 specificity	 of	 the	 established	 techniques	 for	intraoperative	 margin	 assessment	 (183).	 The	 results	 of	 the	 current	 study	 show	that	 for	 invasive	 cancer	 the	 handheld	 TPI	 probe	 does	 provide	 sufficient	performance	 in	 terms	 of	 sensitivity	 (≥86%),	 but	 currently	 underperforms	 with	regards	to	specificity	(≤66%).	Note	that	these	results	are	obtained	from	a	first-in-human	proof	of	principle	study.	By	improving	the	system’s	signal	stability	and/or	correct	 for	 instabilities	 through	 calibration,	 there	 may	 be	 room	 for	 significant	improvement	in	diagnostic	accuracy.	Similar	to	TPI,	CLI	is	still	at	very	early	stage	
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of	development	with	only	one	clinical	pilot	study	conducted	so	far.	The	sensitivity	and	 specificity	 of	 intraoperative	 18F-FDG	 CLI	 in	 the	 current	 study	 could	 not	 be	determined	because	 the	 imaging	dataset	did	not	 contain	data	 from	histologically	positive	margins.	A	challenge	of	performing	CLI	with	18F-FDG	is	that	this	tracer	is	not	 tumour-specific,	 and	 the	 uptake	 is	 dependent	 on	 metabolic	 activity,	 which	varies	 amongst	 other	 factors	 between	 tumour	 types	 (invasive	 ductal	 carcinomas	usually	have	a	higher	FDG	uptake	than	invasive	lobular	carcinoma	and	DCIS),	and	tumour	 grade	 (higher	 grade	 tumours	 generally	 take	 up	 more	 FDG)	 (397).	However,	 an	 important	 strength	 of	 CLI	 is	 the	 ability	 to	 use	 a	 spectrum	 of	radiotracers,	 and	 there	 are	 some	 breast	 tumour	 specific	 tracers	 currently	 being	trialled	 for	 market	 approval	 including	 18F-FES	 (targeting	 the	 ER-receptor)	 and	












5. Conclusion	The	work	 described	 in	 this	 thesis	 has	 demonstrated	 that	 both	 TPI	 and	 CLI	 hold	promise	 for	 intraoperative	 assessment	 of	 tumour	 resection	 margins	 in	 patients	with	invasive	breast	cancer.		The	TPI	handheld	probe	discriminates	malignant	from	benign	breast	tissue	with	a	high	sensitivity	and	an	encouraging	degree	of	accuracy.	The	main	challenge	for	 TPI	 is	 accurate	 discrimination	 of	 cancer	 from	 tissue	 containing	 a	 high	percentage	of	fibrous	cells	due	to	the	similarities	in	the	THz	pulse	between	these	two	types	of	tissue.		Intraoperative	18F-FDG	CLI	is	feasible	and	a	low	risk	procedure.	There	was	good	agreement	in	margin	width	between	CLI	and	histopathology	in	showing	clear	margins	 of	 excision.	Due	 to	 a	 lack	 of	 positive	 histological	margins	 in	 the	 dataset	diagnostic	 accuracy	 could	 not	 be	 assessed.	 Sentinel	 nodes	 were	 successfully	detected	 in	 all	 patients	 using	 an	 increased	 99mTc	 dose	 of	 150	 MBq	 and	 a	 high-energy	collimator	to	facilitate	SLN	detection	against	the	gamma-probe	background	signal	from	18F-FDG.	Radiation	dose	to	staff	was	low.	Elimination	of	image	artefacts	from	tissue	dissection	with	the	monopolar	diathermy	device	 is	needed	to	 further	improve	the	applicability	of		18F-FDG	CLI.	Larger	 studies	 to	 assess	 the	 diagnostic	 accuracy	 of	 each	 technique	 in	patients	with	both	invasive	cancer	and	DCIS,	and	the	impact	on	re-operation	rate,	are	 warranted	 and	 due	 to	 commence	 soon.	 The	 outcome	 of	 these	 studies	 will	determine	 the	 true	value	of	both	 techniques	 in	 improving	quality	of	 care	 in	BCS,	and	will	inform	further	research	to	evaluate	this	technology	for	other	solid	cancer	types.			
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PATIENT INFORMATION SHEET 
Invitation to take part in this research study 
We would like to invite you to take part in a research study. Before deciding, it is important 
to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully, discuss it with people who are close to 
you and do not hesitate to ask us any question. Participation in the study is entirely 
voluntary. Your level of care will not be affected whether you take part in the study or not.  
Why have I been invited? 
You are being invited to take part in this research study because you are about to have a 
PET-scan during which you will receive an injection of a radioisotope called 18F-FDG. A 
maximum of 20 patients will take part in the study. The study is only taking place at this 
hospital. 
What is the purpose of the study? 
The study is to measure the highest and lowest signal from the radioisotope (18F-FDG) that 
is injected as part of your PET-scan. The signal will be measured in the left and right 
Study Title: Gamma probe cross talk from 18F-FDG in technetium- 
99m energy window 
Sponsor: Kings College London / Guy’s and St Thomas’ NHS Trust 
Principal Investigator: Professor Gary Cook 
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armpit, using a handheld detection device (called a gamma probe) that is currently being 
used to detect other radioisotopes during surgery.  
We are hoping to use the results of this study in a new surgical device trial that may help 
surgeons detect during surgery whether all the breast tumour (cancer) has been removed. 
Removing all cancer will reduce the need for further surgery, and thus benefit future 
patients with breast cancer. 
Do I have to take part? 
No, it is up to you to decide whether you would like to join this research study. If you agree 
to take part, we will ask you to sign a consent form. If you do not want to take part in the 
study or withdraw at any time without giving a reason, the treatment and care you receive 
from the doctors and nurses here at Guy’s and St Thomas’ Foundation Trust will be no 
different than you would normally receive.  
What will happen to me if I take part? 
All patients taking part in this study will receive the same level of care and same treatment 
as those who are not. 
If you choose to take part in the study, some basic information about you will be collected - 
for example, your age, height, weight and the reason why you are undergoing a PET-scan. 
As part of the routine PET scanning procedure, you will receive a radioisotope injection and 
you will need to wait for 90 minutes before your scan can be done. This period of time allows 
the tracer to circulate in the blood stream and go into the tissues. We will take our 
measurements during your waiting time, so we will not be interfering with your scan. 
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We will position a handheld detection device  (called a gamma probe) in your right armpit 
and measure the highest and lowest signal. We will then measure the highest and lowest 
signal in your left armpit. The head of the probe will be placed against your skin to take the 
readings and is approximately the size of a ten pence coin. You will only feel a slight 
pressure against your skin.  
The measurements will take just a few minutes and will not affect you or your treatment in 
any way. Your participation will end once the measurements have been completed. There 
is no follow up in this study.  
The information from these measurements will help us to design an accurate protocol for 
another research study to help surgeons detect during surgery whether all of a breast 
tumour (cancer) has been removed.  
What are the possible disadvantages and risks of taking part? 
There are no risks or side effects associated with this research study. You will not receive 
any drugs or undergo any invasive procedures as part of this study. Your routine care will 
not be affected in any way. 
What are the possible benefits of taking part? 
There are no direct benefits to you from taking part in this research. Future patients that 
undergo surgery for breast cancer may benefit if the technique works. 
What if there is a problem? 
The trial does not affect your treatment and does not involve any invasive procedures so it is 
highly unlikely that anything will go wrong with your treatment or care. The research team 
will always be available in the event of any problems or if you have any queries (contact 
numbers are listed at the end of this document). If you wish to complain about any aspect of 
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the way you have been approached or treated during the course of the study, you can do so 
using the National Health Service (NHS) complaints procedure. 
There are no special compensation arrangements as we do not anticipate any adverse 
events. However, the healthcare professionals working on the clinical studies are covered by 
NHS Indemnity, which covers harm due to medical negligence. 
Any concerns should be raised by speaking to a member of staff at your at your hospital or 
by talking the local Patient Advice and Liaison Service (PALS) which has been established 
in every NHS Trust and Primary Care Trust (PCT). 
Will my taking part in this study be kept confidential? 
Yes. We will follow all ethical and legal regulations and all information about you will be 
handled in confidence. Only Guy’s and St Thomas’ staff will collect information about you 
during the course of the research and this will remain confidential and be stored in a secure 
area of the hospital. 
What will happen to the results of the research study? 
At the end of the study the results will be included in a report.  You will not be identified in this, 
or any other written report. The report may form part of an application to the Regulatory 
Authorities. You will not be identified in the report. 
What is organizing and funding the research study? 
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Who has reviewed the study? 
All research in Guy's and St Thomas' NHS Foundation Trust is reviewed by an independent 
group of people called an Ethics Committee to protect your safety, rights and wellbeing. This 
study has been reviewed by from the South East Scotland Research Ethics Committee.. 
Involvement of the General Practitioner/Family doctor (GP) 
Your doctor (general practitioner) will be notified of your involvement in this study 
Further information and contact details 
If you have any questions or wish to obtain any further information later, please contact the 
following individuals: 
 
Research Nurse: Vernie Ramalingam   02071880743 
Research Fellow: Maarten Grootendorst                     02071880743 
Clinical Trials Coordinator: Sweta Sethi                       02071880743/ 07795646473 
 
For an independent opinion please contact: 
Fernanda Castro                                                           02071886380 
 
Thanks 







            
 






INFORMED CONSENT FORM 
 
Please read carefully and initial each of the boxes below: 
 
 
1. I confirm that I have read and understood the Patient Information sheet version 
2, dated 24/01/2014, about the study named above. I have been given the 
opportunity to take the information into consideration, ask questions and have 
had these answered to my satisfaction. 
2. I am fully aware that participation is voluntary and that I have the right to 
withdraw at any time, without mentioning any reasons and without this having 
any influence on my medical treatment or legal rights. 
3. I understand that the collected data may be assessed during this study by 
representatives of an ethics committee or health authorities. I give my 
consent for these people to have access to my data. 
4. I understand that the study data will be kept for a period of 15 years after the 
end of the study.  
5.  I consent to my GP being informed of my participation in this study. 
 
6. I agree to participate in this study 
     
             Name of patient  Date  Signature 
     
     Name of person taking  
 consent 
 Date  Signature 
 
Complete in duplicate, one copy to be given to the patient and another copy to be stored in the study file. 
Study Title: Gamma probe cross talk from 18F-FDG in technetium-99m energy 
window 
Sponsor: King’s College London / Guy’s and St Thomas’ NHS Trust 
Principal Investigator: Professor Gary Cook 
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7.2.3 GP	letter	
   
 
 
Page 1 of 1 
 
GP letter version 1.0 
24 January 2014 












Dear Dr   , 
Patients name: 
Patient’s	address:		 	 	
	 	 	  
Gamma probe detection in patients undergoing a PET-scan study	
 
Your patient has consented to participate in this observational study that has been designed 
to measure the amount of cross talk between a gamma-probe signal from 18F-FDG and the 
gamma-probe signal from 99mTc (Technetium-99m) in patients undergoing a diagnostic PET 
scan.  
 
Patients that are about to have a routine PET-scanning procedure will be receive an injection 
of the radioisotope 18F-FDG for the PET scan. After they have been given the injection, a 
gamma probe will be placed in their right and then left armpit.  The highest and lowest signal 
will be measured.  
 
A copy of the patient information sheet is enclosed, but if you require further information 



















7.3 Appendix	 3:	 Intraoperative	 18F-FDG	 Cerenkov	 luminescence	
imaging	clinical	study	documents	
7.3.1 Patient	information	sheet	and	consent	form	






PATIENT INFORMATION SHEET 
 
Invitation to take part in this research study 
We would like to invite you to take part in a research study. It is important you 
understand why the research is being done and what it would involve for you before 
making your decision. Take your time to read the following information carefully and 
please talk to friends and family members about the study if you wish. 
Participation in the study is entirely voluntary. If you have any questions about the study 
after you have read this information, please discuss this with the study doctor or study 
staff. When you believe that you have sufficient information, you can decide whether or 
not you wish to take part in the study. 
What is the research testing? 
This study is testing a new device that could help surgeons know if they have removed all 
of a tumour (cancer) during surgery. The device is known as the CLI Specimen Analyser 
(see picture below). This new device is use to look at the lump and any other tissue 
removed from your breast during surgery. 
Picture 1 
The CLI Specimen Analyser 
 
Short Title: The CLI Specimen Analyser study 
Study Title: A pilot study to evaluate Cerenkov Luminescence Imaging for 
measuring margin and lymph node status in breast cancer 
surgical specimens. 
Sponsor: Lightpoint Medical Limited 
Study Code: LPM-001 
Principal Investigator: Professor Arnie Purushotham 
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What is the purpose of the study? 
The purpose of this study is to find out if this new device can be used, in the future, to 
detect cancer in tissue removed during surgery.  This is a small pilot study to help 
researchers understand more about how the device works. Some people have already 
taken part in this study and we know that we can use the new device to look at the cancer 
that has been removed during surgery. However, we need some more people to take part 
in the study, so that we can understand how best to use the new device.  The results of 
this study will be used to make improvements to the device and to plan larger studies to 
test how well the device works. 
Why have I been invited? 
You are being invited to join this research study because you are about to have 
surgery for breast cancer. A maximum of 30 people will take part in the study, which is only 
taking place at this hospital. 
Do I have to take part? 
It is up to you to decide to join this research study.  A member of the research team will 
describe the study and go through this form with you. You will be given as much time as 
you need to read and understand the information leaflet and make your decision. You 
may want to talk to your family or GP about taking part and you will be given the 
opportunity to do so. If you agree to take part, we will then ask you to sign a consent form. 
If you do not want to take part in the study, the treatment and care you receive from the 
doctors and nurses here at Guy's Hospital will be exactly the same as you would normally 
receive. 
What will happen to me if I take part? 
All patients taking part in this study will receive the same level of care and same 
treatment as those who are not. 
If you choose to take part in the study, some basic information about you will be 
collected. For example, your age, height, weight and the reason you are having surgery. 
On the day of surgery, your blood sugar level will be measured. This is done by pricking 
your finger with a small needle (lancet) and collecting a drop of blood. If your blood sugar 
level is too high (12 mmol/l or higher), you will not be able to take any further part in the 
study. 
Patients who take part in the study will be given an injection of a radioactive compound 
called fluorine FDG (18F-FDG) just before their surgery. This is a sugar substance that is 
taken up in many types of cancer. It is normally used during a test called a PET scan, which 
helps to show your doctor where cancer cells are located.  This injection is given during 
the study because the new device being tested detects very low level light given off by 
cancer cells containing fluorine FDG. The radioactivity from the injection leaves your body 
quickly and will not make you feel unwell. As radiation can harm unborn children, if you 
are interested in taking part in the study you will be asked if it is possible that you could 
be pregnant. You may be asked to take a pregnancy test. 
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If your doctor is planning to perform a sentinel lymph node biopsy during your surgery, 
you will normally be given another radioactive compound called 99mTc-colliod 
(technetium colloid). If you take part in the study, you will be given more 99mTc-colliod 
than normal (150 MBq instead of 20-40 MBq) 
Once surgery has begun, the surgeon will perform the operation as normal. The lump and 
any tissue that is removed from your breast during the operation will be examined using 
the CLI device. We will also examine any lymph nodes that are removed from the armpit. 
The CLI device will take pictures of the tissue, like Picture 2 below. 
The tissue will then be sent to the laboratory to be examined for cancer using standard 
tests. The results from the CLI device will not be known until after your operation and will 
not be used to make any decisions about your care. You will not be provided with the 
results from the CLI device. 
Picture 2 
A picture of breast tissue taken in the CLI Specimen Analyser. The orange-coloured areas show 
where there is tumour. 
 
 
What are the alternatives for treatment? 
Taking part in this study will not change the treatment you receive in any way. The results 
from tests using the CLI Specimen Analyser will not be used to make any decisions about 
your treatment. You doctor will provide the best treatment that is available to you. 
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What are the possible disadvantages and risks of taking part? 
Patients taking part in the study will be given an injection of fluorine FDG and technetium 
colloid which are radioactive tracers required for the study. Both tracers are used 
routinely; fluorine FDG in PET-CT scanning and technetium colloid in sentinel node biopsy 
procedures.  For this study the amount of fluorine FDG is the same as is given for a 
standard PET-CT scan. The amount of radiation for the technetium colloid is greater than 
standard care. The amount of radiation you will receive from the injection reduces rapidly 
over a few hours and by the time you leave the operating theatres the amount of 
radiation left in you so small that it is safe for you to travel home and be with your family 
and friends. 
The amount of radiation you will receive in this study is 6.4milliSieverts (mSv). This is 
similar to: 
 The radiation dose from a typical chest CT scan (7.0mSv). 
 Around 3 years’ natural background radiation. Natural background radiation is 
approximately 2.2mSv per year in the UK. In some places, the natural background 
radiation is higher - the average annual background radiation dose to a person living 
in Cornwall is slightly higher (7.8mSv) than the amount of radiation you will receive in 
this study. 
 Around 300 transatlantic flights (a 7 hour flight is 0.02mSv). 
It is known that high levels of radiation can cause cancer. While the amount of radiation 
you receive if you take part in the study is small, it is possible that this may increase the 
risk of developing cancer later on in life. This risk changes depending on your age now. If 
you are in your thirties, the additional risk of developing cancer later on in life because of 
the radiation exposure is 1 in 2,300. This means that if 2,300 people aged 30-39 were 
exposed to the level of radiation received from taking part in this study, 1 of them would 
develop cancer later in life because of the radiation. The table below shows the increase 
in risk for each age group. 
Age now Increased risk of cancer later in life 
30-39 1 in 2300 (0.043%) 
40-49 1 in 2700 (0.037%) 
50-59 years 1 in 3500 (0.029%) 
60-69 years 1 in 5000 (0.020%) 
70-79 years 1 in 8700 (0.011%) 
80-89 years 1 in 20,000 (0.005%) 
90-99 years 1 in 1,000,000 (0.0001%) 
 
What are the possible benefits of taking part? 
There are no direct benefits to you from taking part in this research. 
The goal of this research study and future studies is to find better ways to see cancer 
during surgery so that surgeons can be sure all the cancer has been removed. It is hoped 
244	
Patient Information Sheet v1.3, 03 February 2016 Page 5 of 8 
that the findings of this research will help develop devices which will in the future benefit 
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What will happen if I do not want to carry on with the study? 
You have the right to stop taking part in the study at any time without mentioning any 
reasons. This decision will not affect your current treatment and care or any future 
treatment and care you receive in our hospital. 
What if there is a problem? 
If you have a concern about any aspects of this study, you should ask to speak to the 
researchers who will do their best to answer your questions.  If you remain unhappy 
and wish to complain formally, you can do this by following the hospital complaints 
procedure. To find out about it, ask a member of staff, look on the hospital website 
or contact the Patient Advice and Liaison Service (PALS) on 020 7188 8801 or 020 7188 
8803 for more information. 
We will provide compensation for any injury caused by taking part in this study in 
accordance with national guidelines. We will pay compensation where the injury probably 
resulted from any procedure you received as part of the study. Any payment would be 
without legal commitment. (Please ask if you wish to receive more information on this). 
We would not be bound by these guidelines to pay compensation where the injury 
resulted from a procedure outside of the study or the study protocol was not followed. 
Insurance has been taken out by the study sponsor to cover injury or death resulting 
from participation in the study. 
If you have private medical insurance you should check with the insurance company that 
your insurance status would not be affected before agreeing to take part in the study. 
Will my taking part in this study be confidential? 
If you agree to take part in the study you will be given a unique study number. Any data 
collected will be recorded using only your study number to identify you. We will not collect 
any personal identifiable information (names, addresses, telephone numbers) for the trial. 
The data that is collected for the study will be kept for up to 15 years after the end of the 
study. No information that could identify you will be used in any publications about the 
study. 
In the UK, all research involving patients is reviewed by an ethics committee. This is to ensure 
that the research is carried out safely and according to regulations. 
Lightpoint Medical (the company sponsoring the study) will also appoint authorized 
representatives  to compare the collected study data with the data in your medical file. This 
will only be the information relating to your cancer diagnosis and your participation in the 
study. This is to check that all data has been accurately recorded. 
We will ask for your consent to allow the use of your data and medical records as mentioned 
above. All information collected will be treated with the strictest confidence; and your study 
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Notifying your General Practitioner 
We will ask for your consent to inform your general practitioner (GP) that you have decided 
to take part in this study.  If you have any objections to your GP being contacted, please 
speak to your study doctor. 
What will happen to any samples I give? 
No samples will be collected for this study. While tissue from your breast and lymph nodes 
removed during surgery will be examined immediately using the CLI Specimen Analyser, 
these will be handled as normal afterwards, and sent to the laboratory for examination. 
Will any genetic tests be done? 
No. 
What will happen to the results of the research study? 
At the end of the study the results will be included in a report.  You will not be named in this, 
or any other document about the study. The report may form part of an application to 
Regulatory Authorities. This study has been placed on internet directories of clinical trials 
(http://isrctn.org/ and www.clinicaltrials.gov) and the result, once available will be posted 
here.  Your study team will also send you a copy of the results upon request. 
Who is organising and funding the research? 
Lightpoint Medical Ltd, a Biotechnology company, is organising this study in partnership with 
Guy's and St Thomas' NHS Foundation Trust and King's College London. The study is funded 
by the Technology Strategy Board. 
Who has reviewed the study? 
To protect your safety, rights and wellbeing, all research in Guy's and St Thomas' NHS 
Foundation Trust is reviewed by an independent group of people called an Ethics 
Committee. This study has obtained ethical approval from the West Midlands - Edgbaston 
ethics committee. 
Further information and contact details 
If you wish to receive additional information or if you still have any questions after having 
read this information sheet or before or during the study, you can always contact members 
of the research team below: 
Professor  Purushotham (breast surgeon)   Tel:  02071883027 
Vernie Ramalingam (research nurse)           Tel:  0207188 0743 
Sweta Sethi (clinical trial coordinator)         Tel:   02071880743 
In cases of emergency you can call our hospital through the general telephone number: 020 
7188 7188. 
A description of this research study will be available on the following websites 
http://public.ukcrn.org.uk/search/, http://isrctn.org/ and http://www.ClinicalTrials.gov. 
These websites will not include information that can identify you. At most, the websites will 
include a summary of the results. You can search these websites at any time. 
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Signing the Informed Consent Form 
If you decide to take part in the study, we will ask you to sign a form in duplicate. You may 
keep one copy yourself and give the other copy to your study doctor, who will ensure it is 
filed in your medical records. By signing this form (i.e. an Informed Consent Form or simply 
Informed Consent), you agree to take part in this study. You will remain free to decide to 
stop taking part in the study for whatever reason relevant to you. The study doctor will also 
sign the form and confirm that he or she has informed you about the study, that he or she 
has given you this patient information sheet and that he or she is prepared to answer any 
questions that may arise. 
 
CONCLUSION 
You must only sign the Informed Consent Form if all of the following are true: 
- You have read and understood this patient information sheet. 
- All your questions about taking part in this study have been answered to your 
satisfaction. 
- You understand all information provided concerning this study. 
- You have voluntarily decided to take part in this study. 
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INFORMED CONSENT FORM 
 
 
Please read carefully and initial each of the boxes below: 
 
 
1. I confirm that I have read and understood the Patient Information Sheet 
(version 1.3 dated: 03 February 2016) about the study named above. I have 
been given the opportunity to take the information into consideration, ask 
questions and have had these answered to my satisfaction. 
2. I am fully aware that participation is voluntary and that I have the right to 
withdraw at any time, without mentioning any reasons and without this 
having any influence on my medical treatment or legal rights. 
3 I understand that I will receive a radioactive injection as part of the study. 
All risks have been explained to me 
3. I understand that relevant information from my medical data and other 
collected data may be assessed during this study by representatives of 
Lightpoint Medical Ltd, companies acting on their behalf, an ethics 
committee or health authorities. I give my consent for these people to 
have access to my data. 
4. I understand that the study data will be kept for a period of up to 15 years 
after the end of the study. 
5. I agree that my general practitioner (GP) will be informed about my 
participation in this study. 
6. I agree to participate in this study. 
 
Short Title: The CLI Specimen Analyser study 
Study Title: A pilot study to evaluate Cerenkov Luminescence Imaging for 
measuring margin status in breast cancer surgical specimens. 
Sponsor: Lightpoint Medical Limited 
Study Code: LPM-001 
Principal Investigator: Professor Arnie Purushotham 
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Please write your name, today's date and sign below. 
 
     
Name of patient  Date  Signature 
     
Name of person taking 
consent 














GENERAL PRACTITIONER INFORMATION 
   
 
Patient’s Name:  
 
Date of Birth:   
 






A pilot study to evaluate Cerenkov Luminescence Imaging for measuring margin and 
lymph node status in breast cancer surgical specimens 
 
I wish to inform you that the above patient has agreed to participate in a clinical performance study of an 
in-vitro diagnostic device. This patient was invited to participate in the study as she is scheduled to have 
Breast Conserving Surgery for breast cancer at Guy's Hospital. 
This study of 30 patients will test the feasibility of using a new medical technology known as Cerenkov 
Luminescence Imaging, or CLI. The study device is a specimen analyser intended for the ex-vivo 
visualisation of surgical specimens to assess tumour margin and lymph node metastatic status during 
surgery. 
In addition to routine care, your patient will have their blood glucose checked on the day of surgery, 
receive an additional intravenous injection of a PET radiotracer (18F-FDG) and, if the patient is having a 
sentinel lymph node biopsy, an increased quantity of technetium 99m. 
 
The study has been reviewed by an independent Research Ethics Committee and it has been agreed 
that it may go ahead. 
 
I would be grateful if you could inform me immediately of any concerns you may have with your patient 
entering this study. 
 








Professor Arnie Purushotham 
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Abstract Cerenkov luminescence imaging (CLI) is a
novel molecular optical imaging technique based on the
detection of optical Cerenkov photons emitted by positron
emission tomography (PET) imaging agents. The ability to
use clinically approved tumour-targeted tracers in combi-
nation with small-sized imaging equipment makes CLI a
particularly interesting technique for image-guided cancer
surgery. The past few years have witnessed a rapid increase
in proof-of-concept preclinical studies in this field, and
several clinical trials are currently underway. This article
provides an overview of the basic principles of Cerenkov
radiation and outlines the challenges of CLI-guided surgery
for clinical use. The preclinical and clinical trial literature
is examined including applications focussed on image-
guided lymph node detection and Cerenkov luminescence
endoscopy, and the ongoing clinical studies and techno-
logical developments are highlighted. By intraoperatively
guiding the oncosurgeon towards more accurate and com-
plete resections, CLI has the potential to transform current
surgical practice, and improve oncological and cosmetic
outcomes for patients.
Keywords Cerenkov luminescence imaging ! Image-
guided surgery ! Cerenkov luminescence endoscopy !
Tumour margins ! Lymph nodes
Introduction
Cancer surgery
The International Agency for Research on Cancer (IARC)
reports that 14.1 million new cancer cases were diagnosed
in 2012 worldwide, with 8.2 million cancer-related deaths.
By 2030, these figures will grow to 21.7 million new cases
and 13 million deaths, simply due to population growth and
ageing [2]. Of the estimated 21.7 million global new cancer
patients in 2030, 17.3 million, or approximately 80 %, will
need surgery as the main form of treatment [3].
For cancer surgery to have curative intent, complete
tumour resection (i.e. excision of all cancer tissue with no
residual loco-regional disease) is mandatory. To achieve
this, surgeons try to identify a tumour’s extent, and aim to
excise the lesion with a surrounding margin of healthy
tissue. In an effort to minimise functional loss and/or
cosmetic impairment, the goal is to remove the least pos-
sible amount of healthy tissue without compromising
oncological safety [4].
Palpation and visual inspection—combined with a sur-
geon’s experience and judgement—are currently the only
widely available ‘modalities’ to guide resection. These are
frequently inaccurate at discriminating between malignant
and normal tissue, resulting in positive tumour margin rates
of up to 50 % in some cancers [5–7]. Positive margins are
associated with a higher risk of local recurrence and poor
prognosis [8–11]. Adjuvant treatments such as radiother-
apy, hormone therapy or chemotherapy, and repeat opera-
tions to excise residual disease are often indicated to reduce
the likelihood of local recurrence, but these treatments can
impact on quality of life by causing significant physical and
emotional distress, and suboptimal cosmetic outcome [12,
13].
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With the above in mind, continuing efforts have been
made to assist surgeons in the process of determining
which tissue needs to be excised during cancer surgery.
Currently used clinical techniques include ultrasonography,
specimen radiography, and intraoperative histology and
cytology techniques. Although all of these techniques are
used to varying degrees in cancer surgery, none has quite
solved the Goldilocks problem of margins, due to limita-
tions in sensitivity, specificity, accuracy, or costs [14, 15].
Cerenkov luminescence imaging
Cerenkov luminescence imaging (CLI) is a novel imaging
modality that has great potential for image-guided surgery
in general, and the issue of surgical margins in particular.
CLI is based on the detection of Cerenkov photons emitted
by positron emission tomography (PET) imaging agents.
Cerenkov photons are emitted by a charged particle
(positron or electron) when travelling through a dielectric
medium at a velocity greater than the velocity of light in
that medium. The Cerenkov phenomenon seems to have
been first observed by Marie Curie in the late 19th century.
In her biography, she describes observing a pale blue glow
from the radium-containing bottles in her laboratory. The
first person to systematically describe Cerenkov radiation
was Pavel Cerenkov, and together with Il’ja Mikhailovic
Frank and Igor Yevgenyevich Tamm who developed the
theoretical framework, they won the Nobel Prize in Physics
in 1958 for their contribution to the discovery of the Cer-
enkov effect. In the lay mind, Cerenkov radiation is known
as the blue glow in the cooling water basins that surround
nuclear reactors.
By detecting the optical photons from PET imaging
tracers, CLI combines optical and molecular imaging.
Robertson et al. were the first who demonstrated that CLI
with PET agents can be used to image cancer in vivo [16],
and since then, this technology has rapidly emerged in the
field of biomedical imaging. In recent years, several review
papers have outlined the various applications of CLI
including its use in Cerenkov luminescence imaging
dosimetry (CLID), radionuclide therapy monitoring,
tumour response monitoring and photoactivation therapy
[17–21]. An in-depth explanation of the complex physics
underlying Cerenkov radiation and CLI has also been
reported [22, 23].
The aim of this review paper is to provide an overview
on the use of CLI for image-guided interventions with a
specific focus on image-guided cancer surgery. The first
section of this paper outlines the characteristics of Cer-
enkov radiation and CLI. Rather than describing these
characteristics using complex physical equations as already
done by others, this review provides a simplified explana-
tion with an emphasis on the features that are relevant to
image-guided surgery. The second section of this paper
contains an overview of the published work in this field to
date, and the last section will highlight the ongoing clinical
studies and technological developments.
Cerenkov radiation: the basics
Cerenkov radiation is produced when a charged particle
travels through a dielectric medium, i.e. a medium that can
be polarised by an electric field, with a speed faster than the
speed of light in that medium [24]. When propagating, the
charged particle (a positively charged positron or nega-
tively charged electron) induces a local polarisation by
displacing the positive and negative charges of the atoms in
the medium (Fig. 1). In a situation where the particle’s
velocity does not exceed the speed of light in that medium,
the polarisation field surrounding the particle is perfectly
symmetrical, and there is no electric field at larger dis-
tances. The net result is that no Cerenkov radiation is
emitted. When the particle’s speed exceeds the speed of
light, however, the polarisation becomes asymmetrical
along the track of the particle, resulting in a dipole electric
field at larger distances from the particle. As the particle
passes the electrons of the atoms return to their ground
state, thereby emitting the transferred energy as optical
photons that are known as Cerenkov radiation. Thus,
Cerenkov radiation is produced as secondary emission; it is
not the charged particle generating light, but the medium as
a reaction to the particle.
For Cerenkov radiation to be emitted, the charged
particle needs to exceed a certain energy threshold. This
threshold is expressed by v ! c=g, where m is the charged
particle’s velocity, c is the speed of light in vacuum, and g
is the refraction index of the medium. From this expres-
sion, it becomes clear that the Cerenkov threshold is
related to the refractive index of the medium. Using the
relationship between the velocity of the particle and its
energy as described by equations 2 and 3 in Gill et al., it is
found that in water with a refractive index of 1.33, the
threshold is 0.264 MeV [25]. In soft tissues, the refractive
index typically ranges from 1.36 to 1.40, resulting in a
threshold for the production of Cerenkov radiation of
approximately 0.219–0.250 MeV. These thresholds are
lower than the beta particle energies from radionuclides
used in PET, and these radionuclides thus emit Cerenkov
radiation in both water and tissue [26]. As the charged
particle travels through the medium, it loses energy due to






absorption and scattering, and eventually, its energy falls
below the threshold, and Cerenkov light is no longer
produced. For the much heavier alpha particles, the Cer-
enkov threshold in water and tissue is 1926 and
1673 MeV, respectively [27]. Although none of the
energies from existing alpha-emitting radionuclides come
near this threshold (typical alpha particle energies range
between 3 and 7 MeV), studies have shown emission of
Cerenkov photons by alpha emitters [27–29]. There are
two explanations for this observation, depending on the
type of radionuclide: either photons arise from the short-
lived beta-emitting daughter radionuclides of some alpha
emitters (e.g. Actinium-225), or they are produced by
electrons that arise from Compton scattered high-energy
gamma photons. Regardless of the mechanism, Cerenkov
radiation from alpha emitters is, thus, produced indirectly
by secondary beta particles. The pure gamma-emitter
Technetium-99 m (99mTc) is also able to produce optical
photons as shown by several groups [30–32]. Although
the mechanism of this optical emission is not yet fully
understood, it is assumed to be from OH radicals that are
excited by the low energy Compton electrons [30] or from
gamma excitation of the luminophores that are present in
99mTc based tracers (e.g. the amino acids in 99mTc-
macroaggregates albumin) [32]. This form of lumines-
cence is known as radioluminescence and differs from
Cerenkov radiation; it has a different wavelength spec-
trum, and its signal intensity is lower in tissue [33]. The
latter may provide additional challenges for its use in
image-guided interventions. In the remainder of this
review, our focus will, therefore, solely be on Cerenkov
radiation.
The number of Cerenkov photons N emitted per distance
travelled x can be calculated using equation 1, which is
derived from the Frank–Tamm equation [25]:
dN
dx







Here, a is the fine structure constant (1/137), b is the ratio
between particle’s velocity and the speed of light in vac-
uum (m/c), and the integral is over the interval k1 to k2.
From this equation, it follows that the intensity of the
Cerenkov radiation depends on a particle’s velocity, and
thus, its energy. Fluorine-18 (18F), the most commonly
used radionuclide in PET imaging, has an average and
maximum b-energy of 250 and 633 keV, respectively. As a
result, only 47 % of the decays produce a positron that
exceeds the energy threshold for production of Cerenkov
radiation in water [22]. Yttrium-90 (90Y), a radionuclide
often used in radiation therapy, has a much higher average
and maximum b-energy of 934 keV and 2.28 MeV,
respectively, and 90 % of its produced electrons are above
the Cerenkov threshold in water. Gill et al. recently studied
47 radionuclides widely used in nuclear medicine, and used
Monte Carlo simulations to quantify the expected Cer-
enkov light yield (photons/decay) for each radionuclide in
tissue (g = 1.4) [25]. They found that 18F emits 2.58
photons per decay in tissue; approximately 23 times less
than the 58.5 photons per decay emitted by 90Y. The light
yield from some commonly used radionuclides in order
from high to low is shown in Table 1. Although it is
important to realise that the reported light yields do not
take into account the wavelength-dependent absorption and
Fig. 1 A charged particle, in this case an electron, passing through a
dielectric medium with a a particle speed (m) lower than speed of light
in that medium (c/g), b a particle speed larger than speed of light in
that medium. The condition such that Cerenkov luminescence is






wavelength-dependent scattering that would occur in
human tissue—this would reduce the number of
detectable photons—it is clear that the signal intensity of
CLI can be improved significantly using higher-energetic
isotopes. However, even with the use of such isotopes, the
Cerenkov light yield from a single radioactive decay pro-
cess is low in comparison to, for example, the light yield
from a single fluorescent molecule. Fluorescein and Indo-
cyanine green (ICG), fluorophores used in fluorescence
image-guided surgery, emit roughly three orders of mag-
nitude more photons [34]. This low light yield requires
strict control of the light environment to obtain a sufficient
signal-to-background ratio (SBR) when using CLI in an
intraoperative setting as explained below.
Another characteristic of Cerenkov light is its broad
emission spectrum that ranges from approximately 350 to
900 nm [16]. The light intensity is inversely proportional to
the square of the wavelength (1/k2). This is why Cerenkov
radiation is strongest towards the blue end of the visible
spectrum, and hence why Cerenkov radiation appears blue.
The fundamental resolution of Cerenkov radiation is
determined by the distance over which a b-particle emits
light. It was found that for 90Y and 18F, this distance is
approximately 2 and 0.3 mm, respectively [22]. This shows
that lower-energetic tracers have a better physical resolu-
tion limit, but the downside is a lower light yield, and thus,
sensitivity.
Characteristics of CLI from an image-guided
surgery perspective
CLI images can be acquired by detecting the Cerenkov
light from PET tracers using ultra-high-sensitivity optical
cameras such as electron-multiplying charge-coupled
device (EMCCD) cameras. The CLI image can be analysed
semiquantitatively in photon radiance. CLI and PET are
directly correlated due to both techniques measuring the
photons produced by positron-emitting radiopharmaceuti-
cals; PET measures the annihilation photons, and CLI
measures the Cerenkov photons. Several studies have
shown a strong correlation between CLI and PET for dif-
ferent radiopharmaceuticals in vitro, ex vivo and in vivo,
thus demonstrating the feasibility of CLI for molecular
Table 1 Relevant characteristics of Cerenkov radiation and CLI for image-guided cancer surgery
Cerenkov radiation definition Optical radiation emitted by charged particles when travelling through a dielectric
medium with a speed larger than the speed of light in that medium
Threshold energy for Cerenkov radiation emission [25] Water (g = 1.33): 0.264 MeV
Biological tissue (g = 1.36–1.40): 0.219–0.250 MeV
Cerenkov radiation is emitted by b?, b-, and a-emitting radionuclides
Cerenkov intensity from radionuclides most commonly
used in clinic in order from high to low [25]
90Y[ 68Ga[ 15O[ 124I[ 11C[ 89Zr[ 18F[ 131I[ 64Cu
Cerenkov radiation spectrum [16] 350–900 nm
Fundamental resolution [22] 0.3–2.00 mm
Camera requirements for Cerenkov radiation detection High-sensitivity optical cameras with single-photon detection capability
Typical penetration depth in tissue [70] *1–2 cm
Typical CLI acquisition times 1–5 min
Types of images acquired with CLI Photographic image: anatomical information
Functional image: information on the uptake and location of the
radiopharmaceutical
Advantages of CLI for image-guided cancer surgery Ability to use clinically approved tumour-targeted radiopharmaceuticals
Potential for multi-modality imaging with the same tracer: preoperative imaging
with gamma-camera, PET or SPECT, intraoperative imaging using CLI ± beta-
probe or gamma-probe
Small form factor of CLI equipment allowing implementation of CLI technology in
intraoperative specimen chamber, flexible endoscope and rigid laparoscope
External excitation source not required: less tissue autofluorescence
Challenges of CLI for image-guided cancer surgery Faint signal
Light-tight imaging conditions required
Radiation dose to patient and staff
Strict regulations for use of radiotracers






imaging of living subjects. An overview of the published
literature on the correlation between CLI and PET is pro-
vided in Table 2. Results on the correlation between CLI
and radiotracer activity are also included in this table.
There are several reasons why CLI has sparked so much
interest in the field of biomedical imaging, and why it is a
promising technology to guide surgical resection. Firstly,
CLI images can be acquired with clinically approved
tumour-targeted radiopharmaceuticals that have been used
for over two decades in molecular medical imaging [26].
This provides great potential for rapid translation of CLI
into clinical practice. Especially, the possibility to use the
most commonly used PET radiopharmaceutical 2-deoxy-2-
(18F)fluoro-D-glucose (abbreviated 18F-FDG) facilitates
wide clinical adoption of CLI, as this is a versatile tracer
that can be used in several solid cancers, including lung
cancer, colorectal cancer, melanoma, head and neck can-
cer, breast cancer and oesophageal cancer [35].
The ability to use clinically approved tumour-specific
tracers is an important advantage over conventional optical
imaging techniques, such as targeted fluorescence imaging,
as to date, there are no tumour-specific fluorescent tracers
that have been approved by the FDA or EMA [36]. Targeted
fluorescence imaging faces a significant commercial hurdle
for clinical adoption, because the process of obtaining reg-
ulatory and reimbursement approval is costly and lengthy
[37], while the revenue of imaging agents is often low
compared to therapeutic agents, which makes it a signifi-
cantly less interesting investment for industry [38, 39].
In addition to the already approved PET tracers, a sig-
nificant number of new tracers are being developed for
market approval including 68Ga-PSMA, 68Ga-DOTATOC,
18F-NaF, 18F-Choline, and 18F-FDOPA [40].
The ability to use the same tracer for both CLI and PET
or SPECT enables dual-modality molecular imaging. PET
and SPECT provide preoperative information on the loca-
tion and extent of the tumour, while CLI can be used as an
intraoperative adjunct to aid lesion identification and guide
surgical resection. The use of the same tracer ensures
visualisation of the same structures and facilitates a more
accurate comparison between modalities. Depending on the
patient pathway and half-life of the tracer, preoperative and
intraoperative imaging could be performed using only one
tracer injection, or by reinjecting the tracer. By capturing a
white-light image with a standard camera at the time of
CLI image acquisition, the functional information from the
CLI image can be combined with the anatomical and
structural information from the photograph, thereby pro-
viding the surgeon unprecedented information on the nat-
ure, location, and extent of the cancerous tissue.
Beta-emitting radiopharmaceuticals can also be detected
by a beta probe or gamma probe [41–43], so these tools
Table 2 Literature overview on the correlation of CLI and PET
CLI parameter PET parameter Correlation between CLI and PET Radiopharmaceutical In vivo, in vitro, ex vivo Refs.
Radiance %ID/g R2 = 0.93, 0.95, 0.93, 0.89 18F-FDG In vivo [71]
Radiance %ID/g R2 = 0.97 18F-FDG In vivo [26]
Radiance Activity R2 = 0.95 18F-FDG In vivo [72]
Radiance Activity R2 = 0.98 18F-FDG In vivo [73]
Radiance PET± P = 0.02 18F-FDG In vivo [61]
Radiance %ID/cm3 R2 = 0.83 18F-FDG In vivo [74]
Radiance %ID R2 = 0.82 18F-FDG In vivo [74]
Radiant vol. Glycolytic vol. R2 = 0.99 18F-FDG In vivo [74]
Radiance Activity R2 = 0.99 18F In vitro [75]
Radiance Activity R2 = 0.97 18F-FDG In vitro [64]
Radiance Activity conc. R2 = 0.99 18F-FDG In vitro [61]
Radiance Activity R2 = 0.97 18F-FDG Ex vivo [72]
Intensity Activity conc. R2 = 0.98 68Ga In vitro [76]
Intensity Activity conc. R2 = 0.99 68Ga In vivo [76]
Radiance %ID/g R = 0.89 89Zr-trastuzumab In vivo [1]
Radiance %ID/g R = 0.98 89Zr-J591 In vitro [28]
Radiance Activity conc. R = 0.98 89Zr-J591 In vitro [28]
Radiance %ID/g R2 = 0.85 89Zr-rituximab In vivo [77]
Radiance Activity R2 = 0.98 Na-131I In vitro [68]
Radiance Activity R2 = 0.99 131I-NGR In vitro [78]
Radiance %IA/g R2 = 0.94, 0.98 90Y-DOTA-AR In vivo [79]






could potentially be used in addition to CLI-guided surgery
to overcome the limited penetration depth of CLI as a
result of absorption and scattering, thereby further ensuring
successful tumour resection.
Another advantage of CLI is that the optical imaging
systems required to acquire an image can be small in
dimension or use fibre-optics or laparoscopic capabilities.
Unlike a PET system, this provides the ability to use CLI in
an operating theatre or in endoscopy equipment, and exam-
ples of such applications are provided in the next section.
CLI faces a number of challenges for routine clinical
adoption. As mentioned earlier, Cerenkov luminescence is
very faint due to the small number of optical Cerenkov pho-
tons emitted by charged particles. In biological applications,
the signal intensity is further reduced by strong tissue atten-
uation from chromophores like (oxy)haemoglobin and light
scattering which is more pronounced in the 400–650 nm
range [44, 45]. Consequently, the acquisition time required to
obtain high-resolution imageswith a sufficient signal-to-noise
ratio (SNR) is longer than with conventional optical imaging.
Typical imaging times in preclinical and clinical CLI studies
range from 1 to 5 min (Table 3). Although these images are
not available in ‘real-time’, these acquisition times are con-
sidered feasible for most intraoperative applications. How-
ever, when imaging with handheld devices (e.g. endoscopes),
it is essential that during image acquisition, the device is not
moved as this causes blurring of the image resulting in a
reduced image quality. In an in vivo environment, this may
prove especially difficult due to bowel activity and breathing
artefacts, and motion-correction algorithmsmay be needed to
correct for this.
The weak light intensity also requires a light-tight
environment as any leakage of ambient light will over-
whelm the CLI signal. Since Cerenkov radiation is stron-
gest in the visible wavelengths, it cannot be spectrally
separated from the much brighter ambient lights currently
used in operating theatres. Control of the light environment
is, therefore, currently achieved by imaging in a light-tight
specimen chamber or room with light-sealed doors, or in
anatomical areas that provide natural darkness (e.g. gas-
trointestinal tract).
An often mentioned limitation of optical imaging, in
general, is the limited light penetration depth, and thereby,
the inability to image deep located tissue. This was nicely
illustrated by Chin et al. who calculated the reduction in
signal intensity from one 18F-isotope and one ICG mole-
cule in 1 mm of tissue, and found a reduction in signal
intensity of 77 and 39 %, respectively [34]. Because Cer-
enkov light is ‘blue-weighted’ and tissue absorption and
scattering are significantly increased for these wavelengths,
CLI is mainly applicable for imaging superficially located
tissue.
Table 3 Overview of published studies on CLI-guided surgery
Preclinical
or clinical





































Colon cancer 18F-FDG 24 MBq Clinically approved rigid laparoscope






Rectal cancer 18F-FDG 9.25 MBq/kg Clinically approved flexible fibre














N/A 18F-FDG 1.2 MBq Ivis optical imager 2 min [52]






Due to the half-life dependency of radiotracers, the
window in which CLI imaging needs to be performed to
obtain a sufficient SNR and image quality is limited. Well-
designed logistics and close collaboration between nuclear
medicine, radiology and surgical departments are, there-
fore, a prerequisite for the successful implementation of
CLI in current clinical and surgical workstreams.
A challenge for CLI-guided surgery in particular is the
radiation exposure to patients and theatre staff from using
radiopharmaceuticals. For patients, the effective dose from
a 300 MBq 18F-FDG injection is approximately 6 mSv;
this is comparable to the radiation dose for a typical chest
CT scan [46] and much lower than the 20–2500 mSv
radiation exposure from diagnostic and interventional flu-
oroscopy procedures [47]. Staff that work in close prox-
imity of the patient during surgery are also exposed to
radiation. The received radiation dose is dependent on the
time between injection and the start of the interventional
procedure, as well as the duration of the procedure. Various
groups have published staff radiation doses from 18F-FDG-
guided cancer surgery procedures [48–50], and have shown
that the radiation dose received per procedure is generally
low. For example, for a 105 min procedure starting
approximately 1 h after injection of 370 MBq 18F-FDG,
the exposure to the surgeon was 42 lSv [48]. However,
depending on the national annual occupational dose limit
(50 mSv in the United States, and 20 mSv in most other
countries) and type of procedure, the number of procedures
an individual can perform per year without exceeding the
permissible limits for professional workers may be
restricted. Regardless of these limits, there are strict
requirements for the use of radioactivity in clinical prac-
tice. For example, routine staff monitoring is a requisite for
each institution that conducts radiotracer guided proce-
dures, strict regulations need to be followed with regards to
clinical waste disposal and handling of radioactive speci-
mens, and staff need to attend radiation safety training
prior to participation in any procedure involving radiation
[51]. These requirements could hinder adoption of radio-
guided surgical technologies, especially in small district
hospitals that do not have access to nuclear medicine or
radiation safety departments. The aforementioned charac-
teristics of Cerenkov radiation and CLI in light of image-
guided surgical applications are summarised in Table 1.
Applications of CLI for image-guided surgery
and ongoing clinical trials
After it was first described in 2009, CLI has gained sig-
nificant scientific interest. A search of Embase and Medline
performed on 28 December 2015 using the keywords
‘Cerenkov Luminescence Imaging’ provided a total of 103
and 59 articles, respectively. Despite the limitations men-
tioned in the previous section, various research groups have
been successful in using CLI for image-guided surgical
interventions. An overview of the results published to date
is provided in Table 3. The majority of this work is pre-
clinical, although one clinical study was also published
recently. In addition to the tumour types shown in Table 3,
CLI-guided surgery could also be applied to other super-
ficial malignancies where precision surgery is essential for
preserving organ function, such as neoplasms in the oral
cavity and genital tract. However, publications of CLI in
these malignancies have not yet emerged.
The published studies show the ability to perform CLI-
guided surgical excision of tumours using a variety of
radiopharmaceuticals and different CLI embodiments,
including standard IVIS optical imaging systems, custom-
build flexible fibre endoscope systems, and clinically
approved rigid laparoscope and flexible endoscope systems
coupled to EMCCD cameras. An example that nicely
illustrates CLI-guided tumour excision is shown in Fig. 2.
An important advantage of using CLI in an endoscopic
setting is that these make use of anatomical dark chambers,
so that there is no interference from external light sources.
Besides, this technology can also be implemented in other
types of endoscopes, such as a bronchoscope or hystero-
scope, and future applications of CLI could, for example,
focus on lung cancer, endometrial cancer and metastatic
lymph nodes in the abdomen, pelvis and thorax.
CLI has also been successfully used for lymph node
identification and image-guided lymph node excision using
18F-FDG and 68Ga-labelled superparamagnetic iron oxide
particles (SPIONs) [52, 53].
Another interesting application of CLI, although not
directly related to image-guided surgery, has been pub-
lished by Spinelli et al. [54]. They imaged the thyroid gland
of a patient treated for hyperthyroidism who received
550 MBq of Iodine-131 (131I). Using an EMCCD camera
positioned in a light-tight room, tracer uptake in the thyroid
could be visualised with a 2-min exposure time. This
application is of clinical interest as imaging the uptake of
beta-emitting radiopharmaceuticals could provide a rapid
and inexpensive alternative for monitoring radiation doses
given to superficial organs.
The successful applications of CLI for image-guided
cancer surgery have resulted in several clinical studies that
are currently ongoing to evaluate the feasibility of this
technique in different tumour types. At Guy’s Hospital
(London, UK), a first-in-woman pilot study evaluates
intraoperative CLI for measuring tumour resection margins
and lymph node status in 30 patients undergoing breast-
conserving surgery (BCS) (ClinicalTrials.gov identifier
NCT02037269). Patients receive an intravenous standard






local excision (WLE) specimens and lymph nodes are
imaged within 1–3 h post-injection using an investigational
intraoperative CLI specimen camera (Lightpoint Medical
Ltd, UK) (Fig. 3). The investigational CLI camera consists
of a light-tight sample chamber, a radiation-shielded ther-
moelectrically-cooled EMCCD camera, and a f/0.95 lens.
The camera provides 8 9 8 cm field of view and 156 lm
intrinsic spatial resolution. Interim results show that ele-
vated radiances are detected in cancer compared to normal
breast tissue, and that the radiation exposure to surgical
staff is low [55, 56]. The results from comparing CLI
resection margin status and lymph node status to the gold-
standard, histopathology, are being prepared for publica-
tion at the time of writing. An example of a CLI image
from a WLE specimen that was scanned intraoperatively in
this clinical study is shown in Fig. 4. This image illustrates
that CLI provides high-resolution functional information
that allows surgeons to accurately assess tumour margins
during surgery.
To evaluate the effect of intraoperative 18F-FDG CLI
on reoperation rate and quality of life in BCS, a
randomised, controlled, multi-centre clinical study is
scheduled to commence in mid-2016 (ClinicalTrials.gov
identifier NCT02666079). This will run across an antici-
pated eight study sites in the UK and Germany, and use the
CE-marked LightPathTM Imaging System (Lightpoint
Medical Ltd, UK).
Another CLI study that is currently being conducted at
Guy’s Hospital and University College London Hospital
focusses on tumour margin evaluation in prostate cancer
(ClinicalTrials.gov identifier NCT02151097). Patients
undergoing a therapeutic radical prostatectomy receive a
370 MBq intravenous injection of 18F-Choline, and the
margins of the resected prostatectomy specimen are
imaged using the investigational intraoperative CLI cam-
era. The initial results show that intraoperative 18F-Choline
CLI is a feasible and low-risk procedure [57]. Elevated
radiances were present in all three primary tumours (tu-
mour-to-background ratio between 2.49 and 4.90), and CLI
imaging did not add additional time to surgery. The
assisting surgeon and scrub nurse received the highest body
dose; 110–180 and 40–80 lSv, respectively. Work is
Fig. 2 89Zr-DFO-trastuzumab CLI-guided tumour excision. a Empty
background image acquired prior to surgery. b Image acquired pre-
incision and c post-incision after removal of the skin. An elevated
tumour radiance is visible in the HER2/neu positive tumour (red
circle); 89Zr-DFO-trastuzumab is not taken up in the HER2/neu
negative tumour, and this tumour, therefore, does not display an
elevated radiance (blue circle). Note the increase in radiance due to a
reduction in tissue absorption and scattering after removal of the skin.
d Image of the surgical cavity after excision of the HER2/neu positive
tumour. An elevated radiance from the excised tumour specimen is
visible (red circle). No CLI signal is left at the excision site indicating
complete tumour resection. e Image of excised tumour alone. f Image
acquired straight after the surgical wound was closed with sutures.






currently being done to perform CLI imaging with the
Gallium-68 (68Ga) labelled prostate specific membrane
antigen (PSMA); a tracer that has strong advantages over
18F-Choline. PSMA is a cell surface target that is highly
expressed by nearly all prostate cancers, and 68Ga-PSMA
is, therefore, highly taken up in prostate cancer cells [58].
The Cerenkov radiance from 68Ga in tissue (g = 1.4) is
approximately 17 times higher compared to 18F, which
could facilitate a reduction in tracer dose, thereby lowering
the radiation exposure to theatre staff. The shorter 68Ga
half-life of 68 min means that contaminated surgical
instruments and surgical waste can be cleaned and disposed
much quicker. Another advantage is that besides imaging
the primary tumour, this tracer also holds promise for
visualising small lymph node metastases [59].
In addition to imaging resected WLE specimens ex vivo,
scanning the post-resection surgical cavity for residual
tumour that cannot be identified by visual inspection or
palpation could further aid achieving complete excision of
cancers. Detection of beta-radiation with handheld betas-
copes can identify small areas of malignant cells [60], and
clinical studies to test the combination of in vivo betascope
detection and ex vivo CLI will soon commence in gas-
trointestinal cancers (ClinicalTrials.gov identifier
NCT02446379) and breast cancer (ClinicalTrials.gov
identifier NCT02151071).
Another interesting application of CLI that is currently
being evaluated is the non-invasive detection of nodal
disease in a preoperative clinical setting (ClinicalTrials.gov
Identifier NCT01664936). In this observational study,
patients with lymphoma, leukaemia and metastatic lym-
phadenopathy scheduled to undergo standard clinical 18F-
FDG PET are included. CLI imaging is performed imme-
diately after the PET-scan in a dark room with a single-
photon sensitive camera positioned on a standard photog-
raphy tripod. The preliminary results of this study from
four patients (two lymphoma, one lung cancer and one
breast cancer) showed that metastatic lymph nodes in the
neck or axilla, located at 1.6 ± 0.5 cm under the skin, had
a statistically significant higher Cerenkov signal than
negative nodes (P = 0.02), and this finding strongly cor-
related with the results from PET [61]. Examples of patient
population that can benefit from accurate preoperative
identification of nodal disease are breast cancer patients
with involved lymph nodes. If positive lymph nodes are
identified preoperatively on CLI, their treatment could
convert from sentinel lymph node biopsy (SLNB) to
immediate axillary node clearance (ANC), thus preventing
the patient from undergoing an unnecessary surgical pro-
cedure. Alternatively, these patients may undergo neoad-
juvant chemotherapy followed by SLNB ± ANC.
Completion of this study will provide further insight in the
Fig. 3 Investigational intraoperative CLI imaging system used in
breast-conserving surgery trial. a Computer aided design (CAD)
rendering. The red object indicates the location of the tissue specimen
within the specimen chamber. b Schematic diagram showing: (1)
thermoelectrically-cooled EMCCD camera, (2) f/0.95 lens, (3) hinged
reflex mirror, (4) CMOS reference camera for anatomical imaging,
(5) specimen holder, (6) lead radiation shielding for EMCCD camera,
(7) focal zone, (8) fixed lens for reference camera, (9) filter wheel,
(10) LED RGB light array, (11) specimen chamber. The purple line
shows the optical paths for the EMCCD camera and the reference






real value of preoperative CLI imaging in aiding surgical
and medical decision-making.
Future technical developments
CLI has only recently been introduced as a modality for
imaging biological tissue, and this technique is, therefore,
still in its infancy. In the last decade, advances in optical
imaging devices in the biophotonics field have progressed
rapidly with the development of highly sensitive, charge-
coupled detectors (CCD), and current technological
developments focus on further increasing the sensitivity of
this imaging technology. This would facilitate a reduction
in acquisition time, and a reduction in the administered
radiopharmaceutical dose.
Improvements in detection sensitivity can be achieved
using more specialised optics and more sensitive detectors.
For example, the Schott-75 glass used in the CLI prototype
device of Liu et al. transmits only 40 % of light at 500 nm,
and impurities in the glass scintillate gamma photons,
which increase background noise [62]. The use of fused
silica, which transmits further in the violet and ultraviolet
wavelengths and has fewer impurities, would significantly
improve detection sensitivity.
In non-invasive CLI imaging, improvements in sensi-
tivity may be obtained by using CCD cameras that are
optimised to detect Cerenkov radiation in the UV for sur-
face imaging, or in the near-infrared (NIR) for deep
imaging. Spinelli et al. showed in a theoretical analysis that
a CCD detector with a quantum efficiency peak in the NIR
range could enhance the number of detected Cerenkov
photons by 35 %, especially for Cerenkov source located
deeper inside the tissue [63].
As already described in the section ‘Cerenkov radia-
tion’, Cerenkov light is mainly weighted towards the
ultraviolet (UV) and blue part of the spectrum. The high
absorption and scattering of these frequencies in bio-
logical tissue hampers CLI detection and quantification.
To overcome these limitations, current work focusses on
shifting the CLI emission spectrum to NIR wavelengths
by ways of Cerenkov radiation energy transfer (CRET).
Different research groups have done this using fluores-
cent quantum dots (QDs) or other fluorophores, in vitro
and in vivo animal models [64–66]. The broad excitation
spectrum that matches the CR spectrum and the narrow
emission spectrum make QDs specifically favourable.
NIR wavelength light would enable the use of spectral
filters to reduce interference from external light source,
thus facilitating the use of CLI in the intraoperative
suite. However, as with targeted fluorescent probes,
nanoparticles have not yet received marked approval,
and these approaches can, therefore, not be used clini-
cally yet.
Another interesting development in the field of CLI is
the acquisition of three-dimensional (3D) images by means
of Cerenkov luminescence tomography (CLT). Different
reconstruction approaches have been proposed using multi-
view [67, 68] or multi-spectral [69] imaging methods, all
showing a good correlation in radiotracer distribution on
CLT and PET or SPECT, respectively. Although each
method is currently still limited in terms of acquisition time
or spatial resolution and has only been used preclinically,
the ability of CLT to provide 3D information on the in vivo
distribution of radiopharmaceuticals could provide a more
Fig. 4 Wide local excision specimen from a patient with a 22 mm,
grade 2, ER?/HER2- invasive lobular carcinoma. The specimen was
incised to expose the primary tumour and margins of excision, and
subsequently scanned with the investigational CLI camera.
a Cerenkov image, b white-light photograph (black and white)
overlaid with Cerenkov signal. An increased radiance from the
tumour is visible (white arrows); mean radiance is 544.0 (SD 71.0)
photons/s/cm2/sr. The tumour-to-tissue background ratio is 2.44.
Phosphorescent signals from the pathology inks used to orientate the
specimen prior to incision are also present (open arrows). The
posterior margin (blue) and superior margin (green) are visible; both






accurate depiction of the location and extent of the tumour,
thereby aiding the surgeon in more accurate tumour
excision.
Conclusions
CLI is a fast-emerging optical imaging technology that
has rapidly progressed from bench to bedside. This rapid
development has been facilitated by the ability to use
clinically approved tumour-targeted PET tracers. Due to
its high-resolution, wide applicability across a range of
solid cancers and small size imaging equipment, CLI is
of particular interest in the field of image-guided sur-
gery. Challenges for the clinical implementation of this
technique include the low signal intensity, the require-
ment for light-tightness, the minute-scale image acqui-
sition times and the logistical issues associated with
using radiotracers intraoperatively. Preclinical studies
have shown that CLI can be successfully used to guide
surgical resection of tumours and lymph nodes, as well
as to detect cancerous lesions using Cerenkov lumines-
cence endoscopy. Several clinical studies on the preop-
erative and intraoperative use of CLI in breast cancer,
prostate cancer, gastrointestinal cancer and metastatic
lymph nodes are currently underway. Results from these
studies, together with ongoing developments in ultra-
sensitive camera technology will help drive widespread
clinical adoption. By improving the accuracy of surgical
resections, CLI has the potential to become a disruptive
technology in cancer surgery.
Acknowledgments The authors gratefully acknowledge grant fund-
ing from Innovate UK.
Compliance with ethical standards
Conflict of interest David Tuch is an employee of and a shareholder
in Lightpoint Medical Ltd. The other authors have no conflicts of
interest to disclose.
Ethical approval All procedures followed were in accordance with
the ethical standards of the responsible committee on human exper-
imentation (institutional and national) and with the Helsinki Decla-
ration of 1975, as revised in 2008. Informed consent was obtained
from all patients for being included in the study. All institutional and
national guidelines for the care and use of laboratory animals were
followed.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Holland JP, Normand G, Ruggiero A, Lewis JS, Grimm J (2011)
Intraoperative imaging of positron emission tomographic radio-
tracers using Cerenkov luminescence emissions. Mol Imaging
10(3):177–186 (171–173)
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global
cancer transitions according to the Human Development Index
(2008-2030): a population-based study. Lancet Oncol
13(8):790–801. doi:10.1016/s1470-2045(12)70211-5
3. Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P,
Aggarwal A, Balch C, BrennanMF, Dare A, D’Cruz A, Eggermont
AM, Fleming K, Gueye SM, Hagander L, Herrera CA, Holmer H,
Ilbawi AM, Jarnheimer A, Ji JF, Kingham TP, Liberman J, Leather
AJ, Meara JG, Mukhopadhyay S, Murthy SS, Omar S, Parham GP,
Pramesh CS, Riviello R, Rodin D, Santini L, Shrikhande SV,
Shrime M, Thomas R, Tsunoda AT, van de Velde C, Veronesi U,
Vijaykumar DK, Watters D, Wang S, Wu YL, Zeiton M, Pur-
ushotham A (2015) Global cancer surgery: delivering safe,
affordable, and timely cancer surgery. Lancet Oncol
16(11):1193–1224. doi:10.1016/s1470-2045(15)00223-5
4. Keereweer S, Van Driel PB, Snoeks TJ, Kerrebijn JD, Baaten-
burg de Jong RJ, Vahrmeijer AL, Sterenborg HJ, Lowik CW
(2013) Optical image-guided cancer surgery: challenges and
limitations. Clin Cancer Res 19(14):3745–3754. doi:10.1158/
1078-0432.ccr-12-3598
5. Waljee JF, Hu ES, Newman LA, Alderman AK (2008) Predictors
of re-excision among women undergoing breast-conserving sur-
gery for cancer. Ann Surg Oncol 15(5):1297–1303. doi:10.1245/
s10434-007-9777-x
6. Iczkowski KA, Lucia MS (2011) Frequency of positive surgical
margin at prostatectomy and its effect on patient outcome.
Prostate Cancer 2011:673021. doi:10.1155/2011/673021
7. McMahon J, O’Brien CJ, Pathak I, Hamill R, McNeil E, Ham-
mersley N, Gardiner S, Junor E (2003) Influence of condition of
surgical margins on local recurrence and disease-specific survival
in oral and oropharyngeal cancer. Br J Oral Maxillofac Surg
41(4):224–231
8. Menes TS, Tartter PI, Bleiweiss I, Godbold JH, Estabrook A,
Smith SR (2005) The consequence of multiple re-excisions to
obtain clear lumpectomy margins in breast cancer patients. Ann
Surg Oncol 12(11):881–885. doi:10.1245/aso.2005.03.021
9. Raziee HR, Cardoso R, Seevaratnam R, Mahar A, Helyer L, Law
C, Coburn N (2012) Systematic review of the predictors of
positive margins in gastric cancer surgery and the effect on sur-
vival. Gastric Cancer 15(Suppl 1):S116–124. doi:10.1007/
s10120-011-0112-7
10. Luryi AL, Chen MM, Mehra S, Roman SA, Sosa JA, Judson BL
(2015) Treatment factors associated with survival in early-stage
oral cavity cancer: analysis of 6830 cases from the National
Cancer Data Base. JAMA Otolaryngol Head Neck Surg
141(7):593–598. doi:10.1001/jamaoto.2015.0719
11. Silberstein JL, Eastham JA (2014) Significance and management
of positive surgical margins at the time of radical prostatectomy.
Indian J Urol 30(4):423–428. doi:10.4103/0970-1591.134240
12. Munshi A, Kakkar S, Bhutani R, Jalali R, Budrukkar A, Dinshaw
KA (2009) Factors influencing cosmetic outcome in breast con-
servation. Clin Oncol (R Coll Radiol) 21(4):285–293. doi:10.
1016/j.clon.2009.02.001
13. Zelefsky MJ, Harrison LB, Fass DE, Armstrong JG, Shah JP,
Strong EW (1993) Postoperative radiation therapy for squamous
cell carcinomas of the oral cavity and oropharynx: impact of
therapy on patients with positive surgical margins. Int J Radiat






14. Butler-Henderson K, Lee AH, Price RI, Waring K (2014) Intra-
operative assessment of margins in breast conserving therapy: a
systematic review. Breast 23(2):112–119. doi:10.1016/j.breast.
2014.01.002
15. Handgraaf HJ, Boonstra MC, Van Erkel AR, Bonsing BA, Putter
H, Van De Velde CJ, Vahrmeijer AL, Mieog JS (2014) Current
and future intraoperative imaging strategies to increase radical
resection rates in pancreatic cancer surgery. Biomed Res Int
2014:890230. doi:10.1155/2014/890230
16. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, Silva
MD (2009) Optical imaging of Cerenkov light generation from
positron-emitting radiotracers. Phys Med Biol 54(16):N355–365.
doi:10.1088/0031-9155/54/16/n01
17. Xu Y, Liu H, Cheng Z (2011) Harnessing the power of
radionuclides for optical imaging: Cerenkov luminescence
imaging. J Nucl Med 52(12):2009–2018. doi:10.2967/jnumed.
111.092965
18. Thorek D, Robertson R, Bacchus WA, Hahn J, Rothberg J,
Beattie BJ, Grimm J (2012) Cerenkov imaging—a new modality
for molecular imaging. Am J Nucl Med Mol Imaging
2(2):163–173
19. Das S, Thorek DL, Grimm J (2014) Cerenkov imaging. Adv
Cancer Res 124:213–234. doi:10.1016/b978-0-12-411638-2.
00006-9
20. Spinelli AE, Boschi F (2015) Novel biomedical applications of
Cerenkov radiation and radioluminescence imaging. Phys Med
31(2):120–129. doi:10.1016/j.ejmp.2014.12.003
21. Tanha K, Pashazadeh AM, Pogue BW (2015) Review of
biomedical Cerenkov luminescence imaging applications.
Biomed Opt Express 6(8):3053–3065. doi:10.1364/boe.6.003053
22. Mitchell GS, Gill RK, Boucher DL, Li C, Cherry SR (2011)
In vivo Cerenkov luminescence imaging: a new tool for molec-
ular imaging. Philos Trans A Math Phys Eng Sci
369(1955):4605–4619. doi:10.1098/rsta.2011.0271
23. Ma X, Wang J, Cheng Z (2014) Cerenkov radiation: a multi-
functional approach for biological sciences. Front Phys. doi:10.
3389/fphy.2014.00004
24. Jelley JV (1955) Cerenkov radiation and its applications. Br J
Appl Phys 6(7):227
25. Gill RK, Mitchell GS, Cherry SR (2015) Computed Cerenkov
luminescence yields for radionuclides used in biology and med-
icine. Phys Med Biol 60(11):4263–4280. doi:10.1088/0031-9155/
60/11/4263
26. Liu H, Ren G, Miao Z, Zhang X, Tang X, Han P, Gambhir SS,
Cheng Z (2010) Molecular optical imaging with radioactive
probes. PLoS ONE 5(3):e9470. doi:10.1371/journal.pone.
0009470
27. Ackerman NL, Graves EE (2012) The potential for Cerenkov
luminescence imaging of alpha-emitting radionuclides. Phys Med
Biol 57(3):771–783. doi:10.1088/0031-9155/57/3/771
28. Ruggiero A, Holland JP, Lewis JS, Grimm J (2010) Cerenkov
luminescence imaging of medical isotopes. J Nucl Med
51(7):1123–1130. doi:10.2967/jnumed.110.076521
29. Boschi F, Meo SL, Rossi PL, Calandrino R, Sbarbati A, Spinelli
AE (2011) Optical imaging of alpha emitters: simulations,
phantom, and in vivo results. J Biomed Opt 16(12):126011.
doi:10.1117/1.3663441
30. Spinelli AE, Lo Meo S, Calandrino R, Sbarbati A, Boschi F
(2011) Optical imaging of Tc-99 m-based tracers: in vitro and
in vivo results. J Biomed Opt 16(11):116023. doi:10.1117/1.
3653963
31. Boschi F, Pagliazzi M, Rossi B, Cecchini MP, Gorgoni G, Sal-
garello M, Spinelli AE (2013) Small-animal radionuclide lumi-
nescence imaging of thyroid and salivary glands with Tc99 m-
pertechnetate. J Biomed Opt 18(7):76005. doi:10.1117/1.jbo.18.
7.076005
32. Kondakov AK, Gubskiy IL, Znamenskiy IA, Chekhonin VP
(2014) Possibilities of optical imaging of the (99 m)Tc-based
radiopharmaceuticals. J Biomed Opt 19(4):046014. doi:10.1117/
1.jbo.19.4.046014
33. Pagliazzi M, Boschi F, Spinelli AE (2014) Imaging of lumines-
cence induced by beta and gamma emitters in conventional non-
scintillating materials. RSC Adv 4(26):13687–13692. doi:10.
1039/C3RA47102K
34. Chin PT, Welling MM, Meskers SC, Valdes Olmos RA, Tanke H,
van Leeuwen FW (2013) Optical imaging as an expansion of
nuclear medicine: Cerenkov-based luminescence vs fluorescence-
based luminescence. Eur J Nucl Med Mol Imaging
40(8):1283–1291. doi:10.1007/s00259-013-2408-9
35. Abouzied MM, Crawford ES, Nabi HA (2005) 18F-FDG imag-
ing: pitfalls and artifacts. J Nucl Med Technol 33(3):145–155
(quiz 162–143)
36. Rosenthal EL, Warram JM, Bland KI, Zinn KR (2015) The status
of contemporary image-guided modalities in oncologic surgery.
Ann Surg 261(1):46–55. doi:10.1097/sla.0000000000000622
37. Frangioni JV (2006) Translating in vivo diagnostics into clinical
reality. Nat Biotechnol 24(8):909–913. doi:10.1038/nbt0806-909
38. Agdeppa ED, Spilker ME (2009) A review of imaging agent
development. AAPS J 11(2):286–299. doi:10.1208/s12248-009-
9104-5
39. Nunn AD (2006) The cost of developing imaging agents for
routine clinical use. Invest Radiol 41(3):206–212. doi:10.1097/
01.rli.0000191370.52737.75
40. Mahajan A, Goh V, Basu S, Vaish R, Weeks AJ, Thakur MH,
Cook GJ (2015) Bench to bedside molecular functional imaging
in translational cancer medicine: to image or to imagine? Clin
Radiol 70(10):1060–1082. doi:10.1016/j.crad.2015.06.082
41. Franc BL, Mari C, Johnson D, Leong SP (2005) The role of a
positron- and high-energy gamma photon probe in intraoperative
localization of recurrent melanoma. Clin Nucl Med
30(12):787–791
42. Gulec SA (2007) PET probe-guided surgery. J Surg Oncol
96(4):353–357. doi:10.1002/jso.20862
43. Povoski SP, Chapman GJ, Murrey DA Jr, Lee R, Martin EW Jr,
Hall NC (2013) Intraoperative detection of (1)(8)F-FDG-avid
tissue sites using the increased probe counting efficiency of the
K-alpha probe design and variance-based statistical analysis with
the three-sigma criteria. BMC Cancer 13:98. doi:10.1186/1471-
2407-13-98
44. Mourant JR, Fuselier T, Boyer J, Johnson TM, Bigio IJ (1997)
Predictions and measurements of scattering and absorption over
broad wavelength ranges in tissue phantoms. Appl Opt
36(4):949–957
45. Weissleder R (2001) A clearer vision for in vivo imaging. Nat
Biotechnol 19(4):316–317. doi:10.1038/86684
46. Brix G, Nosske D, Lechel U (2014) Radiation exposure of
patients undergoing whole-body FDG-PET/CT examinations: an
update pursuant to the new ICRP recommendations. Nuk-
learmedizin 53(5):217–220. doi:10.3413/Nukmed-0663-14-04
47. Mahesh M (2001) Fluoroscopy: patient radiation exposure issues.
Radiographics 21(4):1033–1045. doi:10.1148/radiographics.21.4.
g01jl271033
48. Heckathorne E, Dimock C, Dahlbom M (2008) Radiation dose to
surgical staff from positron-emitter-based localization and
radiosurgery of tumors. Health Phys 95(2):220–226. doi:10.1097/
01.hp.0000310962.96089.44
49. Povoski SP, Sarikaya I, White WC, Marsh SG, Hall NC, Hinkle
GH, Martin EW Jr, Knopp MV (2008) Comprehensive evaluation
of occupational radiation exposure to intraoperative and periop-
erative personnel from 18F-FDG radioguided surgical proce-







50. Andersen PA, Chakera AH, Klausen TL, Binderup T, Grossjo-
hann HS, Friis E, Palnaes Hansen C, Schmidt G, Kjaer A, Hesse
B (2008) Radiation exposure to surgical staff during F-18-FDG-
guided cancer surgery. Eur J Nucl Med Mol Imaging
35(3):624–629. doi:10.1007/s00259-007-0532-0
51. ICRP (2007) Recommendations of the International Commission
on Radiological Protection. ICRP Publication 103, vol 37
52. Thorek DL, Abou DS, Beattie BJ, Bartlett RM, Huang R, Zan-
zonico PB, Grimm J (2012) Positron lymphography: multimodal,
high-resolution, dynamic mapping and resection of lymph nodes
after intradermal injection of 18F-FDG. J Nucl Med
53(9):1438–1445. doi:10.2967/jnumed.112.104349
53. Madru R, Tran TA, Axelsson J, Ingvar C, Bibic A, Stahlberg F,
Knutsson L, Strand SE (2013) (68)Ga-labeled superparamagnetic
iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/
Cherenkov luminescence imaging of sentinel lymph nodes. Am J
Nucl Med Mol Imaging 4(1):60–69
54. Spinelli AE, Ferdeghini M, Cavedon C, Zivelonghi E, Calandrino
R, Fenzi A, Sbarbati A, Boschi F (2013) First human
Cerenkography. J Biomed Opt 18(2):20502. doi:10.1117/1.jbo.
18.2.020502
55. Grootendorst M, Purushotham A (2015) Clinical feasibility of
intraoperative 18F-FDG Cerenkov Luminescence Imaging in
breast cancer surgery. J Nucl Med 56:S3
56. Grootendorst MR, Kothari A, Cariati M, Hamed H, Douek M,
Kovacs T, Cook G, Allen S, Sibley-Allen C, Britten A, Pawa A,
Nimmo F, Vyas K, Tuch D, Pinder S, Purushotham A (2015)
P094. Clinical feasibility of Cerenkov Luminescence Imaging
(CLI) for intraoperative assessment of tumour excision margins
and sentinel lymph node metastases in breast-conserving surgery.
Eur J Surg Oncol 41(6):S53. doi:10.1016/j.ejso.2015.03.132
57. Michel C, Freeman A, Jameson C, Waddington W, Tuch D,
Harboe M, Cathcart P (2015) P7: intra-operative margin detection
using Cerenkov Luminescence Imaging during radical prostate-
ctomy; Initial results from the PRIME study. Eur J Surg Oncol
41(11):S271. doi:10.1016/j.ejso.2015.08.112
58. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart
HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil
C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The
diagnostic value of PET/CT imaging with the (68)Ga-labelled
PSMA ligand HBED-CC in the diagnosis of recurrent prostate
cancer. Eur J Nucl Med Mol Imaging 42(2):197–209. doi:10.
1007/s00259-014-2949-6
59. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M,
Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Rothke
M (2014) Comparison of PET/CT and PET/MRI hybrid systems
using a 68 Ga-labelled PSMA ligand for the diagnosis of recur-
rent prostate cancer: initial experience. Eur J Nucl Med Mol
Imaging 41(5):887–897. doi:10.1007/s00259-013-2660-z
60. King MT, Carpenter CM, Sun C, Ma X, Le QT, Sunwoo JB,
Cheng Z, Pratx G, Xing L (2015) Beta-Radioluminescence
imaging: a comparative evaluation with Cerenkov luminescence
imaging. J Nucl Med 56(9):1458–1464. doi:10.2967/jnumed.115.
158337
61. Thorek DL, Riedl CC, Grimm J (2014) Clinical Cerenkov
luminescence imaging of (18)F-FDG. J Nucl Med 55(1):95–98.
doi:10.2967/jnumed.113.127266
62. Liu H, Carpenter CM, Jiang H, Pratx G, Sun C, Buchin MP,
Gambhir SS, Xing L, Cheng Z (2012) Intraoperative imaging of
tumors using Cerenkov luminescence endoscopy: a feasibility
experimental study. J Nucl Med 53(10):1579–1584. doi:10.2967/
jnumed.111.098541
63. Spinelli AE, Boschi F (2012) Optimizing in vivo small animal
Cerenkov luminescence imaging. J Biomed Opt 17(4):040506.
doi:10.1117/1.jbo.17.4.040506
64. Hu Z, Qu Y, Wang K, Zhang X, Zha J, Song T, Bao C, Liu H,
Wang Z, Wang J, Liu Z, Liu H, Tian J (2015) In vivo
nanoparticle-mediated radiopharmaceutical-excited fluorescence
molecular imaging. Nat Commun 6:7560. doi:10.1038/
ncomms8560
65. Thorek DL, Ogirala A, Beattie BJ, Grimm J (2013) Quantitative
imaging of disease signatures through radioactive decay signal
conversion. Nat Med 19(10):1345–1350. doi:10.1038/nm.3323
66. Lewis MA, Kodibagkar VD, Oz OK, Mason RP (2010) On the
potential for molecular imaging with Cerenkov luminescence.
Opt Lett 35(23):3889–3891. doi:10.1364/ol.35.003889
67. Li C, Mitchell GS, Cherry SR (2010) Cerenkov luminescence
tomography for small-animal imaging. Opt Lett
35(7):1109–1111. doi:10.1364/ol.35.001109
68. Hu Z, Liang J, Yang W, Fan W, Li C, Ma X, Chen X, Ma X, Li
X, Qu X, Wang J, Cao F, Tian J (2010) Experimental Cerenkov
luminescence tomography of the mouse model with SPECT
imaging validation. Opt Express 18(24):24441–24450. doi:10.
1364/oe.18.024441
69. Spinelli AE, Kuo C, Rice BW, Calandrino R, Marzola P, Sbarbati
A, Boschi F (2011) Multispectral Cerenkov luminescence
tomography for small animal optical imaging. Opt Express
19(13):12605–12618. doi:10.1364/oe.19.012605
70. Ma X, Yang W, Zhou S, Ma W, Hu Z, Liang J, Wang J (2012)
Study of penetration depth and resolution of Cerenkov lumines-
cence emitted from (18)F-FDG and (131)I. J Nucl Med 53:S1
71. Xu Y, Chang E, Liu H, Jiang H, Gambhir SS, Cheng Z (2012)
Proof-of-concept study of monitoring cancer drug therapy with
cerenkov luminescence imaging. J Nucl Med 53(2):312–317.
doi:10.2967/jnumed.111.094623
72. Zhang X, Kuo C, Moore A, Ran C (2013) In vivo optical imaging
of interscapular brown adipose tissue with (18)F-FDG via Cer-
enkov luminescence imaging. PLoS ONE 8(4):e62007. doi:10.
1371/journal.pone.0062007
73. Hu H, Cao X, Kang F, Wang M, Lin Y, Liu M, Li S, Yao L,
Liang J, Liang J, Nie Y, Chen X, Wang J, Wu K (2015) Feasi-
bility study of novel endoscopic Cerenkov luminescence imaging
system in detecting and quantifying gastrointestinal disease: first
human results. Eur Radiol 25(6):1814–1822. doi:10.1007/
s00330-014-3574-2
74. Robertson R, Germanos MS, Manfredi MG, Smith PG, Silva MD
(2011) Multimodal imaging with (18)F-FDG PET and Cerenkov
luminescence imaging after MLN4924 treatment in a human
lymphoma xenograft model. J Nucl Med 52(11):1764–1769.
doi:10.2967/jnumed.111.091710
75. Timmermand OV, Tran TA, Strand SE, Axelsson J (2015)
Intratherapeutic biokinetic measurements, dosimetry parameter
estimates, and monitoring of treatment efficacy using cerenkov
luminescence imaging in preclinical radionuclide therapy. J Nucl
Med 56(3):444–449. doi:10.2967/jnumed.114.148544
76. Cao X, Chen X, Kang F, Lin Y, Liu M, Hu H, Nie Y, Wu K,
Wang J, Liang J, Tian J (2014) Performance evaluation of
endoscopic Cerenkov luminescence imaging system: in vitro and
pseudotumor studies. Biomed Opt Express 5(10):3660–3670.
doi:10.1364/boe.5.003660
77. Natarajan A, Habte F, Liu H, Sathirachinda A, Hu X, Cheng Z,
Nagamine CM, Gambhir SS (2013) Evaluation of 89Zr-rituximab
tracer by Cerenkov luminescence imaging and correlation with
PET in a humanized transgenic mouse model to image NHL. Mol
Imaging Biol 15(4):468–475. doi:10.1007/s11307-013-0624-0
78. Hu Z, Yang W, Ma X, Ma W, Qu X, Liang J, Wang J, Tian J
(2013) Cerenkov luminescence tomography of aminopeptidase N
(APN/CD13) expression in mice bearing HT1080 tumors. Mol
Imaging 12(3):173–181
79. Lohrmann C, Zhang H, Thorek DL, Desai P, Zanzonico PB,






Cerenkov luminescence imaging for radiation dose calculation of
a (9)(0)Y-labeled gastrin-releasing peptide receptor antagonist.
J Nucl Med 56(5):805–811. doi:10.2967/jnumed.114.149054
80. Fan D, Zhang X, Zhong L, Liu X, Sun Y, Zhao H, Jia B, Liu Z,
Zhu Z, Shi J, Wang F (2015) (68)Ga-labeled 3PRGD2 for dual
PET and Cerenkov luminescence imaging of orthotopic human
glioblastoma. Bioconjug Chem 26(6):1054–1060. doi:10.1021/
acs.bioconjchem.5b00169
81. Carpenter CM, Ma X, Liu H, Sun C, Pratx G, Wang J, Gambhir
SS, Xing L, Cheng Z (2014) Cerenkov luminescence
endoscopy: improved molecular sensitivity with beta–emitting
radiotracers. J Nucl Med 55(11):1905–1909. doi:10.2967/
jnumed.114.139105
82. Song T, Liu X, Qu Y, Liu H, Bao C, Leng C, Hu Z, Wang K, Tian
J (2015) A novel endoscopic Cerenkov luminescence imaging








16.1 Introduction to Breast Cancer
16.1.1 Breast Cancer Key Facts
Breast cancer is by far the most common cancer among women, both in developed and in developing 
regions. Worldwide, an estimated 1.38 million women are diagnosed with the disease each year, making 
it the second most frequently diagnosed cancer after lung cancer (Ferlay et al. 2010). Among men, breast 
cancer is far less common, accounting for <1% of male cancer cases.
The incidence rate of breast cancer in women is higher in developed countries compared with other 
countries; Western Europe has the highest incidence rate (89.7 per 100,000) and Middle Africa the 
 lowest (19.3 per 100,000). A range of factors contribute to this variation in incidence rates, particularly 
relating to lifestyle (Youlden et al. 2012). In the United Kingdom and other parts of Western Europe, the 
incidence rate of breast cancer has increased by almost 50% in the period 1980–2008. Currently, the esti-
mated lifetime risk of developing breast cancer in women in the United Kingdom and the United States 
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Although the incidence rate is significantly higher in developed countries, the range in mortality 
rate is much less (6–19 per 100,000). This is due to a combination of factors, including earlier detec-
tion, favorable treatment modalities, and better access to these modalities. However, with approximately 
189,000 deaths per annum, breast cancer is, together with lung cancer, the most frequent cause of cancer 
death in women in the world, both in developed and developing regions.
Breast cancer therefore remains a large health problem, despite the fact that early diagnosis and more 
effective treatment have lowered the mortality rate in several countries. Therefore, there is a need to 
improve and optimize breast cancer care globally.
16.1.2 Types of Breast Cancer
There are various types of breast cancer, each type presents with different symptoms and characteristics. 
Although it was previously believed that in some cases breast cancer arose in the ducts and in other 
cases in the lobules, it is now clear that this disease derives from the terminal ductal lobular unit (TDLU) 
(see Figure 16.1). Breast cancer can be roughly divided into noninvasive and invasive cancer.
Noninvasive breast cancers are cancers that have not yet broken through the myoepithelial layer and 
basement membrane and hence are confined within the ductolobular units and are termed carcinoma 
in situ. Ductal carcinoma in situ (DCIS) is the most common form of in situ breast cancer and starts 
within the duct system, involving almost always a single duct within the breast. DCIS generally has 
no signs or symptoms, although a small number of patients may present with a small palpable lump. 
If DCIS cells die and pile up, tiny specks of calcium form within the broken cells (called calcifications 
or microcalcifications). These calcifications are usually very small and therefore difficult to identify by 
imaging techniques.
Over time, cancer cells can penetrate through the wall of the ducts and lobules, thereby infiltrating the 





















FIGURE 16.1 Schematic of the human mammary gland. (a) The human mammary gland is organized into lob-
ules interconnected by a network of branched ducts. (b) The ducts consist of an inner layer of luminal epithelial 
cells and an outer layer of myoepithelial cells. The large duct separates into extralobular ducts, which then separate 
into intralobular ducts. The main functional unit of the breast is the TDLU that consists of the lobule, intralobular 
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and breast cancer in general, is invasive ductal carcinoma (IDC). IDC is diagnosed in more than 80% of all 
breast cancer patients (Cancer Research UK 2012b) and is more common as women grow older. Invasive 
lobular carcinoma is the second most common invasive cancer and accounts for 10% of all invasive cancers.
Invasive carcinomas tend to form hard, palpable lesions, while DCIS is mostly nonpalpable. This pres-
ents additional challenges for accurate preoperative and intraoperative identification.
16.1.3 Breast Cancer Surgery
Most women with breast cancer undergo some type of surgery to remove the primary tumor, which has 
moved from radical to more conservative over the last century. Breast cancer surgery can roughly be 
divided in breast-conserving surgery (BCS) and mastectomy (i.e., the complete removal of the breast). 
The choice between BCS or mastectomy depends on several factors, including the size of the tumor rela-
tive to the size of the breast, its location, the presence of diffuse microcalcifications (DCIS), and patient’s 
preference. The purpose of adopting BCS is to minimize the psychological and physical morbidity asso-
ciated with mastectomy.
16.1.3.1 Breast-Conserving Surgery
A combination of patient and physician awareness and increased use of screening mammography has sig-
nificantly impacted on the stage at which cancers are diagnosed. Women with stage 0 (carcinoma in situ), 
stage 1 (invasive tumor <2 cm), or stage 2 (invasive tumor <5 cm) are ideal candidates for BCS, and due to 
the earlier stage of diagnoses, approximately two-thirds of newly diagnosed breast cancer patients in the 
United Kingdom and the United States undergo BCS as initial treatment (Jeevan et al. 2011; Katipamula 
et al. 2009).
The aim of BCS is to remove the primary tumor while conserving as much healthy breast tissue if pos-
sible to provide good cosmetic outcome and to reduce physical trauma. BCS is often followed by a course of 
postoperative radiotherapy, and the combination of BCS with radiotherapy provides similar survival rates 
to those achieved with mastectomy alone for women with invasive disease (Fisher et al. 2002). However, 
incomplete removal of the tumor results in involved tumor margins and involved margins are one of the 
main risk factors for local recurrence and affect disease-free survival (Singletary 2002; Veronesi et al. 2002).
There are various imaging techniques used to diagnose breast cancer, including x-ray mammogra-
phy, ultrasound (US) imaging, and magnetic resonance imaging (MRI). These preoperative imaging 
techniques provide information on the location and size of the tumor, but these techniques have limited 
intraoperative capabilities. The correlation between tumor size estimation with preoperative imaging 
techniques and histopathological size remains suboptimal, thereby creating an element of uncertainty 
when deciding how much tissue is to be excised during surgery. Hence, surgeons can use this informa-
tion only as a rough guide to define the margins of the tumor.
The techniques used to obtain intraoperative information on tumor margins depend on whether the 
tumor is palpable or nonpalpable. Palpable tumors are localized with the tip of the surgeon’s thumb and 
index fingers, a technique known as palpation-guided surgery. By feeling for the tumor, the surgeon can 
determine the extent of the tumor, and after the boundaries are identified, the surgeon aims to excise the 
tumor together with a region of healthy tissue. One can appreciate that this is a very subjective method. 
Nonpalpable tumors cannot be identified by touch, so additional techniques are required to localize 
the lesion and to determine its boundaries. The various techniques that are available are outlined in 
Section 16.2 and make use of a wire, radioactive material, or US waves. The surgeon uses these tech-
niques to guide the excision of the lesion, thereby aiming to obtain an adequate margin of healthy tissue.
The aforementioned surgical guidance techniques provide macroscopic information on tumor mar-
gins, and in order to determine if the tumor is excised completely, the tumor margins of the excised 
specimen need to be analyzed on a microscopic level. These so-called microscopic margins are deter-
minative to whether a procedure is considered successful. There are currently two techniques available 
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However, as explained in more detail in Section 16.2, both techniques have disadvantages, and there-
fore, only a small number of hospitals utilize these techniques.
The golden standard for assessing microscopic margins is postoperative histological examination. 
During this procedure, the pathologist inks the surface of the excised specimen, and the closest distance 
of an inked surface to tumor cells is reported within several days after surgery. Most institutions con-
sider a margin width of >2 mm as negative, 0–2 mm as close, and 0 mm as positive (Houssami et al. 2010; 
Morrow et al. 2012) (see Figure 16.2). Although there is no consensus on what constitutes an adequate 
microscopic margin, the majority of centers advise patients with positive or close margins to undergo a 
reoperation to remove residual disease.
During a reoperation, the surgeon reopens the site of the original surgery and removes a further slice 
of tissue of the margin reported to be involved. The reexcised tissue then undergoes a similar postop-
erative histological examination procedure as the BCS specimen to determine if all the cancer has been 
excised, and a second or third reexcision operation may be required if the reexcision did not result in 
clear margins. A mastectomy is performed in cases where an attempt to reexcise the residual disease 
fails multiple times. Approximately 10% of patients with BCS as primary surgery eventually undergo a 
mastectomy to obtain clear margins (McCahill et al. 2012; Waljee et al. 2008).
The need to perform a reoperation in patients with involved margins after initial BCS has various 
undesirable consequences. It most likely will cause a delay in adjuvant treatment, and there is evi-
dence that patients with positive margins after initial BCS have a higher chance of local recurrence 
(Kouzminova et al. 2009). Reoperations will result in a significantly poorer cosmetic outcome, for both 
reexcisions and mastectomies (Munshi et al. 2009). The additional procedures also increase the health 
economic costs, thus representing a burden to the health-care system. The last and probably the most 
important consequence of reoperations is the emotional distress patients experience after being told 
their cancer is not removed completely. This may result in delays in recovery, causing adverse socioeco-
nomic effects because patients cannot resume work or other activities.
Due to a lack of adequate intraoperative tools to identify and assess tumor margins in current clinical 
care, positive resection margins have been reported in up to 41% of patients and are more likely in 
patients with a carcinoma in situ component (Jeevan et al. 2012; Talsma et al. 2011; Waljee et al. 2008). 
Because of the high percentage of patients that currently need to undergo a reoperation as a consequence 
of positive margins, there is a clear need for new, intraoperative techniques to accurately assess resection 
margins in patients undergoing BCS.
16.1.3.2 Mastectomy
A mastectomy is a surgical procedure that involves removal of all breast tissue to ensure no disease is left 
behind. This procedure is more extensive than BCS and is associated with more postsurgery side effects 
and a longer recovery time. Reconstruction surgery can be carried out at the same time as the mastectomy 
(immediate reconstruction) or sometime after the initial mastectomy surgery (delayed reconstruction).
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Mastectomies are generally performed in patients that are not suitable for BCS, including patients 
with a large tumor (particularly in women with small breasts), a tumor in the middle of the breast, mul-
tifocal disease or areas of DCIS in the rest of the breast, or in patients where the initial BCS along with 
one or more reexcisions has not completely removed the cancer.
Due to the earlier stage at which breast cancer is currently being diagnosed in most developed coun-
tries, mastectomies are performed much less often than BCS as initial treatment.
There are different types of mastectomies, varying from removal of only breast tissue to a more radi-
cal procedure where in addition to removal of the breast, the lymph nodes in the armpit (axilla) and 
the chest wall muscles under the breast are also removed. Each type of mastectomy encompasses the 
removal of all breast tissue, and therefore positive tumor margins resulting from incomplete removal of 
the tumor rarely occur.
16.1.4 Conclusion
A key problem that currently hampers the success of BCS is the lack of accurate, real-time techniques 
that provide intraoperative information on tumor margins. This leads to reexcision in up to 41% of 
patients. Reoperations have a significant physical and emotional impact on patients and cause a finan-
cial burden for the health-care sector. Therefore, there is a need for a technique that can accurately assess 
tumor margins intraoperatively, thereby reducing the number of reoperations.
THz radiation possesses a number of properties that make it a viable technique for tumor margin 
assessment. Section 16.3 will focus on the interaction of THz radiation with human breast tissue and 
cancer and the results that have been obtained with different THz imaging devices. The other tech-
niques for intraoperative assessment of tumor margins are outlined in Section 16.2.
16.2  Other Techniques for Intraoperative 
Assessment of Tumor Margins
There are a number of techniques, either in current use, in clinical trials, or in the research phase, that 
provide the surgeon with intraoperative information on tumor margins. All these techniques aim to 
reduce the reexcision rate. However, in choosing or developing such techniques, there are important 
clinical criteria to consider, including time, detection depth, and sampling area.
This paragraph gives an overview of the performance, advantages, and limitations of techniques that 
are currently available as well as techniques that are in the development phase. The currently available 
techniques can be divided into intraoperative tumor localization techniques and intraoperative patho-
logical techniques. The former provides information on tumor margins at a macroscopic level, while the 
latter assesses tumor margins microscopically.
16.2.1 Currently Available Intraoperative Tumor Localization Techniques
16.2.1.1 Wire-Guided Localization
Approximately 35% of breast cancers smaller than 5 cm are nonpalpable (Lovrics et al. 2009; Skinner 
et al. 2001), and the most commonly used technique to determine the location of these tumors is wire-
guided localization (WGL).
The wire used for localizing the lesion is 20–25 cm long and bent at the tip to form a V-shaped hook. 
A needle is used to target the lesion guided by x-ray, US, or MRI. After introduction of the needle, a wire 
is threaded down through the needle (hook end first) to lodge at the target tissue. The needle is then 
removed, and the hook expands upon removal of the needle, thereby anchoring the wire in the lesion. 
Mammography is used to confirm the wire is positioned correctly, and after confirmation, the external 
































302 Terahertz Biomedical Applications
During the operation, the surgeon views the mammograms to get an indication of the tumor 
localization, and the wire is used as a guide to find the nonpalpable lesion. Since the tip of the wire is 
in the lesion, the surgeon needs to deviate from the wire before he or she reaches the tip to obtain an 
adequate margin of healthy tissue.
Literature shows that 30%–37% of wire-guided procedures result in positive margins (Gajdos et al. 
2002; Lovrics et al. 2009). From these results can be concluded that WGL is suboptimal in aiding com-
plete excision of nonpalpable breast cancers.
One of the reasons for the high positive margin rate is that the guide wire does not provide a clear 
three-dimensional perspective on the various tumor edges, and the required extent of resection needed 
to achieve negative margins still remains an estimate. Furthermore, the guide wire is prone to move 
before or during surgery and may therefore provide inadequate information on tumor localization. 
Other disadvantages include the time required to place the wire and the associated patient discomfort, 
resulting in increased levels of stress and arousal (Kelly and Winslow 1996). Because of the high reexci-
sion rates and patient discomfort, other techniques have been developed to assess tumor margins.
16.2.1.2 Radioisotope Labeled Localization
Radioisotope labeled localization is an alternative technique to WGL for intraoperative localization and 
simultaneous resection of nonpalpable breast tumors. There are two variations of this technique: radio-
guided occult lesion localization (ROLL) and radioguided seed localization (RSL). In ROLL, a radioac-
tive tracer is injected into the tumor preoperatively, and a gamma probe is used to guide the resection 
during surgery. To facilitate correct positioning, the injection of the radioactive tracer is performed 
under stereotactic or ultrasonographic guidance. After the primary tumor is excised, the gamma probe 
can be used to search and identify residual disease in the breast cavity. RSL is almost identical to ROLL, 
but instead of a radiotracer, a radioactive seed is used.
Numerous studies have been performed to evaluate the oncologic safety of the ROLL and RSL 
procedures (Barentsz et al. 2013; Donker et al. 2013; Hughes et al. 2008; Lovrics et al. 2011; Medina-
Franco et al. 2008; Monti et al. 2007; Sarlos et al. 2009; Thind et al. 2011). Positive margins varied 
from 4% to 27%, although Sarlos et al. reported a 35% positive margin rate in patients with DCIS. 
Hughes et al. compared RSL with WGL and found significantly lower positive margin rates with 
RSL as compared to wire localization, while Lovrics et al. reported similar positive margin rates. 
A recently published large multicenter clinical trial compared ROLL to WGL in patients with invasive 
breast carcinoma (Postma et al. 2012). They found similar positive margin rates for ROLL and WGL, 
and ROLL was considered comparable in terms of complete tumor excision and reexcision rates. 
However, they found a larger excision volume in the ROLL group and concluded that ROLL cannot 
replace WGL as standard of care.
Although the oncologic safety of ROLL and RSL might be similar to WGL, both techniques have 
several advantages over WGL. They are easy-to-perform radiological and surgical procedures, and the 
tumor can be identified in three dimensions allowing for more precise excision. More importantly, 
both techniques are more patient friendly; hence, the pain rankings reported by patients are signifi-
cantly lower (Lovrics et al. 2011; Rampaul et al. 2004). However, these guidance tools are still invasive 
like WGL and therefore associated with patient discomfort. Moreover, the use of radioactive material 
exposes patients and health-care workers to radiation, is heavenly controlled by legislation, and is avail-
able only in hospitals with a nuclear medicine department.
16.2.1.3 Intraoperative Ultrasound–Guided Resection
Intraoperative US (IOUS) is a method of excising a tumor under direct visualization, thus providing the 
surgeon with real-time information of the tumor extent.
Immediately after excision, ex vivo US examination of the specimen is performed in the operating 
theater to check the completeness of the specimen. In case of positive or close margins, residual disease 
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The COBALT trial compared IOUS-guided resection with palpation-guided resection for invasive 
palpable tumors and found tumor-involved margins in 11% of the IOUS-guided group and 28% in the 
palpation-guided group (p = 0.0031) (Krekel et al. 2012). Besides, IOUS-guided surgery resulted in sig-
nificantly smaller excision volumes. Moore et al. also found a significant improvement in margin status 
in IOUS-guided surgery compared to palpation-guided surgery (Moore et al. 2001).
For nonpalpable invasive breast cancers, positive margins were found after IOUS-guided surgery in 
4.3%–19% of patients (Bennett et al. 2005; Krekel et al. 2011; Ngô et al. 2007; Rahusen et al. 2002; Snider 
and Morrison 1999). Rahusen et al. reported significantly improved margin status using IOUS com-
pared to WGL (11% vs. 45%, respectively), and this finding was supported by Krekel et al. Besides, Snider 
et al. found a smaller resection volume compared to WGL.
These results indicate that IOUS-guided surgery can lower the proportion of tumor-involved resec-
tion margins compared to palpation-guided and wire-guided localization, while decreasing resection 
volumes. US is widely available, does not require radiation, and minimizes patient trauma and discom-
fort as there is no need for additional interventions (i.e., a wire or material). However, IOUS also has 
some important disadvantages. The technique is not suitable for detecting microcalcifications as these 
are not sonographically visible, and DCIS can therefore not be identified. Besides, the lesion must be 
above a certain size to be imaged, and it is shown that 50% of nonpalpable tumors are missed (Klimberg 
2003). Other possible restrictions are that the technique does not have the sensitivity and resolution to 
find residual disease after excision of the primary tumor and that a radiologist must be present in the 
operating theater during the procedure.
16.2.1.4 Intraoperative Specimen Radiography
Intraoperative specimen radiography is a technique often used to image the excised specimen in patients 
with nonpalpable breast tumors. In conventional specimen radiography, the surgical specimen is trans-
ported from the operating theater to the diagnostic imaging department, while intraoperative digital 
specimen mammography (IDSM) entails imaging in the operating theater. The former can entail sig-
nificant time for transport (≈30 min). If specimen radiographs reveal involved margins, the surgeon can 
shave the associated cavity edges to remove any residual malignant disease.
In 2007, Kaufman et al. compared IDSM with CRF for assessing tumor margins. The sensitivity of 
IDSM and CRF for detecting positive margins was 36% and 31%; specificity was 71% and 74% (Kaufman 
et al. 2007). More recently, Bathla et al. evaluated the performance of an IDSM device for intraoperative 
margin assessment and found a sensitivity and specificity of 58.5% and 91.8%, respectively (Bathla et al. 
2011). The positive predictive value was 82.7%; the negative predictive value was 76.7%.
A disadvantage of intraoperative specimen radiography is that in situ cancers will show up only if 
there is sufficient contrast or microcalcifications associated with it. Thus, even if the tumor seems to be 
adequately removed on the radiography image, reoperation may still be needed if histopathology identi-
fies an in situ component near or at the margin. Besides, specimen radiography provides information on 
margin status at a macroscopic level and can therefore not be relied on solely.
16.2.2 Currently Available Intraoperative Pathological Techniques
A disadvantage related to all the aforementioned techniques is that no information is provided on the 
microscopic margin status. Therefore, some centers use additional intraoperative pathological techniques 
to provide the surgeons with information on the microscopic extent of the tumor. The most commonly used 
intraoperative pathological techniques are frozen section analysis (FSA) and touch imprint cytology (TIC).
16.2.2.1 Frozen Section Analysis
FSA is used to intraoperatively assess microscopic margin status in many oncologic procedures, 
including breast cancer. While the patient is still on the operating table, the excised specimen is inked, 
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This takes approximately 30 min. Surgery continues during the pathological analysis, and the surgeon 
closes the wound if the pathological result takes longer than the surgical procedure. In case involved 
margins are identified, the wound of the patient is reopened and additional cavity shaving is performed.
Reported sensitivity rates for the assessment of resection margin status range between 73% and 83%, 
whereas specificity rates are in between 87.5% and 99% (Esbona and Wilke 2012; Hunt et al. 2007; Olson 
et al. 2007; Weber et al. 2008). The lower sensitivity is mainly a result of unreliable detection of small 
tumors (<10 mm) and microcalcifications (i.e., DCIS). Two large studies evaluated the number of reop-
erations after FSA, and both studies demonstrated that frozen section leads to low reoperation rates 
(9% and 10%, respectively) (Esbona and Wilke 2012; Riedl et al. 2009). Apart from the unreliable detec-
tion of small tumors and microcalcifications, FSA does not provide the surgeon with information on 
tumor extent prior to excision, therefore not aiding in decreasing resection volumes. Furthermore, FSA 
is labor intensive and requires an experienced on-site pathologist and may therefore not be performed 
in hospitals where the pathology department is located outside of the hospital. Besides, FSA requires a 
relatively large part of the specimen, which may compromise postoperative evaluation by the patholo-
gist, and freezing artifacts are common in fatty tissue, which may interfere with accurate identification 
of cell types.
16.2.2.2 Touch Imprint Cytology
Intraoperative TIC is a simple and rapid alternative to FSA. The excised specimen is oriented and pressed 
onto specifically coated slides, making an imprint of all six margins. Cells sticking to the glass surface 
are then fixed, stained, and microscopically analyzed (Klimberg et al. 1998). This technique is based on 
the difference in cellular surface characteristics between malignant cells and mammary fat; malignant 
cells will adhere to the slides and adipose cells will not.
The results of TIC are reported within 15 min, which is definitely quicker than FSA, and for most 
surgeries, the result is received before the wound is closed. Another advantage over FSA is that it 
saves tissue for permanent sectioning and histopathological examination, and that it is less expensive 
than FSA.
Esbona et al. performed a systematic review on reexcision rates, sensitivity, and specificity of TIC 
and compared the performance with FSA and postoperative histopathological evaluation (Esbona and 
Wilke 2012). The reexcision rate of TIC was 11%, against 10% and 35% for FSA and postoperative histo-
pathology. The sensitivity and specificity were 72% and 92%, respectively, compared to 83% and 95% for 
FSA. In line with the results for FSA as described previously, most false-negative results with TIC were 
observed in tumors with in situ disease. However, there was a greater degree of variation present in the 
sensitivity of TIC. The difference in cytopathological proficiency between pathologists may account for 
the degree of variation, as the technique requires extensive cytology expertise.
Although the results of this technique seem very promising, so far it has not been as widely used as 
FSA. One of the explanations is that close margins are not taken into account, because only superficial 
tumor cells are detected with the technique. Therefore, no information is gathered on margin width, 
multifocality, and quantity of cancerous cells approaching the cut edge (Pleijhuis et al. 2009). There 
is also the potential of artifacts caused by draught and surface cautery, and TIC seems less effective in 
identifying lobular carcinoma (Valdes et al. 2007).
16.2.3 Techniques under Development
The previously described techniques all have certain disadvantages and result in positive resection 
margins in a significant amount of patients. The main disadvantage of all these techniques is the 
inaccuracy in detecting DCIS, and the need to detect DCIS is significant as it is considered a more 
challenging intraoperative assessment target. Currently, several techniques are being developed for 
assessing tumor margins intraoperatively, with a particular focus on techniques that are able to identify 
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16.2.3.1 Radiofrequency Spectroscopy: MarginProbe®
The MarginProbe (Dune Medical Devices, Framingham, USA) uses radiofrequency spectroscopy to 
detect minute differences in electromagnetic properties of tissue with and without cancer, and provides 
this key information as a positive or negative readout to breast surgeons intraoperatively. The device 
consists of a console and a disposable handheld probe with an effective measurement area of 7 mm and 
a detection depth of about 1 mm.
A prospective, randomized, multicenter trial was conducted to evaluate the performance of the 
device in assessing surgical margins (Allweis et al. 2008). After excision of the main lumpectomy speci-
men, patients were randomized to a device and a control arm. In the device arm, the surgeon applied 
the device to the six margins (medial, lateral, superior, inferior, deep, and anterior), and reexcised tissue 
if the device indicated positive margins. In the device arm, 60% of the involved margins were correctly 
identified and reexcised, compared with 40% in the control arm (p = 0.044). The percentage of patients 
with correctly identified margins in a nonpalpable subgroup was also higher (69% vs. 39%, respectively). 
The need for reoperation in case of positive margins was not defined or dictated by the study, so the 
actual decrease in reexcision rate from using the device cannot be determined from this study.
One of the advantages of the technique is the potential to detect DCIS (Pappo et al. 2010; Thill et al. 2011), 
so the MarginProbe can be of special interest for this group of patients. Other advantages include a short 
measurement time (1–2 s per measurement) and controlled, user-independent tissue measurements using a 
vacuum-based mechanism. The main disadvantage of this technique is that the performance of the device 
decreases for tissue with a more heterogeneous composition, that is, the probe is less sensitive to measure-
ment sites with a small cancer feature size (Pappo et al. 2010). Consequently, patients with small tumors 
might still need to undergo a second surgery to obtain clear margins. Besides, the technique samples only 
an area of 7 mm, and positive margins can be missed if the surgeon does not accurately cover each entire 
margin.
16.2.3.2 Diffuse Reflectance Spectroscopy
Diffuse reflectance spectroscopy (DRS) can identify tissue characteristics by measuring their intrinsic 
light absorption and scattering properties at different wavelengths in the UV–visible range. Diffuse 
reflectance spectra can be obtained by illuminating tissue with a selected light spectrum, and these 
spectra reflect the absorption and scattering properties of the tissue. The absorption coefficient is 
directly related to the concentration of physiologically relevant absorbers in the tissue, which include 
oxygenated and deoxygenated hemoglobin. The scattering coefficient reflects the size and density of 
scattering centers in tissue, such as cells and nuclei. Since changes in human tissue associated with 
malignant transformation include alterations in cellular composition, metabolic rate, and tissue mor-
phologic characters, the reflectance spectra can be used to differentiate tumor from normal tissue.
Bigio et al. performed one of the earliest studies on the applicability of DRS for assessing tumor mar-
gins (Bigio et al. 2000). They used elastic scattering spectroscopy (a variant of DRS) implemented in a 
fiber-optic probe assembly and measured diffuse reflectance spectra from the tumor cavity in vivo after 
resection. The probe had a sensing depth of 300 μm, which is sufficient to detect disease at the surface. 
The measured tissue was biopsied for pathologic correlation, and the spectra were fed into classification 
algorithms to provide estimations for the presence of residual disease. They measured 72 breast tissue 
sites, and the sensitivity and specificity were 69% and 85%, respectively.
More recently, a biomedical group from the Duke University has developed a diffuse reflectance imag-
ing device and studied 55 resection margins in an ex vivo setting in 48 patients. They were able to detect 
positive margins, regardless of pathology or depth from the margin, with 79% sensitivity and 67% speci-
ficity (Ramanujam et al. 2009; Wilke et al. 2009) (see Figure 16.3). Interestingly, positive margins for DCIS 
were correctly identified in eight of nine margins, corresponding with a sensitivity of 89%. However, of 
the eight patients who received neoadjuvant therapy, only four patients had their margins assessed cor-
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Another group combined diffuse reflectance and autofluorescence spectroscopy (Keller et al. 2010). 
Excised specimens were measured by a fiber-optic probe, and diffuse reflectance and autofluorescence 
spectra were then classified as benign or malign using a two-part classification method. Tissues from 
32 patients were measured, and the sensitivity and specificity were 85% and 96%, respectively.
These preliminary results suggest that DRS (in combination with autofluorescence) could provide a 
useful tool to assess tumor margins intraoperatively. The potential to detect DCIS is of particular inter-
est, as all currently available techniques lack the ability to accurately detect DCIS. However, due to the 
small scan area of the current probes, which is restricted by the output of the optical fibers, only a small 
tissue volume can be scanned. Hence, in order to cover the entire margin, multiple sites must be mea-
sured, which is time consuming and subject to user errors. Therefore, an important challenge for this 
technique is to increase the scan volume to make the technique suitable for intraoperative use.
16.2.3.3 Spatially Offset Raman Spectroscopy
Another optical technique that can potentially be used for breast tumor margin evaluation is Raman 
spectroscopy. Raman spectroscopy is a form of vibrational spectroscopy. Laser light (mostly in the 
visible, near-infrared (NIR), or near-ultraviolet range) is nonelastically scattered from molecules that 
are excited by the incident light, and this inelastic scattering can be used to identify organic mol-
ecules, such as fat, collagen, cell cytoplasm, and nucleus. These molecules have been shown to provide 
a signature associated with abnormality (Frank et al. 1995), thus providing the possibility for margin 
assessment.
Keller et al. used spatially offset Raman spectroscopy (SORS), which is a variant of Raman spectros-
copy, for breast tumor surgical margin evaluation (Keller et al. 2011). They developed a SORS probe with 
one source fiber and multiple detection fibers, allowing the detection of spectral signatures from tumor 
within the first 2 mm in depth from the tissue surface. A total of 35 excised specimens were scanned: 
15  samples with negative margins (>2 mm) and 20 samples with positive invasive tumor margins 
(<2 mm). The spectra were then classified to predict if a margin was positive or negative. They found a 
sensitivity, specificity, negative predictive value, and positive predictive value of 95%, 100%, 94%, and 
100%. Although their findings are based on a small data set and did not include actual reexcision rates, 
their results seem very promising. However, the diameter of their probe is approximately 5 mm, thus 
covering only a small tissue area. The biggest challenge for this technique is therefore similar to DRS: 
adapt the probe to interrogate larger areas of tissue in order to meet the clinical criteria of sufficient area 
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FIGURE 16.3 (See color insert.) Diffuse reflectance spectroscopy for tumor margin assessment. Parameter 
maps per margin were obtained from the ratio of β-carotene (absorption parameter) and the wavelength-averaged 
reduced scattering coefficient (scattering parameter). Blue areas generally represent healthy tissue, whereas red 
areas represent tumor. (a) Pathologically confirmed negative margin. (b) Pathologically confirmed margin posi-
tive for DCIS. (c) Pathologically confirmed margin positive for IDC. (Reproduced from Wilke, L. G., J. Brown, 
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16.2.3.4 Optical Coherence Tomography
In the last decade, optical coherence tomography (OCT) has emerged as a high-resolution optical diag-
nostic imaging modality that is currently being used in ophthalmology and dermatology. More recently, 
OCT has been investigated as a technique to assess breast tumor margins. OCT is an optical equivalent 
of US, but instead of acoustic waves, it is based on the reflection of light from a low-coherence broadband 
light source (typically employing NIR light). By measuring backscattered or back-reflected light, cross-
sectional tomographic images of the tissue microstructure can be obtained with a similar resolution as 
histopathology (μm).
Nguyen et al. at the University of Illinois used OCT images to intraoperatively assess exposed tumor 
margins (Nguyen et al. 2009). Their system operates in the spectral region around 1300 nm, providing 
a lateral and axial resolution of 35 and 5.9 μm in tissue, respectively. They scanned excised specimens 
(including DCIS) from 37 patients. The OCT images from the first 17 patients were used to establish 
imaging protocols and OCT criteria for identifying positive margins, and the images from the remain-
ing patients were used for the study set. Eleven margins were identified as positive and nine as negative 
on OCT imaging, giving a sensitivity, specificity, and overall accuracy of 100%, 82%, and 90%, respec-
tively. The increased scattering, due to strong reflections from tightly packed cells, was the main feature 
for classifying margins as positive.
The main challenge for this technique is to decrease acquisition and processing time, allowing to 
scan larger areas in a shorter time interval. Recent developments in OCT technology may make it pos-
sible to decrease scanning times, but these advances will result in significant increases in data volume. 
This requires automated classification algorithms, as individual analysis and interpretation of the OCT 
images would be too time consuming. However, once these challenges are overcome, the technique may 
provide useful intraoperative information to reduce the number of reoperations.
16.2.3.5 Near-Infrared Fluorescence Imaging
In near-infrared fluorescence (NIRF) imaging, an NIR fluorophore is administered, after which the 
breast tissue is irradiated by an external laser in the NIR spectral range (650–900 nm). Upon excitation, 
the fluorophore will release photons of a higher NIR wavelength, which are captured by an NIRF camera 
system and digitally converted into a visible image. In the 650–900 nm range, the absorption coefficient 
in tissue is minimum, resulting in decreased light scattering and autofluorescence, and increased pen-
etration depth compared to visible and UV light.
Fluorophores can be conjugated to a specific targeting ligand or monoclonal antibody to image 
tumor-targeted molecules that have been identified with breast cancer, including Her2/Neu recep-
tor, vascular endothelial growth factor (EGF) receptor, and EGF. The tumor-specific binding proper-
ties of these so-called tumor-targeted fluorophores seem perfectly suitable for image-guided surgery, 
as it provides the surgeon with real-time, tumor-specific information on the location and extent of 
the lesion.
However, the need to administer exogenous fluorophores limits the clinical application of the tech-
nique due to the requirement to be approved for human use. Indocyanine green (ICG) is currently the 
most often used NIR fluorophore, but ICG does not offer the possibility of tumor-specific antigen cou-
pling. Another reason why the development of this technique has been hampered is the lack of dedicated 
intraoperative imaging systems.
To date, a minimal number of studies have been published that use NIRF imaging to guide surgi-
cal excision in breast cancer. Mieog et al. used NIRF in a breast cancer rat model. Seventeen rats were 
operated on, resulting in a complete resection of seventeen out of seventeen tumors (Mieog et al. 2011). 
Moreover, the technique enabled the identification of remnant tumor in the surgical cavity, which is an 
important advantage over WGL and US. Aydogan et al. performed a feasibility study in two patients. 
They injected nontargeted ICG in the breast lesion under US guidance. Surgery was performed 1 h after 
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Overall, NIRF imaging seems a suitable candidate for early intraoperative introduction, as it is a 
fast and simple-to-operate technique, with a sufficient penetration depth to assess tumor margins. 
However, progress needs to be made with clinically available fluorophores and dedicated imaging 
systems. Furthermore, the technique does not provide information on microscopic margin status. 
Thus, it is likely that it will be used together with a technique that provides microscopic information 
on tumor margins.
16.2.4 Conclusion
The intraoperative techniques that are currently being used in BCS all have their limitations. The overall 
disadvantage of all these techniques is the inaccurate detection of DCIS, and this limitation will become 
of greater importance in the near future, as patients will be diagnosed at an earlier stage. The techniques 
that are currently in the clinical trial or research phase have the potential to assess tumor margins with 
a similar or even better accuracy than current techniques. Moreover, most of these techniques seem to 
be able to detect DCIS, thus providing additional value in this specific patient population. However, 
technological developments are required for these techniques to meet the clinical criteria of sufficient 
area sampling within practical time constraints, and further studies must be performed to elucidate 
their value in decreasing reoperation rates in BCS.
16.3 THz Technology in Breast Cancer
16.3.1 Introduction
In recent years, there has been growing interest in the application of terahertz (THz) technology to 
the field of biomedical research (Berry et al. 2004; Fitzgerald et al. 2006; Knab et al. 2007; Pickwell 
et al. 2004; Reid et al. 2007; Woodward et al. 2003). THz has been used to successfully characterize 
DNA (Nagel et al. 2006) and proteins (Knab et al. 2007) in this range, demonstrating the ability of 
the radiation to probe intermolecular interactions. Typical THz imaging systems produce radiation 
of wavelengths in the range of 3 mm to 80 μm; this is longer than that of the visible spectrum or infra-
red, so THz radiation is less susceptible to scattering within biological tissue (Han et al. 2000), and in 
general, scattering is assumed to be negligible. Due to the unique sensitivity of THz to water and the safe 
nature of the wavelengths used, THz techniques have been investigated for imaging of tissues (Arnone 
et al. 1999; Ashworth et al. 2006, 2008; Berry et al. 2004; Brucherseifer et al. 2000; Fitzgerald et al. 2006; 
Han et al. 2000; Markelz et al. 2000; Nagel et al. 2006; Nakajima et al. 2007; Pickwell et al. 2004). Many 
tissues in the human body are made up of about 70% water, and the adult human body is about 57% 
water by mass (Hall 2010). It is known that many cancers have a higher concentration of water than 
normal tissue. THz radiation is uniquely sensitive to water, which, together with the advantages listed 
earlier, makes it a viable tool for medical imaging and in particular of cancers.
Wallace et al. working at TeraView Ltd (Cambridge, UK) demonstrated the application of THz reflec-
tion images to differentiate between normal skin and cancerous skin on both ex vivo and in vivo sam-
ples (Fitzgerald et al. 2004; Pickwell et al. 2004; Wallace et al. 2006) and additionally performed THz 
spectroscopy to characterize the properties of different tissue types. Further work has been done to 
identify contrast between healthy colon tissue, dysplasia, and cancer by Reid et al. at University College, 
London (Reid 2009).
16.3.2 Application of THz Technology to Breast Cancer
The application of THz technology to breast cancer was first proposed by Fitzgerald et al. in 2004 
(Fitzgerald et al. 2004). Using a portable THz pulsed imaging (TPI) system developed for use in a hos-
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generate and detect THz pulses with a frequency content from 0.1 to 4 THz. Several freshly excised breast 
samples were imaged. Two parameters from the time domain impulse functions were used to produce 
images: the minimum of the THz impulse function, Emin, and the ratio of the Emin to the maximum of 
the impulse function, Emax. The images showed contrast between healthy and cancerous tissues with 
good agreement to histology. Interestingly, the images also highlighted DCIS. This preliminary study 
demonstrated the potential of TPI to image breast tumors and encouraged further studies to determine 
the ability of the technique to discriminate between different types of breast tissue (Fitzgerald et al. 2004).
A more comprehensive study performed in 2006 by Fitzgerald et al. (2006) confirmed that TPI could 
be used to identify contrast between healthy breast tissue and breast cancer by using Emin and Emin/Emax. 
The shape and size of the tumor on TPI correlated well with histopathology (see Figure 16.4). This work 
showed that THz can be used to distinguish invasive lobular and ductal breast cancer from normal and 
adipose breast tissue, and that it is likely that DCIS can be imaged as well (Fitzgerald et al. 2006).
Given it quasi-3D nature, THz imaging produces large volumes of data due to the two spatial and 
temporal components both being recorded. Fitzgerald et al. (2012) investigated data reduction meth-
ods prior to the classification of THz data from freshly excised breast cancer tissues. THz images have 
typically been formed using a range of parameters (or features), derived from the pulse or spectral 
profiles (Fitzgerald et al. 2002; Woodward et al. 2002). This heuristic approach to data reduction was 
compared to an unsupervised method that has traditionally been used in other areas, called princi-
pal component analysis (PCA) (Hutchings et al. 2009). PCA provides a theoretically optimal linear 
reduction, which requires no underlying assumptions about the statistical nature of the data. The PCA 
method was applied to the THz pulses and compared with the heuristic parameters. Classification for 
this study was performed using the support vector machine algorithm, which is well suited to finding 
complicated decision boundaries and has been used with good effect on other THz data sets (Yin et al. 
2007). The classification results from the THz signals were then compared with histopathology. It was 
shown that using appropriate data reduction methods, based on parametric features and/or principal 
components, THz signals reflected from freshly excised breast cancer tissue can be classified with 
accuracies up to 92%.
This chapter provides further evidence on the efficacy of the technique and points to methods to 
improve classification of signals obtained when using THz in breast cancer. With these encouraging 
results, it was suggested that this technique of imaging could potentially be used to intraoperatively 
assess tumor margins in patients undergoing BCS, eventually aiming to reduce the number of reopera-
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FIGURE 16.4 (See color insert.) This figure shows two terahertz images generated using the maximum of the 
reflected pulse (Emax) and the ratio between maximum and minimum of the reflected pulse (Emax/Emin). In the Emax 
image, all the tissues are shown, tumor with surrounding adipose tissue. In Emax/Emin, only the tumor is visible 
and correlated well with the tumor shown in the histology image. (Reproduced from Ashworth, P. C., E. Pickwell-
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16.3.3 Handheld THz Probe for Intraoperative Use
In order to use THz technology for intraoperative assessment of breast tumor margins, a handheld THz 
imaging probe has been developed (see Figure 16.5) (Wallace et al. 2005). The system uses a photocon-
ductive emitter and receiver to produce and detect THz pulses of bandwidth 0.1–2.0 THz. The THz 
pulse beam is focused to the probe tip, from which they are reflected back, through a silicon lens and a 
system of Risley beam steering prisms. The THz pulse beam is scanned back and forth across the active 
area by controlled rotation of the Risley prisms, resulting in an imaging window with a length of 8 mm.
This probe has been used to study tissue samples, obtained from freshly excised lumpectomy and 
mastectomy specimens, from 37 patients at Guy’s Hospital in London (Ashworth et al. 2008). Figure 16.6 
shows typical impulse responses observed upon the reflection of THz pulses from the three main breast 
tissue types—adipose, fibrous, and cancerous. A number of distinguishing parameters (features) were 
identified, and Figure 16.7 shows the average values for four parameters for each of the three key tissue 
types. It is clear from these two figures that it is easy to identify differences between adipose tissue and 
cancer with the probe. However, as expected, the discrimination between fibrous tissue and cancer is 
more challenging. By examining the pulse integral and full width half maximum in Figure 16.7, we can 
see subtle differences in the average values of these parameters between fibrous tissue and cancer. PCA 
was applied to the full-time domain THz pulse data, and then linear discriminant analysis was used to 
predict the tissue types of individual specimens as listed in Table 16.1. This shows that a promising value 
of 90% was found for the sensitivity and 81% for specificity (Ashworth 2010).
It is clear that these studies with a handheld THz probe are promising; THz technology is now 
becoming sufficiently versatile that it is possible to build such a probe and achieve a good level of perfor-
mance in a clinical environment. One of the limitations of the handheld probe is that due to the small 
imaging window, only a small tissue volume can be scanned. If in the near future the THz probe is used 
to scan complete lumpectomy specimens, multiple measurements per margin must be performed, which 
is time-consuming and sensitive to user errors. A potential limitation of the use of THz for assessing 
breast margins in general is the limited penetration depth as a result of high attenuation of THz in water. 
Tumor cells located at a depth >1 mm may therefore not be detected, but further studies are needed to 
determine the actual penetration depth of THz in breast tissue. There are still improvements that can 
be made in order to increase the SNR, reduce errors in data registration, and remove contaminant data 
from the training data set for discriminate analysis. These improvements may well bring the perfor-
mance of the technique closer to routine use during surgery.
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FIGURE 16.7 Bar graph showing the average values of four parameters for each of the three tissue types. Error 
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16.3.4 Understanding THz Signals from Breast Tissue
There is a need to understand the mechanisms that cause contrast in THz images of breast cancer and 
relate reflected pulse data to changes in tissue pathology. As a first step, Ashworth et al. measured the 
absorption and refractive indices of both healthy and diseased breast tissues in the THz region via time-
domain THz pulsed spectroscopy (TPS) (Ashworth et al. 2009). THz transmission spectroscopy or TPS 
has previously been used to obtain the THz optical characteristics of skin tissue and basal cell carcinomas 
(BCCs) (Pickwell et al. 2004; Wallace et al. 2006), including the refractive index and absorption coefficient 
spectra. In the Ashworth study, 74 fresh breast tissue samples were measured, of these 33 were classified 
as cancer, 22 as healthy fibrous, and 19 as healthy fat. Figures 16.8 and 16.9 show the measured average 
absorption coefficient and refractive index for each of these groups, respectively. The error bars displayed 
TABLE 16.1 Table Listing the Results 
of Linear Discriminant Analysis on Data 
Collected Using Handheld Probe
Histology Result 
THz Prediction Cancer Healthy 
Cancer 27 34
Healthy 3 142
Total N 30 176
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represent 95% confidence intervals derived from the standard error of the mean. The error bars for the 
refractive index are constant for fibrous tissue and fat but are slightly larger at high and low frequencies 
for the cancer samples. This is due to low signal in these ranges caused by attenuation through the sample.
Due to the nature of fibrous tissue within the breast, it was a challenging task isolating sufficient 
fibrous tissue from fatty tissue intact such that it would be suitable for our spectroscopy needs. As a 
result, the fibrous tissue group had a higher percentage fat than the tumor group, as tumors formed solid 
lumps that proved easier to separate.
There is a clear difference in the refractive indices between all pure tissue types and also a differ-
ence between the absorption coefficient of fat and the other two tissue types. In Figure 16.8, the shape 
of the spectrum of the cancer is very similar to fibrous tissue, but the transmitted signal is lower due 
to the increased attenuation in the cancer. The attenuation is a combination of absorption and scat-
tering, and it would be impossible with this type of measurement to determine the contribution from 
each mechanism. As discussed previously, increased water content in the cancer tissue would lead to 
increased absorption, and in cancer tissue samples, we therefore assume absorption to be dominant 
and scattering negligible. But if one looks at studies on dehydrated, wax-embedded samples, attenua-
tion also increases for regions of cancer, which can only result from structural changes, which, in turn, 
change the scattering properties (Berry et al. 2004; Nakajima et al. 2007). It is seen that breast tumor 
tissue has a higher refractive index than both healthy fatty and healthy fibrous tissues with the greatest 
difference being at 0.32 THz. Furthermore, around 0.32 THz, the absorption coefficient of breast tumor 
tissue increases slightly compared with fibrous breast tissue. Simulations were carried out to predict 
the impulse responses from performing THz pulsed reflection imaging on these tissues. A large differ-
ence was seen, as expected, between the impulse responses of healthy fat and those of healthy fibrous 
and breast tumor tissues. A difference in peak height of about 60% was seen on the impulse responses 
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In conclusion, the contrast seen when imaging breast cancer in reflection is mainly caused by an 
increase in the refractive index between cancer and healthy tissues and also in part due to an increase 
in the absorption coefficient. The root cause of the increases in these fundamental properties is yet to 
be determined.
Acquiring spectroscopic THz data allows us to simulate the reflected time domain response 
functions of healthy fibrous breast tissue and breast cancer tissue. Pickwell et al. have looked at the 
refractive index and absorption coefficient separately to characterize tissues. They have used the same 
model to investigate correlations between THz data and pathology and identify parameters of the 
simulated reflected impulse response function and corresponding spectroscopic properties with a view 
to improving our ability to distinguish between the fibrous and cancer tissues in the breast (Pickwell-
Macpherson et al. 2012).
16.4 Conclusion
The field of medical imaging using THz technology is very much in its infancy, and there is a great deal of 
work yet to be done to show its true potential before the modality would be widely adopted by the medi-
cal community. At present, only skin, colon, and breast cancers have been examined in an ex vivo setting 
where the water content of the tissues is close to that of in vivo tissue. It would be interesting to look at the 
potential use of THz in identifying other cancers that can either be accessed topically or in cases where a 
conservative excision is required. These may, for example, include head and neck cancers such as mouth, 
throat, or brain cancers, cervical cancer, or rectal cancer. However, it is important not to lose focus and to 
ensure that the development of THz technology with a view to intraoperatively diagnosing those cancers 
for which contrasts have already been identified continues, and current techniques are improved.
There are several challenges to using this technique during surgery, such as the presence of blood 
and other fluids in the region, maintaining good contact of the probe with the breast tissue, and inter-
patient variability. Although the presence of blood and other fluids can be managed during surgery, 
for example, through cauterization, this may also affect the THz response of the tissue to a varying 
degree and thus will require further study.
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Rationale: In early-stage breast cancer, the primary treatment option for the majority of women is 
breast-conserving surgery (BCS). There is a clear need for more accurate techniques to assess 
resection margins intraoperatively, as on average 20% of patients require further surgery to achieve 
clear margins. Cerenkov luminescence imaging (CLI) combines optical and molecular imaging by 
detecting light emitted by 18F-fluorodeoxyglucose (18F-FDG). Its high-resolution and small size 
imaging equipment makes CLI a promising technology for intraoperative margin assessment. A first-
in-human study was conducted to evaluate the feasibility of 18F-FDG CLI for intraoperative 
assessment of tumor margins in BCS. 
 
Methods: Twenty-two patients with invasive breast cancer received 5 MBq/kg 18F-FDG 45-60 min 
prior to surgery. Sentinel lymph node biopsy (SLNB) was performed using an increased technetium-
99m (99mTc)-nanocolloid activity of 150 MBq to facilitate nodal detection against the gamma-probe 
background signal (cross-talk) from 18F-FDG. The cross-talk and 99mTc dose required was evaluated in 
two lead-in studies. Immediately after excision, specimens were imaged intraoperatively in an 
investigational CLI imaging system. The first 10 patients were used to optimize the imaging protocol; 
the remaining 12 patients were included in the analysis dataset. CLI images from incised BCS 
specimens were analyzed postoperatively by two surgeons blinded to the histopathology results, and 
mean radiance and margin distance were measured.  Agreement between margin distance on CLI 
and histopathology was assessed. Radiation doses to staff were measured. 
 
Results: Ten of the 12 patients had an elevated tumor radiance on CLI. Mean radiance and tumor-to-
background ratio were 560 ± 160 photons/s/cm2/sr and 2.41 ± 0.54, respectively. All 15 assessable 
margins were clear on CLI and histopathology. Agreement in margin distance and inter-rater 
agreement was good (κ = 0.81 and 0.912, respectively). Sentinel lymph nodes (SLNs) were 
successfully detected in all patients. Radiation dose to staff was low; surgeons received a mean dose 








Conclusions: Intraoperative 18F-FDG CLI is a promising, low-risk technique for intraoperative 
assessment of tumor margins in breast-conserving surgery. A randomized controlled trial will evaluate 
the impact of this technique on re-excision rates. 
 
Key words: Cerenkov luminescence imaging; breast-conserving surgery; tumor margins; 18F-FDG; 































In early-stage breast cancer, the primary treatment option for the majority of women is BCS by wide 
local excision (WLE) of the tumor. WLE often fails to achieve clear surgical margins, and on average 
20% of patients who undergo BCS will require repeat surgery to achieve clear margins (1) (although 
this may vary since there is no global agreement of the definition of ‘clear margins’). Re-operations 
potentially have several negative consequences including delayed commencement of adjuvant 
therapy, worse cosmesis, increased patient anxiety and costs (2,3). 
There have been several attempts to assess surgical margins intraoperatively in order to 
reduce breast cancer re-operation rates post-WLE (1). Techniques evaluated to date include 
specimen radiography, intraoperative ultrasound, touch imprint cytology, frozen section, and 
radiofrequency spectroscopy. However, these all have limitations in terms of adequate performance, 
practicality and/or cost-effectiveness (1). Experimental methods evaluated include Raman 
spectroscopy, ambient mass spectrometry, optical coherence tomography, diffuse reflectance 
spectroscopy, confocal microscopy, and (targeted) fluorescence imaging (1). Each of these 
techniques have unique limitations, and the diagnostic performance remains to be evaluated in large-
scale studies.  
Positron emission tomography (PET) using 18F-FDG is a powerful tool for in vivo imaging of 
breast cancer. While whole-body PET has limited diagnostic sensitivity for primary breast cancer, 
high-resolution PET imaging with positron emission mammography has shown high sensitivity (92-
96%) and specificity (84-91%) for breast cancer diagnosis (4-6). Intraoperative high-resolution imaging 
of 18F-FDG could therefore provide a powerful tool for surgical guidance. However, intraoperative PET 
is impractical due to the large size and expense of a PET scanner and PET’s low spatial resolution. 
Development of a compact, high-resolution, intraoperative PET scanner could address these 
limitations.  
Recently, it has been discovered that PET imaging agents emit optical photons via a 
phenomenon called Cerenkov luminescence (7). Cerenkov photons are generated by positrons 
travelling at super-relativistic speeds in tissue. Optical imaging of Cerenkov photons emitted by PET 
agents is an emerging imaging modality called CLI. CLI combines high diagnostic performance and 







thus making it a promising technology for intraoperative margin assessment in breast cancer surgery 
(8).  
In this first-in-human clinical trial we evaluated the feasibility, safety, and preliminary 
performance of 18F-FDG CLI using a novel intraoperative CLI camera to assess tumor margin status in 
breast cancer patients undergoing WLE with SLNB or with axillary lymph node dissection (ALND).  
 
MATERIALS AND METHODS 
Intraoperative 18F-FDG CLI in breast-conserving surgery 
     Patient recruitment and patient preparation on the day of surgery. Research Ethics Committee 
approval was obtained prior to patient recruitment (ClinicalTrials.gov identifier NCT02037269). 
Between June 2014 and February 2016, patients with histologically confirmed invasive breast cancer 
on core biopsy with or without associated ductal carcinoma in situ (DCIS), due to undergo primary 
BCS and SLNB or ALND, were recruited at Guy’s Hospital in London after written informed consent 
was obtained. Exclusion criteria were: age <30 years, previous surgery or radiotherapy to the 
ipsilateral breast in the preceding two years, neoadjuvant systemic therapy, pregnancy or lactation, 
blood glucose level of ≥12 mmol/l on the day of surgery and known hypersensitivity to 18F-FDG. 
Females of childbearing age required a negative pregnancy test (by beta HCG qualitative analysis), 
history of surgical sterilization, or history of amenorrhea in the past twelve months.   
On the day of surgery patients scheduled to undergo SLNB received a periareolar intradermal 
injection of 150 MBq 99mTc-albumin-nanocolloid (NanocollTM, GE Healthcare, UK). The increased 
99mTc activity of 150 MBq was calculated based on the results from two lead-in cross-talk studies 
(Supplemental Material). Patients were then injected intravenously with 5 MBq/kg 18F-FDG (up to a 
maximum of 300 MBq) and typically 45-60 min post-18F-FDG injection were taken to the operating 
theatre.  
 
     Surgery and intraoperative specimen radiography. Following induction of anesthesia, patients due 
to undergo SLNB received a periareolar subdermal injection of 2ml Patent Blue V and 3ml of normal 
saline. To minimize radiation exposure to theatre staff by reducing the time spent in close proximity to 







was performed ahead of SLNB/ALND to minimize signal intensity reduction from radiotracer decay in 
the time between 18F-FDG injection and CLI imaging. The WLE specimen was excised using 
monopolar diathermy (Valleylab Force FXTM electrosurgical generator with HCP-01 Skintact surgical 
pencil). The excised specimen was orientated with sutures and metal surgical clips as per local 
protocol.  
Post-excision WLE specimens were x-rayed intraoperatively (Faxitron Bioptics, USA), and 
excision of cavity shave margins was performed if the tumor was deemed to be close to the edge of 
the specimen on radiography.  
Following excision of the WLE specimen, SLNB or ALND was performed. For SLNB a 
Europrobe 3 gamma probe with a high-energy collimator was used (Eurorad SA, France). SLNs were 
defined as nodes that were radioactive, blue, or palpable (9). The number of excised SLNs, the ex 
vivo SLN gamma probe signal (counts per second), and the presence of blue nodal discoloration were 
recorded. Upon completion of the procedure the gamma probe background signal in the axilla was 
measured.  
 
     Intraoperative CLI of WLE specimens and lymph nodes. Following specimen radiography, CLI 
imaging of the WLE specimen was performed using an investigational intraoperative CLI imaging 
system (Lightpoint Medical Ltd, UK). This system consists of a custom-built light-tight dark box 
containing two optical pathways: one for CLI and one for white-light imaging for anatomic reference 
(Fig. 1A). The CLI imaging pathway includes a fast f/.95 lens and a reflex mirror to fold the optical 
pathway into an electron-multiplying charge coupled device (EMCCD) camera. The field-of-view of the 
CLI camera is 8×8 cm, and the acquisition matrix is 512×512 to give a pixel resolution of 156.25 µm. 
The EMCCD is thermoelectrically-cooled to -80°C and radiation-shielded with lead to prevent 
annihilation photons from scintillating in the EMCCD chip, i.e. “gamma strikes”. The white-light imaging 
pathway provides a photographic reference image using a standard complementary metal-oxide-
semiconductor camera.  
The WLE specimen was positioned on a specimen table (Fig. 1B), the margin of interest 
placed in the center of the field-of-view by using the surgical sutures to guide orientation, and 







Following intact WLE specimen imaging, the surface of the specimen was immediately inked 
intraoperatively in order to preserve its orientation for histopathological analysis (Supplemental 
Material Fig. 1A). Six distinct ink colors (Davidson®, Bradley Products Inc., USA) were applied to the 
six margins. The inked specimen was then incised through the posterior margin to visualize the 
primary tumor and tumor margins, and the incised WLE specimen was imaged (Supplemental Material 
Figs. 1B and 1C). In one patient sequential image acquisition over a 50-minute time-period was 
performed to determine the half-life (t1/2) of the radiance observed in the tumor.   
The first 10 patients were included in the optimization dataset and the remaining 12 patients in 
the analysis dataset. In the first 10 patients, the image acquisition protocol was optimized by testing 
different image acquisition times (100, 300, 400 sec) and pixel binning settings (2x2, 4x4, 8x8). A 300-
sec acquisition time and 8x8 pixel binning was found to provide sufficient sensitivity for tumor 
detection and acceptable spatial resolution (1.25 mm) within a time-window feasible for intraoperative 
use, and these setting were used in the remaining 12 patients included in the analysis dataset. Upon 
completion of WLE CLI, the activity of the WLE specimen was estimated using a scintillation monitor 
(Type 41/44A, ThermoScientific, USA) or handheld radiation spectrometer (Raymon10 GR1, Kromek 
PLC). SLNs were also imaged intraoperatively with CLI using the same imaging settings.  
After imaging was completed, WLE specimens were sent for histopathological analysis as per 
standard practice. 
 
     Radiation safety monitoring. Radiation safety monitoring was performed to ensure safe working 
practices were maintained and that work was compliant with UK legislation regarding ionizing radiation 
(10-12). Prior to commencing the study all staff received training to become familiar with radiation 
control procedures, occupational risks, and learned how to minimize exposure without compromising 
patient care. Staff members were issued with electronic personal radiation dose monitors (PDM-112 
and PDM-122, Hitachi-Aloka Medical Ltd., Japan) for the body, and thermo-stimulated luminescent 
ring dosimeters for extremities (Landauer, UK). Radiation contamination monitoring of staff, rooms, 
equipment and waste was carried out after each procedure using a scintillation monitor (Type 41/44A, 
Series 300 mini-monitor, ThermoScientific, USA). As 99mTc has a longer half-life (6.02 hours) than 18F 







procedures. The time taken for the various stages of the procedure, i.e. from induction of anesthesia 
to recovery, were recorded. 
 
     Histopathology. Histopathological analysis was performed as per UK National guidelines: the WLE 
specimen was sliced at 2 mm intervals, and representative sections of the tumor and all 6 relevant 
margins were selected by the pathologist, processed, paraffin wax embedded and 3 to 4 micron 
sections were cut and stained with hematoxylin and eosin. Microscopic margin distance 
measurements were performed by a Consultant breast pathologist (S.E.P.). Microscopic invasive 
tumor size and whole tumor size (including DCIS extending from the main invasive mass) were also 
measured. Positive margins were defined as invasive cancer or DCIS <1 mm from the specimen 
surface. The histological margin distances were reported in increments of 1 mm, but margins more 
than 5 mm were reported as >5 mm. The pathologist was blinded to the interpretation of the CLI 
images. 
 
     Image analysis. All CLI and radiography images were analyzed postoperatively in order to provide 
a controlled and standardized analysis environment. Measurements of the mean radiance 
(photons/s/cm2/sr) were performed by drawing region-of-interests on the unprocessed CLI images. 
Region-of-interests were selected in areas showing increased signal intensity (‘tumor’) and no 
increased signal (‘tissue background’). Tumor-to-background ratios (TBRs) were calculated.  Gamma 
strikes were excluded from region-of-interest analysis. The tumor radiance from the sequential incised 
WLE images was fit to a monoexponential, to determine the radiance half-life.  
Assessment of margin status on CLI was performed on the incised WLE specimen images. 
The analysis was done independently by two experienced breast surgeons (AP and AK), and 
performed prior to analysis of the radiography images to prevent potential confirmation bias from a 
priori knowledge of the radiological margin status. Prior to analysis CLI images were processed by 
applying a median filter (filter size range 5 – 10, filter threshold range 10 – 15) and Gaussian filter 
(filter width: 1, filter threshold: 0.5). A stronger Gaussian filter (filter width: 4 or 5) was applied to 
images with a low TBR to increase the visibility of the tumor. The preoperative diagnostic information 
that would typically be available to the surgeon was provided including patient age, clinical, 







and receptor status on core biopsy. Per patient, a color image containing information on specimen 
orientation was shown together with a grey-scale image and Cerenkov image. All images were 
displayed on a standard computer monitor (23”, 1920 x 1080 pixels, 250 cd/m2 luminance). The grey-
scale image was overlaid with the Cerenkov signal to provide a fused image containing both functional 
and anatomical information. The leveling was set using the software’s default leveling, and manually 
adjusted based on the surgeon’s clinical judgment. Both surgeons then independently reported 
whether an elevated radiance from the tumor could be identified on CLI; in patients displaying an 
elevated tumor radiance the margin distance of the margins visible in the image was measured using 
the ruler function in the imaging software (Mirada XD3, Mirada Medical, Oxford, UK). The total time 
required to complete margin assessment was approximately 2 min per patient. As an exploratory 
outcome measure, tumor size was also measured. Upon completion of the measurements surgeons 
were asked whether, given the CLI image, they would have performed a cavity shaving had the image 
been available at the time of surgery. Surgeons also scored image quality on a 5-point Likert scale: 1 
= very poor – image not interpretable, 2 = poor but interpretable, 3 = fair, 4 = good, 5 = very good. 
Following CLI image analysis, specimen radiography image analysis was performed on a 
Coronis 3MP screen (20.8”, 1536 x 2048 pixels, 500 cd/m2 luminance) using standard GE PACS 
imaging software. Surgeons were presented with the same preoperative diagnostic information, but 
the images were shown in a different order to avoid potential sequential bias. The number of surgical 
marker clips was noted, and the reliability of specimen orientation assessed. If the orientation was 
considered reliable, the margin distance and tumor size on radiography was measured. Whether an 
additional cavity shaving would have been performed based on the radiography image was also 
noted.  
The final histopathology results of the surgically excised tissue were not available at the time 
of CLI and radiography image analysis, and could therefore not bias the surgeon’s assessment. 
 
     Statistics. Weighted Kappa coefficients were calculated to assess the agreement in margin 
distance between CLI and definitive histopathology, and to assess the inter-rater agreement between 
surgeons (‘irr’ package, version 3.2.2, R statistical software). A kappa coefficient (κ) greater than 0.75 







CLI and radiography respectively was assessed by calculating the mean difference in tumor size ± std, 
and intraclass correlation coefficients (ICC) (SPSS® version 23.0; IBM, Chicago).  
 
RESULTS 
Intraoperative imaging of WLE specimens  
A total of 22 patients were included in the study. The CLI results and postoperative histopathology 
results from the 12 patients included in the analysis dataset are shown in Table 1. The mean 
administered 18F-FDG activity was 295 ± 18 MBq (range 259 – 325). The mean time between 18F-FDG 
injection and WLE excision was 86 ± 26 min (range 50 – 146), and the mean time between 18F-FDG 
injection and commencement of CLI image acquisition was 118 ± 26 min (range 88 – 180).  
Tumor margin assessment was performed on incised WLE specimen images to allow for 
visualization of the tumor extent and to avoid image artifacts created by the monopolar diathermy. Ten 
of the 12 patients in the analysis dataset had elevated tumor radiance on CLI (Table 1). Mean tumor 
radiance and TBR in these 10 patients was 560 ± 160 photons/s/cm2/sr (range 308 – 871) and 2.41 ± 
0.54 (range 1.63 – 3.22). The half-life of the tumor radiance was 115.5 min, which is consistent with 
the 109.8-minute half-life of 18F. This concordance supports that the detected tumor radiance is 
Cerenkov luminescence from 18F-FDG. Mean radioactivity in the WLE specimen at the time of CLI 
imaging was 90 ± 48 kBq in patients with an elevated radiance; in the 2 patients without an elevated 
radiance radioactivity was 14 kBq and 19 kBq, respectively. 
In the 10 patients with elevated tumor radiance, a total of 60 margins could be assessed 
histologically, 26 margins were evaluable on specimen radiography, and 15 margins were assessable 
on CLI. Of the 45 histological margins that were not evaluable on CLI, 40 were not in the field-of-view 
of the CLI image, and 5 could not be assessed due to migration of the specimen orientation ink onto 
the margin edge, preventing optical margin interrogation. Eighteen of the 60 histological margins were 
not assessable on specimen radiography due to the inability to reliably orientate the specimen on the 
radiography image, and 16 margins were not in the image field-of-view. 
The margin distance from the 15 margins as measured on CLI and histopathology is shown in 
Table 1. Two margins measured between 1 and 5 mm on CLI and histopathology (Figs. 2 and 3); the 
remaining 13 margins were >5 mm by both modalities. There was good agreement between the 







surgeon 2, respectively (κ surgeon 1 = 0.76, κ surgeon 2 = 0.86). The agreement in margin distance 
between surgeons was also good (κ = 0.91).  
Five margins could be assessed on both CLI and specimen radiography, and all were >5 mm 
on both modalities, as well as histologically. An example of a CLI, radiography and histopathology 
image from a patient with >5 mm resection margin widths is shown in Fig. 4.  
Two patients (17%) had a positive margin on postoperative histopathological analysis; both 
were medial margins with DCIS <1 mm distant. These margins were not visible in the CLI image as 
specimen incision had only exposed the superior, inferior and posterior margins; the medial margin 
could therefore not be assessed. 
In 8 of the 10 patients tumor size could be measured on CLI, and compared to histopathology: 
the agreement is shown in Table 1. In 2 patients the orientation inks prevented measurement of tumor 
size on CLI. Invasive tumor size showed excellent agreement; mean difference for both surgeons 
combined was -0.84 ± 2.8 mm. ICC was 0.84 and 0.81 for surgeons 1 and 2, respectively. Whole 
tumor size was underestimated on CLI; mean difference for both surgeons combined was -4.7 ± 5.0 
mm. ICC was 0.65 and 0.69 for surgeons 1 and 2, respectively. Inter-rater agreement between 
surgeons was excellent (ICC = 0.97).  
The agreement between invasive tumor size on histopathology and on radiography was good; 
mean difference for both surgeons combined was 1.0 ± 3.1 mm. ICC was 0.56 and 0.58 for surgeons 
1 and 2, respectively. Whole tumor size was underestimated on radiography; mean difference for both 
surgeons combined was -5.2 ± 8.9 mm.  
CLI image quality in the 10 patients with successful CLI was scored as 4.3 (range 4 – 5) by 
both surgeons.  
 
Sentinel lymph node detection and 18F-FDG Cerenkov lymph node 
imaging  
SLNB was performed in 21 of the 22 patients; 1 patient underwent an ALND. SLNs were successfully 
identified in all 21 patients. A total of 43 SLNs were removed. The average number of SLNs per 
patient was 2 (range 1 – 4). Two of the 21 SLNB patients had macrometastatic SLNs.  
The mean gamma probe signal of the ‘hottest’ SLN per patient was 4991 ± 2521 counts per 







2632 counts per second (range 7368 – 50). Mean axillary background signal, measured in 13 patients, 
was	 192 ± 70 counts per second (range 55 – 270). This signal is lower than the 18F-FDG gamma 
probe cross-talk measured in the lead-in study (Supplemental Material), and is mainly due to the 
longer time between 18F-FDG injection and SLNB (mean 93 ± 34 min). A total of 7 nodes had a 
gamma probe signal below the background signal; 6 of these were blue. This indicates the importance 
of using the combined technique of radioisotope and blue dye in 18F-FDG CLI guided breast surgery, 
as low-uptake nodes may be missed if gamma probe detection is used alone. 	
All SLNB procedures were performed with the monopolar diathermy device and due to the 
observed image artifact from diathermy on CLI, the SLN images were uninterpretable.  
 
Radiation dose to staff  
A summary of the whole body effective radiation dose to primary personnel from all 22 procedures is 
shown in Table 2. Surgeons received the highest mean and maximum dose of 34 µSv and 74 µSv 
respectively. Mean duration of surgery was 39 ± 11 min (range 21 – 61) during which the surgeon was 
generally <0.5 meters from the patient. Mean radiation dose to the left and right hand of the surgeon 
was 126 ± 95 µSv (0 – 250) and 78 ± 75 µSv (0 – 200), respectively. Mean and maximum radiation 
dose received by the anesthetist standing at approximately 1 meter from the patient, with closer 
patient contact at the time of induction of anesthesia and at the end of the procedure, was 11 µSv and 
18 µSv, respectively. Surgical equipment had low levels of radioactive contamination, which was 
undetectable 1-3 days later. No staff members were found to be contaminated with radioactivity after 
the procedures.   
 
DISCUSSION 
This first-in-human study evaluated the feasibility of intraoperative 18F-FDG CLI for assessing tumor 
margin status in patients with invasive breast cancer undergoing BCS, and SLNB or ALND. Tumor 
margin assessment on CLI could be performed in 10 of the 12 patients in the analysis dataset, and 
there was strong agreement between CLI and definitive histopathology on margin width. An 
exploratory outcome measure assessed the correlation between tumor size on CLI and 
histopathology; the size on CLI and histopathology correlated well for invasive cancer, while whole 







monitoring program demonstrated that the procedure can be carried out safely while maintaining low 
radiation exposures to the staff involved. 
 In 2 patients margin assessment could not be performed because the tumors did not display 
elevated radiance on CLI. The absence of signal in these patients is probably due to the small tumor 
size, a factor known to be associated with lower 18F-FDG uptake (14), and the late time points at 
which these tumors were imaged (135 min and 180 min post 18F-FDG injection; the first and third 
longest injection-imaging time of all patients). Unsuccessful CLI imaging due to the absence of a 
detectable tumor signal highlights the importance of ongoing developments focused on improving 
detection sensitivity of camera systems to aid detection of tumors with low 18F-FDG uptake including 
lower grade tumors and DCIS (4).  
   Since its discovery in 2009, CLI has rapidly emerged as a powerful technique for cancer 
imaging. CLI is readily translatable to the clinic due to existing regulatory approval and widespread 
availability of PET imaging agents (15). In contrast, targeted fluorescence imaging requires prohibitive 
clinical development times and capital investment for regulatory and reimbursement approval of novel 
imaging drugs (16). Three clinical pilot studies of CLI have been published to date. These have 
focused on the use of CLI to image radiopharmaceutical uptake in the thyroid, CLI for non-invasive 
detection of nodal disease, and Cerenkov luminescence endoscopy to aid detection of cancerous 
lesions in the GI tract (17-19). To our knowledge, this is the first report of intraoperative CLI. Its high-
resolution, small size imaging equipment and minute-scale image acquisition (5 min) and image 
analysis (~2 min) times, make CLI of particular interest for image-guided surgery. The feasibility of 
intraoperative CLI as shown in this study in combination with the wide applicability of 18F-FDG across 
a range of solid cancers provides a stepping stone for clinical evaluation of this technology in other 
cancer types.  
 The low radiation exposure to staff found in this study is in accordance with previously 
reported exposure levels from 18F-FDG guided breast surgery procedures (20,21), and comparable to 
the radiation dose reported for interventional cardiology procedures (1 – 50 µSv) (22). The number of 
18F-FDG CLI-guided BCS procedures that could be performed in a routine clinical setting depends on 
the occupational limits on radiation exposure per country (Table 2). In the UK and US the occupational 
annual dose limit is 20 mSv (23) and 50 mSv (24), respectively. Good practice would dictate that the 







below the dose limits. In practice in the UK, if a worker is likely to receive annually more than 6mSv 
they would be designated a classified worker, necessitating annual medical surveillance and longer 
term record keeping of their radiation exposure.  
 Image artifacts on CLI from tissue excised with the monopolar diathermy device prevented 
tumor margin assessment on intact WLE specimens and assessment of SLNs. Although the source of 
this ‘false-signal’ is not yet fully understood, current evidence from pre-clinical experiments points 
towards long-lived, thermally-induced chemiluminescence (25). Since the emission seems to be 
related to temperature, which can reach up to 250°C at the tip of the diathermy device, electrosurgical 
devices that operate at much lower temperatures are currently being tested (26). In addition to 
potentially facilitating margin assessment on intact WLE specimens, an advantage of low-temperature 
devices over monopolar diathermy is the reduced collateral tissue damage, which could also improve 
the accuracy of assessing tumor resection margins on histopathology (27).   
 Although CLI imaging of incised WLE specimens is feasible for assessing tumor margin 
status, this approach has some limitations over margin assessment on intact specimens. Firstly, 
migration of the wet pathology ink onto the margin edge immediately after specimen incision hinders 
margin interpretation with CLI. Methods to accelerate drying of inks by applying acetic acid to the 
painted tissue or by using fast drying inks may be solutions to this problem, but this has not been 
tested in this study. Secondly, in our institution specimen incision could only be performed through the 
posterior margin to ensure accurate postoperative histological assessment of radial margins. 
Consequently, only a limited number of margins could be assessed with CLI imaging per patient, and 
two histologically positive margins that were not visible in the CLI image were therefore missed. In 
order to assess more margins per patient specimen incision may be performed in multiple planes, but 
good communication between surgeons and pathologists is paramount in order to not compromise 
patient care. 
A randomized, controlled, multi-center clinical study is scheduled to commence in late 2016 to 
evaluate the effect of intraoperative 18F-FDG CLI on re-operation rate and Quality of Life in BCS 
(ClinicalTrials.gov identifier NCT02666079). The study will run across an anticipated 8 study sites in 
the UK and Germany and use the CE-marked LightPathTM Imaging System (Lightpoint Medical Ltd, 
UK).  The smaller field-of-view of 6 x 6 cm and improved imaging software may provide substantial 







analyzing larger subgroups of patients with a range of tumor types (including DCIS), size, histological 
grades and hormone receptor status, further insight should be obtained into which breast-cancer 
patient populations may most benefit from CLI-guided surgery.  
 
CONCLUSION 
Intraoperative 18F-FDG CLI in BCS for invasive breast carcinoma is a promising and low-risk 
procedure. CLI imaging of incised WLE specimens provides high-resolution functional information that 
allows surgeons to accurately assess margin status with good correlation to gold-standard 
histopathological examination. Further work, focused on suppressing the optical signal from the 
monopolar diathermy device, will assist margin assessment on intact WLE specimens and potentially 
identification of SLN metastases on CLI. SLNB can be performed successfully during 18F-FDG CLI-
guided surgery by using 150 MBq 99mTc-nanocolloid and blue dye. Based on the results of this study a 
larger randomized controlled study is warranted to evaluate the impact of intraoperative 18F-FDG on 
re-operation rate and Quality of Life in BCS. 
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FIGURES WITH LEGENDS 
 
Figure 1: Investigational intraoperative CLI specimen camera. (A) Schematic diagram. Component 
labels: 1) EMCCD camera, 2) f/.95 lens, 3) Hinged reflex mirror, 4) Complementary metal-oxide-
semiconductor reference camera,  5) Specimen table, 6) Lead radiation shielding for EMCCD camera, 
7) Focal zone, 8) Fixed lens for reference camera, 9) Filter wheel, 10) LED RGB light array, 11) 
Specimen chamber. The purple line shows the optical paths for the EMCCD camera and the reference 
camera as determined by the angle of the reflex mirror. (B) Specimen chamber. The specimen table is 





















Figure 2: WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. 
(A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased 
signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean 
TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a 
cavity shaving would have been performed if the image had been available intraoperatively. The 
medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented 
assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen 
radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position 
of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined 
histopathology image from two adjacent pathology slides on which the posterior margin (bottom of 
image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin 

















Figure 3: WLE specimen from a patient with a grade 3, ER+/HER2-, NST carcinoma admixed with 
high grade DCIS. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov 
signal. An increased signal from the tumor is visible (white arrows); mean radiance is 406 ± 51 
photons/s/cm2/sr, mean TBR is 2.03. The posterior margin (outlined in blue) is 2 mm or 3 mm on CLI 
as measured by surgeons 1 and surgeon 2, respectively; both surgeons would have performed a 
cavity shaving. The medial margin (outlined in green) is >5 mm. (C) Specimen radiography image. All 
4 radial margins were >5 mm, and both surgeons indicated they would not have performed a cavity 
shaving. (D) Histopathology image showing the posterior margin (left side of image) and part of the 




























Figure 4: WLE specimen from a patient with a grade 3, ER+/HER2-, NST carcinoma admixed with 
high grade DCIS. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov 
signal. An elevated signal (white arrow) from the tumor can be seen. Mean radiance is 637 ± 47 
photons/s/cm2/sr; mean TBR is 1.63. Both surgeons measured the posterior margin (outlined in blue), 
medial margin (outlined in green) and lateral margin (outlined in red) distances as >5 mm; a cavity 
shaving would not have been performed based on the CLI image. (C) Specimen radiography image. 
All 4 radial margins were >5 mm as measured by both surgeons and did not prompt resection of cavity 
shave margins (D) Histopathology image from large-format pathology block. The tumor is >5 mm from 























Mean tumor  
radiance 
(photons/s/cm2/sr) 
TBR3 Margin distance 

















1 NST  DCIS 2 Pos/Neg -
4 - - - - 13 13 
2 NST  DCIS 3 Neg/Pos 453.59 2.34 6, 6 >5 *
6 22 22 
3 NST 3 Neg/Neg 871.16 3.22 2, 2 28, 30 
3 
>5 20, 18 20 20 
4 NST  DCIS 3 Neg/Neg -
4 - - - - 14 14 
5 NST  DCIS 3 Pos/Neg 405.76 2.03 2, 3 5 18, 18 20 20 
6 ILC 2 Pos/Neg 544.04 2.44 9, 9 >5 20, 19 22 22 
7 NST 3 Pos/Neg 667.47 2.72 10, 11 >5 *6 25 25 




>5 19,19 15 35 




>5 14, 15 18 19 
10 NST  DCIS 3 Pos/Neg 648.29 2.46 8, 8 >5 22, 22 19 29 
11 NST  DCIS 2 Pos/Neg 466.03 2.54 15, 14 >5 13, 11 13 13 







12, 10 14 14 
1. NST: invasive carcinoma of ductal/no special type, DCIS: ductal carcinoma in situ, ILC: invasive lobular carcinoma 
2. Pos: positive, Neg: negative 
3. Tumor-to-background ratio 
4. No elevated tumor radiance on CLI  
5. Histopath: histopathology 
6. Presence of orientation inks prevented measuring tumor size on CLI. 
7. Margin distance and tumor size are shown for surgeon 1 and 2, respectively 
8. The histopathological tumor size displayed in the table is the tumor size measured in the same direction as the tumor size measurement on CLI. In patient 3, 11 and 






Table 2: Measured effective radiation doses by occupation from 22 surgical procedures. 
 
Staff Group N1 Mean Effective Dose per procedure ± std (µSv) 
Range 
(µSv) 
Estimated number of procedures per 
individual per year2 
Estimated number of procedures per 
individual per year2 
ICRP3 (20 mSv annual limit) USNRC4 (50 mSv annual limit) 
Surgeon 46 34 ± 15 8 – 74 270 676 
Anesthetist 22 11 ± 5 0 – 18 1111 2778 
NM technologist 22 9 ± 4 1 – 15 1333 3333 
Anesthetist assistant 22 6 ± 3 0 – 11 1818 4545 
Trial Co-coordinator 21 5 ± 2 1 – 10 2000 5000 
Recovery Nurse 43 4 ± 3 0 – 14 1429 3571 
Scrub Nurse 22 2 ± 1 0 – 5 4000 10000 
Periphery Nurse 23 1 ± 1 0 – 4 5000 12500 
Research fellow 36 1 ± 2 0 – 13 1538 3846 
Ward Nurse 15 0 0 – 1 20000 50000 
Tissue Biobank Practitioner  14 0 0 – 1 20000 50000 
1. N = number of measurements 
2. Based on maximum Effective Dose per procedure per staff group 
3. ICRP: International Commission on Radiological Protection 






Standard practice requires the use of 99mTc–labeled radiopharmaceuticals for SLNB. The presence of 
18F-FDG in study subjects results in greater than normal background signal being detected by the 
handheld gamma probe used for SLNB, due to the down-scatter of 511keV Fluorine-18 (18F) gamma 
photons into the 99mTc energy window. This cross-talk background could potentially hinder detection of 
low-activity SLNs. To assess the 18F cross-talk and to determine the activity of 99mTc-nanocolloid 
required to successfully perform standard of care SLNB in patients undergoing 18F-FDG CLI-guided 
surgery, two lead-in studies were conducted prior to commencing the CLI study.  
 
Lead-in study I: SLNB simulations using the GAPS simulator 
To determine the effects of the cross-talk background on the detectability of radioactive lymph nodes a 
simulation study was performed using the computerized gamma probe simulator (GAPS) (1).  The 
GAPS system has previously been used in the UK national breast SLNB training program ‘NEW 
START’, and provides simulations of the radioactivity distribution and gamma probe response that 
allows accurate objective assessment of the surgeon’s ability to localize SLNs on the surface of a 
manikin of the female breast and axilla.  
The aim of the study was to measure the accuracy of gamma probe guided localization of 
nodes with varying levels of radioactivity and varying levels of cross-talk background. 
The measurements were performed by two breast surgeons (AP and AK), with extensive 
experience of performing SLNB procedures. After one test case to familiarize the surgeons with the 
GAPS system, each surgeon was presented with 3 simulated SLNB cases individually. In each case 
the injection site, two SLNs and a spatially uniform 18F background signal with Poisson distributed 
noise were simulated. The simulated SLN count rates ranged between 56 and 373 counts per second, 
and were based on a 150MBq 99mTc injection, a SLN tracer uptake ranging from 0.06% to 0.4% of the 
administered dose, an average SLN depth (30mm from the axillary skin surface) (2), and a time 
between tracer injection and SLN detection of 3 hours, which is common for 1-day SLNB protocols. 
The dose of 150MBq 99mTc is markedly higher than the standard dose of 20MBq used for 1-day SLNB 







count rate, thus facilitating SLN detection in a 18F background, whilst keeping within a dose range that 
is well established (3). The range in SLN % tracer uptake covers the lower spectrum of tracer uptake 
reported in literature (4), thus assessing the surgeon’s performance in the clinically most challenging 
situation of identifying SLNs with a low count rate. The 18F background signal was set to a mean of 
560 cps, corresponding to an 18F-FDG dose of 5MBq/kg, which is the dose CLI study patients 
received. Calibration measurements of count rates from 99mTc and 18F sources with the same gamma 
probe system and high-energy collimator as in the CLI study, the Europrobe 3 (Eurorad S.A., France), 
were used to set the count rates simulated by the GAPS system. The signal-to-noise ratio, defined as 
the ratio of the node count rate to the background count rate, varied from 0.67 and 0.10 in the 
simulations.  
The surgeons performed surface scans with the GAPS gamma probe to localize as many 
nodes as they could, and to indicate when they thought they had localized a SLN. SLN detection was 
only considered successful if the surgeon indicated that they had located a node and if the position 
pointed at by the probe was within 10mm of the virtual node.  
 
Lead-in study II: Gamma probe measurements in 18F-FDG PET patients 
Following on from the SLNB simulations, gamma probe measurements of the axilla were performed in 
patients scheduled for a diagnostic 18F-FDG PET scan to confirm that the simulated 18F background 
signal corresponded to the gamma probe cross-talk found in vivo. 
After research ethics committee approval and written informed consent was obtained, a total 
of 20 female patients were included at the PET Centre at St Thomas’s Hospital (ISRCTN29552671). 
Approximately 60 minutes after receiving an intravenous injection of 18F-FDG, but prior to PET 
imaging, the Europrobe 3 gamma probe with a high energy collimator was used to perform 10 second 
measurements of the lowest and highest count rates in the left and right axilla, respectively. The 
measurements of both axillae were performed shortly after each other (within 5 minutes) so that 
effects of radioactive decay between measurements were negligible. The background count rate was 
also measured, and the 10s count rates were averaged to give cps. The gamma probe system and 
configurations used to perform the 18F-FDG axillary cross-talk measurements were the same as in the 
CLI study. The axilla was defined as the triangle between the pectoralis major, the latissimus dorsi and 







Patient and injection characteristics such as height, weight and injected activity were recorded. An 
independent samples t-test was performed to compare the highest signal in the right axilla and left 
axilla respectively, and a p-value of <0.05 was considered statistically significant.    
 
RESULTS 
Lead-in study I: SLNB simulations using the GAPS simulator  
The SLN detection results per surgeon can be found in Supplemental Table 1. The majority of the 
SLNs were accurately detected. Nodes with 0.4% (373 cps), 0.3% (280 cps) and 0.1% (93 cps) of 
injected activity were found by both surgeons, representing successful localization of nodes even with 
a signal-to-noise ratio as low as 0.17. Both surgeons missed the SLN with the lowest simulated uptake 
(0.06% uptake, 56 cps). The mean spatial accuracy for detected nodes was 2.6mm and 4.0mm for 
surgeon 1 and surgeon 2, respectively.  
 
Lead-in study II: Gamma probe measurements in 18F-FDG PET patients  
The patient and 18F-FDG injection characteristics can be found in Supplemental Table 2. The mean 
and standard deviation of the lowest and highest gamma probe signal in the right axilla was 310 ± 77 
cps (range 133 – 488) and 372 ± 85 cps (range 233 – 616), respectively. The mean and standard 
deviation of the lowest and highest gamma probe signal in the left axilla was 299 ± 80 cps (range 161 
– 553) and 359 ± 74 cps (range 236 – 582), respectively. These mean values are lower than the 
560cps (5MBq/kg) used in the SLNB simulations, which were obtained from gamma probe calibration 
measurements with 18F distributed in a water volume. The lower values probably reflect the renal 
excretion and non-uniform uptake in vivo. The highest count rate, which is clinically most relevant as it 
causes the greatest interference when detecting SLNs, did not differ between left and right axilla (p = 
0.596), thus indicating that the cross-talk is similar in both axillae. 
 Based on the findings from both lead-in studies the investigators were confident that by using 
an increased administered activity of 150 MBq 99mTc-nanocolloid, a gamma probe collimator suitable 
for 511 keV energy photons and blue dye, SLNB could be performed safely and successfully, and 







FIGURES FOR SUPPLEMENTAL MATERIAL 
 
Supplemental Figure 1: Intraoperative inking and incising of WLE specimen. (A) Inks and sutures were 
applied to the WLE specimen to aid anatomical specimen orientation. (B) WLE specimen following 
initial incision through the posterior (black) margin, exposing the primary tumor and margins of 
excision. (C) White-light image of incised WLE specimen obtained with the CLI imaging system. 
Compared to (B) the specimen was further incised and opened to maximize the visibility of the 
posterior margin (outlined in blue), medial margin (outlined in green) and lateral margin (outlined in 





















TABLES FOR SUPPLEMENTAL MATERIAL 
Supplemental Table 1: SLN detection results from SLNB simulations using the GAPS simulator. 
 














error SLN 2 
(mm) 
1 1 560 373 Y 2.50 93 Y 6.40 
 2 560 280 Y 1.40 93 Y 2.43 
 3 560 280 Y 0.50 56 N - 
2 1 560 373 Y 1.27 93 Y 3.99 
 2 560 280 Y 3.00 93 Y 9.70 
 3 560 280 Y 2.00 56 N - 
1. BG = background signal 



























Supplemental Table 2: Patient and 18F-FDG injection characteristics from the gamma probe cross-talk 
study in PET patients. 
 
Characteristic Mean (range) 
Age (years) 61.5 (40-81)  
Height (cm) 161 (145-178)  
Weight (kg) 69.3 (45-101) 
Blood glucose level (mmol/L) 5.7 (4.3-16.4) 
Injected Activity (MBq) 343.8 (307.5-387.0) 
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Surgical relevance (150 words) 
There is a clear need for more accurate techniques to assess tumour resection margins 
intraoperatively in breast-conserving surgery (BCS), since approximately 10 – 30% of patients require 
further surgery to achieve clear margins. Due to the sensitivity of terahertz radiation to changes in 
water content and tissue composition, the millimetric penetration depth and submillimeter imaging 
resolution, Terahertz pulsed imaging (TPI) represents a promising technology for intraoperative 
margin assessment. A TPI handheld probe system (Teraview, Cambridge, UK) has been developed to 
facilitate the use of TPI to scan breast specimens ex vivo. In this study, we found that the TPI probe 
can discriminate invasive breast cancer from benign breast tissue with a high sensitivity (86%) and an 
encouraging degree of accuracy (75%). These promising results warrant larger studies to assess the 
diagnostic accuracy of TPI on different cancer types including ductal carcinoma in situ (DCIS), and its 


























There is a clear need for developing new techniques to more accurately assess tumour resection 
margins during breast-conserving surgery (BCS), since currently approximately 10 – 30% of patients 
undergoing BCS require a re-operation to achieve clear margins. This study evaluates the diagnostic 
accuracy of a handheld terahertz pulsed imaging (TPI) system to discriminate benign from malignant 
breast tissue ex vivo. 
 
Method: 
A total of 46 freshly excised invasive breast cancer samples from 32 patients were scanned with a TPI 
handheld probe system (Teraview Ltd., UK). For each sample, detailed pathology data were obtained 
and correlated with the THz data. Two data reduction and classification methods were applied to the 
THz data to determine diagnostic accuracy: (1) heuristic parameters in combination with support 




On the full dataset accuracy, sensitivity, specificity, positive predictive value and negative predictive 
values were 75%, 86%, 66%, 67% and 85% for method 1, and 69%, 87%, 54%, 60%, 84% for method 
2, respectively. These values increased to 88%, 87%, 96%, 98% and 61% when high percentage 
fibrous tissue was excluded from the analysis. 
 
Conclusion: 
The TPI handheld probe can discriminate invasive breast cancer from benign breast tissue with high 
sensitivity and an encouraging degree of accuracy. Accurate discrimination of cancer from tissue 
containing a high percentage of fibrous cells is challenging. Larger studies are warranted to assess 











Breast cancer is by far the most common cancer among women worldwide1. A combination of an 
increased use of screening mammography, neoadjuvant chemotherapy and neoadjuvant endocrine 
therapy to downstage the size of the tumour, has significantly increased the number of patients 
suitable for breast-conserving surgery (BCS). Currently approximately two-thirds of newly diagnosed 
breast cancer patients in the United Kingdom and the United States undergo BCS as initial treatment2, 
3.  
A key problem in BCS is that approximately 20% of patients in the UK require a re-operation 
because of close or positive tumour margins on postoperative histopathological analysis4. A positive 
margin, defined as ‘tumour on ink’, is associated with a 2-fold increased risk for developing local 
recurrence 5, 6. Although what constitutes an adequate negative margin of excision is a subject of 
intense debate, the 2015 Association of Breast Surgery (ABS) of Great Britain and Ireland consensus 
agreement defined a clear histological margin for invasive cancer and ductal carcinoma in situ (DCIS) 
as tumour cells >1 mm from the inked resection edge7.  
Re-operations potentially have a significant impact on patients and healthcare systems. They 
can result in an increased rate of surgical complications8, compromise cosmetic outcome9, delay 
adjuvant therapy, and increase anxiety and stress for patients and their families. Re-excision surgery 
also presents a high cost burden to healthcare systems; a recent study in the United States showed 
that the costs for a re-excision was $4721 per patient10.  
In an attempt to decrease the re-operation rate, techniques to intraoperatively assess tumour 
resection margins have been developed. Clinically established techniques include specimen 
radiography, intraoperative ultrasound, radiofrequency spectroscopy, frozen section analysis and 
touch imprint cytology. However, these all have limitations in terms of diagnostic accuracy, logistical or 
technical demands or cost-effectiveness11. Emerging techniques include Raman spectroscopy12, 
diffuse reflectance spectroscopy13-17, optical coherence tomography18-20, mass spectroscopy21, 22, bio-
impedance spectroscopy23, and (targeted) fluorescence imaging24.  These techniques each have 
unique limitations, and their potential value for improving quality of care and reducing healthcare costs 
is yet unknown.  
Terahertz pulsed imaging (TPI) employs terahertz (THz) radiation (0.1 – 4 THz) for imaging 







water content and tissue composition, and the submillimeter imaging resolution of TPI, this technique 
holds promise for imaging cancer25. Work performed to date has shown the ability of TPI to 
discriminate malignant from benign tissue in skin, colon, oral, gastric, brain and breast cancer26. In 
2006, Fitzgerald et al. were the first to demonstrate the potential of TPI for identifying breast cancer 
during BCS27. They measured 22 freshly excised breast tissue samples, and demonstrated a good 
correlation between tumour size and shape assessed by TPI compared with histopathology. To better 
understand the origin of the observed contrast on TPI, Ashworth et al. used THz spectroscopy and 
showed that the absorption coefficient and refractive index of tumour were different to that of normal 
breast tissue in the THz region of the spectrum28. Following from their initial work, Fitzgerald et al. 
imaged 51 breast samples and assessed the diagnostic accuracy of TPI by using a range of THz 
image parameters and classification techniques29. They demonstrated an accuracy, sensitivity and 
specificity of 92%, 90% and 92%, respectively. However, the TPI device used in their study is not 
suitable for intraoperative assessment of intact breast specimens due to the requirement for physical 
tissue disruption to obtain samples that fit the 20 x 20 mm sample holder. Importantly, the tissue 
samples included in their dataset had a ‘homogeneous’ tissue composition, i.e. contained more than 
50% of a single tissue type. This is not an accurate representation of the tissue composition found at 
the resection border of patients with close or positive margins, as involved margins are often identified 
microscopically as a small number of tumour cells immersed in a ‘background’ of fibrous and/or 
adipose tissue30. Thus, the diagnostic accuracy of TPI for detecting tumour close or at the margin 
remains underdetermined.  
To facilitate the use of TPI to scan tumour resection margins intraoperatively, Teraview Ltd. 
(Cambridge, UK) has developed a handheld probe system. Therefore, a single centre study was 
performed to evaluate the ability of the TPI handheld probe to discriminate benign from malignant 
breast tissue in an ex vivo setting.  The aims of the study were to obtain a dataset that closely 
resembles the mixture of benign and tumour tissue commonly found at the resection border of patients 
with involved margins, and to evaluate the diagnostic performance of the TPI handheld probe in terms 











TPI handheld probe system 
The TPI handheld probe produces and detects THz pulses by guiding laser pulses from a 
femtosecond fibre laser (Menlo Systems GmbH, Martinsreid, Germany) down optical fibres to a 
photoconductive emitter and detector (Supplementary Material Figure 1).  The 0.1 – 1.8 THz pulses 
are then guided by an oscillating mirror via a monolithic silicon section onto a quartz window present 
at the tip of the probe, scanning 26 pixels in an area of 15 x 2 mm at a frequency of 4 Hz 
(Supplementary Material Figure 2).  During scanning each pixel acquires THz pulses over time to form 
a TPI image (Figure 1). 
 
Data acquisition  
Between August 2013 and August 2014, following written, informed consent, breast tissue samples 
from patients who underwent BCS or mastectomy at Guy’s Hospital in London were scanned with the 
TPI probe (REC 12-EE-0493). Within 60 minutes post-excision, BCS or mastectomy specimens were 
inked and sliced by an Advanced Practitioner in the King’s Health Partners Cancer Biobank located 
adjacent to the operating theatre. Tissue samples were obtained for the study subject to the amount of 
tissue required for diagnostic purposes. 
Prior to scanning the samples, a Tegaderm layer (3M Tegaderm Film, 3M, Bracknell, UK) was 
applied to the probe’s quartz window, and the remainder of the probe was wrapped in a disposable 
protective sheath to prevent contamination from tissue. Data was collected from a 60 second water 
measurement to act as a control measurement and to assess the signal intensity and shape of the 
THz pulses emitted by the TPI system on each day of measurement. To enable consistent and 
controlled TPI measurements, tissue samples were placed in a standard histology cassette 
(UnisetteTM, Simport, Beloeil, Canada) that tightly fitted the head of the probe (Supplementary Material 
Figure 3). All samples were scanned for 20 seconds. Upon completion of each measurement a 
photograph of the sample in the cassette was taken to facilitate accurate correlation of the TPI data 
with the final histology slide.   
After the sample was scanned, the Tegaderm layer was removed from the probe and a 60 
second air measurement was performed that was used as a reference for data processing. For 







after which the histology cassette containing the sample was closed, and placed in formalin for 24-48 
hours, processed and paraffin wax embedded. Three to 4 micron sections were then cut and stained 
with haematoxylin and eosin. The histology slides were digitalised, and subsequently viewed and 
analysed using histopathology slide viewer software (NDP.view2, Hamamatsu, UK).  
 
TPI data processing 
Each pixel of the TPI probe acquired raw THz pulses throughout the duration of the measurement. 
These pulses were deconvolved with the reference (“air without Tegaderm”) pulses and a double 
Gaussian filter was applied to reduce noise. All pulses were aligned in time to compensate for small 
offsets in the phase of the detected pulses due to changes in the optical path length that occur when 
optical fibres deform slightly with movement during scanning. The deconvolved pulses – called 
impulse functions - of each pixel were then averaged over time, resulting in 26 impulse functions, one 
for each of the 26 pixels to be used for discriminating benign from malignant breast tissue (Figure 1). 
 
Correlation of TPI with histopathology  
By using the photograph depicting the imprint of the probe’s scan window on the sample, and the clear 
contrast from the air-tissue interface and tissue composition on the TPI image, the 15 x 2 mm TPI 
scan area was mapped onto the digital histopathology image (Figure 1). To reduce potential 
inaccuracies in correlating TPI with histopathology, samples were excluded from further analysis if the 
number of tissue-containing pixels on TPI and histopathology differed by more than three. 
 
Histopathological analysis and selection of TPI data 
The digital histopathology slide of each sample was analysed in the viewer software by a Consultant 
breast histopathologist (S.E.P.), and the percentage of different tissue types, namely tumour, fibrous, 
and adipose, were recorded in 5% intervals. For a subset of samples an intra-rater variability analysis 
was performed to assess the ability of the histopathologist to consistently score the tissue samples. 
For this analysis, a total of 92 pixels from 7 tumour samples and 125 pixels from 7 benign samples 
were re-evaluated in a blinded method by the same histopathologist 8 weeks after the first analysis. 
Weighted kappa coefficients were calculated to assess the agreement in subgroup classification 







A kappa coefficient (κ) greater than 0.80 was considered excellent agreement31. A Wilcoxon signed-
rank test was performed to assess whether evaluation 1 was statistically significantly different from 
evaluation 2. The level of significance was defined as p < 0.05. 
 Based on the histopathological information, pixels were selected by drawing region of 
interests (ROIs) on the TPI images, and subsequently grouped according to tissue type and tissue 
percentage (Table 1). Pixels containing tumour tissue, and pixels containing pure fibrous tissue or a 
mixture of fibrous and adipose tissue, were divided into groups of 20% (i.e. 1 – 20%, 21 – 40%, 41 – 
60%, 61 – 80%, and 81 – 100%). Pure adipose pixels were grouped separately in a “100% adipose” 
group. 
 
TPI data analysis and classification 
Classification of each of the selected impulse functions as malignant or benign was performed using 
two data analysis and classification methods: (1) heuristic parameters in combination with support 
vector machine (SVM) classification and (2) Gaussian wavelet deconvolution with Bayesian 
classification. 
The impulse function of each pixel is made of values at 301 time points, and given that 
information from both the time and frequency domain can be used to classify pixels, it was 
advantageous to reduce the dimensionality of the data for classification. In method 1 this was done by 
using parameters that described significant features in the impulse function or spectrum. Since a large 
number of time points or frequency points can be selected to form a parameter, a Receiver operator 
Characteristics (ROC) analysis was used to select the optimal characterising parameters. The area 
under the ROC curve (AUROC) was used as an estimate of the classification ability of each parameter 
(illustrated in Supplementary Material Figure 4). AUROC analysis was performed on the data from 3 
pathology groups; (i) the entire tumour and fibrous groups (excluding pure adipose), (ii) the tumour 
and 100% fibrous groups, and (iii) the tumour and 100% adipose groups. From this analysis the top 11 
parameters were selected to be used for classification of the data in the SVM (Table 2). To avoid 
effects of overfitting, the parameters chosen were tested to ensure they were not correlated, 
eliminating any parameters with an absolute correlation coefficient of 0.7 or more. The SVM function 
used for classification was from the Matlab native functions svmtrain.m and svmclassify.m using a 







Inc., Natick, MA, 2013). A grid search method was applied to optimise the sigma and box constraint 
terms as 0.3 and 1.1, respectively.  
Tissue classification was also performed using Gaussian wavelet deconvolution in 
combination with a Bayesian classifier. In contrast to heuristic parameters, Gaussian wavelet 
deconvolution can be applied to the full impulse function. This method was considered a suitable 
approach because of the similarities between the signal features of a Gaussian function and its 
derivatives, and the TPI impulse functions from breast tissue.  Gaussian derivatives of order 0 (normal 
Gaussian function), 1, 2, 3 and 4 were applied to the impulse function of each pixel. Higher order 
Gaussian derivatives were not used to avoid potential overfitting. The Gaussian deconvolved data 
were then fed into a Bayesian classification algorithm32, and classified as tumour, fibrous or adipose, 
respectively. Pixels classified as adipose and fibrous were then grouped together as ‘benign’ in order 
to calculate the diagnostic performance of TPI. Similar to SVM, pixels were marked as tumour when 
containing any amount of cancer cells.  
The SVM and Bayesian classifier were trained individually using the leave-one-out method 
(LOO); leaving out the pixels of a single sample to be classified, and training each classifier on the 
other samples. The trained classifiers were then applied to the pixels of the sample that was left out. 
This process was repeated for all the samples, leaving each of them out in turn, and the results 
compiled to give accuracy, sensitivity, specificity, positive predictive value, and negative predictive 
value for distinguishing malignant from benign tissue.   
 
Results 
Tissue sample characteristics and histopathology intra-rater reliability  
In total, 126 samples from 106 patients were scanned; 46 samples from 32 patients met the strict 
criteria established to ensure accurate correlation of TPI with histology, i.e. a photograph was 
available of the sample in the histology cassette, and the number of tissue containing pixels on TPI 
and histopathology differed by 3 or less. These samples were included for analysis. Of these, 20 
samples contained tumour; 16 invasive ductal/no special type (NST) carcinoma, 2 NST admixed with 
DCIS, 2 invasive lobular carcinoma (ILC). Twenty-two samples contained pure fibrous tissue or a 
mixture of fibrous and adipose tissue, and 4 samples contained pure adipose tissue. The total number 







The intra-rater reliability analysis showed excellent agreement in cell density subgroup 
classification between histopathological evaluation 1 and evaluation 2 (κ = 0.89) (p = NS).  This 
confirmed that the established subgroups reliably reflected the tissue composition of the samples, and 
thus could be used to evaluate the performance of the TPI handheld probe system for different tissue 
groups. 
 
Heuristic parameters and SVM classification  
A total of 11 parameters were selected based on the AUROC analysis: 10 time domain parameters 
and 1 frequency parameter (Table 2) (Supplementary Material Figure 5). Most of the time domain 
parameters capture the area around the minimum amplitude of the pulse, and the return to baseline 
after the minimum. P1 – P7 were selected based on their overall ability of discriminating tumour from 
fibrous tissue with adipose, while P8 – P11 were specifically selected to enhance the TPI probe’s 
ability to discriminate tumour from pure fibrous tissue. All 11 parameters showed strong discriminative 
power to distinguish tumour from pure adipose tissue (mean AUROC = 0.97, range 0.84 – 1.0).  
The SVM classification results of the individual parameters, and the combination of 
parameters that performed best in terms of accuracy, may be found in Table 3. Overall, the 
combination of P1 and P6 provided the best performance with an accuracy, sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) of 75%, 86%, 66%, 67% and 
85%, respectively. These values were obtained as a result of 16 of the 115 tumour pixels being 
misclassified as benign; 48 of the 142 benign pixels were misclassified as tumour. All misclassified 
tumour pixels had a tumour content ≤60%. Of the 48 misclassified benign pixels, 46 were fibrous 
pixels containing 81 – 100% fibrous cells; only 2 of the 1 – 80% fibrous pixels were misclassified as 
tumour, and all 26 pure adipose pixels were correctly identified as benign. The two-dimensional 
parametric plot of P1 and P6 showed very little differences between tumour and high percentage 
fibrous tissue (Figure 2A); this provides an explanation for why most of the SVM classification errors 
occurred in these two tissue groups (Figure 2B). Pixels with a high adipose content (1 – 80% fibrous 
pixels and pure adipose pixels) were generally clearly different from pixels containing a high 
percentage of fibrous tissue (81 – 100%) and cancer (Figure 2A). The accuracy, sensitivity, specificity, 
PPV and NPV for discriminating 1 – 80% fibrous and pure adipose tissue from tumour (i.e. excluding 






Gaussian wavelet deconvolution and Bayesian classification  
The accuracy, sensitivity, specificity, PPV and NPV of Gaussian wavelet deconvolution and Bayesian 
classification was 69%, 87%, 54%, 60%, 84%, respectively (Table 3).  Of the 115 tumour pixels, 15 
were misclassified as benign. All misclassified pixels contained ≤60% tumour cells. Sixty-six of the 142 
benign pixels were wrongly classified as tumour; 64 of these were 81 – 100% fibrous pixels, only two 1 
– 80% fibrous pixels were misclassified. All pure adipose pixels were correctly classified. The 
accuracy, sensitivity, specificity, PPV and NPV of the handheld probe for discriminating 1 – 80% 
fibrous and pure adipose from tumour was 88%, 87%, 96%, 98% and 61%, respectively.  
 
Discussion  
This study has evaluated the performance of a TPI handheld probe system to discriminate breast 
cancer from benign breast tissue in an ex vivo setting.  A total of 257 pixels acquired from scanning 46 
breast tissue samples were included for analysis. The tumour samples predominantly contained low-
to-moderate tumour cell percentages, resembling the tissue composition found at the resection border 
of breast specimens from patients with positive margins after BCS. Two data analysis and 
classification methods were assessed: (1) heuristic parameters in combination with SVM classification 
and (2) Gaussian wavelet deconvolution with Bayesian classification. On the full dataset the former 
provided the best performance in terms of accuracy (75%). Both methods had excellent sensitivity 
(86% and 87%, respectively) and thus show promise for identifying tumour cells close to or at the 
resection margins, allowing immediate further excision of appropriate margins and reducing 
subsequent second operations/re-excision rates if the TPI handheld probe had been used 
intraoperatively. Specificity however, was 66% and 54% for SVM and Bayesian respectively; for both 
methods the lower specificity was due to pixels with 81 – 100% fibrous tissue that were wrongly 
classified as tumour. The accuracy, sensitivity and specificity increased to 88%, 87%, and 96% 
respectively after excluding the 81 – 100% fibrous tissue from the classification results.   
 The reported pooled sensitivity and specificity of the established techniques to intraoperatively 
assess tumour margins during BCS are 53% (95% CI 45 – 61%) and 84% (95% CI 77 – 89%) for 
specimen radiography, 59% (95% CI 36 – 79%) and 81% (95% CI 66 – 91%) for ultrasound imaging, 
71% and 68% for radiofrequency spectroscopy, 86% (95% CI 78 – 91%) and 96% (95% CI 92 – 98%) 






cytology, respectively11. Thus, based on the results of the present study, the TPI handheld probe 
appears to perform similarly or better in terms of sensitivity, while the performance in terms of 
specificity is lower. Compared to specimen radiography and ultrasound, which are also imaging 
technologies, TPI has the potential advantage that image interpretation is not needed as the device 
can provide a binary read-out (tumour or no tumour). This may overcome the need for the training 
required for obtaining ultrasound accreditation33. Potential advantages over the histopathological 
techniques frozen section analysis and imprint cytology are the fact that TPI is non-invasive (i.e. 
physical tissue disruption is not required), it does not require an on-site cytologist or histopathologist, 
and allows for assessing a larger tissue surface.  
 Results published to date on the diagnostic performance of emerging techniques for margin 
assessment have shown a sensitivity and specificity of 92% (95% CI 86 – 96%) and 97% (95% CI 93 
– 98%) for Raman spectroscopy12, 67 – 85% and 67 – 96% for diffuse reflectance spectroscopy13-17, 
60 – 100% and 69 – 92% for optical coherence tomography18-20, 93 – 100% and 91.9 – 100% for mass 
spectroscopy21, 22, and 87% and 76% for bioimpedance spectroscopy23, respectively. Although the 
performance of the handheld probe in this study is somewhat lower than some of the other emerging 
techniques, TPI uses a different region of the electromagnetic spectrum and thus provides 
complementary information. It is possible that combinations of technologies could significantly improve 
the overall accuracy of identifying involved margins. 
Several papers have reported on the ability of TPI to discriminate freshly excised benign from 
malignant breast tissue27, 29, 34, 35. Ashworth et al. performed a small pilot study using a prototype 
version of the TPI handheld system34; all other studies were conducted with systems not suited for 
intraoperative imaging of WLE specimens. Similar to the present results, Ashworth et al. found that 
THz impulse functions from fibrous tissue and breast cancer had strong similarities, while impulse 
functions from adipose tissue had clearly different features. However, none of the TPI studies in breast 
cancer published to date have used a dataset representative of the tissue composition found at the 
resection border of patients with positive margins, as all tumour samples included for analysis 
contained >50% tumour cells.  Thus, the results in our study are the first that can be used to derive 







The accuracy, sensitivity and specificity of the TPI probe for discriminating tumour from mixed 
fibrous and adipose tissue, and pure adipose tissue, was 87%, 86%, and 96% for SVM, and 88%, 
87% and 96% for Bayesian, respectively. Discrimination of these tissue types is most relevant 
clinically, as the incidence of breast cancer is higher in older women, who are likely to have fatty or 
mixed fibrous and fatty breasts compared to younger women who may have more dense breasts 
primarily composed of fibrous tissue36.  
While the results of this feasibility study are promising, two limitations were noted. Firstly, the 
0.6 mm pixel distance used for correlating TPI and histopathology was based on a linear movement of 
the THz pulse beam across the 15 x 2 mm scan area. However, in practice the THz beam moves 
faster in the centre of the scan window and slows down upon reaching the top and bottom boundary, 
resulting in a larger distance between pixels located in the centre compared to the edges. This 
introduces a degree of inaccuracy, which was not accounted for in this study. Secondly, the current 
dataset does not contain THz pulses from cases of pure DCIS. These samples could not be assessed, 
as DCIS is generally non-palpable and particularly problematic to sample in the fresh state without 
impairment of gold-standard histological assessment. However, since DCIS is often the cause of the 
clinical recommendation for re-operations in BCS, it is of key importance to assess the sensitivity of 
the TPI handheld probe for detecting DCIS. Based on the results of this feasibility study, a study will 
be performed in which TPI data will be acquired on tissue specimens with DCIS, to determine the 
ability of TPI to accurately detect DCIS. 
In conclusion, the results of this study show that the TPI handheld probe can discriminate 
invasive breast cancer from benign breast tissue with a high sensitivity and an encouraging degree of 
accuracy. The main challenge for TPI is accurate discrimination of cancer from tissue containing a 
high percentage of fibrous stroma due to the similarities in the THz pulse between these two types of 
tissue. Larger studies are warranted to assess the performance of this technique on different tumour 
types including DCIS, and its impact on re-operation rate. 
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Figures with legends 
 
 
Figure 1: Correlating TPI with histopathology. (A) Typical impulse function from breast tissue 
containing a high percentage of tumour, fibrous, and adipose cells, and air, respectively. Clear 
differences are seen between the impulse functions from air and from tissue, and between adipose 
and tumour/fibrous tissue, especially at time points t = 7.97 ps, t = 8.93 ps, and t = 9.67 ps (black 
arrows). (B) TPI image from sample based on the amplitude of the impulse function at t = 7.97ps. A 
clear contrast can be seen at the air-tissue interface at pixel 5 and pixel 17. Note an ‘edge effect’ at 
these interfaces, causing a distortion in the impulse functions of these pixels. (C) Digital 
histopathology slide of the same tissue sample. By using the photograph of the sample in combination 
with the air-tissue interface visible in the TPI image, the TPI 15 x 2 mm scan area can be accurately 
mapped onto the histopathology slide (black rectangle). The pixels are displayed as intermittent 
horizontal lines at 0.6 mm distance in the scan window. Pixel 5 – 17  contain invasive ductal/no special 
type (NST) carcinoma; the percentage of tumour cells in each of these pixel areas ranges between 5 – 
10%. The tissue immedialtely surrounding the tumour cells (background) is composed of fibrous 









Figure 2: Two-dimensional parametric plot (A) and SVM classification results (B) for the combination 








Tables with legends 
Table 1: Pixel characteristics analysis dataset. A total of 257 pixels were included in the TPI dataset: 
115 tumour pixels, 116 fibrous pixels and 26 pure adipose pixels. The tumour pixels predominantly 
consisted of invasive ductal/no special type carcinoma (N = 92) and invasive lobular carcinoma (N = 
19). Most of the tumour pixels contained a low to moderate percentage of tumour cells ranging 
between 1 – 60% (N = 98). Almost all tumour cells had a background of pure fibrous tissue; only 5 had 
a background containing a mix of fibrous and adipose. Most of the fibrous pixels had a high 
percentage of fibrous cells ranging between 81 – 100% (N = 91). Only 26 of the 257 pixels consisted 
of pure adipose tissue. 
 









ILC No. of 
pixels 
BG No. of 
pixels 
BG No. of 
pixels 
81 – 100  3 1  4 F 91 A 261 
 
61 – 80  11 2  13 F 2 A 
 
 
41 – 60  22  6 28 F 7 A 
 
 
21 – 40  33 1 12 46 F: 43 
F/A: 3 
 
3 A  
1 – 20   23  1 24 F: 22 
F/A: 2 
13 A  
No. of pixels 92 4 19 115  116  26 
NST = invasive ductal/no special type carcinoma; DCIS = ductal carcinoma in situ; ILC = invasive 
lobular carcinoma; BG = background tissue. In our dataset the background consisted of fibrous tissue 
(F), adipose tissue (A), or a mixture of fibrous and adipose tissue (F/A).   







Table 2: Overview of selected time domain and frequency domain parameters and their AUROC 
values. 
 
Parameter Definition AUROC value  
(cell density group)1 
P1 Quadratic fit 9.85 – 10.48 ps  0.76 (All T and F) 
P2 Linear fit 9.42 – 9.67 ps   0.73 (All T and F) 
P3 Amplitude at t = 9.42 ps  0.72 (All T and F) 
P4 Integral 9.14 – 9.65 ps  0.72 (All T and F) 
P5 Peak to peak (Emax minus Emin) 0.71 (All T and F) 
P6 Emin (minimum amplitude) 0.70 (All T and F) 
P7 Amplitude at t = 10.05 ps 0.70 (All T and F) 
P8 Quadratic fit 8.26 – 8.79 ps 0.74 (1 – 20% T, 100% F) 
P9 Integral 7.47 – 9.62 ps 0.83 (41 – 60% T, 100% F) 
P10 Emax (maximum amplitude) 0.73 (81 – 100% T, 100% F) 
P11 Power in spectrum at frequency = 1.11 THz 0.82 (61 – 80% T, 100% F) 
1. T = tumour, F = pure fibrous tissue or a mixture of fibrous and adipose tissue, 100% F = pure 







Table 3: Performance of heuristic parameters with SVM classification, and wavelet deconvolution with 
Bayesian classification. SVM classification results are shown for individual parameters and parameter 
combinations that performed best in terms of accuracy. The best individual parameter and parameter 













(%)	P1	 73	 87	 62	 65	 85	P2	 72	 81	 64	 65	 81	P3	 70	 77	 65	 64	 78	P4	 72	 77	 69	 67	 78	P5	 72	 92	 56	 63	 90	P6	 69	 86	 56	 61	 83	P7	 69	 87	 54	 61	 84	P8	 68	 90	 49	 59	 86	P9	 56	 69	 46	 51	 64	P10	 68	 93	 48	 59	 89	P11	 56	 56	 57	 51	 61	P1	and	P6	 75	 86	 66	 67	 85	P1,	P6	and	P11	 71	 72	 70	 66	 76	P1,	P6,	P9	and	P11	 67	 56	 75	 65	 68	
Gaussian	wavelets	 69	 87	 54	 60	 84	
1. PPV = Positive predictive value 










Supplementary figures with legends 
 
Supplementary Material Figure 1: Schematic illustration of TPI handheld probe system. The emitted 
laser pulses are split into a “pump beam” and a “probe beam”. The pump beam is guided through the 
optical fibres in the umbilical cord, and subsequently incident on the photoconductive emitter to 
produce THz pulses. The probe beam is guided onto the photoconductive detector to detect the THz 
pulses reflected from the tissue sample. By altering the path length of the probe beam, the time of 
arrival at the detector in respect to the incident THz pulse can be changed, thus sampling the THz 





















Supplementary Material Figure 2: TPI handheld probe system. (A) Main unit with computer monitor, 
handheld imaging probe and black umbilical cord (visible on the right). (B) Close up of the handheld 
imaging probe. (C) Close up of the head of the imaging probe showing the black quartz window. The 






























Supplementary Material Figure 3: TPI measurement of tissue sample. (A) TPI handheld probe 
measurement of tissue sample positioned in histology cassette. Note that the head of the imaging 
probe tightly fits in the cassette, which facilitates applying a consistent pressure throughout the 
measurement, while preventing displacement of the probe. (B) Photograph of the tissue sample 
obtained after the sample was scanned. The imprint of the scan window on the sample is clearly 
visible. This photograph was used to facilitate accurate correlation of TPI data with histopathology. (C) 
Photograph of tissue sample after it was inked. Inking was performed to enable spatial orienation of 



























Supplementary Material Figure 4: AUROC analysis to evaluate the discriminative power of the 
amplitude parameter for time indices 5.0 – 12.6 ps. The highest AUROC values of 0.72 and 0.70 were 
found at t = 9.42 ps and t = 10.05 ps respectively, and these two parameters were therefore selected 

























Supplementary Material Figure 5: Visualisation of the selected parameters used in SVM classification. 
Each parameter is displayed in red. 
 
